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 The human body is exposed to a multitude of prevalent viruses, requiring ongoing 
surveillance and protection by the immune system. Maintenance of human anti-viral adaptive 
immunity in diverse tissue sites is determined by a multitude of factors and critical for long-term 
protection against repeat exposure to viral infection. Yet, studies of anti-viral immunity have 
primarily been limited to animal studies and studies of peripheral blood in humans. Studies in 
mice have demonstrated that memory T cells in tissues provide superior protection against viral 
infection compared to circulating T cells, particularly tissue-resident memory T cells (TRM), 
which remain in tissues long-term without re-entering circulation. However, much remains to be 
understood about how anti-viral immune responses are maintained in human tissues and how 
adaptive immune cells in various tissues sites function upon re-exposure to viral antigens. 
 We have established a human tissue resource through a collaboration with LiveOnNY, a 
local organ procurement organization, to obtain blood and multiple lymphoid and mucosal sites 
from donors of all ages. Using this tissue resource, we employed comprehensive cellular and 
molecular analysis to investigate tissue immunity to three prevalent but distinct viruses—
influenza A, CMV, and SARS-CoV-2. We compared CD8+ T cells recognizing ubiquitous and 
longstanding viruses influenza A and CMV across multiple tissue sites of 58 organ donors ages 
1-78 years in order to elucidate how covariates of virus, tissue, age, and sex impact the anti-viral 
immune response. Using flow cytometry, T cell receptor repertoire sequencing, functional 
assays, and single-cell transcriptional profiling, we showed that virus specificity and tissue 
 
 
localization are the primary drivers of anti-viral T cell immune responses in the human body, 
with age and sex further influencing T cell subset differentiation. Specifically, virus specificity 
correlated with virus-specific T cell distribution, memory subset differentiation, and clonal 
repertoire, while tissue localization determined overall subset distribution and functional 
responses. We further investigated the tissue-localized immune response to emergent SARS-
CoV-2. By examining multiple tissues of organ donors who had recovered from natural infection 
by SARS-CoV-2, we showed that adaptive memory immune responses persisted months after 
infection, with memory T and B cells preferentially localized in the lung and lung-associated 
lymph node. Persisting memory cell populations included tissue-resident T and B cells, 
particularly in the lung, as well as germinal center B cells in the lung-associated lymph node 
along with follicular helper T cells, indicating ongoing generation of humoral immunity. 
Together, these findings highlight the importance of tissue-localized anti-viral immunity and 
help to define characteristics of site-specific protective immunity that may be leveraged for the 
development of more effective treatment and prevention strategies.  
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Chapter 1: Introduction 
Adapted and expanded significantly from: Poon, M.M.L., Farber, D.L. (2020) The whole body 
as the system in systems immunology, iScience, and Poon, M.M.L., Farber, D.L. (2021) Lasting 
memories to SARS-CoV-2 infection, Journal of Experimental Medicine. 
 
1.1 The human immune system in tissues  
The human immune system protects the body from infection by pathogens, exposure to 
environmental toxins and allergens, and cellular damage that may lead to cancer. The immune 
system also plays a critical role in maintaining homeostasis by mediating tissue repair and 
controlling inflammation 1-4. Unlike other organ systems that are contained within a specific 
tissues or structures (for example, the heart and blood vessels in the cardiovascular system), the 
immune system is comprised of a diverse population of specialized immune cells that provide 
surveillance to all tissues, forming a complex network across the human body. Therefore, it is 
essential to sample key tissues that contain diverse immune cell populations, including primary 
and secondary lymphoid organs (bone marrow [BM], lymph nodes [LNs], spleen, tonsil), 
mucosal and barrier sites (skin, intestines, lungs), and metabolic organs, such as the liver and 
pancreas. 
This vast and intricate system of cell-cell interactions across multiple anatomic sites has 
proven particularly challenging to study. Current knowledge of human immunology is largely 
based on studies of peripheral blood, isolated tissues or biopsies, and animal models. However, 
studies of peripheral blood provide a limited view, as the majority of immune cells localize in 
tissues. Moreover, while animal studies have provided valuable insights into the cellular and 
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molecular mechanisms underlying immune defense, challenges translating data from mice to 
humans has emphasized the importance of studying human immunology directly in humans 5-8.  
Recent work utilizing human tissue resources has illustrated the remarkable complexity 
of the human immune system—immune cell identity, development, function, interaction, and 
maintenance in states of inflammation and homeostasis throughout the body and over life. Some 
of these studies utilized tissue samples acquired from surgical resections, such as skin from 
cosmetic surgery, tonsils from tonsillectomy, or spleens from pancreatectomy 9-15. Others utilized 
samples obtained from deceased transplant organ donors 16-21. Analyzing multiple sites within an 
individual and among individuals can also provide insight into how the immune system functions 
as a network across diverse organ tissues within the human body across decades of life 22-31.  
 
Cells of the human immune system 
The human immune system is divided into two main branches—innate and adaptive 
immunity. The innate immune system responds broadly and quickly but lacks specificity and 
immunological memory against particular pathogens, while the adaptive immune system is 
characterized by its vastly diverse repertoire of antigen-specific receptors and ability to retain 
immunological memory over decades. Within human tissues are multiple innate and adaptive 
immune cell types and subsets; notably, similar immune cell lineages exhibit distinct features 
depending on whether they circulate in blood or localize in tissues. Adding to the complexity are 
tissue-specific adaptations that immune cells adopt within certain sites, as well as the 
heterogeneity among individuals as a result of age and development or health versus disease 
states. Described below and in Figure 1-1 and Table 1-1 are the key cellular components of 
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innate and adaptive immunity, their segregation in blood and different tissue sites, and their roles 
in the immune response.  
In peripheral blood, innate immune cells comprise the majority of the immune cell 
compartment, with neutrophils being particularly abundant and T and B lymphocytes found in 
smaller proportions (Figure 1-1). Within organs and barrier sites, the innate and adaptive 
immune cells coordinate responses to provide tissue-specific immunity. The key tissue innate 
cells are macrophages, professional phagocytes that ingest cellular debris, pathogens, and other 
foreign substances. Long-lived tissue macrophages are established prenatally from embryonic 
precursors, self-renew in situ and are highly specialized for their tissue of residence 32-35. These 
include brain microglia, lung alveolar macrophages, spleen red pulp macrophages, and liver 
Kupffer cells 36-41 (Table 1-1). 
Dendritic cells (DCs) are the innate immune cells that link innate and adaptive immunity 
through their role as antigen-presenting cells (APCs) crucial for T cell activation. Because of 
their unique ability to carry antigens from mucosal sites to T cell zones of tissue-draining lymph 
nodes, conventional DCs (cDCs), including cDC1 and cDC2 subsets perform the crucial task of 
presenting antigens to induce T cell responses (Table 1-1) 25, 42-47. Circulating plasmacytoid DCs 
(pDCs) represent a small subset of DCs that infiltrate tissues to secrete large amounts of type I 
and type III interferons in response to viral infection and are particularly abundant in human 
tonsil at steady state 45, 48-51. Other innate cell types are innate lymphoid cells, which include 
natural killer (NK) cells abundant in human blood and tissues, as well as helper-type innate 
lymphoid cells (ILCs) ILC1, ILC2, and ILC3 that are mostly tissue-resident in different sites 
(Figure 1-1) 9, 52-56. NK cells are important for anti-tumor and anti-viral immunity, while ILCs 
may act to promote tissue repair 57, 58. While innate immune cells have classically been described 
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as having a rapid, short-lived response, studies in the past decade have shown that the function of 
myeloid and innate lymphoid cells can be shaped and enhanced by prior antigenic exposure 
through epigenetic and metabolic changes, or through modulation of surface receptor expression 
59-63.  
The adaptive immune system consists of T and B lymphocytes, which facilitate the cell-
mediated and humoral immune responses, respectively. Unlike the innate immune system in 
which cells express germline-encoded receptors, the adaptive immune system is highly 
“adaptable,” because mechanisms like V(D)J recombination (recombination of receptor gene 
segments) and somatic hypermutation (mutation affecting the variable regions of 
immunoglobulin genes) allow a limited number of genes to generate a diverse repertoire of 
antigen receptors. During primary exposure to foreign antigens, the adaptive immune system 
exhibits a delayed response and requires antigen presentation or activating signals from innate 
immune cells. However, re-exposure to the same antigen results in an immediate and robust 
response 64, 65.  
T lymphocytes recognize specific antigens through interactions between their unique 
surface T cell receptor (TCR) and peptide-bound MHC molecules on APCs 66. Conventional T 
cells are categorized into CD4+ helper and CD8+ cytotoxic T cells. CD4+ T cells recognize 
antigens presented on major histocompatibility complex (MHC) class II molecules, while CD8+ 
T cells recognize antigens presented on MHC class I molecules. Activation of either requires 
antigen presentation, as well as co-stimulatory signals, most canonically by the binding of CD28 
on the T cell surface with CD80/CD86 on an APC (Figure 1-2). Upon activation, naïve CD4+ T 
cells proliferate and differentiate into one of several helper T cell lineages defined by their 
function and cytokine production 67 – TH1 68, TH2 69, 70, TH17 (Ivanov, et al., 2006; Korn, et al., 
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2009), follicular helper T cell (TFH) 71-73, and regulatory T cell (Treg) 74-76 (Table 1-1). The 
development of these T cell subsets is discussed in more detail in Section 1.2. CD8+ cytotoxic T 
cells comprise a less diverse group of conventional T lymphocytes and when activated 
proliferate and can secrete proinflammatory cytokines and cytotoxic mediators for killing of 
infected cells and tumor cells 77. Following the effector phase, during which expanded clones of 
antigen-specific T cell subsets coordinate antigen clearance, most T cells undergo apoptosis. 
However, a small number of T cells survive and differentiate into heterogeneous subsets of 
CD45RA-/CD45RO+ memory T cells, which provide long-term immunosurveillance and 
enhanced recall responses. 
Diverse memory T cell subsets populate blood and virtually every tissue site. Circulating 
subsets include central memory T cells (TCM) that express LN-homing chemokine receptor 
CCR7 and circulate through lymphoid tissues, CCR7- effector memory T cells (TEM) that migrate 
through nonlymphoid tissues, as well as terminally differentiated effector memory T cells 
(TEMRA) that re-express CD45RA and display high effector function 78, 79. Additionally, resident 
memory T cells (TRM), often characterized by their expression of CD69 (and CD103 in mucosal 
sites), are a unique memory T cell subset that resides within peripheral tissues long-term and 
provide optimal protective immunity to pathogens in situ 20, 21, 23, 26, 78, 80-90 (Figure 1-2 and 1-3). 
Differentiation of memory T cell fates is further discussed in Section 1.2. Other types of T cells 
with more restricted recognition properties and invariant TCR—invariant natural killer T (iNKT) 
cells, gd T cells, and mucosal-associated invariant T (MAIT) cells—play important roles in 
immune protection at mucosal sites and exhibit tissue residence. Unlike conventional T cells that 
bear TCR a/b chains and recognize peptide antigens, iNKT and MAIT cells recognize lipids and 
vitamin B metabolites, respectively, while gd T cells express TCR g/d chains and are distinct 
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from ab T cells in antigen recognition  66, 91-94. Their role and interaction with conventional ab T 
cells in mediating tissue immune responses is an active area of study 
 B cells can also be found in circulation and in tissues, but they are largely confined to 
lymphoid sites (LNs, spleen, BM) and comprise a relatively rare immune population in 
nonlymphoid organs, often far outnumbered by T cells 23, 26, 95, 96. B cells express a unique 
membrane-bound B cell antigen receptor (BCR) immunoglobulin that, when activated, is 
secreted as antibodies in plasma that can directly bind antigens. In secondary lymphoid organs 
(SLOs) and in isolated lymphoid follicles (ILFs) found along the length of the gastrointestinal 
(GI) tract and in Peyer’s patches (PPs), follicular B cells form clusters surrounded by a T cell 
zone, while marginal zone B cells populate the interface between nonlymphoid red pulp and 
lymphoid white pulp in the spleen in other lymphoid tissues 97. During an active immune 
response, these B cell follicles form germinal centers that facilitate T-B cell interactions, 
immunoglobulin class switching, and B cell differentiation to antibody secreting plasma cells 
and memory B cells. Humoral immunity is maintained through maintenance of memory B cells 
in lymphoid sites, plasmablasts in circulation, and long-lived plasma cells in BM 98, 99.  
 
Distribution of immune cells in human tissues 
 The human immune system is shaped as much by its arsenal of immune cells as the 
location in which these specialized cells perform their essential functions. 
 SLOs, such as spleen and LNs, serve as crucial sites of immune cell-cell interactions 
leading to the priming of immune responses. They provide an optimal environment for T and B 
cells to encounter antigens presented by APCs and receive cytokine signals that inform them to 
either differentiate into effector cells or facilitate tolerance within peripheral tissues.  
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 The spleen is a unique SLO which contains two types of tissue, red pulp and white pulp. 
Red pulp makes up the majority of the human spleen and contains its own population of tissue 
macrophages—red pulp macrophages— that express FcgR, which allows them to filter the blood 
of senescent or damaged red blood cells through phagocytosis of IgG opsonized erythrocytes 41, 
100. Separated from red pulp by a marginal zone, white pulp consists entirely of lymphoid tissue 
containing B cell follicles surrounded by a T cell zone. These B cell follicles are populated by 
follicular DCs, germinal center and mantle zone B cells, plasmablasts, and plasma cells with 
abundant CD27+ memory B cells and CD4+ T cells at the follicle surface 101. An estimated 33% 
of all splenic mononuclear cells are B cells (compared to 4% in the peripheral blood), 
approximately 46% of which are memory B cells 12. Immunohistochemistry studies have shown 
that cDCs and pDCs localize at the surface of B cell follicles, while flow cytometry studies of 
human spleen DCs at steady state have identified all four DC subsets—cDC1, cDC2, pDC, and 
monocyte-derived DC—which phenotypically and transcriptionally resemble blood DCs 25, 101, 
102. Although white pulp macrophages have been shown in mice to phagocytose apoptotic B cells 
eliminated in the selection process, they have not been extensively studied in humans 103. In 
contrast, splenic T cells have been characterized extensively in recent studies by our laboratory 
using organ donor tissues. The majority of T cells in the spleen are memory T cells, including 
CD4+/CD8+ TEM, CD4+ TCM, CD8+ TEMRA, and CD4+/CD8+ CD69+ TRM; but, unlike mucosal 
sites, the spleen contains only a small population of CD69+ CD103+ CD8+ TRM 23, 26.  
LNs are specialized lymphoid structures often closely associated with their corresponding 
mucosal site and are thus crucial for maintaining balance between inflammation and tolerance in 
peripheral tissues. APCs, including cDCs, migrate to LNs via afferent lymphatics draining from 
mucosal sites, whereas pDCs and monocytes enter from the blood via high endothelial venules 
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(HEV) during infection and inflammation. Similar to many other tissues, LNs contain more 
cDC2s than cDC1s with rare populations of pDCs at steady state 18, 25. LN DCs also display a 
higher mature:immature ratio than spleen DCs 25. These MHCIIhi mature cDCs have been shown 
to display migratory characteristics and retain characteristics unique to cDCs in their 
corresponding mucosal site, suggesting that at least a portion of mature cDCs in the LN are 
derived from cDCs that have matured at the mucosal site and migrated to the draining LN 25. 
Circulating lymphocytes also enter LNs from the blood via HEV and then organize into B cell 
follicles surrounded by T cells in the interfollicular region. While the composition of B cell 
follicles in human LNs is not well characterized, it is likely that they follow a pattern similar to 
follicles in other SLOs. Within the adaptive immune cell compartment, T cells are approximately 
2- to 4-fold more abundant than B cells 23, 26. LN CD4+ T cells are maintained primarily as TCM 
followed by naïve T cells, while CD8+ T cells are maintained as naïve T cells, followed by 
CD69+ TRM, which do not express mucosal site residency marker CD103 23, 26. 
 Mucosal sites, such as the lung and intestinal tract, host diverse populations of innate and 
adaptive immune cells with characteristics unique to the site and distinct compartmentalization 
within each tissue. In the human small intestine (SI), immune cells play a crucial role in 
maintaining immune tolerance to harmless food antigens and commensal bacteria, while 
protecting against invading pathogens 9, 23, 25, 104-106. In the intestinal myeloid compartment, 
monocytes are much more abundant than DCs, and cDC2s are more abundant than cDC1s and 
pDCs 25. The SI also contains phenotypically and functionally distinct macrophage populations, 
including short-lived (CD14+ CD11c+) macrophages that resemble blood monocytes and long-
lived (CD14+ CD11c-) mature macrophages that are highly proficient in uptake and processing of 
antigens but hyporesponsive to inflammatory stimuli 106. Meanwhile, cytotoxic intraepithelial 
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NKp44+ CD103+ CD56+ CD3- NK/ILC1s that produce IFN-g, perforin, and granzyme also 
express markers of tissue residency (CD49a, CXCR6, CD69, CD103) 53, 54. With regards to the 
intestinal adaptive immune population, T cells are far more abundant than B cells (>15- to 20-
fold in the jejunum, 5- to 8-fold in the ileum and colon) 23, 26. The SI contains long-lived plasma 
cells that secrete high affinity IgA antibodies, memory B cells found at low frequencies in the 
lamina propria, and naïve-mature B cells in ILFs that are found along the length of the intestinal 
tract at the base of the lamina propria and in Peyer’s patches of the ileum 20, 107. ILFs lymphoid 
structures contain both naïve and memory T cells with memory T cells predominating 20, 26. In 
mucosal tissue, CD69+ CD4+ and CD69+ (± CD103) CD8+ TRM are by far the most abundant T 
cell subsets, while gut-associated lymphoid tissues (GALT) have a relatively higher frequencies 
of naïve CD4+/CD8+ T cells and CD4+ TCM 20, 23, 26. The human intestine also contains Treg cells, 
localized in aggregates within GALT, which are crucial for maintaining tolerance against 
innocuous antigens 20. Finally, along the intestinal epithelium, iNKT cells represent 50-70% of 
all intraepithelial lymphocytes (IELs) in the SI and 40-45% of IELs in the colon, though they 
comprise only approximately 0.4% of all T cells in the human intestine 108-111. 
 The human lung barrier site, where O2 and CO2 exchange occurs, is continuously exposed 
to environmental and microbial antigens. To protect the body from infection while preventing 
tissue damage, the lung is home to a diverse population of immune cells. Major immune cell 
types in the human lung at steady state include neutrophils, myeloid cells (monocytes, 
macrophages, and DCs), and T cells 23. Like the intestine, lung monocytes are much more 
abundant than DCs, and cDC2s are more abundant than cDC1s and pDCs 25. Alveolar 
macrophages serve as the lung’s tissue-resident macrophage and are found in the airway lumen 
and alveolar spaces, serving as phagocytes and essential regulators of immune responses 112, 113. 
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Like other tissue macrophages, alveolar macrophages are thought to be derived from embryonic 
precursors. However, studies of lung transplant patients have shown that, in addition to long-
lived and self-renewing donor alveolar macrophages, recipient monocyte-derived macrophages 
can differentiate into tissue macrophages and contribute to the alveolar macrophage population 
112. The adaptive immune system of the human lung is predominantly T cells, >90% of which are 
memory T cells 26. The lung is enriched for CD4+/CD8+ TRM with a considerable proportion of 
TCM among CD4+ T cells; it also contains a sizable CD8+ TEMRA  population, whereas the SI and 




Figure 1-1. Heterogeneity of immune cells in human tissues. 
The human immune system is characterized by multilevel heterogeneity. Within an individual, 
immune cells are localized in multiple sites, including blood, primary and secondary lymphoid 
organs, organs of the respiratory and GI tract (lungs, intestines, pancreas liver), and barrier sites 
(skin, mucosal surfaces). Within tissues are diverse types of innate and adaptive immune cells—
some that are present in circulation and migrate through blood and different tissues and others 
that establish and maintain residence within specific tissue sites. The composition, phenotype, 
function, and tissue-specific adaptations of diverse populations of immune cells differ between 
sites. Between individuals, immune responses vary depending on factors, such as age and 
conditions of health or disease. Understanding the whole body as a system requires investigation 














Table 1-1. Cellular components of the innate and adaptive immune system. 
 Immune cell type Role in Immunity * 
Blood 
Innate 
Neutrophils • Phagocytic granulocytes that release soluble antimicrobials during infection 
Eosinophils & Basophils • Circulating granulocytes involved in allergy/asthma and parasitic infections 
Monocytes 
• Phagocytic granulocytes involved in antigen presentation and wound healing 
• Serve as circulating precursors of monocyte-derived DCs and macrophages recruited during infection 
and inflammation 
Dendritic cells pDC 
• Small subset of DCs with round, lymphocyte-like morphology found mainly in circulation and lymphoid 
tissues 
• Critical in anti-viral immunity 




Naïve T cell • Protect against new and unrecognized infections; delayed primary response 
TCM • Circulate primarily between blood and lymphoid tissues; predominantly CD4+ 
TEM • Migrate through tissue sites 
TEMRA • Re-express CD45RA after prolonged antigenic stimulation; predominantly CD8+ 
Treg • Immune regulation and homeostasis 
Circulating  
B lymphocytes 
Naïve B cell • Protect against new and unrecognized infection delayed primary response 
Plasmablast • Short-lived and proliferative antibody-secreting B cell that is generated early in an infection 
Memory B cell • Patrol for previously encountered antigens; quick and robust secondary response 
Tissue 
Innate 
Mast cells • Express high-affinity IgE receptors (FceRI) that recognize antigens bound it IgE antibodies 
• Release histamine and other molecules responsible for symptoms associated with anaphylaxis 
Tissue macrophages 
• Professional phagocytes that reside in tissues to ingest cellular debris and foreign material 
• Long-lived; maintained by self-renewal 
• Highly specialized and distinct depending on their tissue of residence 




NK cell • Anti-tumor and anti-viral tissue immunity 
• Maintenance of precursor NK cell populations 
Helper-type ILC 
• Cytokine production profiles match corresponding help T cell subset (e.g. ILC1 secrete IFN-g, ILC3 
secrete IL-17 and IL-22) 
• Promote tissue repair and display functional plasticity 
Adaptive Tissue-resident  T lymphocytes 
ab T cell 
TRM • Reside long-term within tissues without re-entering circulating 
• in situ protection against pathogens and tumors 
Treg • Suppression of tissue inflammation and tissue repair 
Tfh • Support B cell maturation and required for germinal center formation 
Innate-like 
T cell 
gd T cell • TCRs comprise g/d chains and are distinct from ab T cells in antigen recognition 
iNKT cell • Recognize lipid antigens presented on CD1d molecules 
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• Long-lived and non-proliferative antibody-secreting B cell generated later in an infection and produces 
high affinity antibodies 
• Localize predominantly in bone marrow 
Memory B cell • Long-lived; recognize previously encountered antigens for faster, more robust antibody response upon secondary exposure 
Follicular B cell • Make high-affinity antibodies; primarily localize in lymphoid follicles of SLOs 
Marginal zone B cell • First line of defense against blood-borne pathogens entering from circulation; primarily localize in marginal zone of the spleen  





1.2 Heterogeneity of T cell development and differentiation 
T cells are unique among immune cells in that they have a specialized organ for their 
development and output—the thymus—which is highly active at birth, declines during childhood 
and is nascently active in adulthood with evidence pointing to thymic shutdown in middle age 
(40-50 yrs) 115-117. In the thymus, BM-derived T cell precursors undergo further development to 
mature T cells, involving rearrangement of T cell antigen receptor genes and selection for T cells 
that lack overt self-reactivity for export to the periphery (Figure 1-2). Recent work analyzing T 
cell development in the human thymus has revealed new insights on fetal development, 
childhood, and adult life 118. Paired analysis of single-cell RNA sequencing data with TCR data, 
revealed a development trajectory for human T cells starting from CD4-CD8- double negative 
(DN) cells to mature CD4+ and CD8+ single positive (SP) cells and elucidated the process of 
TCRb selection, providing evidence for progressive recombination of the TCRa allele starting 
with proximal V-J pairs followed by distal pairs 118. In addition, Park, et al. described a diverging 
lineage of gd T cells between the DN and DP stages and Treg cells branching from ab T cells 118. 
This in-depth analysis reveals the developmental trajectories for T cells that uniquely occur 
within thymic tissue and prior to export of mature naïve CD4+ and CD8+ T cells to peripheral 
sites.  
Upon export from the thymus, mature T cells populate blood and virtually every tissue 
site in the body. Depending on signals received from the tissue microenvironment and 
interactions with other immune cells, these T cells can differentiate into one of many cell fates. 
In particular, in addition to the different memory T cell subsets, discussed previously, naïve 
CD4+ may development into one of five main subsets – TH1, TH2, TH17, TFH, or Treg (Figure 1-2). 
TH1 development occurs when IL-2 and IFN-g predominate during early naïve T cell activation, 
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resulting in the activation of transcription factor T-bet and the development of IFN-g-producing 
effector T cells. TH2 cells arise when IL-4 predominates, activating transcription factor GATA-3 
and resulting in IL-4, IL-5, and IL-13 production. TH17 development requires IL-6, IL-23, and 
TGF-b, leading to the induction of transcription factor RORgt and IL-17/22-producing CD4+ T 
cells. TFH cells, which require transcription factor Bcl-6 require IL-6 for development and 
promote B cell development and proliferation through the production of IL-21. Finally, Treg 
development outside of the thymus requires TGF-b and IL-2 to induce the activation of 
transcription factor FoxP3, resulting in TGF-b and IL-10 production to suppress immune 
responses and inflammation. Numerous studies in humans and mice have also suggested that a 
notable degree of plasticity exists among CD4+ T cell subsets, adding further to the heterogeneity 
of T cells 119, 120. Upon activation, CD8+ naïve T cells upregulate transcription factors T-bet and 
Eomes and differentiate into cytotoxic T lymphocytes (CTLs) that can secrete proinflammatory 
cytokines and cytotoxic mediators for killing of infected cells and tumor cells 121-123(Figure 1-2). 
In addition to subsets of T cells with differing effector functions, activated T cells also 
develop into heterogeneous CD45RO+ memory subsets that persist to mediate protective 
immunity upon re-exposure to pathogens and other foreign antigens, as well as are capable of 
self-renewing to maintain the body’s memory T cell pool 124. These memory subsets are 
distinguished by surface marker expression, display unique tissue homing patterns, and include 
TCM (CCR7+ CD45RA-), TEM (CCR7- CD45RA-), TEMRA (CCR7- CD45RA-), TSCM (CCR7+ 
CD45RA+CD95+), and TRM (CCR7- CD45RA- CD69+) (Figure 1-3). 
TCM, which are mostly CD4+, constitutively express homing/chemokine receptor CCR7, 
which is required for extravasation through HEV and migration to T cell zones of SLOs 125, 126. 
They localize primarily in lymphoid tissues with the ability to re-circulate. Moreover, TCM have 
17 
 
been described to possess high proliferative capacity, produce mainly IL-2, and have the ability 
to self-renew 78, 124, 127. TEM lack the expression of CCR7 and are able to enter peripheral tissues 
and migrate throughout non-lymphoid tissue sites 128, 129. They display chemokine receptors and 
adhesion molecules required for homing to inflamed tissues and mediate rapid effector function 
at sites of inflammation 127-129. They have also been shown to produce inflammatory cytokines, 
such as IFN-g and TNF-a, more rapidly than TCM 130. TEMRA, which are primarily CD8+, lack 
CCR7 expression but re-express CD45RA. They possess high cytotoxic function, with increased 
production of granzyme and perforin, as well as display characteristics of terminal 
differentiation, including shortened telomere length and expression of replicative senescence 
marker CD57 131, 132. Studies of peripheral blood T cells have suggested that naïve T cells may 
differentiate into TCM, then TEM, and ultimately to TEMRA based on their differentiation state, 
activation characteristics, proliferative capacity, and telomere length; though precise mechanisms 
of differentiation within human tissues remains to be defined 133, 134. More recently, TSCM specific 
for viral and tumor antigens were described in human peripheral blood, though more work needs 
to be done to elucidate their role in human tissues 134-136. Like naïve T cells, TSCM express both 
CCR7 and CD45RA; however, they can be distinguished by their expression of memory T cell 
marker CD95 and display epigenetic marks indicative of previous activation.  
Human T cell subsets also follow a tissue-dependent pattern of distribution and 
maintenance, but unlike innate cells, tissue intrinsic subset composition exhibits age-associated 
changes, as reviewed elsewhere 137. Naïve T cells are the predominant population in lymphoid 
tissue sites in early life and childhood, while memory T cells populate mucosal, exocrine, and 
barrier sites with the accumulation of antigen experience during childhood 28, 29, 137. As a results, 
for most of adult life, there is a stable segregation of naïve T cells being only found in blood and 
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lymphoid tissue (LN, spleen), while memory T cells predominate in virtually every non-
lymphoid tissue examined, including mucosal sites (lungs, intestines), skin, exocrine tissues, 
liver and brain 80, 88, 138-140. The majority of these tissue memory cells comprise non-circulating 
TRM cells that exhibit distinct phenotypic and transcriptional profiles that enable their retention in 
tissue sites 80, 141; tissue-specific proportions of TRM in each site are stably maintained with age 20, 
28. Given that TRM are formed early in life, and can be detected in mucosal sites in infants and 
children and during an active infection 29, 142, it is possible that TRM maintain long-term immunity 
for maintenance of tissue homeostasis.  
TRM exhibit polyfunctionality, heterogeneity, and tissue-specific properties that are 
starting to be defined using transcriptomics and single-cell approaches. Globally, TRM have been 
shown to upregulate transcription factor Hobit and related Blimp1 143. In lymphoid sites, such as 
LNs, tissue memory T cells exhibit increased expression of transcription factors and functional 
markers associated with stem-ness and denoting maintenance in a more quiescent state compared 
to memory T cells in spleen and BM, which exhibit a more differentiated state with increased 
turnover 144. Conversely, TRM localized across the GI tract exhibit distinct phenotypes and 
metabolic signatures whether they localize to the small intestine, associated lymphoid tissue, or 
the pancreas 140, and unique localization of TRM in liver sinusoids requires specific adaptations 
145, 146. Further elucidation of tissue memory T cell heterogeneity and tissue adaptations, both in 
the polyclonal and antigen-specific context are required to understand how memory T cells in 
tissue sites are maintained and poised to respond to challenge. 
A recent study by Miron, et al. (2021) performed high-throughput bulk TCR sequencing 
to extensively profile and systematically analyze human memory T cell clonal repertoires across 
tissue sites. This study found that characteristics of clonal expansion and dissemination are 
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intrinsic to memory T cell subsets, while different clones within a tissue compartment share site-
adapted features. TEMRA clones display the highest degree of clonal expansion and can be found 
across multiple sites, which TRM exhibit tissue-specific expansions. TEM and TRM share a 
substantial proportion of clones within and across tissue sites, suggesting an initial priming event 
can result in both circulating and non-circulating tissue memory T cells and that certain tissue 
sites, such as the lung, may favor maintenance of non-recirculating and site-adapted TRM. In 
contrast, TCM display minimal sharing between sites and with other memory T cell subsets. This 
study also identified TRM clones that preferentially localized in tissue sites, such as the lung, LN, 
or BM, which suggests that they may respond to tissue-specific signals leading to adaptation to 
specific sites. TRM also appear to maintain clonal diversity with age, while circulating memory 
subsets showed age-associated clonal expansion 31. 
Recent studies have also provided new insights into the diverse functions and subtypes of 
T cells and how these vary as a function of tissue site. A recent study using single-cell RNA 
sequencing (scRNA-seq) profiling of resting and activated T cells isolated from blood, BM, lung, 
and lung-associated lymph node (LLN) from human donors identified functional modules 
conserved across all sites and specific signatures that distinguish blood and tissue T cells 27. 
Unsupervised clustering of scRNA-seq data from BM, lung, and LLN from two organ tissue 
donors revealed three unique CD4+ T cell activation states distinguished by differential 
expression of IL2, TNF, and IL4R, and two major functional states for CD8+ T cells 
characterized by differential expression of genes associated with pro-inflammatory cytokines and 
chemokines and cytotoxic mediators 27. Applying single-cell Hierarchical Poisson Factorization 
147, revealed activation and functional “modules” that were highly conserved across tissues and 
donors, including a proliferation module, an IFN response module, and two unique cytotoxicity 
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modules. Moreover, projection of blood T cells profiles onto Uniform Approximation and 
Projection method (UMAP) embeddings of T cells from tissue donors revealed that tissue T cells 
upregulated genes associated with cell structure, extracellular matrix, adhesion, and tissue 
residency, suggesting that T cells adopt structural changes that facilitate interactions with tissue 
matrix 27. Together, these analyses demonstrate that T cells adopt a spectrum of functional states 
when activated and are able to adapt when localized in peripheral tissues. 
 Functional heterogeneity of T cell subsets, such as Tregs and antigen-specific T cells, is 
also being elucidated. A recent study of scRNA-seq profiling identified the activation trajectory 
of Tregs between draining LNs and colon 16. They showed that there is a continuous range of 
functional states from resting Tregs in mesenteric lymph nodes to colonic Tregs, which express 
high levels of functional regulatory molecules 16. Variations in T cell functional states are 
hallmarks of diverse diseases, and scRNA-seq analysis can uncover new insights important for 
understanding disease pathogenesis and new therapeutic targets. A recent study identified 
specific functional states for Tregs and allergen-specific T cells isolated from the blood of 
individuals with atopy and asthma, revealing both allergy-associated cytokines and an interferon 
response state 148, similar to that identified from scRNA-seq analysis of CD4+ T cells in tissues 
27. As scRNA-seq is applied to the increasing number of datasets, it will be possible to identify 
specific genes associated with disease and those which are part of the healthy spectrum of 
functional states.   
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Figure 1-2. T cell development, activation, and differentiation of effector function. 
T lymphocyte progenitors from the bone marrow migrate to the thymus for development into 
naïve CD4+ or CD8+ T cells, which are released from the thymus into circulation and peripheral 
tissues. Activation of naïve CD4+ and CD8+ T cells requires presentation of antigen by APCs. 
Formation of a TCR:MHC-peptide complex, as well as a co-stimulatory signal, are required for 
activation of naïve T cells. Once activated, T cells proliferate, driven by the production of IL-2, 
as well as differentiate into effector T cells with varying effector functions. These different 
effector T cells include CD4+ T cell subsets – TH1, TH2, TH17, TFH, and Treg – and CD8+ CTLs, 
each uniquely characterized by transcription factor upregulation and cytokine production. 








Figure 1-3. Differentiation and localization of memory T cell subsets in human tissues. 
Upon activation, a small portion of T cells differentiate into memory T cells and are maintained 
long-term to provide immune surveillance against re-exposure to foreign antigen. Each memory 
T cell subset can be distinguished by surface marker expression: TCM, CCR7+ CD45RA-; TEM, 
CCR7- CD45RA-; TEMRA, CCR7- CD45RA-; TSCM, CCR7+ CD45RA+CD95+; and TRM, CCR7- 
CD45RA- CD69+. These subsets are characterized by unique tissue localization patterns, with re-
circulating subsets TCM and TEM primarily located in lymphoid tissues and mucosal/barrier sites, 
respectively. TEMRA are primarily circulate throughout peripheral blood and blood-rich tissues, 
while TRM are maintained in tissues without re-circulating. TSCM have been described in human 
peripheral blood, but their maintenance in human tissues has not been extensively studied. 




1.3 Coordination of anti-viral immune response 
 Humans are exposed to countless viruses over a lifetime. An adequate anti-viral immune 
response requires a concerted effort by innate and adaptive immune cells to limit tissue damage, 
clear the infection, and establish memory for future encounters with a similar infectious agent.  
 
Anti-viral innate immune response 
 Once a virus has successfully invaded a barrier site, they are recognized by innate 
immune receptors expressed on the host cell surface or inside the host cell. These include Toll-
like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), 
and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs). TLR-3, TLR-7, TLR-8, and 
TLR-9, found within the membrane of endosomes, are particularly important in anti-viral 
defense, as they recognize viral nucleic acids of endocytosed viruses. Signaling by nucleic-acid-
sensing TLRs results in the induction of an inflammatory response through cytoplasmic adaptor 
molecules MyD88 or TRIF, which then leads activation of members of the interferon regulatory 
factor (IRF) transcription factor family (Figure 1-4A). This signaling cascade then results in the 
production of inflammatory immune mediators, including anti-viral cytokines type I interferons 
(IFN-a/b) and other cytokines that recruit immune cells and elicit inflammation. TLR-3 is 
preferentially expressed by CD8a+ DCs, while TLR-7 and TLR-9 are preferentially expressed 
by pDCs. Cytoplasmic NLRs and RLRs recognize viral genomic DNA and RNA, respectively. 
Activation of NLRs leads to activation of activation of NF-kB pathway, production of type-1 
interferons, inflammasome formation triggering cell death, and recruitment of immune cells to 
the site of infection (Figure 1-4B). In contrast, activation of RLRs results in the induction of type 
I interferons and pro-inflammatory cytokines through activation of NF-kB and IRFs pathways 
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(Figure 1-4B). In addition, viral genomes can be recognized via cytosolic DNA sensors signaling 
through stimulator of interferon genes (STING), resulting in DNA-dependent inflammasome 
activation and type I interferon production (Figure 1-4B) 120, 149, 150 
 Innate immune cells recruited to the site of infection play a crucial role in amplifying the 
inflammatory response, limiting the infection, activating adaptive immune responses, and 
minimizing tissue damage. Cytokines and chemokines released by activated macrophages and 
DCs recruit and activate innate and adaptive immune cells, as well as trigger systemic acute-
phase response driven by TNF-a, IL-1b, and IL-6. Circulating pDCs are uniquely equipped to 
make abundant type I interferons. Meanwhile, APCs, such as cDCs, carry viral antigens to LNs 
through lymphatics draining from tissue sites to activate elicit an adaptive immune response. 
Importantly, DCs and macrophages have also been shown to produce regulatory molecules, such 
as IL-10 and TGF-b, which limit the inflammatory response to minimize damage of host tissue. 
Among the innate immune cells that are recruited to the site of infection, NK cells are 
particularly important for controlling viral infections. Activated in response to type I interferons, 
NK cells kill infected cells by releasing cytotoxic granules to trigger apoptosis or by antibody-
dependent cellular cytotoxicity (ADCC) during which antibodies attached to Fc receptors (FcR) 
on NK cells are crosslinked through binding of antigens on the target cell (Figure 1-4C). These 
cells are instrumental in containing viral infections in the early stages while the adaptive immune 
response generates antigen-specific T cells and neutralizing antibodies to clear the infection. 120, 
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Anti-viral adaptive immune response 
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 Viral infections that are not contained by the innate immune system alone trigger 
adaptive immune responses. Formation of adaptive immune responses to new viruses requires 
antigen presentation, clonal expansion, and differentiation into effector cells, and thus result in a 
delayed response. However, once the virus has been cleared, a portion of virus-specific adaptive 
immune cells are maintained in diverse tissue sites as memory cells, which respond quickly upon 
secondary exposure to previously encountered viral antigens.  
 When introduced to a new virus, naïve B cells in LNs are activated through antigen 
binding of the BCR in coordination with accessory signals from TFH cells (though B cells do not 
always require T cell help and may be activated directly by pathogen antigens)71, 152(Figure 1-5). 
In the setting of viral infection, studies in numerous mouse infection models have shown that TFH 
cells play a critical role in germinal center formation, where they facilitate the generation of 
memory B cells and plasma cells 153-156. Circulating TFH cells in humans have also been linked to 
antibody responses to viruses 157-160. However, TFH – B cell interactions in germinal centers in 
humans has not been extensively studied, in part due to difficulty sampling human tissues. TFH 
cells express high levels CD40L, which interacts with CD40 expressed on B cells to promote B 
cell activation and differentiation, antibody production, and cytokine signaling 71, 72, 161. Once 
activated, B cells then differentiate into antibody-secreting plasmablasts and plasma cells, while 
a subset of B cells migrate into lymphoid follicles and proliferate to form germinal centers in 
which B cells undergo affinity maturation to generate B cells with high affinity for viral antigens, 
as well as class switching of immunoglobulins to produce antibodies with a variety of effector 
functions. Circulating neutralizing antibodies secreted by plasmablasts and long-lived memory 
plasma cells, protect against infection and re-infection by blocking the binding of virus receptors 
and preventing fusion of the viral envelope and the cell membrane (Figure 1-6). Meanwhile, 
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memory B cells do not produce antibodies but are maintained in circulation and in tissues long-
term, poised to activate and differentiate during a secondary immune response upon re-exposure 
to a recognized antigen 12, 120, 162. 
 Generation and persistence of cell-mediated anti-viral immunity is dependent on the 
characteristics of the viral infection. Acute viral infections are characterized by an initial 
expansion of virus-specific effector T cells, followed by contraction and persistence of a small 
portion of memory T cells maintained long-term, while persistent viral infections result in 
accumulation of memory T cells overtime as a result of intermittent reactivation and exposure to 
viral antigens (Figure 1-7). Perhaps most crucial to an effective anti-viral adaptive immune 
response are cytotoxic CD8+ T cells. While CD4+ T cells help to recruit other immune cells, 
promote engagement of CD8+ T cells with DCs, and aid in CD8+ T cell priming and function 163, 
the cytotoxic functions of CD8+ T cells are crucial for killing virus-infected cells and viral 
clearance. Like NK cells, cytotoxic CD8+ T cells induce programmed cell death of target cells 
through activation of caspase pathways following antigen-specific binding of peptide:MHC 
complexes on a target cell and direct release of cytotoxic molecules stored within granules; 
cytotoxic CD8+ T cells also facilitate apoptosis via Fas/Fas-ligand binding (Figure 1-8). This 
direct killing of target cells helps to ensure destruction of virally infected cells while limiting 
damage to host tissues. Cytotoxic CD8+ T cells also function through release of cytokines, such 
as IFN-g and TNF-a to inhibit viral replication, promote expression of MHC class I and peptide 




Figure 1-4. Anti-viral innate immune defenses. 
Anti-viral immune protection by the innate immune system involves pattern recognition 
receptors and innate immune cells. (A) Endosomal TLRs – TLR-3, TLR-7, TLR-8, and TLR-9 – 
recognize viral nucleic acids of endocytosed viruses. Upon binding of nucleic acids, TLR-3 
signals through TRIF, while TLR-7, -8, and -9 signal through MyD88. Activation of TRIF and 
MyD88 then leads activation of transcription factor NF-kB and members of the IRF transcription 
factor family, resulting in the expression of inflammatory mediators. (B) Viral nucleic acids in 
cell cytoplasm are recognized by NLRs, RLRs, and cytosolic DNA sensors. Activation of these 
pathways lead to inflammasome formation, as well as the induction NF-kB and IRF3 pathways. 
(C) NK cells are crucial for controlling viral infections. Once activated, NK cells kill infected 
cells by releasing cytotoxic granules (left) or by ADCC (right) to induce apoptosis in virus-










Figure 1-5. Germinal center TFH:B cell interactions are crucial for adaptive anti-viral 
immune response. 
Interactions between TFH and B cells through binding of TCR and MHC class II, as well as of 
CD40 and CD40L facilitate the activation of B cells. Once activated, B cells then proliferate, 
differentiate, produce antibodies, undergo affinity maturation and class switching, and 
differentiate into memory B cells and long-lived plasma cells. This process is critical for an 






Figure 1-6. Neutralizing antibodies prevent viral fusion. 
Plasmablasts and plasma cells secrete neutralizing antibodies, which circulate and protect against 







Figure 1-7. Cell-mediated immune response against acute versus persistent viral infection. 







Figure 1-8. Cytotoxic CD8+ T cells target virus-infected cells. 
Cytotoxic CD8+ T cells specific for viral antigens mediate targeted killing of infected cells while 






1.4 Influenza A and the immune system 
Influenza A virus 
 Influenza A virus, along with Influenza B and C viruses, causes acute respiratory 
infection and poses a major threat to global health despite annual vaccinations formulated to 
generate strain-specific neutralizing antibodies against highly variable surface proteins, 
hemagglutinin (HA) and neuraminidase (NA). Influenza A belongs to the Orthomyxoviridae 
family and is an enveloped virus containing a single-stranded negative-sense segmented RNA 
genome with 8 segments (Figure 1-9). These RNA segments encode proteins, including surface 
glycoproteins HA, which binds to sialyloligosaccharides on host cells, and NA, which facilitates 
release of viral particles by cleavage of sialyloligosaccharide residues from the surface of host 
cells (as well as release of viral particles bound to mucins and other natural defense proteins that 
carry sialyloligosaccharide to which HA binds). HA and NA serve to distinguish influenza A 
subtypes, such as H1N1 and H3N2, which circulate annually and cause influenza epidemics 164, 
165. 
 The prevalent nature of influenza A virus is due in part by its ability to rapidly mutate 
and re-assort its RNA segments. In a process known as antigenic drift, influenza viruses are able 
to acquire mutations in their HA and NA proteins, allowing them to evade the immune system. 
In addition, new strains of influenza A virus capable of infecting humans emerge via antigenic 
shift, during which co-infection by multiple virus strains allows the virus to re-assort its RNA 
segments, often in animal reservoirs 164, 166. As a result influenza A virus’s ability to undergo 
rapid mutation and re-assortment of its RNA segments, annual vaccinations have proven 
inefficient and often ineffective due to the difficulty in predicting prevalent strains of the 
upcoming influenza season and the tendency for vaccine efficiency to wane overtime 167-170. 
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 Influenza viruses are transmitted through three mechanisms: aerosol, droplet and direct 
contact. Aerosolized viral particles, such as those released when an infected person sneezes or 
coughs, can be inhaled into the upper and lower respiratory tract. Larger droplets often deposit in 
the upper respiratory tract, while contact transmission involves transfer of viral particles from the 
environment directly onto mucosal surfaces 164. In general, influenza A virus infects humans via 
the epithelial cells of the upper respiratory tract; however, highly pathogenic strains, such as 
H5N1, have been shown to preferentially infect type 2 pneumocytes deep in the lower 
respiratory tract of the human lung 165. Once infected, the presentation of influenza infection 
ranges from asymptomatic infection to mild respiratory symptoms, such as cough and sore 
throat, to systemic illness with symptoms, such as fever, chills, headache, body aches, fatigue. 
Severe infections leading to involvement of the lower respiratory tract can further progress to 
lung inflammation and pneumonia 164. 
 
Innate immune response to influenza A virus 
 Airway epithelial cells, as the first target of influenza A virus, initiate the anti-viral 
immune response and recruit innate immune cells. The single-stranded RNA segments of 
influenza A virus are detected by TLR-7 on endosomal membranes and cytoplasmic RLRs. 
Detection of viral genome the leads to the activation of IRF3, IRF7, and NFkB transcription 
factors and the subsequent production of type I interferons and other inflammatory proteins, such 
as acute-phase response cytokines TNF-a, IL-1b, and IL-6, as well as chemokines, such as 
CCL2, which recruit monocytes/macrophages to the lung 165, 171. Alveolar macrophages 
phagocytose influenza A virus-infected cells to limit viral spread and regulate adaptive immune 
response. NK cells eliminate virus-infected cells via binding of HA to cytotoxicity receptors 
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NKp44 and NKp46. cDCs migrate from lungs to LNs to present viral antigens to T cells to 
bridge the innate and adaptive immune response 171. 
 
Adaptive immune response to influenza A virus 
 Adaptive immunity plays a crucial role in limiting and clearing influenza A virus 
infection. While humoral immunity provides narrower and strain-specific protection primarily 
against surface HA and NA, cell-mediated immunity affords cross-strain protection against 
conserved internal virion proteins, such as nucleoprotein (NP), matrix protein (M1), and viral 
polymerase (BP1)172-174.  
 Antibody responses to surface glycoprotein HA are protective against influenza A virus 
infection and are leveraged in the formulation of influenza vaccines, see review by Krammer 
2019 175. In a natural infection, antibodies against NA, M1, and NP have also been reported 175. 
Antibodies against HA block the interaction between the virus and sialylated host cell receptor, 
limiting the binding and fusion of the viral envelop with the host cell membrane, as well as the 
fusion of the viral envelop with the endosome to prevent release into the cytoplasm (Figure 1-
10). Meanwhile, antibodies against NA have been shown to inhibit NA’s enzymatic activity, 
preventing the release of newly formed viruses from the host cell, as well as the release of 
incoming virions from mucins and other defense proteins 175, 176 (Figure 1-10). In addition, 
influenza-specific antibodies can trigger FcR-mediated effector functions, such as ADCC by NK 
cells, antibody-dependent cellular phagocytosis by macrophages, and complement-dependent 
lysis 175 (Figure 1-4). 
 Once the adaptive cell-mediated immunity is primed in LNs through presentation of 
antigen to T cells by APCs, influenza A virus-specific T cells play a crucial role in complete 
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viral clearance during acute infection, particularly in the lung (Figure 1-7, 1-11). Influenza A 
virus-specific T cells mainly recognize conserved internal virion proteins and thus can provide 
heterosubtypic immunity again influenza infection. Influenza-specific lung-resident memory T 
cells in humans have been shown to be abundant, polyfunctional, and diverse in their receptor 
sequences 177, 178, while mouse studies by our laboratory and others have shown that lung TRM 
provide optimal cross-strain protection long after viral clearance 179-186. Animal and human 
studies have demonstrated that CD4+ T cells play a crucial role in protection against influenza 
infection, reviewed in Jansen, et al. 2019 187. Mouse studies have shown that CD4+ T cells are 
able to protect against infection, independent of B cells and CD8+ T cells, while studies of 
human peripheral blood have demonstrated that influenza-specific cross-reactive CD4+ T cells 
recognize conserved epitopes and that pre-existing CD4+ T cells were associated with lower 
virus shedding and better clinical outcomes 187. In addition, animal infection models have 
demonstrated that influenza-specific CD8+ T cells eliminate virus-infected cells by releasing 
perforin and granzyme B, inhibiting viral replication through production of IFN-g and other pro-
inflammatory cytokines, and inducing apoptosis through Fas/Fas ligand interactions 187 (Figure 
1-8). Finally, innate T cell subsets, such as MAIT, iNKT, and gd T cells, have been shown in 
animal models and studies of human peripheral blood to influence protection against influenza A 
virus, reviewed in Nüssing, et al. 2018. 
 
Escaping the host immune surveillance 
 Just as the immune system adapts to newly encountered strains of influenza virus, the 
virus also possesses mechanisms to circumvent immune surveillance. Non-structural protein-1 
(NS1) is an interferon antagonist protein that suppresses host interferon response by blocking 
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RIG-I activation and thus subsequent activation of anti-viral innate responses. NS1 can also 
inhibit the production of interferons and promotes viral replication through multiple mechanisms, 
including inhibiting protein kinase R and inducing express ion small non-coding RNA, blocking 
the NFkB pathway, and dampening JAK-STAT pathways by lowering phosphorylation levels of 
STAT1, STAT2, and STAT3 171. Another mechanism to evade host immune surveillance is the 
suppression of interferon signaling by HA—HA protein has been shown to facilitate the 
ubiquitination and degradation of the interferon-α/β receptor, resulting in decreased levels of 
type I interferons and reduced expression of interferon-stimulated anti-viral proteins 188. In 
addition, it has been shown that influenza A virus can use NA to inhibit the recognition of HA by 
NK cell cytotoxicity receptors and prevent activation of NK cells 189. Despite the mechanisms by 
which influenza A virus counters immune surveillance, the host’s immune system, particularly 
cell-mediated immunity, is able to effectively clear the virus in most immunocompetent 
individuals and establish memory cells capable of preventing future infections. To better 
understand how this occurs, it is crucial to understand how influenza-specific memory cells are 
maintained and function throughout the body long-term.   
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Figure 1-9. Structure of Influenza A. 
Influenza A is an enveloped virus consisting of 8 single-stranded negative-sense RNA segment 










Figure 1-10. Mechanisms of HA- and NA-specific antibodies against Influenza A infection. 
HA-specific antibodies (turquoise) block the binding of viral HA protein and sialylated host cell 
receptor to prevent fusion of the viral envelop with the host cell membrane. HA-specific 
antibodies also prevent fusion of the viral envelop with the endosomal membrane. NA-specific 
antibodies inhibit the release of influenza A virus from mucins and other defense proteins and  






Figure 1-11. Influenza-specific T cell responses at lung site of infection. 
Viral antigens are presented by APCs in the LNs to T cells. Activated influenza A virus-specific 
T cells then move into the lung site of infection to enact effector functions. After viral clearance, 







1.5 Human cytomegalovirus and the immune system 
Human cytomegalovirus 
 Human cytomegalovirus (CMV), also known as human herpesvirus 5 (HHV-5), is a 
ubiquitous virus that results in persistent systemic infection, exhibiting intermittent low-level 
reactivation that requires ongoing surveillance by the immune system (Figure 1-7, 1-12). CMV is 
transmitted through direct contact with body fluids or from mother to fetus and has a reported 
seroprevalence of 51-65% in the United States and > 95% in some South American, African, and 
Asian countries 190, posing major health risks, especially in the setting of immune compromise 
(e.g., aging, transplant, chemotherapy), when it may reactivate and cause devastating outcomes 
with manifestations ranging from asymptomatic viremia to life-threatening tissue invasive 
diseases (e.g., nephritis, meningoencephalitis, pneumonitis, myocarditis, pancreatitis)191-194. 
Additionally, CMV contracted during pregnancy can be transmitted to the developing fetus, 
resulting in congenital CMV infection which is associated with dire outcomes, such as 
intellectual disability, hearing, and death 193, 195. However, in immune competent individuals, 
CMV is able to co-exist with its host for decades, evading detection and elimination by the 
human immune system. 
 CMV is a member of the Betaherpesvirinae family. It is an enveloped double-stranded 
DNA viruses with a large genome expressing hundreds of protein-encoding open reading frames 
196(Figure 1-12A). Equipped with many genes, each viral genome encodes an array of 
immunomodulatory molecules that can dampen the host’s innate and adaptive immune defenses. 
In addition, CMV displays broad cellular tropism, capable of infecting multiple organs and 
multiple cell types, including fibroblasts, epithelial cells, endothelial cells, and monocytes cells 
197, 198. In fibroblasts, CMV replicates via lytic cycle to produce infectious virus participles. In 
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other cell types, there is an initial lytic burst followed by the establishment of latency. In 
particular, CMV exploits latently infected monocytes, which can migrate to various organs, 
resulting in disseminated viral infection. In the BM, CMV infects hematopoietic progenitor cells, 
establishing a lifelong latent infection 199. CMV infection can be divided into three phases: The 
first is the replication phases during which the virus replicates in many peripheral tissues, 
activating the innate immune response and priming adaptive immunity. The second is tissue-
localized persistent infection lasting months to years. Finally, the final phase consists of a long 
period of multisite latency with low-level intermittent reactivation and restricted viral gene 
expression 196, 199 (Figure 1-12B).  
 
Innate immune response to CMV 
 Upon initial acute infection by CMV, replicating virus activates innate defenses. 
Detection of CMV involves a number of pattern recognition receptors, including TLR-2, -3, -4 -
5, and -9, reviewed in 200 and 201. TLR-2 recognizes viral glycoproteins gB and gH and leads to 
activation of NF-kB and production of inflammatory cytokines, including increased levels of IL-
6 and IL-8, which has been shown in studies of human peripheral blood mononuclear cells 
(PBMCs) infected with CMV 200. Studies have also shown that, in mast cells, TLR-3 activates 
adaptor molecule TRIF and subsequent phosphorylation of IRF3, which results in production of 
type I interferons 202. Meanwhile, TLR-9 in DCs recognizes unmethylated CpG motifs in viral 
DNA and triggers NF-kB-mediated production of immune mediators to amplify anti-viral 
immune responses and recruit immune cells (Figure 1-4). 
A number of innate immune cells play critical roles in protection against CMV infection. 
In mouse models, infection by mouse CMV (MCMV) has shown that NK cells and type I 
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interferons are crucial for early control of infection. NK cells expressing activating receptor 
Ly49H binds to the MCMV m157 protein expressed on the surface of infected cells and reduce 
viral replication by lysing infected cells 196.While NK cells are commonly thought to function in 
an non-antigen-specific manner, studies have suggested that they can also facilitate antigen-
specific memory responses upon re-exposure to or re-activation of CMV antigens 59. In addition, 
pDCs and cDCs produce high levels of type I interferons, IL-12, and IL-18 during the initial 
burst of MCMV viral replication, which serves to further amplify NK responses and prime 
adaptive immunity 196. Other innate immune cells such as macrophages and neutrophils have 
been shown to limit spread of initial infection, as well as mast cells, which have been shown to 
produce chemokines and recruit cytotoxic CD8+ T cells 196. 
 
Adaptive immune response to CMV 
Establishment of latency and persistence requires initiation and ongoing maintenance of 
adaptive immunity against CMV. In particular, CD4+ and CD8+ T cells have been shown in 
mouse models to be crucial for controlling CMV infection. In the initial infection phase, control 
of MCMV replication was shown to correlate with initial expansion of effector T cells, after 
which small portion of virus-specific CD4+ and CD8+ T cells persist as a stable memory pool 203, 
204. Studies of human CMV infection in seropositive organ transplant recipients have also 
demonstrated CD8+ T cells and IFN-g-secreting CD4+ T cells correlate to better protection 
against CMV infection 195. In addition, populations of inflationary T cells, which expand during 
the persistent infection phase and do not contract, exhibit a TEMRA phenotype and display signs of 
continued antigen exposure without exhaustion 196, 205. These inflationary T cells contribute large 
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circulating populations of CMV-specific T cells in seropositive subjects, particularly in older 
individuals 205-208. 
While most studies of CMV infection is limited to animal models and human peripheral 
blood, our laboratory has shown the maintenance of CMV-specific CD8+ T cells in multiple 
tissue sites from deceased human organ donors. In this study, we observed heterogeneous 
distribution patterns of CMV-specific T cells in diverse tissue sites; distribution patterns can be 
categorized into donors with highest frequency in blood (20% of donors), BM (45% of donors), 
or LN (15% of donors) and low frequency overall (20% of donors)209. Moreover, we 
demonstrated that CMV-specific T cells displayed signs of previous activation (such as reduced 
CD28 expression), as well as functional capacity, expressing perforin and IFN-g upon 
stimulation with PMA/ionomycin 209. This study also compared T cell responses to viral 
transcripts within tissue sites and found that the presence of CMV genomes inversely correlates 
with the T cell response, with the lungs having the higher frequencies of viral genomes detected 
but lower frequencies of CMV-specific T cells compared to blood and BM, where there were no 
detectable CMV genomes but high frequencies of CMV-specific T cells 209. These findings 
suggest an intimate and reciprocal relationship between CMV and the cell-mediated immunity.  
CMV infection also induces a strong humoral response. Inflation of CMV-specific IgG 
has been observed in healthy seropositive individuals. Meanwhile, mouse models have 
demonstrated that IgG reduces viral spread during initial infection and increases during persistent 
infection. Interestingly, MCMV infection in mice lacking B cells does not affect overall immune 
protection, suggesting either that humoral immunity does not play a significant role or that 




Evading host immune surveillance 
 With its large genome, CMV has evolved a number of mechanisms to evade host 
detection. In fact, it is estimated that only one-third of the virus’s open reading frames are 
required for viral replication, suggesting that at least a portion the remaining genome has evolved 
to modulate the host immune response 196. For example, CMV proteins US7 and US8 impair 
TLR-3 and TLR-4 activation, while US9 and UL82 inhibit STING signaling and interferon 
production. Immediate-early 2 (IE-2) gene product IE86 has also been shown to inhibit IFN-b 
and chemokine production by preventing binding of NF-kB to the IFN-b promoter and inhibiting 
NF-kB transcription of other immune mediators, such as IL-8 and CCL5 200. Moreover, the 
UL18 family of genes encode MHC class I homologues that interfere with host cell MHC class I 
expression to evade NK cell detection while limiting peptide presentation to CD8+ T cells, while 
members of the US6 family result in downregulation of MHC class I and interfere with peptide 
loading 195, 196.  
CMV has also been shown to specifically target host immune cells. The US12 of proteins 
regulate NK cell ligands 195. Members of the RL11 family have been shown to bind IgG and 
inhibit FcR activation to block ADCC 195. UL141 restricts expression of CD155 and CD122, 
which are expressed on host cell surface to activate NK cells, as well as inhibits NK-mediated 
cell death by inhibition expression of TRAIL death receptors 196. With regards to T cells, mouse 
models have shown that MCMV inhibits expression of costimulatory molecules like B7 and 
enhances expression of inhibitory ligands like PD-L1, while primate models have demonstrated 
that the virus encodes orthologs of IL-10 to enact immunosuppressive effects 196.  Human CMV 
has also been shown to promote IL-10 production by circulating virus-specific CD4+ T cells in 
latent infection 210. In addition, UL144 selectively binds to BTLA to block T cell proliferation 
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196. While it is evident that CMV interacts closely with the host immune system, shaping the 
maintenance of anti-viral T cell populations, much remains to be understood how CMV-specific 




Figure 1-12. CMV structure and phases of infection. 
(A) CMV is an enveloped double-stranded DNA virus with a large genome. (B) The three phases 
of CMV infection are 1) replication phase, 2) persistent infection, and 3) multisite latency with 
low-level intermittent reactivation and restricted viral gene expression. Adapted from Picarda 






1.6 SARS-CoV-2 and the immune system 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
 SARS-CoV-2 is a novel coronavirus that causes the ongoing pandemic coronavirus 
disease 2019 (COVID-19). A member of the Coronaviridae family, SARS-CoV-2 is an 
enveloped positive-sense single-stranded RNA virus. Its genome encodes 16 nonstructural 
proteins, nine accessory proteins, and four structural proteins: spike (S), envelope (E), membrane 
(M), and nucleocapsid (N) (Figure 1-13). S protein is highly variable and mediates entry into 
host cells using its receptor-binding domain (RBD) via direct contact with angiotensin 
converting enzyme 2 (ACE2) receptor. It also has an S1/S2 polybasic site that is cleaved by 
transmembrane protease serine 2 (TMPRSS2) and cellular cathepsin L, which facilitate viral 
fusion in at the cell membrane and endosome membrane, respectively 211.  
SARS-CoV-2 is highly transmissible, primarily through respiratory droplets, though 
aerosols, contact with contaminated surfaces, and fecal-oral transmission have been reported 211. 
Primarily causing respiratory illness, the respiratory tract is the main tropism of SARS-CoV-2, 
although studies of tissue biopsies have shown that viral transcripts can be found in small 
intestines 212. One factor potentially contributing to its high rates of transmission is its incubation 
period of approximately one week, during which infected individuals may be asymptomatic 
while still shedding viral particles 211.  
The clinical presentation of SARS-CoV-2 infection is highly variable. While most 
individuals experience asymptomatic or mild disease, SARS-CoV-2 can cause severe “flu-like” 
symptoms leading to acute respiratory distress and multi-organ dysfunction, including impaired 
consciousness, ageusia, arrhythmias, and diarrhea 211. In a fraction of infected individuals, post-
acute sequelae, referred to as “long COVID” has also been observed. These individuals may 
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experience prolonged fatigue, reduced lung capacity, and more rarely cognitive deficiencies and 
other outcomes 213. However, it remains unclear the mechanisms by which these lingering 
symptoms occur.  
 
Innate immune response to SARS-CoV-2 
In the midst of the devastating COVID-19 pandemic, the scientific community has come 
together in an unprecedented global effort to understand the immune responses to SARS-CoV-2 
infection in order to develop effective strategies for treatment and prevention of disease. Studies 
have shown that SARS-CoV-2 is particularly effective at delaying innate immune response, 
leading to impaired control of viral replication and delayed priming of adaptive immunity, 
reviewed in 213. SARS-CoV-2 infection leads to local (particularly in virus-tropic upper and 
lower respiratory tract tissue) and systemic changes in immune cell populations and tissue 
damage with significant innate immune cell infiltration, including inflammatory monocytes and 
macrophages that predominate alveolar spaces in early disease stages, as well as neutrophils and 
NK cells 214-216 217. Studies of peripheral blood during acute SARS-CoV-2 infection have shown 
reduced numbers of NK cells in circulation. Along with increased NK cells and chemokines in 
patient bronchioalveolar lavage (BAL) samples, it has been postulated that activated NK cells 
home to the lung to perform anti-viral functions 218. NK cells have also been demonstrated to be 
highly activated and proliferating with retained functional capacity 218, 219. In addition, involvement 
of innate-like unconventional T cells, such as MAIT cells, has also been studied in SARS-CoV-2 
infection 220. Similar to NK cells, studies have described decrease in circulating MAIT cell pool 




Adaptive immune response to SARS-CoV-2 
Thus far, analyses of SARS-CoV-2-specific adaptive immune responses have been 
largely limited to circulating blood lymphocytes and animal studies. Studies in mouse infection 
models and extensive analysis of human samples from acutely infected and convalescent 
individuals have shown that SARS-CoV-2-specific antibodies, CD4+ T cells, and CD8+ T cells 
play prominent roles in anti-viral protection 221-225.  
Studies of convalescent patients have shown that SARS-CoV-2-specific T cells are 
reactive against multiple viral proteins – the most predominant and robust are S-protein-specific 
CD4+ T cells, which further correlate with antibody responses 221, 222. Interestingly, SARS-CoV-2 
CD4+ T cell responses have been shown to be more robust, polyfunctional, and longer lasting 
than CD8+ T cell responses 221, 222, 226. Studies in acute and convalescent patients have revealed 
that SARS-CoV-2-specific CD4+ T cells have the strongest association with decreased disease 
severity in COVID-19 compared to CD8+ T cells or antibody responses and was associated with 
accelerated viral clearance 221, 227. Additionally, one recent study investigated the persistence of 
cellular immunity to SARS-CoV-2 infection in previously infected individuals at two distinct 
timepoints – 1 and 6 months after infection – compared to healthy controls, examining the 
maintenance and functional capacity of virus-specific T cells by stimulating peripheral blood 
CD4+ and CD8+ T cells with SARS-CoV-2 peptide pools corresponding to surface structural 
proteins – S and Membrane protein (Memb) – and internal virion proteins – Nucleoprotein 
(NCAP) and Protein 3a (AP3a)228. They showed that while both CD4+ and CD8+ virus-specific T 
cells are broadly reactive against all four SARS-CoV-2 epitopes tested, the magnitude of the 
CD4+ T cell response was much greater, while CD8+ T cell responses were more variable and 
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less robust, as assessed by secretion of cytokines (IL-2, IFN-γ, TNF-α, Mip-1β) and expression 
of activation/cytotoxicity markers (CD154, CD107a)(Figure 1-14A)228.  
While SARS-CoV-2-specific CD8+ T cells are less consistently observed and appear to 
be less long-lasting than virus-specific CD4+ T cells, CD8+ T cells with specificity to a broad 
range of SARS-CoV-2 antigens have been reported in convalescent patients and in seropositive 
individuals months after infection 221, 226, 229. In acute COVID-19, SARS-CoV-2-specific CD8+ T 
cells in circulation have also been shown to exhibit high levels of cytotoxic effector molecules, 
such as IFN-g, granzyme B, and perforin 221, 225, 230. In seropositive individuals months post-
infection, one study showed that the majority of circulating memory SARS-CoV-2-specific 
CD8+ T cells were TEMRA 231.  
The majority of patients with COVID-19 become seropositive within 5-15 days post-
symptom onset, suggesting involvement of humoral immunity in anti-viral defense 213. While S 
and N serve as the primary antigens driving the humoral response, S protein, in particular the 
RBD, is the main target of neutralizing antibodies213. The generation of neutralizing IgG 
antibodies directed against the S protein on the virus surface, which binds the cellular receptor 
for viral entry, can block infectivity, provide protection in an animal model, and is the target of 
available vaccination strategies 232-234. With regard to humoral immune memory, the longevity of 
humoral immunity and memory B cells has been examined in a number of studies months post-
infection 212, 231, 235. They found that IgM, IgG, and IgA can be detected in circulation up to 8 
months after infection, with IgM titers decreasing rapidly over time and IgG and IgA titers 
remaining more stable 212, 231, 236. These studies also confirmed the persistence of neutralizing 
antibodies, which appear to decrease but remain detectable at 6 months after infection. 
Interestingly, the frequencies of circulating memory B cells increased between 1 and 6 months 
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post-infection 212, 231. Gaebler, et al. further demonstrated that the maintenance of humoral 
immunity to SARS-CoV-2 is dynamic and evolves over time. Sequencing of SARS-CoV-2-
specific paired antibody heavy and light chains from individuals at 1 and 6 months after infection 
revealed a significant increase in somatic hypermutation at 6 months compared to earlier 
samples, consistent with ongoing evolution of the antibody response (Figure 1-14B). In addition, 
when comparing antibodies present at both time points, antibodies at 6 months exhibited 
increased neutralization potency (Figure 1-14B). Together, these studies indicate that the 
humoral response not only persists following SARS-CoV-2 infection, but also further adapts to 
provide enhanced protection against secondary exposure, perhaps by prolonged germinal center 
reactions mediated by antigen persistence in tissues (Figure 1-14B). This elevation in the 
frequency and potential affinity of the memory B cell response may compensate for any 
diminishment in T cell responses that occur over time.  
 
Local immune responses to SARS-CoV-2 
 Although studies of human peripheral blood have been crucial for understanding SARS-
CoV-2 infection and corresponding anti-viral responses, protective immune functions occur at 
the site of infection and thus necessitate study of tissue-localized responses. In particular, the 
generation of TRM is paramount for viral clearance upon reinfection and thus mitigating severe 
side effects 237-239. Studies of localized immune responses in SARS-CoV-2 infection are limited 
due to sampling difficulties. However, highly activated and functional TRM have be detected in 
the airway of infected patients and associated with improved disease outcomes, but this 
population is not readily detected in peripheral blood 240-242. It remains to be understood to what 
extent tissue-localized adaptive memory is maintained against SARS-CoV-2.   
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Figure 1-13. Structure of SARS-CoV-2. 
SARS-CoV-2 is a positive-sense single-stranded RNA virus with four structural proteins: Spike, 







Figure 1-14. Maintenance and evolution of circulating SARS-CoV-2 adaptive immunity. 
(A) T cell–mediated immunity consists of SARS-CoV-2–specific CD4+ and CD8+ T cells that 
produce cytokines upon stimulation and are reactive against a broad range of viral epitopes. 
Charts show relative responses to different viral epitopes (S, Memb, NCAP, AP3a) measured in 
peripheral blood of patients 1 and 6 mo after infection as reported in a study by Breton et al. 
(2021). CD4+ T cell responses specific for the S protein predominate and are maintained long-
term, while T cells specific for other viral epitopes are reduced at 6 mo after infection; CD4+ T 
cell responses are more robust than CD8+ T cell responses. (B) Humoral immunity to SARS-
CoV-2 is maintained by circulating antibodies, particularly IgG and IgA, and memory B cells. 
Memory B cells undergo somatic hypermutation and prolonged germinal center reactions after 




1.7 High-dimensional profiling of the human body 
Defining the heterogeneity of different immune cell subsets, understanding their 
functional immune responses, and dissecting their variability between and within sites, over age, 
and in disease requires advanced experimental and computational methods. Assays of increasing 
resolution have led to new insights into immune cell populations on the protein, transcriptomic, 
and genomic level, including single-cell technologies such as high-dimensional cytometry, 
adaptive immune cell receptor sequencing, and scRNA-seq that have been instrumental in 
elucidating heterogeneity of immune cells across tissues, among individuals, and over 
development (Figure 1-15). In addition, advancements in profiling of immune mediators 
(cytokines, chemokines, and growth factors) have led to important insights into functional 
responses and immune cell interactions (Figure 1-16). 
 
Cytometry 
Cytometry is one of the most tried and true methods for analyzing immune populations at 
the population and single-cell level (Figure 1-15). Flow cytometry utilizes fluorophore-
conjugated antibodies that bind to surface and intracellular proteins expressed by immune cells, 
which can then be analyzed based on the emission spectrum upon illumination with specific 
wavelengths. Previously, the number of parameters was limited by the spectral overlap of 
fluorescent markers, but with advances in instrumentation and fluorochromes, current 
technologies have the capability of analyzing up to 50 different parameters at high resolution 52, 
243, 244. Most recently, spectral flow cytometry, which captures the entire spectrum of 
fluorescence, has enabled the use of fluorochromes with closely overlapping emission spectra 
and allows for an ever increasing number of parameters 245. Flow cytometry also enables 
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isolation of populations defined based on these multiple parameters using different types of 
fluorescent-activated cells sorters.  
 An alternative to flow cytometry is mass cytometry, or Cytometry by Time-of-Fight 
(CyTOF), which replaces fluorophore labels with heavy metal tags and analyzes cells using a 
time-of-flight mass spectrometer (Figure 1-15). Eliminating the issue of spectral overlap 
encountered in flow cytometry, CyTOF allows for analysis of up to 100 parameters though is 
often limited to 40-50 parameters 144, 246-248. Studies using CyTOF technology have provided new 
insights in human CD8+ T cell activation, monocyte heterogeneity, DC development and 
interindividual variation, memory T cell maintenance in LNs, remodeling of T cell populations 
following viral infection, and compartmentalization of immune cells in fetal tissues 10, 13, 14, 144, 
249-251. Limitations of CyTOF are that a smaller, less dynamic range in expression can be 
discerned compared to flow cytometry, and the cells, once analyzed, cannot be sorted for 
isolation.  
 
Bulk and single-cell RNA sequencing 
Advances in detection of gene expression on the population and single-cell level has 
increased the depth and breadth at which we can analyze the human immune system. Whole 
transcriptome profiling by RNA sequencing (RNA-seq) generates read counts of all the 
transcripts within a populations and differential gene expression analysis can reveal signatures 
that define specific subsets 252. RNA-seq has been used to define TRM as a distinct subset in mice 
and humans 80, 143, 253, and distinct features of human B cell subsets in blood and tissues 254.  
Applying whole transcriptome profiling to single cells—scRNA-seq—enables 
identification and stratification of cell subsets based on differential gene expression and can lead 
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to de novo discovery of new cell types and cell states, as well as tissue-specific adaptations of 
cell types within and across tissues (Figure 1-15). Since the introduction of scRNA-seq in 2009 
255, new technological advances in scRNA-seq methods including plate-based approaches (such 
as pooled library amplification for transcriptome expression sequencing, or PLATE-seq) and the 
10X Genomics approach, which employs microdroplet-based systems enable rapid and efficient 
capture of high transcript numbers per cell 256-258. Recent studies using scRNA-seq approaches 
have led to identification of cell types and progenitors, developmental processes, activation 
trajectories, and functional signatures for diverse immune cell lineages 14, 17, 27, 248, 259-264.  
 
TCR and BCR sequencing 
 T and B cells exhibit an additional level of genomic complexity in their expression of 
uniquely rearranged antigen receptor genes. Each T and B cell that develops expresses a distinct 
TCR or BCR that can be identified by high-throughput sequencing of the variable portion 
containing the complementarity region 3 (CDR3) of the TCRb chain for T cells and the IGH 
gene for B cells) 265, 266 (Figure 1-15). Sequencing methods capturing beyond the CDR3 region 
also exist 267. Common methods for high-throughput antigen receptor sequencing include PCR 
amplification of genomic DNA and sequencing or reverse transcription of mRNA transcripts to 
cDNA 268, 269. Other approaches include multiomic single-cell technologies, such as 10X 
Genomics Single Cell Immune Profiling with V(D)J sequencing 118, and innovative analysis 
methods that allow researchers to extract receptor sequences from RNA sequencing data 270, 271. 
These approaches have enabled parallel analysis of TCR/BCR repertoire and transcription 
profile. While the 10X Genomics approach involves a primer-based amplification of the antigen 
receptor locus, extraction of receptor sequences from RNA sequencing data ensures that there is 
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no primer bias 272. However, in both methods, the data likely represent only a fraction of the total 
clonal diversity due to limited sampling. Sequencing TCR and BCR can identify how unique B 
and T cell clones of the adaptive immune response are expanded and maintained across the 
human body in health, as well as their role in inflammatory and autoimmune immune diseases 
and in cancer 16, 19, 22, 28, 273. 
 
Computational techniques 
 Along with the innovations in instrumentation for single-cell profiling, advancements in 
computational techniques have been crucial to analyze rapidly expanding datasets and extracting 
novel insights. Dimensionality reduction techniques have allowed for unbiased and more 
intuitive visualization of high-dimensional data. Common dimensionality reduction techniques 
include principle component analysis (PCA), t-distributed stochastic neighbor embedding (t-
SNE), and Uniform Approximation and Projection method (UMAP) (Figure 1-15) 274-276. Cluster 
analysis methods group cells based on similarity of gene expression profiles, providing structure 
to heterogeneous immune populations. Unsupervised clustering methods are particularly useful, 
because they provide an unbiased, data-driven approach to organizing unlabeled data that has led 
to discoveries of distinct immune subsets 14, 250, 277. Longitudinal analyses of human immune 
responses are less readily accomplished compared to animal models; however, trajectory 
inference analysis, such as “pseudotime” or “pseudospace”, of single-cell data is a technique that 
orders individual cells along a trajectory based on expression profiles to infer a continuum of cell 
states from a static time point 278-280. This technique has been used to understand dynamic 
immune responses, capture transition states, define gene regulatory networks, and follow 
immune cell development and differentiation (Figure 1-15) 260, 281-285. Finally, emerging 
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computational strategies allow projection of data onto existing datasets, enabling direct 
comparison of immune responses under different conditions and in health and disease (Figure 1-
15) 27.  
Emerging single-cell technologies now enable simultaneous analysis of multiple data 
sources, including genomic DNA and mRNA transcription 286, gene and protein expression using 
DNA-labeled antibodies as in cellular indexing of transcriptomes and epitopes by sequencing 
(CITE-seq) 287, 288, gene expression and TCR/BCR repertoire 16, 289, and gene expression along 
with DNA methylation 290, 291. In addition, new technologies pairing single-cell transcriptomics 
and spatial profiling – spatial transcriptomics – enable deeper understanding of the role of tissue 
topography and environment in the function and organization of the human immune system 292-
294. As single-cell profiling technologies become more advanced and data sets become larger and 
more complex, the integration of systems biology is essential for identifying key features of the 
human immune system in health and disease. 
 
Multiplex cytokine profiling  
 Immune cells communicate using cytokines and direct contact to perform defense, repair, 
and homeostatic responses. Cytokines, chemokines, and growth factors are soluble proteins 
secreted by immune cells that facilitate communication between cells to inform cell activation, 
migration, differentiation, and a host of other crucial cellular processes. As such, innovative 
technologies for measuring production of immune mediators, such as multiplex cytokine 
profiling, have been instrumental in understanding immune function. Multiplex cytokine 
profiling technologies, such as Luminex and the MesoScale Discovery (MSD) platforms allow 
for simultaneous measurement of up to 100 analytes. Luminex technology uses color-coded 
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beads internally dyed with fluorophores that correspond to a unique spectral signature. 
Antibodies specific to a desired analyte are coupled to a unique bead region, which can then be 
incubated with the sample upon which captured analytes can be detected using lasers that excite 
the internal dyes (Figure 1-16). While Luminex platforms share similarities with flow cytometry, 
MSD technology is more akin to multiplexed enzyme-linked immunosorbent assay (ELISA). 
MSD microplates coated with capture reagents for analytes capture immune mediators within a 
sample and are then measured enzyme-linked detector antibodies conjugated with SULFO-TAG 
electrochemiluminescent labels. Electricity is then applied to the plate electrodes, leading to light 
emission by electrochemiluminescent labels; light intensity is then used to quantify target 
analytes (Figure 1-16). More recently, Isoplexis has introduced a single-cell functional 
proteomics approach, where single cells are captured and barcoded within the microchambers of 
IsoCode chips. This proprietary technology enables measurement of > 30 analytes from each 
cell. Isoplexis also offers an ELISA-based CodePlex platform for measuring bulk cytokine data. 
These technologies have been used to study cytokine profiles, particularly in 
infection/vaccination and cancer/cancer therapeutics 240, 295-299.  
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Figure 1-15. Single-cell technologies for studying the human immune system. 
Diagram shows the different single-cell technologies, such as cytometry and genomic sequencing 
techniques, and computational approaches that have been instrumental to systems-wide study of 
the human immune system. Flow cytometry and mass cytometry enable characterization of 
immune cell phenotype and function through quantification of cell surface proteins, intracellular 
proteins, and cytokine production. Single-cell RNA sequencing measures differentially 
expressed genes among single cells to elucidate heterogeneity within an immune population and 
identify distinct functional modules and regulatory networks. Antigen receptor sequencing 
characterizes lymphocyte repertoires, which inform the connectivity of adaptive immunity across 
diverse tissues within an individual through assessment of clonal overlap between sites, gene 
segment usage, and clonal abundance. Computational approaches for data visualization and 
analysis (bottom row) include methods for dimensionality reduction and unsupervised clustering 
(e.g. t-SNE, UMAP), trajectory inference analysis, and data projection onto existing datasets to 
directly compare immune parameters between tissues, individuals, under different conditions, 









Figure 1-16. Multiplex cytokine profiling assays. 
(A) Luminex assays use color-coded beads internally dyed with fluorophores and coupled to 
analyte-specific capture antibodies. Biotinylated analyte-specific detection antibodies are added 
to form an antibody-analyte sandwich, after which Phycoerythrin (PE)-conjugated streptavidin is 
added and bind to biotinylated detection antibodies. Unique color of the bead determines the 
identity of the analyte, while the magnitude PE quantifies the amount of analyte. (B) MSD 
microplates are coated with analyte-specific capture antibodies. SULFO-TAG-labeled detection 
antibodies are then added to form an antibody-analyte sandwich. Electricity is then applied to the 
plate electrodes, leading to light emission by SULFO-TAG-labeled antibodies. Light intensity is 





1.8 Thesis objectives 
Humans are exposed to a multitude of acute and persistent viruses over a lifetime, 
including ubiquitous viruses like influenza A and CMV, as well as emergent viruses like SARS-
CoV-2. With each exposure, the immune system recognizes antigens derived from various 
viruses, then activates and mobilizes T cells to the primary site of infection to coordinate viral 
clearance. While most T cells undergo apoptosis after the virus is eliminated or contained, a 
small portion differentiate into memory T cells, which remain in circulation and in tissues, 
providing long-term surveillance and immunity. Mouse studies have shown that TRM, which are 
noncirculating and reside in peripheral tissues long-term, are essential in providing protection 
against secondary influenza A infection and reactivation in persistent CMV infection, and are 
associated with improved disease outcomes in SARS-CoV-2 infection. However, despite the 
profound impact of viral infections both on global health and in shaping an individual’s immune 
system throughout life, the role of tissue-localized and circulating T cells in anti-viral immunity 
is not well understood.  
The human immune response to virus is also remarkably heterogeneous, shaped by a 
multitude of factors, including the cause of the infection, tissue compartmentalization of 
response, and biological factors of the individual. Previous studies by our laboratory have shown 
that T cells are compartmentalized within tissue sites as distinct subsets of naïve and memory T 
cell subsets 26, 28. However, thus far studies on human anti-viral immunity have been largely 
confined to the sampling of peripheral blood and do not capture the full heterogeneity of tissue 
responses. Moreover, age-associated changes of the circulating immune system have been linked 
to defective immune memory, impaired T responses in primary exposure to viral infection and 
vaccinations, and alterations of the circulating T cell compartment and T cell receptor repertoire 
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diversity 300, 301. Meanwhile, studies work examining sex differences in circulating immune 
responses have shown that males and females exhibit different T cell responses, including 
distinct activation, proliferation, cytotoxicity, and regulatory activity 302-304. Thus, we need to 
examine anti-viral T cell responses in across individuals to multiple viruses and throughout the 
whole body in order to understand the factors that shape anti-viral immune responses and 
facilitate the development of more effective therapeutic strategies to promote lasting immunity 
and optimize anti-viral response. Our goals are to examine the maintenance and function of 
T cells recognizing different viruses and across diverse tissue sites, as well as to understand 
the factors that shape the adaptive anti-viral immune response. We hypothesize that 
understanding the heterogeneity of anti-viral adaptive immunity requires comprehensive 
analysis of tissues, virus, and interindividual diversity.   
 Our first objective is to investigate the factors that shape anti-viral tissue immunity 
through examination of CD8+ T cells specific for two prevalent but distinct viruses, acute 
respiratory influenza A virus and persistent systemic CMV. Comparing influenza-specific and 
CMV-specific T cells in circulation, primary and secondary lymphoid organs, and mucosal sites, 
we show that virus specificity and tissue localization are the key factors in shaping anti-viral T 
cell immune responses in the human body, with age and sex influencing T cell subset 
differentiation. Results from our first object reveal that virus specificity determines the 
frequency, tissue localization, memory subset differentiation, and clonal repertoire of virus-
specific T cells, while persistence of TRM subsets and functional capacity is highly correlated 
with the site. Age and sex influence T cell differentiation and dissemination in tissues. Our 
findings elucidate the influence of tissue, age, sex, and virus on shaping the phenotypic and 
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functional characteristics of the human anti-viral immune response, providing a multifaceted 
view on how virus-specific T cells are maintained in the human body. 
 Our second objective is to examine the maintenance of tissue-localized adaptive immune 
memory to newly emergent virus SARS-CoV-2, elucidating the coordination of cellular and 
humoral memory immune responses following encounter with a novel virus. While our first 
objective focuses on how multiple encounters with antigens derived from prevalent viruses shape 
the adaptive immune response overtime, this second objective explores the persistence of 
adaptive immune memory following initial encounter with new viral antigen. Following its 
emergence in 2019, SARS-CoV-2 has incurred a significant disease burden globally and has 
been the subject of an explosion of studies trying to understand its pathogenesis and anti-viral 
immune protection. Unfortunately, due to difficulty accessing human tissue samples, the 
majority of studies examining SARS-CoV-2 immune responses have been limited to peripheral 
blood and more rarely airway washes or single tissue biopsies. Our objective is to utilize the 
unique organ donor tissue resource established by our laboratory (see Materials and Methods) to 
understand not only the characteristics of memory B and T cells recognizing SARS-CoV-2 in 
diverse tissue sites, but also how these immune cell populations correlate to each other. Our 
results reveal virus-specific memory T and B cell memory cells persist up to 6 months after 
infection, particularly in the lung and lung associated LNs, as well as ongoing germinal centers 
in the lung-associated LN accompanied by TFH in the lung and lymphoid sites. In addition, 
significant correlations between circulating and tissue-resident memory T and B cells in all sites 
suggest tissue-wide coordination of cellular and humoral immune memory against SARS-CoV-2.   
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Chapter 2: Materials and Methods 
2.1 Acquisition and processing of human tissue samples 
Acquisition of human tissue samples 
Human tissues were obtained from deceased organ donors at the time of organ 
acquisition for clinical transplantation through an approved protocol and material transfer 
agreement with LiveOnNY, the organ procurement organization (OPO) for the New York 
metropolitan area, as previously described 20, 23-25, 28, 80, 209. Human tissues from deceased 
pediatric donors were obtained at the time or organ acquisition for clinical transplantation 
through arrangements with multiple OPOs across the US through the Human Atlas of Neonatal 
Development-Immunity (HANDEL-I) program associated with nPOD (network for Pancreatic 
Organ Donors with Diabetes)305. Donors were free of cancer and seronegative for hepatitis B, C, 
and HIV. Work done utilizing these samples does not qualify as “human subsets” research, as 
confirmed by the Columbia University IRB, as tissues samples were obtained from brain-dead 
(deceased) individuals. Tissues collected for research include: blood, BM, spleen, lung, LNs 
(lung-associated, mesenteric, iliac, inguinal), and jejunum.  
 
Isolation of single-cell suspensions from human tissue samples 
Tissue samples were maintained in cold saline or media and transported to the laboratory 
within 2-4 hours of organ procurement for adult organs, and shipped to the laboratory on ice 
within 24 hours of procurement for pediatric donors. Tissue processing protocols were adapted 
from protocols previously described 20, 23-25, 79, 144, with some recent optimizations 306-311, and 
processed in a timely manner, resulting in high yields of live leukocytes.  
69 
 
For blood and BM, samples were first diluted with 4 equivalent volumes of DPBS-FBS-
EDTA solution: Dulbecco’s Phosphate Buffered Saline (DPBS; Thermo Fisher Scientific) 
containing 5% fetal bovine serum (FBS; Thermo Fisher Scientific) and 2mM EDTA (Thermo 
Fisher Scientific). Then, mononuclear cells were isolated by density centrifugation using Ficoll-
Paque PLUS (GE Healthcare Life Sciences). The settings for lymphocyte separation 
centrifugation were 1200g at 20°C for 20 minutes with acceleration set at 4 and breaks set at 0. 
Cell suspensions were then spun down at 400g at 4°C for 10 minutes to wash and then 120g at 
°C for 10 minutes to remove platelets. If residual red blood cell contamination was present, cells 
were then incubated in 5mL of ACK lysis buffer (Corning Cellgro) for 5 minutes at room 
temperature, followed by a wash and resuspension in cell culture media: IMDM (Thermo Fisher 
Scientific) or RPMI (Thermo Fisher Scientific) containing 10% FBS and 1% 
Penicillin/Streptomycin/Glutamine (PSQ; Thermo Fisher Scientific).  
Spleen was processed using mechanical dissociation, followed by pushing through 
100µm filters (Thermo Fisher Scientific), and Ficoll-Paque PLUS density centrifugation, as 
above. Single-cell suspensions were then washed, platelets were removed, and if necessary, 
residual red blood cells were lysed and removed, as above.  
Lymph nodes and mucosal tissues were minced and incubated at 37°C in enzymatic 
digestion media, containing either RPMI or IMDM, 10% FBS, 1mg/ml Collagenase D (Sigma-
Aldrich) and 0.1mg/ml DNaseI (Thermo Fisher Scientific) for 30-45 minutes at 37ºC on a 
shaker, followed by addition of EDTA 0.5M pH 8.0 (Thermo Fisher Scientific), filtration, 
density centrifugation, and platelet removal. A summary of tissue processing workflow is 
provided in Figure 2-1.  
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2.2 Peptide megapool (MP) design and preparation 
Peptide MPs used in this research were synthesized and provided by Dr. Alessandro Sette 
and laboratory members at the La Jolla Institute for Immunology. Peptides were synthetized as 
crude material by A&A ltd, San Diego, resuspended in dimethyl sulfoxide (DMSO), and pooled 
followed by sequentially lyophilization, as previously described 222, 229, 312.  
For CD8 Flu, the MP was developed as previously described 313, 314. Epitopes were 
retrieved by querying the IEDB (www.iedb.org) on July 12, 2019 315. The epitopes were 
extracted using the following query; Organism: Influenza virus (ID:1000204), positive assays 
only, no B cell assays, no MHC ligand assays, MHC restriction type: MHC class I, host: Homo 
sapiens. The resulting epitopes were filtered for size (8-11 amino acids) and discovered using 
one of the following assays: cytotoxicity, ELISPOT, ICS, and multimer/tetramer assay 
platforms, and response frequency scores >0. In total, 170 were selected for synthesis.  
In the case of CD8 CMV, the MP was developed based on epitopes of 8-11 residues in 
length available in the IEDB (www.iedb.org) on Jan 14, 2019 using the following query; 
Organism: human herpesvirus 5 (ID:10359), positive assays only, no B cell assays, no MHC 
ligand assays, MHC restriction type: MHC class I, host: Homo sapiens. The resultant data set 
was further filtered to include only epitopes characterized using cytotoxicity, ELISPOT, ICS, 
and multimer/tetramer assay platforms, and response frequency scores >0. In total, 126 epitopes 
were selected for synthesis.  
For SARS-CoV-2 MPs, MP_S consisted of 253 15-mer peptides overlapping by 10 
residues and covering the entire S protein. MP_CD4_R consisted of 221 predicted HLA class II 
CD4+ T cell epitopes covering all proteins apart from S protein. For SARS-CoV-2 CD8 epitopes, 
MPs were synthesized based on epitope predictions for 12 most common HLA class I A and B 
72 
 
alleles; these resulted in 628 predicted CD8+ T cell epitopes, which were separated into 





2.3 In vitro T cell stimulations 
Mononuclear cells were thawed, and dead cells were removed using the EasySep Dead 
Cell Removal (Annexin V) Kit (STEMCELL Technologies). Cells were then plated in 96-well 
U-bottom plates in RPMI medium containing 10% heat-inactivated human AB serum (Gemini) 
and 1% PSQ at a concentration of 106 cells/well and left overnight (5% CO2, 37°C). Cells were 
stimulated by the addition of individual virus-specific MPs (1µg/mL) for either 6 or 24 hours. 
Immunocult Human CD3/CD28 T cell activator (STEMCELL Technologies) was used as a 
positive control, and equimolar amount of DMSO was used as negative control. For measuring 
upregulation of activation-induced markers (AIMs, see section 2.10), prior to the addition of 
peptide MPs, cells were blocked for 15 minutes with 0.5µg/mL of anti-CD40 monoclonal 
antibody (Miltenyi Biotec), as previously described (62). For measuring cytokine production via 
intracellular staining and flow cytometry, 4 hours prior to end of stimulation, 0.7µL/mL of 
GolgiStop (Monensin; BD Biosciences) and 1µL/mL of GolgiPlug (Brefeldin A; BD 
Biosciences) were added to each cell culture well. After stimulation, (1) cells were stained for 
AIMs, (2) cells were analyzed for cytokine production via intracellular staining and flow 
cytometry, (3) cells were prepared for single-cell RNA sequencing via pooled library 
amplification for transcriptome expression sequencing (PLATE-seq), or (4) supernatant was 





2.4 Flow cytometry and cell sorting 
Flow cytometry staining and data acquisition 
For flow cytometry analysis of virus-specific T cells, cells were stained in 96-well U-
bottom plates protected from light using fluorochrome-conjugated antibodies and multimer 
reagents listed in Table 2-1 and Table 2-2. Single cell suspensions were washed with FACS-
buffer (PBS containing 2% FBS). For samples stained with multimer reagent, cells were 
resuspended with multimer reagent staining cocktail (10uL of each multimer reagent, plus 
addition of PBS to achieve total staining volume of 60uL per sample) for 10 minutes at room 
temperature (RT), followed by washing. For all flow cytometry samples, cells were then 
incubated in Human TruStain FcX (BioLegend), followed by surface staining with 
fluorochrome-conjugated antibodies in FACS-buffer for 20 minutes at RT, and subsequently 
fixed in fixation buffer for 25 minutes at RT (Tonbo). For intracellular staining, surface stained 
cells were fixed for 25 minutes at RT in fixation buffer (Tonbo), followed by staining with 
fluorochrome-conjugated antibodies for 30 minutes at RT in permeabilization buffer (Tonbo). 
Control samples included unstained, single fluorochrome-stained compensation beads Ultra 
Comp eBeads (eBioscience) and fluorescence minus one (FMO) controls.  
Flow cytometry analysis of SARS-CoV-2-specific B cells were performed by our 
collaborator Dr. Shane Crotty and lab members. For flow cytometry analysis of SARS-CoV-2-
specific B cells, biotinylated protein antigens multimerized on fluorescently-labeled streptavidin 
were used as probes to detect antigen-specific B cells (see Table 2-1 for antibodies used in the B 
cell flow cytometry panel). Avi-tagged full-length SARS-CoV-2 S (2P-stabilized, double 
streptavidin-tagged) and RBD proteins were generated by our collaborator Dr. Shane Crotty and 
lab members in-house. Biotinylation was performed using biotin protein ligase standard reaction 
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kit (Avidity) following the manufacturers protocol and dialyzed against PBS. Biotinylated S was 
mixed with streptavidin BV421 (BioLegend) and streptavidin BUV737 (BD Biosciences) at 20:1 
ratio (~6:1 molar ratio). Biotinylated RBD was mixed with streptavidin PE-Cy7 (BioLegend) 
and streptavidin BUV661 (BD Biosciences) at 2.2:1 ratio (~4:1 molar ratio). Streptavidin PE-
Cy5.5 (Thermo Fisher Scientific) was used as a decoy probe for non-specific streptavidin-
binding B cells. The probes were then mixed in Brilliant Stain Buffer (BD Biosciences) 
containing 5µM free d-biotin (Avidity). Cells (~107) were prepared in U-bottom 96-well plates 
and stained with 50µL antigen cocktail containing 400ng S (200ng per probe), 100ng RBD (50ng 
per probe), and 20ng streptavidin PE-Cy5.5 at 4°C for one hour followed by staining for surface 
markers in Brilliant Stain Buffer at 4°C for 30 minutes. Dead cells were stained using 
LIVE/DEAD Fixable Blue Stain Kit (Thermo Fisher Scientific) in PBS at 4°C for 30 minutes. 
Cells were then fixed and permeabilized using eBioscience Intracellular Fixation & 
Permeabilization Buffer Set (Thermo Fisher Scientific) before staining with antibodies against 
transcription factors in eBioscience Permeabilization Buffer (Thermo Fisher Scientific). In each 
experiment, PBMCs from a known COVID-19 convalescent individual and an unexposed subject 
were included to ensure consistent sensitivity and specificity of the assay.   
Flow cytometry data were acquired on BD LSRII (BD Biosciences) or 5-laser Cytek 
Aurora flow cytometer (Cytek Bio) and analyzed using FlowJo (Tree Star), FCS Express (De 
Novo Software), Prism (GraphPad Software), and custom Python scripts.  
 
Fluorescence-activated cell sorting (FACS) 
For isolating of bulk CD3+ T cells and of CD4+ and CD8+ T cell subsets by fluorescence-
activated cell sorting (FACS) as related to Chapter 3, single cell suspensions were surface 
76 
 
stained with fluorochrome-conjugated antibodies in FACS-buffer for 20 minutes at RT. For 
isolating of multimer+ CD8+ T cells as related to Chapter 4, single cell suspensions were first 
enriched for CD8+ T cells using EasySep Human CD8+ T Cell Enrichment Kit (STEMCELL 
Technologies). Enriched cells were then stained with specific multimers as above, and 





Table 2-1. Antibodies used for flow cytometric analysis. 
Reagent Source Clone Panel 
Streptavidin BUV661 BD Biosciences  Chapter 4 B cell panel 
Streptavidin BUV737 BD Biosciences  Chapter 4 B cell panel 
Streptavidin BV421 BioLegend  Chapter 4 B cell panel 
Streptavidin PE-Cy7 BioLegend  Chapter 4 B cell panel 
Streptavidin PE-Cy5.5 Thermo Fisher Scientific  Chapter 4 B cell panel 
Anti-Bcl6 Alexa Fluor 647 BD Biosciences K112-91 Chapter 4 B cell panel 
Anti-IRF4 PerCPCy5.5 BioLegend IRF4.3E4 Chapter 4 B cell panel 
Anti-Ki67 BV711 BioLegend Ki-67 Chapter 4 B cell panel 
Anti-Tbet BV605 BioLegend 4B10 Chapter 4 B cell panel 
Anti-Human CCR6 BV785 BioLegend G034E3 Chapter 4 B cell panel 
Anti-Human CCR7 BV421 BioLegend G043H7 Chapter 4 T cell panel 
Anti-Human CCR7 APC-Cy7 BioLegend G043H7  Chapter 3 
Anti-Human CD103 BUV395 BD Biosciences Ber-act8 Chapter 3,  Chapter 4 T cell panel 
Anti-Human CD103 BV421 BD Biosciences Ber-act8 Chapter 3 
Anti-Human CD107a BUV395 BD Biosciences H4A3 Chapter 3 
Anti-Human CD11c PE/Cyanine5 BioLegend 3.9 Chapter 4 B cell panel 
Anti-Human CD134 (OX40/TNFRSF4) 
Alexa Fluor 488 R&D Systems 
Clone # 
977960 Chapter 4 T cell panel 
Anti-Human CD137 (4-1BB) PE BioLegend 4B4-1 Chapter 4 T cell panel 
Anti-Human CD138 BV480 BD Biosciences MI15 Chapter 4 B cell panel 
Anti-Human CD14 PerCP BioLegend 63D3 Chapter 4 B cell panel 
Anti-Human CD14 PerCP-Cy5.5 BD Biosciences M5E2 Chapter 3,  Chapter 4 T cell panel 
Anti-Human CD154 (CD40L) APC BioLegend 24-31 Chapter 4 T cell panel 
Anti-Human CD16 PerCP BioLegend 3G8 Chapter 4 B cell panel 
Anti-Human CD19 BUV395 BD Biosciences SJ25C1 Chapter 4 B cell panel 
Anti-Human CD19 PerCP-Cy5.5 Tonbo HIB19 Chapter 3,  Chapter 4 T cell panel 
Anti-Human CD20 BV510 BD Biosciences 2H7 Chapter 4 B cell panel 
Anti-Human CD21 Alexa Fluor 700 BioLegend Bu32 Chapter 4 B cell panel 
Anti-Human CD25 BV605 BioLegend BC96 Chapter 3,  Chapter 4 T cell panel 
Anti-Human CD27 BB515 BD Biosciences M-T271 Chapter 4 B cell panel 
Anti-Human CD274 (B7-H1, PD-L1) 
PE/Dazzle 594 BioLegend 29E.2A3 Chapter 4 T cell panel 
Anti-Human CD279 (PD-1) BUV661 BD Biosciences EH12.1 Chapter 4 T cell panel 
Anti-Human CD3 BUV496 BD Biosciences UCHT1 Chapter 3,  Chapter 4 T cell panel 
Anti-Human CD3 BV650 BioLegend OKT3 Chapter 3 
Anti-Human CD3 PerCP BioLegend SK7 Chapter 4 B cell panel 
Anti-Human CD307α (FCRL1) BUV615 BD Biosciences E3 Chapter 4 B cell panel 
Anti-Human CD38 APC/Fire 810 BioLegend HIT2 Chapter 4 B cell panel 
Anti-Human CD38 BUV737 BioLegend HB7 Chapter 4 T cell panel 
Anti-Human CD4 BUV737 BD Biosciences SK3 Chapter 3,  Chapter 4 T cell panel 
Anti-Human CD4 BV650 BD Biosciences SK3 Chapter 4 T cell panel 
Anti-Human CD4 PE-Cy7 Tonbo RPA-T4 Chapter 3 
Anti-Human CD45 Alexa Fluor 700 BioLegend HI30 Chapter 3,  Chapter 4 T cell panel 
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Anti-Human CD45 BV711 BioLegend HI30 Chapter 3 
Anti-Human CD45RA Alexa Fluor 700 BioLegend HI100 Chapter 3 
Anti-Human CD45RA BV570 BioLegend HI100 Chapter 4 T cell panel 
Anti-Human CD45RA BV605 BioLegend HI100 Chapter 3 
Anti-Human CD56 PE-Cy5 BioLegend 5.1H11 Chapter 3 
Anti-Human CD56 PE-Cy7 BioLegend 5.1H11 Chapter 4 T cell panel 
Anti-Human CD56 PerCP BioLegend HCD56 Chapter 4 B cell panel 
Anti-Human CD69 BV650 BioLegend FN50 Chapter 4 B cell panel 
Anti-Human CD69 BV711 BioLegend FN50 Chapter 3,  Chapter 4 T cell panel 
Anti-Human CD71 PE-Dazzle 594 BioLegend CY1G4 Chapter 4 B cell panel 
Anti-Human CD8 BUV496 BD Biosciences RPA-T8; Chapter 4 T cell panel 
Anti-Human CD8 BV510 BioLegend SK1 Chapter 3,  Chapter 4 T cell panel 
Anti-Human CXCR3 BUV805 BD Biosciences 1C6 Chapter 4 B cell panel 
Anti-Human CXCR5 BV750 BD Biosciences RF8B2 Chapter 4 T cell panel 
Anti-Human GzmB Alexa Fluor 700 BD Biosciences GB11 Chapter 3 
Anti-Human HLA-DR PerCP-eFluor 710 Thermo Fisher Scientific L243 Chapter 4 T cell panel 
Anti-Human IFN-γ BB700 BD Biosciences B27 Chapter 3 
Anti-Human IgA Vio Bright FITC Miltenyi Biotec IS11-8E10 Chapter 4 B cell panel 
Anti-Human IgD PacificBlue BD Biosciences IA6-2 Chapter 4 B cell panel 
Anti-Human IgG PE BioLegend M1310G05 Chapter 4 B cell panel 
Anti-Human IgM BV570 BioLegend MHM-88 Chapter 4 B cell panel 
Anti-Human Perforin BV510 BioLegend dG9 Chapter 3 
Anti-Human TNF-α PE-Cy7 BD Biosciences MAb11 Chapter 3 
Fixable Viability Dye eFluor 780 Thermo Fisher Scientific  
Chapter 3,  
Chapter 4 T cell panel 
LIVE/DEAD Fixable Blue Dead Cell 
Stain Kit Thermo Fisher Scientific  
Chapter 3,  




Table 2-2. Multimer reagents used for research. 
Multimer Source Fluorochrome 
HLA-A*0101[YSEHPTFTSQY]-CMV pp65 ProImmune APC 
HLA-A*0101[VTEHDTLLY]-CMV pp50 ProImmune APC 
HLA-A*0201[NLVPMVATV]-CMV pp65 Immudex APC 
HLA-A*0201[VLEETSVML]-CMV IE-1 Immudex APC 
HLA-A*2402[QYDPVAALF]-CMV pp65 ProImmune APC 
HLA-A*2402[VYALPLKML]-CMV pp65 ProImmune APC 
HLA-B*0702[TPRVTGGGAM]-CMV pp65 ProImmune APC 
HLA-B*0702[RPHERNGFTVL]-CMV pp65 ProImmune APC 
HLA-A*0101[VSDGGPNLY]-Flu PB1 ProImmune APC 
HLA-A*0101[CTELKLSDY]-Flu NP Immudex APC 
HLA-A*0101[CTELKLSDY]-Flu NP Immudex PE 
HLA-A*0201[GILGFVFTL]-Flu MP Immudex APC 
HLA-A*0201[GILGFVFTL]-Flu MP Immudex PE 
HLA-B*0702[SPIVPSFDM]-Flu NP Immudex APC 
HLA-B*0702[SPIVPSFDM]-Flu NP Immudex PE 
HLA-B*0702[QPEWFRNVL]-Flu PB1 Immudex APC 
HLA-B*0702[QPEWFRNVL]-Flu PB1 Immudex PE 
HLA-A*0201[ALIAPVHAV]-negative control Immudex APC 




Table 2-3. Antibodies used for FACS. 
Reagent Source Clone Panel 
Anti-Human CD14 PerCP-Cy5.5 BD Biosciences M5E2 Chapter 3 Multimer
+  
Chapter 3 PLATE-seq 
Anti-Human CD19 PerCP-Cy5.5 Tonbo HIB19 Chapter 3 Multimer
+  
Chapter 3 PLATE-seq 
Anti-Human CD3 APC BioLegend SK7 Chapter 3 T cells 
Anti-Human CD3 BV650 BioLegend OKT3 Chapter 3 Multimer
+  
Chapter 3 PLATE-seq 
Anti-Human CD4 PE-Cy7 Tonbo RPA-T4 
Chapter 3 T cells 
Chapter 3 Multimer+  
Chapter 3 PLATE-seq 
Anti-Human CD45 Alexa Fluor 700 BioLegend HI30 
Chapter 3 T cells 
Chapter 3 Multimer 
Anti-Human CD56 PE-Cy5 BioLegend 5.1H11 
Chapter 3 Multimer+  
Chapter 3 PLATE-seq 
Anti-Human CD69 BV711 BioLegend FN50 Chapter 3 PLATE-seq 
Anti-Human CD8 PE BioLegend SK1 Chapter 3 T cells 
Anti-Human CD8 BV510 BioLegend SK1 Chapter 3 Multimer
+  
Chapter 3 PLATE-seq 
Fixable Viability Dye eFluor 780 Thermo Fisher Scientific  
Chapter 3 T cells 
Chapter 3 Multimer 





2.5 T cell receptor (TCR) repertoire profiling 
DNA extraction, TCR Vb  gene amplification, library preparation, and sequencing 
 T cells for TCR sequencing were sorted directly into cell lysis solution (Qiagen). DNA 
isolation and TCR sequencing was performed by the Human Immunology Core at the University 
of Pennsylvania in collaboration with Dr. Eline T. Luning Prak. DNA was isolated from cell 
lysate using the Gentra Puregene Kit (Qiagen). The quantity of DNA isolated and sequenced per 
sample is listed in Table 2-5. Targeted PCR was used for amplification of TCR Vb sequences 
from genomic DNA, using a cocktail of forward primers specific for framework region 2 (FR2) 
sequences of 23 TRBV subgroups (gene families), and 13 TRBJ region reverse primers adapted 
from the BIOMED2 primer series. Amplicons were purified using the Agencourt AMPure XP 
beads system (Beckman Coulter). To generate the sequencing libraries, second-round PCRs were 
carried out using NexteraXT Index Primers S5XX and N7XX. Libraries were sequenced using 
an Illumina MiSeq in the Human Immunology Core Facility. 2x300 bp paired end kits were used 
for all experiments (Illumina MiSeq Reagent Kit v3, 600 cycle, Illumina).  
 
TCR read counting and clone mapping 
 Raw reads were first processed using pRESTO and filtered as previously described 22, 31, 
316. Briefly, sequences were trimmed of poor-quality bases, paired reads were aligned into full 
length contiguous sequences, short sequences were filtered out, bases with low quality scores 
were replaced with Ns, and any sequence containing more than 10 such bases was removed from 
further analysis. Filtered sequences were further processed by MiXCR v3.0.7 271 and VDJtools 
v1.2.1 317-319 for clone collapsing using default settings. Clones with only one copy sequences 




TCR diversity, clonality, TRBV usage, clonal overlap, and cosine similarity 
 Clonal abundance plots were generated using the clonal.proportion and 
vis.top.proportions functions in the tcR package in R 320. Shannon entropy is a measure of 
immune diversity, with values ranging from 0 to 1, where 0 indicates no diversity and 1 indicates 
the most diversity. To calculate Shannon entropy with a given clone denoted x and frequency 
denoted p(x), "ℎ$%%&%'%()&*+(-) = −∑ *(2)3∈5 log9*(2). Clonality is a measure of clonal 
expansion, with values ranging from 0 to 1, where 0 indicates least clonally expanded and 1 
indicates most clonally expanded. To calculate clonality, given a clone denoted x, frequency 






For analysis of TRBV gene usage, heatmap visualization was generated using 
CalcSegmentUsage function of VDJtools 317. Principal component analysis was visualized using 
the factoextra package in R 321. For clonal overlap analysis, heatmap visualizations were 
generated using TrackClonotypes function of VDJtools 317. Cosine similarity analysis and 





2.6 Single-cell transcriptome profiling of antigen-responsive CD8+ T cells 
Single-cell transcriptome profiling was performed on antigen-responsive CD8+ T cells, 
using PLATE-seq 257, 322. To isolate virus-responding T cells for PLATE-seq, cells cultured with 
peptide MP, as described above, for 24 hours were first stained using the IFN-g Secretion Assay 
– Detection Kit, human (Miltenyi Biotec), which allows isolation of intact IFN-g-secreting cells 
using an IFN-g catch reagent that attaches to CD45 on the surface of leukocytes and subsequent 
labeling of caught IFN-g with a fluorochrome-conjugated detection antibody. Then, cells were 
stained with fluorochrome-conjugated antibodies listed in Table 4-1. Single T cells stained for 
CD69 and IFN-g were sorted using BD Influx Cell Sorter directly into 96-well plates containing 
7.5µl of lysis buffer [0.2% Triton X-100 (Sigma), SUPERaseIN (1 U/µl) (Thermo Fisher 
Scientific), 2 mM deoxyribonucleotides (dNTPs) (Thermo Fisher Scientific), and 2 µM reverse 
transcriptase (RT) primer (Integrated DNA Technologies)]. Library preparation, RNA 
sequencing was done by the J.P. Sulzberger Columbia Genome Center, as described in detail 
previously 322.    
For analysis of PLATE-seq data, for each 96-well plate, empty wells were removed, 
leaving 981 cells. Several filtering steps were performed for quality control. Non-coding genes 
and features were removed from the dataset. Cells with less than 200 genes or cells with a 
mitochondrial percentage greater than 10% were removed. Three outlier cells were removed 
based on a principal component analysis (PCA) plot, leaving 793 cells in the final dataset. 
Further data processing was performed using the R package Seurat, designed for single-cell 
RNA-sequencing analysis 323. 
The counts data was log normalized and scaled according to Seurat’s methods. Highly 
variable features were identified, of which the top 2,000 were plotted and the top ten genes 
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labeled. Dimensionality reduction was performed using the Python implementation Uniform 
Manifold Approximation and Projection (UMAP), based on these selected 2,000 features and the 
first 15 components of PCA. A KNN graph based on the Euclidean distance in PCA space was 
constructed using the FindNeighbors() Seurat function, which then identified five clusters via the 
Louvain algorithm with a resolution of 0.5. Positive cluster markers were found using 
differential expression analysis, with a threshold requiring at least 25% of the cluster’s 
population to express the marker gene. A heatmap was constructed to show the expression levels 
of the top ten markers for each cluster ranked by FDR value. 
Differential expression analyses were performed to identify markers genes that differed 
between Flu and CMV peptide-stimulated CD8+ T cells for each tissue type. Significant markers 
with FDR value < 0.1 were identified in the BM Flu versus CMV analysis, as well as one gene in 
the spleen Flu versus CMV analysis. 
Additional differential expression analyses were performed to compare markers between 
specific tissues, irrespective of virus stimulation. Significant markers with FDR value < 0.1 were 
identified from spleen versus lung, BM, and LLN CD8+ T cell populations. Log fold change of 
expression was plotted with pairwise comparisons at each axis, highlighting significant genes in 




2.7 Multiplex cytokine secretion assay 
Quantification of 50 total human cytokines, chemokines, and growth factors was 
performed on culture supernatant from in vitro T cell stimulation experiments (described above) 
by Eve Technologies Corp. (Calgary, Alberta). Luminex xMAP technology was used for 
multiplexed quantification of 2 human immune mediators in one array (Perforin, Granzyme B) 
and 48 human cytokines, chemokines, and growth factors in a separate array (sCD40L, EGF, 
Eotaxin, FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GROα, IFNα2, IFNγ, IL-1α, IL-1β, 
IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-
15, IL-17A, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10, MCP-1, MCP-3, M-CSF, MDC 
(CCL22), MIG, MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, TGFα, TNFα, TNFβ, 
VEGF-A). The multiplexing analysis was performed using the Luminex 200 system with assay 
kits sourced by Millipore MILLIPEX (MilliporeSigma, Burlington, Massachusetts, USA) 
according to the manufacturer’s protocol.  
Observed concentrations were calculated with the standard curve based on the 
fluorescence intensity of the bead population for a specific analyte. For analysis and visualization 
of cytokine/chemokine production by antigen-responding cells in multiple tissues sites within 
each individual donor, observed concentrations for each analyte were first subtracted from 
DMSO negative control then scaled across samples for each individual donor on a maximum 
absolute scale, with values ranging from -1 to 1 across all analytes, using the MaxAbsScaler 
features of sklearn.preprocessing function of the Python scikit-learn library 324. Heatmap 
visualizations were generated using the Python data visualization library seaborn 325. For 
analysis comparing the production of analytes between cells stimulated with MPs of different 
virus specificities (Flu vs. CMV) observed concentrations were normalized by log (x+1) 
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followed by statistical analysis by paired t-test between Flu and CMV for each analyte in each 
tissue site. For analysis comparing the production of analytes across donors and tissue sites, 
either absolute observed concentrations or DMSO-background-subtracted values were used, 
followed by statistical analysis using one-way ANOVA, corrected for multiple comparisons by 




2.8 SARS-CoV-2 serology testing 
Blood from deceased organ donors (D495, D498, HDL113) was collected and serum 
obtained following centrifugation using serum separating clot activator tubes (Thermo Fisher 
Scientific). SARS-CoV-2 serology testing for N protein was then performed by the Center for 
Advanced Laboratory Medicine (CALM) at Columbia University Irving Medical Center to 
determine previous exposure to SARS-CoV-2 for inclusion in the study. 
  SARS-CoV-2 ELISA titers were determined as previously described by our collaborator 
Dr. Shane Crotty and his lab members 229. Briefly, Corning 96-well half-area plates (Thermo 
Fisher Scientific) were coated with 1µg/mL SARS-CoV-2 S protein, RBD protein, or N protein 
(SinoBiological) overnight at 4°C. The next day, plates were blocked with 3% milk (Skim Milk 
Powder; Thermo Fisher Scientific) in PBS containing 0.05% Tween 20 (Thermo Fisher 
Scientific) for 2 hours at RT. Heat-inactivated serum (30 minutes at 56 °C) was then added to the 
plates and incubated for 1.5 hours at RT. Plates were washed 5 times with 0.05% PBS/Tween 20. 
Secondary antibodies were diluted in 1% milk containing 0.05% Tween 20 in PBS. IgG titers 
were determined using anti-human IgG peroxidase antibody (Hybridoma Reagent Laboratory) at 
1:1000 dilution. Endpoint titers were plotted for each sample using background subtracted data. 




2.9 Pseudovirus (PSV) Neutralization Assay 
The PSV neutralization assays were performed as previously described by our 
collaborator Dr. Shane Crotty and his lab members 229. Briefly, 2.5x104 Vero cells (ATCC) were 
seeded in clear flat-bottom 96-well plates (Thermo Fisher Scientific) to produce a monolayer at 
the time of infection. Recombinant SARS-CoV-2-S-D614G pseudotyped VSV-ΔG-GFP were 
generated by transfecting HEK293T cells (ATCC) with plasmid phCMV3-SARS-CoV2-Spike 
and then infected with VSV-ΔG-GFP. Pre-titrated rVSV-SARS-CoV-2-S-D614G was incubated 
with serially diluted human heat-inactivated serum at 37°C for 1-1.5 hours before addition to 
confluent Vero cell monolayers. Cells were incubated for 16 hours at 37°C in 5% CO2 then fixed 
in 4% paraformaldehyde in PBS pH 7.4 (Santa Cruz) with 10µg/ml Hoechst (Thermo Fisher 
Scientific) and imaged using a CellInsight CX5 imager to quantify the total number of cells and 
infected GFP-expressing cells to determine the percentage of infection. Neutralization titers or 
inhibition dose 50 (ID50) were calculated using the One-Site Fit Log IC50 model in Prism 8.0 
(GraphPad). As internal quality control to define the inter-assay variation, three samples were 
included across the PSV neutralization assays. Samples that did not reach 50% inhibition at the 




2.10 AIM assays for identifying antigen-specific T cells 
AIM+ antigen-specific CD4+ T cells were identified as positive following Boolean OR 
gating of the CD40L+OX40+, 4-1BB+OX40+, 4-1BB+CD40L+ subsets (see Figure 5-2 for gating 
strategy). The resultant gate was used to quantify AIM+ CD4+ T cell frequency. AIM+ antigen-
specific CD8+ T cells were identified as 4-1BB+CD25+. Antigen-specific CD4+ and CD8+ T cells 
were measured as DMSO-background-subtracted data. For quantification of the frequency of 
total SARS-CoV-2-specific CD4+ T cells, a weighted average was taken for percentage of AIM+ 
CD4+ T cells identified for samples stimulated with MP_S or MP_CD4_R MPs. For 
quantification of the frequency of total SARS-CoV-2-specific CD8+ T cells, a weighted average 
was taken for percentage of AIM+ CD8+ T cells identified for samples stimulated with MP_S, 





2.11 Statistical Analysis 
Descriptive statistics of compiled flow cytometry data and statistical testing were 
performed using Prism (GraphPad). Graphs were generated using Prism (GraphPad), Python 
matplotlib and seaborn libraries 325, 326, and RStudio corrplot package 327. Differences in means 
between two sample groups were compared using two-tailed t-tests or nonparametric test of null 
hypothesis Mann-Whitney U test, as indicated in the text or figure legends. For comparing paired 
samples within an individual, we used paired two-tailed t-tests. Pearson correlations were used to 
correlate age and T cell subset frequencies (Chapter 3) or to evaluate immune memory 
relationships (Chapter 4). Multiple group comparisons were done using one-way ANOVA, 
corrected for multiple comparisons by false discovery rate (FDR) using two-stage linear step-up 
procedure of Benjamini, Krieger, and Yekutieli when comparing seropositive and seronegative 
donors. For comparing immune mediator profiles across tissue sites, statistical analyses were 
performed via one-way ANOVA, corrected for multiple comparisons by Tukey’s multiple 
comparison test. P-values below 0.05 were considered as statistically significant. For all figures, 
**** denotes p-value £ 0.0001, *** denotes p-value £ 0.001, ** denotes p-value £ 0.01, and * 
denotes p-value £ 0.05. 
 Correlograms in Chapter 4 were analyzed and plotted using the Pearson product moment 
correlation coefficient (r) between all parameter pairs from blood, lung, and LLN lymphocyte 
populations. Correlograms were created with the corrplot package (v0.88) 327 running under R 
(v4.0.2) in RStudio (1.4.1103). Visual clustering of parameters was performed using the ‘hclust’ 
option of corrMatOrder. Two-sided p-values were calculated using corr.test (stats v4.0.2) and 




Chapter 3: Heterogeneity of human anti-viral immunity shaped by 
virus, tissue, age, and sex 
ABSTRACT: 
 The persistence of anti-viral immunity throughout the human body is essential for 
protection, and exhibits profound heterogeneity across individuals. Here, we elucidate the factors 
that shape the maintenance and function of anti-viral T cell immunity by comprehensive 
profiling of virus-specific T cells across blood, lymphoid organs, and mucosal tissues of organ 
donors. We used flow cytometry, T cell receptor analysis, single-cell transcriptomics, and 
cytokine analysis to profile virus-specific CD8+ T cells recognizing ubiquitous pathogens 
influenza and cytomegalovirus. Our results reveal that virus specificity determines the overall 
magnitude, tissue distribution, differentiation, and clonal repertoire of virus-specific T cells. Age 
and sex influence T cell differentiation and dissemination in tissues, while T cell tissue residence 
and functionality is highly correlated with the site. Together, our results demonstrate how the 
covariates of virus, tissue, age, and sex impact the anti-viral immune response, important for 
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The human immune response to virus infection is remarkably heterogeneous. As starkly 
revealed in the global COVID-19 pandemic where over 170 million people became infected with 
the novel respiratory virus, SARS-CoV-2, some people experienced mild or no symptoms, while 
others succumbed to severe disease. There is a well-established association of COVID-19 
severity with age and sex; children are largely spared from disease, older adults are more 
vulnerable with higher mortality, and women fare better than men 328. The factors which drive 
the magnitude, quality, and protective efficacy of the human immune response to this and other 
viruses remain unknown. Moreover, the age- and sex-related influences on anti-viral immunity 
are incompletely understood and important for promoting protective immunity to current and 
future pathogens.   
T lymphocytes are essential for anti-viral immunity, and tissue localization is critical for 
T cell function and maintenance. During a virus infection, dendritic cells at the tissue site of 
infection migrate to the tissue-associated lymph node (LN) where they present viral antigens to 
activate naïve, virus-specific T cells to proliferate and differentiate to tissue-homing effector T 
cells for coordinating viral clearance through multiple mechanisms. After resolution of infection, 
expanded populations of virus-specific T cells die by contraction or persist as memory subsets 
including central-memory (TCM) and effector-memory (TEM) cells, which migrate through 
lymphoid and non-lymphoid/peripheral tissues, respectively, or become terminal effector cells 
(TEMRA) 81, 124, 127. Memory T cells can also persist as non-circulating, tissue-resident subsets 
(TRM cells) in multiple non-lymphoid and lymphoid sites; TRM are distinguished from circulating 
memory T cells based on their specific retention in tissues, expression of canonical markers 
CD69 and CD103, and a distinct transcriptional profile (for reviews, see 253, 329, 330. Importantly, 
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both CD4+ and CD8+ TRM can mediate optimal protective immunity to viruses in mice 331, 
including influenza and SARS-CoV in the lung 181, 332-334, and LCMV in mucosal sites 335. These 
studies demonstrate the importance of tissue-localized T cells in maintaining and directing anti-
viral protective immunity.  
Much of our knowledge of human anti-viral immunity, including innate responses, 
cytokines, antibodies, and T cells is limited to blood (for a review, see 336). However, blood 
contains a small fraction of the total immune cells throughout the body and lacks tissue-resident 
immune cells 337-339. The generation of memory T cell responses to infection and vaccination can 
be followed in peripheral blood 231, 340-343, while studies of infection or vaccination sites have 
revealed distinct dynamics, functions, and immune cell compositions compared to blood 240, 344, 
345. Defining the full heterogeneity of virus-specific T cell responses therefore requires 
comprehensive profiling across multiple sites.  
We have established a human tissue resource to obtain blood and multiple lymphoid and 
mucosal tissues from individual organ donors of all ages, enabling investigations of immune 
cells and responses across tissues over life (for reviews, see 338, 339). Our prior studies using these 
tissues reveal that T cell subset composition, phenotype, function, and transcriptome profiles are 
specific to the tissue and exhibit site-specific variations with age 137. We identified TRM cells 
(expressing specific phenotypes and transcriptional profiles) as the predominant T cell subset in 
mucosal, exocrine, and barrier sites throughout the body across age 28, 80, 137. Analysis of T cells 
specific for cytomegalovirus (CMV), a systemic persistent virus, revealed broad distribution of 
CMV-specific T cells across sites that varied between individuals 209, although the bases for 
these variations was not clear.  
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 Here, we present a comprehensive cellular and molecular analysis of virus-specific T 
cells in blood and tissues from individual donors of all ages, revealing the role of virus, site, age, 
and sex in shaping anti-viral T cell immunity. We examine CD8+ T cells specific for prevalent 
but distinct viruses – influenza A (Flu) virus as a ubiquitous acute virus confined to the 
respiratory tract, compared to CMV – in blood, primary and secondary lymphoid organs, and 
mucosal sites from 58 organ donors aged 1-78 years. We show that virus specificity and tissue 
localization are the key factors in shaping anti-viral T cell immune responses in the human body, 
with age and sex influencing T cell subset differentiation. Importantly, virus specificity is 
correlated with T cell tissue tropism and the clonal repertoire, while tissue localization is 
associated with differential maintenance of T cell subsets and functional responses. Our findings 
elucidate how different factors contribute to the heterogeneity of the human anti-viral immune 






Heterogeneous maintenance of virus-specific CD8+ T cells across human tissue sites 
 We analyzed virus-specific T cells across blood and multiple tissue sites of individual 
organ donors directly ex vivo by examining their frequency, distribution, phenotype, T cell 
receptor (TCR) expression, and functional profile (see schematic in Figure 3-1A).  Mononuclear 
cells were isolated from blood, bone marrow (BM), spleen, lung, lung-associated lymph node 
(LLN), iliac lymph node (ILN), mesenteric lymph node (MLN), and jejunum obtained from 58 
donors, aged 1-78yrs (Table 3-1), as previously described 23, 25, 26, 28, 80, 209.  For detection of T 
cells specific for the ubiquitous viruses, Flu and CMV, we used fluorescently labeled multimer 
reagents consisting of MHC Class I receptor proteins (HLA-A1, A2, A24, B7) complexed with 
immunodominant peptide epitopes encountered during natural infection as previously 
determined (Flu: MP, NP, PB1; CMV: IE-1, pp50, pp65 172, 173, 346), compared to staining with 
negative control HLA-multimers containing irrelevant peptides (Figure 3-2). Only CMV-
seropositive individuals exhibited significant frequencies of CMV-specific T cells across sites 
209, while Flu-specific T cells were identified in all donors.  
 Based on multimer staining, we found differences in the frequency and tissue distribution 
of Flu- compared to CMV-specific T cells, which also varied between individuals. Both Flu- and 
CMV-specific T cells were distributed in multiple sites, and particularly in blood, BM, spleen, 
lungs, and LN, with very low-to-negligible frequencies in intestines (Figure 3-1B, C). In the BM, 
spleen, and lung, there was a significantly greater frequency of CMV- compared to Flu-specific 
CD8+ T cells, which also varied between donors (Figure 3-1C). This may relate to CMV being a 
persistent virus and has been detected in these sites in seropositive individuals 209. Heatmaps 
with color intensities based on row normalized frequencies of virus-specific T cells revealed that 
96 
 
certain sites contained higher frequencies of Flu- or CMV-specific CD8+ T cells within each 
individual, which varied between individuals but not with age (Figure 3-1D). From this analysis, 
a substantial frequency of donors (29%) was found to have the highest frequency of Flu-specific 
T cells in the lung relative to other sites, while for CMV-specific T cells, a substantial frequency 
(31%) of donors had highest frequencies in the BM compared to other sites (Figure 3-1E). These 
results indicate that the frequency and tissue distribution of virus-specific T cells is shaped in 
part, by the tissue tropism of the virus. 
 As another approach for detection of Flu- and CMV-specific T cells independent of HLA 
type, we stimulated mononuclear T cells from multiple sites with peptide megapools (MPs) that 
allow simultaneous presentation of a large number of virus-specific epitopes predicted using the 
Immune Epitope Database and Analysis Resource (IEDB) and bioinformatic approaches (see 
Materials and Methods) 313-315, 347. T cell reactivity to each virus was assessed by production of 
multiple cytokines and cytolytic mediators by intracellular staining (Figure 3-3A). Consistent 
with our results from multimer analysis, we were able to detect Flu- and CMV-reactive T cells in 
the BM, spleen, lungs, and LLN of multiple donors, with variable responses between donors 
(Figure 3-3B, C). Notably, Flu-responsive T cells in the lung and LLN exhibited features of 
multifunctional memory T cells (Figure 3-3B, C), and highly elevated frequencies of CMV-
reactive T cells were detected in the BM of some donors (Figure 3-3C). Together, these results 
indicate that Flu- and CMV-reactive T cells are dispersed across multiple sites, though Flu-
specific memory T cells are more biased to the lung and associated LN.  
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Figure 3-1. Differential maintenance of Flu- and CMV-specific CD8+ T cells across diverse 
tissue sites.  
(A) Schematic diagram illustrating human tissues obtained and experimental workflow for this 
study. (B) Distribution of influenza A (Flu)-specific (red) and cytomegalovirus (CMV)-specific 
(blue) CD8+ T cells in different human tissues of two representative donors (D420, top; D457, 
bottom) based on staining with multimer reagents containing viral epitopes shown in 
representative flow cytometry plots (see Figure S1 for gating strategy). Numbers indicate 
frequency of multimer+ cells within total CD8+ T cells. (C) Frequencies of Flu- multimer+ (red) 
and CMV-multimer+ (blue) CD8+ T cells from 7-27 donors for each tissue site. (D) Heatmaps 
showing frequency of Flu-specific (left) and CMV-specific (right) CD8+ T cells in blood and 
tissues sites for individual donors from which data from two or more tissues were obtained. 
Donors are arranged by increasing age and color intensity of each cell is based on row 
normalization of (mix-max scaled) values (white cells indicate no sample). Pearson correlation 
analysis of age and multimer frequency is indicated by “pearsonr” correlation coefficients and p-
values are listed underneath each heatmap. (E) Pie charts showing percentage of donors for 
which the indicated tissue contains the greatest frequency of Flu-multimer+ (top) or CMV-
multimer+ (bottom) cells among the tissue sites studied for that donor. Statistical significance for 
comparison of means was calculated by unpaired t test and indicated by *, p £ 0.05. M, male; 
BM, bone marrow; LLN, lung-associated lymph node; ILN, iliac lymph node; MLN, mesenteric 









Table 3-1. Information about donors in this study. 
 




D25 50 F White 2, 11 7, 65 + Flu/CMV multimer 
D97 40 M Black/African American 2, 30 42, 58 + Flu/CMV multimer 
D117 32 M Hispanic/Latino 1, 2 35, 51 + Flu/CMV multimer 
D178 51 M Black/African American 2, 30 52, 63 - Flu multimer 
D194 53 M Asian 24, 29 7, 52 + Flu/CMV multimer 
D210 37 M Hispanic/Latino 2, 24 35, 51 + Flu/CMV multimer 
D217 49 M Black/African American 68, 68 7, 42 + Flu/CMV multimer 
D226 66 F White 1, 3 13, 35 + Flu/CMV multimer 
D238 21 M White 1, 2 7, 8 - Flu multimer 
D245 50 F Black/African American 1, 74 7, 8 + Flu/CMV multimer 
D282 32 F Hispanic/Latino 24, 32 35, 49 + CMV multimer 
D289 58 M White 2, 24 44, 49 + Flu/CMV multimer 
D296 62 F Black/African American 2, 3 7, 13 + 
Flu/CMV multimer, 
cytokine profile 




given + Cytokine profile 
D324 56 M White 2, 32 13, 35 + Flu/CMV multimer 
D331 32 M Black/African American 2, 24 51, 60 - Flu multimer 
D353 20 M Hispanic/Latino 24, 24 35, 37 + Cytokine profile 
D362 37 F White 2, 2 7, 62 + Flu/CMV multimer 
D374 62 F White 2, 2 8, 78 + Flu/CMV multimer 
D376 28 F Black/African American 1, 6601 44, 44 - Flu multimer 
D382 62 F Asian 2, 11 46, 56 + Flu/CMV multimer 
D393 55 F Hispanic/Latino 2, 2 18, 44 + Flu/CMV multimer 
D399 39 F White 2, 66 7, 58 + Flu/CMV multimer, cytokine profile 
D400 18 M White 2, - 44, 57 + Flu/CMV multimer 
D416 37 F White 24, 26 7, 38 + Flu/CMV multimer 
D417 78 M Black/African American 2, 24 41, 57 + Flu/CMV multimer 
D418 52 M Black/African American 2, 68 35, 50 - Flu multimer 
D420 34 M White 2, 30 13, 27 + Flu/CMV multimer 
D421 18 F Hispanic/Latino 3, 29 7, 44 + Flu/CMV multimer 
D426 43 F Hispanic/Latino 3, 68 7, 27 + Flu/CMV multimer 
D431 64 F Black/African American 2, 33 53, 65 + Flu/CMV multimer 





D435 55 F White 1, 3 7, 44 + Flu/CMV multimer, cytokine profile 








D445 47 M Black/African American 2, 33 63, 53 + Flu/CMV multimer 
D447 40 F Hispanic/Latino 2, 68 39, 44 + Flu/CMV multimer, TCRseq 




D459 52 F Black/African American 1, 3 53, 53 + Flu/CMV multimer 
D481 29 M Hispanic/Latino 3, 29 35, 44 + PLATE-seq 
D487 34 M Black/African American 2, 30 45, 65 + 
Flu/CMV multimer, 
cytokine profile 
D495 42 M Black/African American 23, 30 72. 45 + Cytokine profile 
Pediatric Donors 
D143 6 M White 2, 3 7, 57 - Flu multimer 
D258 1 M White 1, 31 8, 60 - Flu multimer 
P003 9 F White 1, 24 7, 8 + Flu multimer 
HDL052 9 M White 2, 24 7, 64 - Flu multimer 
HDL053 2 M White 2, 11 35, 60 + Flu multimer 
HDL060 3 M White 2, 24 18, 44 - Flu multimer 
HDL062 4 F White 2, 3 62, 47 - Flu multimer 
HDL069 6 M Hispanic/Latino 1, 2 8, 53 - Flu multimer 
HDL072 5 M White 1, 24 7, 50 - Flu multimer 
HDL081 8 M White 2, 3 7, 62 + Flu multimer 
HDL094 11 M White 1, 2 27, 37 + Flu multimer, cytokine profile 
HDL098 10 M Hispanic/Latino 2, 2 35, 52 + Flu multimer 
HDL099 4 M White 1, 2 13, 62 + Flu multimer 
HDL101 9 M Unknown 2, 3 7, 45 - Flu multimer 
HDL102 2 F Hispanic/Latino 2, 24 44, 61 + Flu multimer 
HDL113 10 M Hispanic/Latino 2, - 51, 52 + Flu multimer, cytokine profile 
*Multimer assays include phenotyping for T cell subset differentiation and tissue residency 
101 
 
Figure 3-2. Gating strategy and controls for flow cytometry analysis.  
(A) Gating strategy for multimer+ virus-specific CD8+ T cells gated on live CD45+CD14-CD19-
CD56-CD3+CD4- T cells. Flu- and CMV-specific CD8+ T cells and bulk CD8+ T cells were 
further characterized based on expression of phenotypic markers CD45RA, CCR7, CD69, and 
CD103 to identify T cell subsets, gated as shown. (B) Representative flow cytometry plots 
showing staining using negative control multimer reagents and virus-specific multimer reagents 
for Flu (top) and CMV (bottom). BM, bone marrow; LLN, lung-associated lymph node; MLN, 











Figure 3-3. Virus-specific CD8+ T cell responses as measured by cytokine production 
following antigen stimulation in adult donors.  
(A) Gating strategy for identification of antigen-responsive CD8+ T cells. CD8+ T cell response 
was measured via production of cytokines IFN-g , TNF-a , GZMB, PRF and expression of 
functional marker CD107a. (B) Dot plots showing frequency of Flu-specific (red) and CMV-
specific (blue) CD8+ T cells that exhibit either 4 functions, 3 functions, or 2 functions of CD8+ T 
cells effector response. (C) Dot plots showing frequency of Flu-specific (red) and CMV-specific 
(blue) CD8+ T cells that produce IFN-g , TNF-a , GZMB, PRF or express CD107a. Each dot 
represents an individual donor. Statistical significance for comparison of means was calculated 
by paired t test between antigen-responsive (either Flu or CMV) versus DMSO control and 
indicated by ****, p £ 0.0001; ***, p £ 0.001; **, p £ 0.01; *, p £ 0.05. BM, bone marrow; 











Role of tissue localization, virus specificity, and age in subset differentiation of virus-specific 
CD8+ T cells 
To understand the factors controlling maintenance of anti-viral T cells, we investigated 
the subset differentiation and phenotype of Flu- and CMV-specific CD8+ T cells across tissues 
and age (18-78 years). We previously determined that tissue sites contain distinct compositions 
of memory T cell subsets as defined by cell surface expression of CCR7 chemokine receptor and 
CD45RA—TCM (CD45RA- CCR7+), TEMRA (CD45RA+ CCR7-), and TEM (CD45RA- CCR7-), 
which is further delineated into circulating CD69- TEM and non-circulating CD69+ CD103+ TRM 
(Figure 3-2A) 26, 28. The subset composition of virus-specific T cells in each site is shown relative 
to the profile of polyclonal T cells (Figure 3-4A) and as compiled frequencies for both Flu- and 
CMV-specific T cells (Figure 3-4B; see Table 3-2 for individualized data for each donor). 
Overall, the subset composition of Flu- or CMV-specific T cells within a site was not equivalent 
to the subset composition of polyclonal T cells in that site, and often differed between the two 
virus specificities (Figure 3-4A).  
The majority of both Flu- and CMV-specific T cells were maintained as CD45RA- 
CCR7- TEM and CD45RA+ CCR7- TEMRA, though the relative distribution of these subsets varied 
between sites and virus specificity. There were also Flu-specific CD45RA+ CCR7+ T cells in the 
blood and LN of some donors, a phenotype usually associated with naïve T cells, but also shown 
to be expressed by long-lived memory T cells in circulation 341. The majority of Flu-specific T 
cells were TEM in spleen, lungs, multiple LNs, and jejunum, while Flu-specific TEMRA cells were 
present mostly in BM (Figure 3-4B). CMV-specific T cells were maintained predominantly as 
TEMRA cells in the BM, spleen, and lung, and TEM cells in LNs (Figure 3-4B). Between the 
different virus-specificities, there were significantly higher frequencies of CMV- compared to 
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Flu-specific circulating CD69- TEM subset in the lung (Figure 3-4C). Additionally, higher 
frequencies of CMV- compared to Flu-specific TEMRA cells were detected in multiple sites 
(blood, spleen, and lung) (Figure 3-4C). The frequency of Flu- or CMV-specific T cells that are 
CD69- TEM or TEMRA in each site did not vary significantly with age, with the exception of Flu-
specific TEMRA in BM, which increased significantly with age (Figure 3-4D, E). Similar 
frequencies of circulating CD69- TEM and TEMRA were observed for donors where detection of 
virus-specific T cells involved use of multimers for HLA-A2 or multiple HLA alleles (Figure 3-
5A, B). Because CD69- TEM and TEMRA are circulating subsets, with TEMRA found at high 
frequencies in blood-rich sites 28, 31, these results are consistent with CMV-reactive T cells being 
more circulating compared to Flu-specific T cells.  
We examined the extent to which Flu- and CMV-specific TEM exhibit phenotypes of 
tissue residence based on the expression of tissue residency markers CD69 and CD103, which 
distinguish human TRM from circulating TEM cells across tissue sites 80. Virus-specific TRM were 
only detected in tissues and not blood (Figure 3-6A, B). Importantly, a higher frequency of Flu-
specific T cells was maintained as TRM in spleen, lung, and LLN compared to low to negligible 
frequencies of CMV-specific TRM in these and other sites (Figure 3-6B); this difference was 
observed across donors where detection of virus-specific T cells involved use of multimers for 
HLA-A2 or multiple HLA alleles (Figure 3-5C). The frequency of Flu-specific TRM was highest 
in the lung (Figure 3-6B), consistent with mouse studies 185, 333. Paired analysis for individual 
donors revealed that Flu-specific TRM cells are maintained at higher frequencies than CMV-
specific TRM cells for each site, with the exception of jejunum, where the low frequencies of 
virus-specific T cells detected were all TRM (Figure 3-6C), consistent with TRM predominance in 
that site 80, 140. With age, the frequency of virus-specific TRM remained constant over six decades 
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of life, except for a marked decrease in frequency of Flu-specific TRM in the LLN and a slight 
accumulation of CMV-specific TRM in the BM (Figure 3-6D). These results suggest that long-
term maintenance of tissue residency of virus-specific CD8+ T cells is shaped primarily by the 





Figure 3-4. Antigen-specific CD8+ T cell subset differentiation and phenotype is based on 
virus-specificity independent of age.  
(A) T cell subset distribution of Flu- specific (red) and CMV-specific (blue) CD8+ T cells based 
on CD45RA and CCR7 expression (CD45RA+/CCR7+; CD45RA-/CCR7+, TCM; CD45RA-
/CCR7-, TEM; CD45RA+/CCR7-, TEMRA) shown in representative flow cytometry plots. Gray 
contour plots depict CD45RA and CCR7 expression of total CD8+ T cells within the same 
sample. Numbers indicate frequency of multimer+ virus-specific cells within each subset. (B) 
Subset distribution of Flu-specific (shades of red) and CMV-specific (shades of blue) CD8+ T 
cells compiled from 3-21 donors in blood and indicated tissue sites. (C) Frequencies of Flu-
multimer+ (red) and CMV-multimer+ (blue) CD8+ T cells maintained as CD69- TEM (top) and 
TEMRA (bottom) from 3-21 donors for each tissue site. (D, E) Frequencies of Flu-specific (red, 
left) and CMV-specific (blue, right) CD8+ CD69- TEM (D) and CD8+ TEMRA (E) in indicated 
tissue sites as a function of age for each individual donor. The line of best fit was determined by 
Pearson correlation; “pearsonr” refers to correlation coefficient, p-values are indicated for each 
comparison, and red font indicates significant correlation for BM. Statistical significance for 
comparison of means was calculated by unpaired t test and indicated by **, p £ 0.01; *, p £ 0.05. 
Subset frequencies shown from donors with ≥10 multimer+ T cells. BM, bone marrow; LLN, 










Table 3-2. Virus-specific T cell memory subset distribution for each tissue site and donor 
(adult donors). 









21 Flu Blood 87.7 2.7 5.5 4.1 
32 Flu Blood 100 0 0 0 
52 Flu Blood 90.7 2.3 2.3 4.6 
52 Flu Blood 69.3 1.6 13.3 15.8 
53 Flu Blood 92 4 0 4 
34 CMV Blood 7.1 0 64.3 28.6 
37 CMV Blood 0.7 0 0 99.3 
40 CMV Blood 58.5 3.8 18.9 18.9 
52 CMV Blood 17.3 1.9 26.3 54.5 
53 CMV Blood 66.7 25 8.3 0 
55 CMV Blood 4 0 58 40 
62 CMV Blood 30 0 50 20 
78 CMV Blood 20 0 12 68 
21 Flu BM 61.2 3.3 22.3 13.2 
32 Flu BM 69.4 4.5 15.9 10.2 
34 Flu BM 7.4 0 4.9 87.8 
34 Flu BM 50 0 33.3 16.7 
37 Flu BM 28.6 0 41.3 30.2 
39 Flu BM 4.8 0 28.6 66.7 
40 Flu BM 16.7 0 33.3 50 
40 Flu BM 5.2 1.7 37.9 55.2 
50 Flu BM 48.3 10.3 6.9 34.5 
52 Flu BM 19.4 0 48.6 31.9 
52 Flu BM 0 0 44 56 
53 Flu BM 11.5 4.2 27.1 57.3 
55 Flu BM 9.1 2.8 19.7 68.5 
64 Flu BM 1.3 1.3 21.7 75.7 
78 Flu BM 11.1 0 1.8 87 
34 CMV BM 3.6 9.1 25.5 61.8 
34 CMV BM 8.5 1.1 34 56.4 
37 CMV BM 6.9 4.6 54.6 33.8 
39 CMV BM 1.1 0.4 59.6 38.9 
40 CMV BM 1.9 0 29.9 68.2 
40 CMV BM 8.7 2 47.7 41.5 
43 CMV BM 8.3 1.4 2.8 87.5 
50 CMV BM 5.4 2.3 32.3 60 
52 CMV BM 0 0 21 79 
53 CMV BM 23.2 5.8 24.6 46.4 
55 CMV BM 1.4 0.3 14 84.3 
62 CMV BM 0 0 66.7 33.3 
64 CMV BM 0.4 0.8 67.6 31.1 
78 CMV BM 10.3 0 7.5 82.2 
18 Flu Spleen 45.5 0 36.4 18.2 
18 Flu Spleen 10.5 5.3 47.4 36.8 
21 Flu Spleen 52.6 7.2 29.9 10.3 
34 Flu Spleen 0 0 27.3 72.7 
34 Flu Spleen 7.7 3.8 50 38.5 
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37 Flu Spleen 7.9 0 78.9 13.2 
39 Flu Spleen 0 3 36.4 60.6 
40 Flu Spleen 18.2 0 36.4 45.5 
40 Flu Spleen 5.6 0 88.9 5.6 
46 Flu Spleen 2.4 0 64.2 33.4 
49 Flu Spleen 8.9 13.3 53.3 24.4 
52 Flu Spleen 19.6 0 56.5 23.9 
52 Flu Spleen 2.2 2.2 86.3 9.4 
52 Flu Spleen 15.7 3.8 41.2 39.3 
55 Flu Spleen 4.2 12.5 54.2 29.2 
55 Flu Spleen 9.1 18.2 45.5 27.3 
56 Flu Spleen 9.1 4.6 68.2 18.2 
58 Flu Spleen 0 0 78.6 21.4 
62 Flu Spleen 0.8 0 1.9 97.3 
18 CMV Spleen 50 0 33.3 16.7 
32 CMV Spleen 0 0 76.9 23.1 
34 CMV Spleen 0.2 0 6.1 93.6 
34 CMV Spleen 3 3 59.6 34.3 
34 CMV Spleen 10 0 20 70 
37 CMV Spleen 1.4 0 1 97.6 
37 CMV Spleen 2.2 3.4 68.5 25.8 
38 CMV Spleen 2.7 0.9 44.5 51.8 
40 CMV Spleen 2.2 0 27.8 70 
40 CMV Spleen 9.8 2 68.6 19.6 
43 CMV Spleen 3.1 1 51.5 44.4 
46 CMV Spleen 3.8 1.1 25.1 70 
49 CMV Spleen 1.5 2.3 70.8 25.5 
52 CMV Spleen 2 2.6 38.7 56.7 
55 CMV Spleen 0.4 1.9 13.1 84.6 
55 CMV Spleen 0.6 0.6 57.7 41 
58 CMV Spleen 2.5 0 30 67.5 
62 CMV Spleen 0.3 0 20.8 78.9 
64 CMV Spleen 4.4 0 60.9 34.8 
66 CMV Spleen 0 0.8 70.8 28.4 
78 CMV Spleen 44.2 0 7.8 48.1 
18 Flu Lung 25 0 31.2 43.8 
28 Flu Lung 0.4 0 57.1 42.4 
34 Flu Lung 0.7 1.5 93.3 4.4 
34 Flu Lung 0 0 16.7 83.3 
34 Flu Lung 48 4.7 23.3 24 
37 Flu Lung 6.2 0 6.2 87.5 
39 Flu Lung 6.2 0 37.5 56.2 
40 Flu Lung 0.5 0.5 92.6 6.4 
40 Flu Lung 9 0.5 73.7 25.8 
46 Flu Lung 2.6 1.3 28.6 67.5 
51 Flu Lung 1.5 3.7 65.4 29.4 
52 Flu Lung 10 0 60 30 
52 Flu Lung 0 1.5 68.2 30.3 
53 Flu Lung 7.9 2.6 60.5 28.9 
55 Flu Lung 1.4 1.4 65.3 31.9 
56 Flu Lung 3 3 75.8 18.2 
62 Flu Lung 6.4 5.6 37.3 50.8 
64 Flu Lung 0.5 5.4 82.7 11.4 
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78 Flu Lung 0 0 36.4 63.6 
18 CMV Lung 3.2 0 31.8 65 
34 CMV Lung 1.7 3.1 62.8 32.4 
34 CMV Lung 0.6 0.4 9.3 89.7 
34 CMV Lung 0.6 1.9 8.1 89.4 
37 CMV Lung 0.8 0 0 99.2 
39 CMV Lung 1.1 0.4 59.6 38.9 
40 CMV Lung 0 0 63.6 36.4 
40 CMV Lung 0.9 0.4 29.8 68.9 
43 CMV Lung 0 0 41.9 58.1 
46 CMV Lung 1.2 0 13.2 85.5 
52 CMV Lung 0.9 2.6 46.3 50.2 
55 CMV Lung 0.4 0 13.3 86.4 
56 CMV Lung 0 13.6 59 36.4 
62 CMV Lung 7.2 3.3 37.9 51.7 
64 CMV Lung 0 3.9 58.8 37.3 
78 CMV Lung 0 0 51.1 48.9 
34 Flu LLN 50 10 30 10 
34 Flu LLN 21.2 1.3 51.3 26.3 
37 Flu LLN 15.8 0 10.5 73.7 
40 Flu LLN 16.9 14.3 45.5 23.4 
46 Flu LLN 25.3 19.4 37.1 18.2 
50 Flu LLN 80 6.7 6.7 6.7 
52 Flu LLN 61.9 5.4 28.5 4.2 
52 Flu LLN 30.8 0 61.5 7.7 
53 Flu LLN 24.6 27.5 40.6 7.2 
56 Flu LLN 23.1 9.2 63.1 4.6 
64 Flu LLN 0 5.3 88 6.7 
18 CMV LLN 64.3 0 14.3 21.4 
34 CMV LLN 3.1 10.8 50.8 35.4 
34 CMV LLN 1.8 0.1 29.4 68.7 
34 CMV LLN 27.3 9.1 45.5 18.2 
37 CMV LLN 3.6 0 1.8 94.6 
40 CMV LLN 8.9 22.3 61.6 7.1 
40 CMV LLN 8.3 0 91.7 0 
43 CMV LLN 20 0 57.1 22.9 
46 CMV LLN 36.7 8.9 32 22.4 
50 CMV LLN 2.4 4.9 46.3 46.3 
52 CMV LLN 17.9 11.1 59.3 11.7 
55 CMV LLN 11 0.5 53.4 35.2 
56 CMV LLN 42.6 3.3 47.5 6.6 
62 CMV LLN 15.8 5.3 42.1 36.8 
64 CMV LLN 0 0 92.7 7.3 
34 Flu ILN 93.2 4.2 1 1.6 
37 Flu ILN 16.7 0 58.3 25 
37 Flu ILN 41.4 1.7 5.2 51.7 
40 Flu ILN 29.4 0 41.2 29.4 
55 Flu ILN 0 83.3 16.7 0 
62 Flu ILN 30 5 40 25 
34 CMV ILN 33.3 8.3 25 33.3 
37 CMV ILN 20 0 70 10 
37 CMV ILN 25 0 3.3 71.7 
40 CMV ILN 16.7 5.6 50 27.8 
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50 CMV ILN 14.1 5.6 40.8 39.4 
52 CMV ILN 31.6 0 42.1 26.3 
55 CMV ILN 1.5 1.1 65.9 31.5 
62 CMV ILN 22.7 18.2 22.7 36.4 
37 Flu MLN 10 13.2 63.2 13.2 
40 Flu MLN 6.7 0 80 13.3 
78 Flu MLN 3.7 0 96.3 0 
34 CMV MLN 25 3.6 39.3 32.1 
37 CMV MLN 15.8 31.6 47.4 5.3 
40 CMV MLN 18.8 0 75 6.2 
62 CMV MLN 1.4 0 64.3 34.3 
47 Flu Jejunum 0 4.8 69 26.2 
56 Flu Jejunum 5.6 44.4 50 0 
62 Flu Jejunum 0 0 7.7 92.3 
62 Flu Jejunum 0 0 60 40 
47 CMV Jejunum 1.7 0 72.4 25.9 
52 CMV Jejunum 2.2 2.2 93.3 2.2 
55 CMV Jejunum 0 6.2 62.5 31.2 
62 CMV Jejunum 12.5 6.2 31.2 50 





Figure 3-5. Subset differentiation and tissue residency of antigen-specific CD8+ T cells 
identified using only HLA-A2 multimers versus a combination of multiple HLA-multimers.  
(A, B) Frequencies of Flu-multimer+ (left) and CMV-multimer+ (right) CD8+ T cells maintained 
as CD69- TEM (A) and TEMRA (B) obtained from donors using multimers containing HLA-A2 
only (dark gray; n=2-11) compared to using a combination of multiple HLA-multimers (light 
gray, n=2-9). (C) Frequencies of Flu-multimer+ (left) and CMV-multimer+ (right) CD69+ 
CD103+ CD8+ TRM obtained from donors using multimers containing HLA-A2 only (dark gray; 
n=3-9) compared to using a combination of multiple HLA-multimers (light gray, n=1-7). 
Statistical significance for comparison of means was calculated by unpaired t test. No 










Figure 3-6. Establishment of tissue residency correlates with virus specificity and site.  
(A) Expression of tissue residency markers CD69 and CD103 by Flu-specific (red) and CMV-
specific (blue) CD8+ T cells in indicated tissue sites shown in representative flow cytometry plots 
with gray contour plots depicting total CD8+ T cells within the same sample; numbers indicate 
frequency of multimer+ virus-specific cells. (B) Frequencies of Flu-multimer+ (red) and CMV-
multimer+ (blue) CD69+ CD103+ CD8+ TRM gated on TEM from 2-18 donors for each site. 
Statistical significance for comparison of means was calculated by unpaired t test and indicated 
by ****, p £ 0.0001; ***, p £ 0.001; **, p £ 0.01. (C) Paired frequencies within individual 
donors of Flu-multimer+ (red) and CMV-multimer+ (blue) CD69+ CD103+ CD8+ TRM from 2-10 
donors for each site. Statistical significance between Flu- and CMV-multimer+ TRM within each 
tissue site were determined by paired t test and indicated by ***, p £ 0.001; **, p £ 0.01; *, p £ 
0.05; ns, no significance. (D) Frequencies of Flu-specific (red, left) and CMV-specific (blue, 
right) TRM in indicated tissue sites as a function of age for each individual donor. The line of 
best fit, Pearson coefficient, and p-value are indicated for each comparison; red font indicates 
significant correlation for LLN. TRM frequencies shown from donors with ≥5 multimer+ TEM. 
BM, bone marrow; LLN, lung-associated lymph node; ILN, iliac lymph node; MLN, mesenteric 












Expression of replicative senescence marker CD57 of Flu-specific versus CMV-specific CD8+ T 
cells 
To investigate immunosenescence of CD8+ T cells recognizing acute Flu and persistent 
CMV, we examined CD57 expression by virus-specific T cells. CD57 has been shown to be 
expressed on CD8+ T cells in late stages of differentiation as a result of repeated antigen 
exposure and has been linked to reduced proliferative capacity and senescence (Brenchley et al., 
2003). CMV-specific T cells in blood, BM, lung, and LLN exhibited significant higher 
frequencies of multimer+ CD57+ cells than Flu-specific T cells (Figure 3-7A, B). Age-associated 
correlation analysis showed that, while frequency of CMV-specific CD57+ CD8+ T cells is 
greater than Flu-specific CD57+ CD8+ T cells in the lung of younger donors, frequency of lung 
CMV-specific CD57+ CD8+ T cells decreases significantly with age. Conversely, Flu-specific 
CD57+ CD8+ T cell frequencies in the lung trends towards increasing with age (Figures 3-7C). 
Age-associated differences were not seen in other tissue sites (data not shown). Together, these 
results show that replicative senescence features of virus-specific CD8+ T cells among adult 
organ donors is primarily determined by virus specificity with age-associated differences within 





Figure 3-7. Expression of CD57 by virus-specific CD8+ T cells across tissues and over age. 
(A, B) CD57 expression by Flu-multimer+ (red) and CMV-multimer+ (blue) CD8+ T cells shown 
in boxplots (A) showing compiled data from 2-11 donors for each tissue site, representative flow 
cytometry histograms (B). (C) Pearson correlation analysis with frequencies of CD57+ Flu-
specific (red) and CMV-specific (blue) CD8+ T cells in the lung as a function of age for each 
individual donor. Statistical significance for comparison of means was calculated by unpaired t 
test and indicated by **, p £ 0.01; *, p £ 0.05. Frequencies shown from donors with ≥10 
multimer+ T cells. BM, bone marrow; LLN, lung-associated lymph node; ILN, iliac lymph node; 













Distinct Flu-specific CD8+ T cell responses in tissues of pediatric versus adult donors 
To investigate further the role of age in the differentiation of virus-specific T cells, we 
analyzed Flu-specific T cells in tissues from a cohort of 13 pediatric organ donors, aged 1-11yrs 
(Table 3-1). We detected Flu-specific T cells by multimer staining in the spleen, lung, LLN, and 
MLN of pediatric donors; the highest frequencies were in the lung and LLN (Figure 3-8A). 
However, the frequencies of Flu-multimer+ CD8+ T cells in pediatric donor tissues were 
significantly lower compared to corresponding frequencies in adult donors (Figure 3-8B). 
Moreover, the subset distribution and tissue residency also differed between pediatric and adult 
donors; Flu-specific CD8+ T cells in lung and LLN of pediatric donors were maintained at higher 
frequencies as TCM and lower frequencies as CD69+ CD103+ TRM compared to adult donors 
(Figure 3-8C, D, and see Table 3-3 for individualized data). These findings demonstrate distinct 
differences in Flu-specific memory T cell generation between children and adults, which could 





Figure 3-8. Distinct frequencies and subset distribution of Flu-specific memory CD8+ T 
cells between adult and pediatric donors.  
(A) Distribution of Flu-specific CD8+ T cells in lung, LLN, and MLN of pediatric and adult 
donors shown in representative flow cytometry plots. Numbers indicate frequency of multimer+ 
cells within total CD8+ T cell population. (B) Frequencies of Flu-multimer+ CD8+ T cells in 
pediatric (pink; n=15) and adult (grey; n=31) donors from 5-21 donors for each tissue site. Inset 
shows frequencies of Flu-multimer+ cells in pediatric tissues with y-axis spanning 0-1%. (C) 
Memory T cell subset distribution of Flu-specific CD8+ T cells in indicated tissues of pediatric 
donors shown in representative flow cytometry plots (left) and compiled in graph (right) showing 
frequencies of Flu-multimer+ CD8+ T cells in pediatric (pink) and adult (grey) donors maintained 
as TCM (left) and TEM (right) in lung (top) and LLN (bottom) tissue sites. Subset frequencies 
shown from donors with ≥10 multimer+ T cells. (D) Expression of tissue residency markers 
CD69 and CD103 by Flu-specific CD8+ T cells in indicated tissues of pediatric donors shown in 
representative flow cytometry plots (left) and compiled in graph (right) showing frequencies of 
Flu-multimer+ CD69+ CD103+ CD8+ TRM (gated on TEM) in pediatric (pink) and adult (grey) 
donors in lung (top) and LLN (bottom) tissue sites. TRM frequencies shown from donors with 
≥5 multimer+ TEM. Statistical significance for comparison of means was calculated by unpaired 











Table 3-3. Virus-specific T cell memory subset distribution for each tissue site and donor 
(pediatric donors). 









2 Flu Lung 37.5 0 0 62.5 
3 Flu Lung 14.3 17.5 46 22.2 
4 Flu Lung 9.8 4.5 43.6 42.1 
5 Flu Lung 10.5 0 15.8 73.7 
8 Flu Lung 14.6 0 31.7 53.7 
9 Flu Lung 1.5 3 82.2 13.3 
9 Flu Lung 10 10 70 10 
10 Flu Lung 4.2 6.3 49.2 40.3 
11 Flu Lung 19 19 38.1 23.8 
2 Flu LLN 58 13 11.6 17.4 
4 Flu LLN 44.7 21.4 28.3 5.6 
5 Flu LLN 85.7 0 0 14.3 
8 Flu LLN 42.6 6.4 14.9 36.2 
9 Flu LLN 12.4 29.8 41.6 16.1 
9 Flu LLN 18.8 18.8 43.8 18.8 
10 Flu LLN 10 56 30.4 3.7 
11 Flu LLN 47.4 47.4 5.3 0 
4 Flu MLN 64.5 8.9 16.9 9.7 
5 Flu MLN 89.4 1.5 6.2 2.9 
6 Flu MLN 58.2 9.9 18.7 13.2 
8 Flu MLN 50 10.7 10.7 28.6 
9 Flu MLN 51.4 8.1 35.1 5.4 
9 Flu MLN 58.3 0 25 16.7 





Sex-related differences in subset delineation of virus-specific T cells 
An individual’s sex can also influence the immune responses, as males and females can 
exhibit distinct T cell responses in peripheral blood 302, 303. When stratified by sex, the ages of 
male and female adult donors in this study were comparable (Figure 3-9A). However, we found 
significant differences in subset delineation of virus-specific CD8+ T cells associated with being 
male or female. Compiled data of CMV-multimer+ T cells across tissue sites show that females 
maintain a significantly higher frequency of CMV-specific CD8+ T cells in the lung than males, 
while such differences were not seen in Flu-specific CD8+ T cells between males and females 
(Figure 3-9B). Moreover, the subset composition of virus specific T cells in certain sites differed 
significantly between males and females; male donors maintained higher frequencies of Flu-
specific CD8+ TEM cells in the spleen and lung, and CMV-specific TEM cells in the lung and LLN 
compared to females (Figure 3-9C). Conversely, females exhibited higher frequencies of Flu-
specific CD8+ TEMRA cells in the spleen and lung, and CMV-specific TEMRA cells in the lung and 
LLN compared to male donors (Figure 3-9D). By contrast, the frequencies of polyclonal TEM and 
TEMRA subsets among total CD8+ T cells in tissues were comparable between males and females 
(Figure 3-9E), indicating that the observed sex-associated differences reflect features of the 
virus-driven response. Flu-specific TRM also differed between sexes; males maintained higher 
frequencies of lung TRM compared to females (Figure 3-9F). These data suggest that sex 





Figure 3-9. Sex-related differences in tissue maintenance of virus-specific CD8+ T cells.  
(A) Age range of male and female donors in this study (male, green, n=19; female, yellow, 
n=20). (B) Frequencies of Flu-multimer+ (left) and CMV-multimer+ (right) CD8+ T cells from 3-
15 donors for each site stratified by sex. (C, D) Frequencies of Flu-multimer+ (left) and CMV-
multimer+ (right) CD8+ TEM (C) and CD8+ TEMRA (D) from 2-13 donors for each site stratified 
by sex. (E) Frequencies of total CD8+ TEM (top) and TEMRA (bottom) from 7-16 donors for 
each site stratified by sex. (F) Frequencies of Flu-multimer+ (left) and CMV-multimer+ (right) 
CD69+ CD103+ CD8+ TRM gated on multimer+ cells from 2-10 donors for each site stratified by 
sex. Subset frequencies shown from donors with ≥10 multimer+ T cells, and TRM frequencies 
shown from donors with ≥5 multimer+ TEM. Statistical significance for comparison of means 
was calculated by unpaired t test and indicated by **, p £ 0.01; *, p £ 0.05; ns, no significance. 
BM, bone marrow; LLN, lung-associated lymph node; ILN, iliac lymph node; MLN, mesenteric 













Virus-specific CD8+ T cell clones disperse across sites with distinct expansion and gene usage 
 To define the connections between virus-specific T cells in blood and tissues we analyzed 
the TCR repertoire of Flu- and CMV-specific CD8+ T cells using high-throughput sequencing of 
the TCRb chain gene (TRBV) as described 31. We sorted multimer+ T cells from 5 donors across 
up to 6 sites per donor (Figure 3-10A, and see Table 3-4 for cell number, DNA content, and 
number of clones). In general, the number of CMV-specific CD8+ T cells isolated was much 
greater compared to Flu-specific cells (consistent with the higher frequency overall, Figure 3-
1C), except in some donors where substantial numbers of Flu-specific T cells were sorted from 
the lungs and LLN (Table 3-4). The number of unique clones obtained for each sample ranged 
from <100 to >1000 (Table 3-4). The majority of the antigen-enriched TCR repertoire (>90%) 
was comprised of 50 clones or fewer (Figure 3-10B). Notably, CMV-specific CD8+ T cells were 
more clonally expanded than Flu-specific CD8+ T cells within and across specific sites (Figure 3-
10B, C). Conversely, Flu-specific CD8+ T cells encompassed a more diverse repertoire 
compared to CMV-specific CD8+ T cells for individual sites (blood and LLN), and across all 
sites (Figure 3-10D). These results indicate that repertoire diversity and clonal expansion of 
virus-specific CD8+ T cells are specific to the virus in a manner consistent across tissue sites and 
donors.  
 We further investigated whether usage of TRBV genes was distinct between donors, 
tissues, and virus specificities. TRBV gene usage for all donors revealed biases in TRBV 
expression between CMV- and Flu-specific T cells; in particular, TRBV19 usage predominated 
among Flu-specific CD8+ T cells across donors and tissues, consistent with findings in blood 348, 
349(Figure 3-11A). Principal component analysis (PCA) of TRBV gene usage based on donor, 
tissue, and virus revealed distinct gene usage by donor and virus, but not tissue (Figure 3-10E). 
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Virus-specific clustering was most apparent, with tight and distinct clustering of TRBV usage for 
Flu- and CMV-specific T cells, showing that the exquisite specificity of human T cells is 
maintained across sites.  
 We examined the overlap of virus-specific CD8+ T cell clones across tissue sites to 
understand how clones are disseminated. Clone tracking plots for the top 100 clones for each 
specificity shaded by their relative abundance showed that the most abundant virus-specific 
CD8+ T cell clones are shared across multiple tissue sites, that certain clones are restricted or 
enriched in specific sites, and that CMV-specific clones do not exhibit substantial overlap with 
Flu-specific clones (Figures 3-10F and 3-11B). The extent of overlap between samples within 
individual donors was calculated using cosine similarity as done previously 22, 31. Samples 
containing clones recognizing the same virus had higher cosine similarity and thus greater clonal 
overlap than samples containing clones for different virus specificities (Figures 3-10G and 3-
11C). The extent of overlap of CMV-specific clones was higher than for Flu-specific T cells for 
3/4 donors and there was greater overlap of clones between BM and spleen in most donors 
(Figure 3-10G and 3-11C).  Together, these analyses demonstrate that virus-specific T cell 
clones disseminate and are maintained in diverse tissue sites, and that clonal expansion and 




Figure 3-10. CD8+ T cell clonal distribution and diversity is shaped by virus specificity.  
(A) Diagram showing donor, tissue and virus-specificity of samples for T cell receptor (TCR) 
sequencing. Flu-multimer+ (red), CMV-multimer+ (blue), and total (grey) CD8+ T cells were 
sorted from indicated tissue sites of five organ donors. (B) Clonal abundance plots showing 
proportion of top n clones per sample for Flu- and CMV-specific CD8+ T cells from indicated 
tissue sites for donors D434 (top left), D447 (top right), D438 (bottom left), and D457 (bottom 
right). (C, D) TCR clonality (C; see Materials and Methods) and Shannon entropy (D; see 
Materials and Methods) by virus specificity for Flu-specific (red) and CMV-specific (blue) CD8+ 
T cell clones stratified by tissue site (left) and in all tissue sites combined (right). (E) Principal 
component analysis (PCA) of TRBV gene usage based on clone counts per sample, labeled and 
grouped by donor, tissue, and virus with confidence ellipses plotted around group mean points 
using the factoextra R package. (F) Sharing of Flu- and CMV-specific CD8+ T cells between 
indicated sites of donor D457 shown in clone tracking plots with each individual clone denoted 
by a line shaded by relative abundance within a tissue site. (G) Cosine similarity between 
pairwise cell populations of Flu- and CMV-specific CD8+ T cell clones in BM, LLN, lung, and 
spleen of donor D457. Color intensity of each cell is based on the normalization of (min-max 
scaled) values of sequenced samples. Statistical significance for comparison of means was 
calculated by unpaired t test and indicated by ***, p £ 0.001; **, p £ 0.01; *, p £ 0.05. BM, bone 










Table 3-4. TCR sequencing sample names, cells sorted, number of clones, and DNA. 
Sample name # of cells sorted # of clones DNA (ng) 
D421_Spleen_CMV 4000 324 5.93 
D421_LLN_CMV 3000 1407 14.43 
D421_Lung_CMV 54000 1017 89.70 
D434_Spleen_CMV 361 47 1.03 
D434_Spleen_Flu 444 61 1.47 
D434_Spleen_BulkCD8 10000 1672 19.37 
D434_LLN_CMV 343 90 <1 
D434_LLN_Flu 838 108 1.69 
D434_LLN_BulkCD8 10000 2484 18.07 
D434_Lung_CMV 296 30 <1 
D434_Lung_Flu 1233 102 3.04 
D434_Lung_BulkCD8 10000 1144 18.20 
D438_Blood_CMV 572 31 <1 
D438_Blood_Flu 3769 86 2.78 
D438_BM_CMV 646 51 <1 
D438_BM_Flu 1366 56 1.68 
D438_Spleen_CMV 1575 78 2.13 
D438_Spleen_Flu 6096 155 7.80 
D438_LLN_CMV 159 39 <1 
D438_LLN_Flu 2906 107 1.94 
D438_Lung_CMV 494 59 <1 
D438_Lung_Flu 17071 184 17.16 
D438_MLN_CMV 1842 68 1.74 
D438_MLN_Flu 8049 199 8.45 
D447_Blood_CMV 330 28 <1 
D447_Blood_Flu 108 33 <1 
D447_BM_CMV 2300 58 2.98 
D447_BM_Flu 1185 134 <1 
D447_LLN_CMV 180 38 <1 
D447_LLN_Flu 240 56 <1 
D447_Lung_CMV 366 66 <1 
D447_Lung_Flu 2448 63 2.33 
D447_Spleen_CMV 199 70 <1 
D447_Spleen_Flu 633 140 <1 
D457_BM_CMV 38683 350 12.98 
D457_BM_Flu 3249 285 6.83 
D457_LLN_CMV 15175 429 27.00 
D457_LLN_Flu 9251 1000 4.80 
D457_Lung_CMV 31935 975 9.30 
D457_Lung_Flu 47451 691 8.93 
D457_Spleen_CMV 17818 565 31.73 




Figure 3-11. TRBV gene usage, clonal overlap, and cosine similarity of virus-specific CD8+ 
T cell clones across multiple tissue sites.  
(A) TRBV gene usage of CD8+ T cell clones from individual samples with donor, tissue, and 
virus specificity indicated by color bars beneath each heatmap. Color intensity of each cell is 
based on column z-score. Each unique clone is counted once per donor. (B) Heatmaps showing 
the relative abundance of shared clones among Flu- specific and CMV-specific CD8+ T cells in 
indicated tissues obtained from donor D434 (left), D438 (middle), and D447 (right). Color 
intensity of each cell is based on the relative abundance of a particular T cell clone within a 
tissue site. (C) Heatmaps showing cosine similarity between pairwise cell populations of Flu-
specific and CMV-specific CD8+ T cell clones in indicated tissues of donors D434 (left), D438 
(middle), and D447 (right). Color intensity of each cell is based on the normalization of (min-
max scaled) values of samples for a given donor. BM, bone marrow; LLN, lung-associated 









Transcriptional and functional signatures of virus-responding T cells segregate by site  
 To address how virus specificity and tissue site influence anti-viral T cell function, we 
performed single-cell transcriptome profiling of virus-specific CD8+ T cells from different sites 
following stimulation with viral antigens. Single-cell suspensions from blood and tissue sites 
were stimulated in vitro with CMV- or Flu-specific peptide MPs, as described above. After 24 hr 
in vitro stimulation with MPs, antigen-responding CD8+ T cells (CD69+ IFN-γ+) were 
individually sorted into wells of 96-well plates (Figures 3-12A and 3-13A, B), followed by 
single-cell RNA sequencing (scRNA-seq) using pooled library amplification for transcriptome 
expression sequencing (PLATE-seq)(see methods) 257, 322, and analysis of single-cell 
transcriptome profiles.  
The top 10 most highly-variable genes expressed by antigen-responding T cells included 
those encoding cytokines and chemokines (CCL3, CCL4, IFNG, GZMB, GNLY)(Figure 3-12B), 
consistent with genes upregulated in activated human CD8+ T cells by scRNA-seq 27. 
Unsupervised clustering of 793 cells yielded 5 clusters (see methods) visualized as Uniform 
Manifold Approximation and Projection (UMAP) embeddings with individual cells colored by 
cluster, tissue, or virus specificity (Figure 3-12C). Some of the clusters corresponded to 
responses within individual tissues; other clusters represented virus-specific responses from 
multiple sites, and one sub-cluster corresponded to CMV-specific T cells from the BM (Figures 
3-12C and 3-14A).  
In total, 703 differentially expressed genes (adjusted p-value ≤ 0.1) were identified 
among the 5 clusters (Table 3-5); top differentially expressed genes in each cluster are shown in 
a heat map (Figure 3-12D) and the expression of key genes in UMAP projections (Figure 3-
14B), and described below. Cluster 0, derived from antigen-responding cells from the BM and to 
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a lesser extent the spleen, was enriched for genes associated with T cell function (CCL5, KLRB1, 
IFITM1, ANXA1, IL7R), transcription factors (STAT1, IRF1), and cell survival (TPT1, XAF1). 
Cells in cluster 1, from spleen and LLN, expressed genes encoding chemokines (XCL2, XCL1, 
CCL4) and transcription factors (EGR2, BATF, NFKB2), and genes associated with cytokine 
signaling (TNFRSF9 (3-1BB), TNFRSF4 (OX40), IL2RG), tissue residency (CRTAM), 
immunoregulation (TIGIT), and cell survival (BCL2A1). Cluster 2 was characterized by genes 
important for anti-viral protection, including genes associated with T cell activation (NME1), as 
we previously showed 27, cytokine production (GZMB, IL2RA, IFNG), and lipid metabolism 
associated with TRM survival (FABP5) 350, 351. Cluster 3, composed of predominantly LLN cells, 
included multiple interferon-inducible genes (IFITM2, IFITM3, IFITM1), cytokine genes (IL32, 
LTB, MIF), and tissue signature genes we previously identified as enriched in T cells in tissues 
but not present in blood 27 (CD226, S100A6, LGALS1). Cluster 4, consisting of antigen-
responding T cells from the lung, was enriched for cells expressing the inhibitory receptor 
CTLA4, which serves as a negative regulator of T cell responses, and the chemokine receptor 
CXCR4 (Figure 3-12D, Table 3-5). Together, these results show differential clustering of gene 
expression and functional patterns largely correlated to the tissue.  
We further analyzed tissue-specific differences in gene expression of antigen-responsive 
cells by defining gene expression differences among virus-specific T cells in the BM, lung, and 
LLN using spleen as a common comparator. We identified a total of 418 genes differentially 
expressed (adjusted p-value ≤ 0.1) by antigen-responsive cells in at least one of three comparison 
pairs—logFC(LLN/Spleen) vs. logFC(Lung/Spleen), logFC(BM/Spleen) vs. 
logFC(LLN/Spleen), and logFC(BM/Spleen) vs. logFC(Lung/Spleen) (Figure 3-13C and Tables 
3-6, 3-7), illustrating site-specific influences on antigen-specific T cell responses. In contrast, 
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there were few genes which differed in CMV- compared to Flu-reactive T cells; the only 
significant differences between CMV- and Flu-responding T cells were identified in the BM (15 
genes, including TNFRSF9 (3-1BB), IFITM1, GZMH) and spleen (1 gene, TNFRSF4 (OX40)) 
(Figure 3-13D and Table 3-8). Together, these findings suggest tissue-mediated regulation of 
anti-viral T cell function, with CMV-driven influences in the BM.  
To further investigate the role of tissue localization in shaping functional response to 
viral antigens, we performed multiplexed quantification of 50 cytokines on supernatant samples 
collected from viral peptide-mediated stimulations of T cells from multiple sites of 12 donors 
(Figure 3-15A). As visualized in heatmaps showing cytokine production normalized to DMSO 
negative control within each individual donor, cells stimulated with Flu MPs or CMV MPs share 
similar cytokine secretion patterns distinct to the tissue site, with the exception of BM where 
CMV-responding T cells exhibit greater levels and cytokine types compared to Flu-responding T 
cells in multiple donors (Figure 3-15B). Pairwise analysis of cytokine levels showed that CMV-
responding BM cells produced significantly greater levels of IFN-g, IL-1b, IL-9, IL-17A, MIP-
1b, and TNF-a compared to Flu-responding cells (Figure 3-12E and 3-15C). In contrast, there 
were few differences in cytokine production between Flu- and CMV-specific responses in blood, 
spleen, lung, and LLN (Figure 3-12E and 3-15C). Analysis of cytokine production across tissue 
sites revealed differences in cytokine levels among blood, BM, spleen, lung, and LLN for 
numerous cytokines (Figures 3-12F and 3-15D). Together, the transcriptional and functional 
results indicate that the recall response of virus-specific T cells upon reactivation is largely 
shaped by the tissue, with virus-specific functional effects specific to certain sites, such as CMV- 
specific influences within the BM. 
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Figure 3-12. Tissue segregation of the anti-viral T cell response revealed by single-cell 
transcriptome and functional profiling.  
(A) Antigen-responding CD69+ IFN- γ+ CD8+ T cells in the spleen and LLN of donor D481 
following stimulation by DMSO negative control, Flu antigen-specific peptide pool, CMV 
antigen-specific peptide pool, and anti-CD3/CD28 bead positive control, shown in representative 
flow cytometry plots. Colored gates (red: Flu; blue: CMV) indicate populations that were 
subsequently sorted for sequencing. (B) Scatterplot showing 2,000 variable genes (red) as 
determined by calculating average expression and dispersion of each gene. The top 10 most 
highly-variable genes are labeled on the graph. (C) UMAP embedding of virus-reactive CD8+ T 
cells colored by cluster as identified via unsupervised hierarchical clustering (see methods), 
tissue, or virus specificity. (D) Heatmap showing top 10 most differentially expressed genes in 
each cluster. See Table 3-5 for complete list of differentially expressed genes (padj < 0.1). (E) 
Pairwise comparisons of log(x+1) normalized cytokine levels in supernatants from in vitro 
stimulation of single-cell suspensions from blood (n=6), BM (n=7), spleen (n=9), lung (n=8), 
and LLN (n=10) with Flu (red) or CMV (blue) peptide pools. Statistical significance between 
Flu- and CMV-stimulated conditions was calculated by paired t test and indicated by **, p £ 
0.01; *, p £ 0.05. (F) Cytokine levels in blood, BM, spleen, lung, and LLN supernatant samples. 
Statistical significance was calculated using one-way ANOVA followed by Tukey’s multiple 
comparisons test indicated by ***, p £ 0.001; **, p £ 0.01; *, p £ 0.05. BM, bone marrow; LLN, 








Figure 3-13. PLATE-seq analysis of Flu- and CMV-specific CD8+ T cell function following 
stimulation with viral peptide pools.  
(A) Strategy for sorting viral antigen-responsive T cells in different sites (live CD14-CD19-
CD3+CD4-CD8+CD69+IFN-g+ cells) isolated after 24-hour in vitro stimulation with Flu- or 
CMV-specific peptide pools (see Materials and Methods). (B) Antigen- responding CD69+ IFN-
g+ CD8+ T cells in the blood, BM, and lung of donor D481 following stimulation by DMSO 
negative control, Flu antigen-specific peptide pool, CMV antigen-specific peptide pool, and anti-
CD3/CD28 bead positive control, shown in representative flow cytometry plots. Colored gates 
(red: Flu; blue: CMV) indicate populations that were subsequently sorted for sequencing. (C) 
Biplots showing logFC of LLN/Spleen versus logFC of Lung/Spleen (left), logFC of BM/Spleen 
versus logFC of LLN/Spleen (middle), and logFC of BM/Spleen versus logFC of Lung/Spleen 
(right) (see methods). Significantly differentially expressed genes (padj < 0.1) are colored based 
on tissue site as indicated. See Table 3-7 for information about differentially expressed genes 
highlighted in biplots. (D) Heatmaps showing all differentially expressed genes (padj < 0.1) 
between CMV- and Flu-specific CD69+ IFN-g+ CD8+ T cells in BM (top) and spleen (bottom). 








Figure 3-14. Tissue distribution and gene expression across clusters identified in PLATE-
seq analysis of antigen-responding CD8+ T cells.  
(A) Tissue origins of antigen-responding CD8+ T cells within clusters identified through 
differential expression analysis and unsupervised clustering. Related to Figure 3-12C. (B) 
Separate UMAP embeddings showing indicated gene expression (based on logFC) from antigen-









Table 3-5. Differentially expressed genes (padj<0.1) among viral-peptide-responsive CD69+ 
IFN-g+ CD8+ T cells within clusters identified via unsupervised clustering. 
gene p value avg_logFC pct.1 pct.2 p adj cluster 
CCL5 7.78E-35 0.96286358 0.89 0.822 1.49E-30 0 
RPS27 9.84E-34 0.48699308 0.963 0.99 1.88E-29 0 
PLAAT4 4.12E-32 1.21264783 0.65 0.331 7.89E-28 0 
TPT1 2.84E-21 0.38787987 0.977 0.99 5.44E-17 0 
RPL13 1.06E-19 0.305118 0.993 0.994 2.03E-15 0 
MT-CO1 1.52E-19 0.34907189 0.98 0.978 2.91E-15 0 
SYNE2 1.64E-19 0.72847604 0.573 0.331 3.14E-15 0 
TMSB4X 1.22E-17 0.38507318 0.923 0.966 2.34E-13 0 
KLRB1 5.57E-17 1.47661574 0.343 0.126 1.07E-12 0 
RPS19 7.17E-16 0.25250694 0.993 0.996 1.37E-11 0 
MT-CYB 1.50E-14 0.37594878 0.97 0.968 2.87E-10 0 
RPL30 1.05E-13 0.31569976 0.96 0.978 2.00E-09 0 
PNRC1 4.70E-13 0.81972959 0.523 0.351 8.99E-09 0 
RPL13A 1.06E-12 0.2598131 0.983 0.994 2.02E-08 0 
XAF1 3.36E-12 0.97781809 0.297 0.118 6.43E-08 0 
STAT1 1.09E-11 1.02995793 0.513 0.377 2.09E-07 0 
RPL21 1.11E-11 0.25280826 0.967 0.98 2.13E-07 0 
RPS3 3.72E-11 0.26631655 0.98 0.992 7.13E-07 0 
IFITM1 6.17E-11 0.76495077 0.63 0.54 1.18E-06 0 
RPL34 8.47E-10 0.26196573 0.93 0.986 1.62E-05 0 
RNF213 1.77E-09 0.57260195 0.797 0.759 3.38E-05 0 
C16orf54 6.21E-09 0.8610439 0.343 0.203 0.00011877 0 
IRF1 8.64E-09 0.67393111 0.493 0.387 0.00016544 0 
GBP5 9.61E-09 0.68165568 0.527 0.422 0.00018389 0 
MT-CO3 2.70E-08 0.26971236 0.947 0.968 0.00051599 0 
TNRC6B 2.86E-08 0.68153888 0.407 0.28 0.00054759 0 
MT-ATP6 4.14E-08 0.35249327 0.87 0.919 0.0007915 0 
RPS15A 4.56E-08 0.257074 0.92 0.961 0.00087197 0 
PTPRC 8.12E-08 0.40860635 0.717 0.704 0.00155342 0 
ANXA1 2.83E-07 0.72138512 0.47 0.398 0.00541617 0 
SLFN5 2.83E-07 0.82014537 0.297 0.17 0.00542351 0 
IL7R 4.30E-07 0.68811668 0.42 0.302 0.00823844 0 
S100A4 5.37E-07 0.49269406 0.597 0.513 0.0102743 0 
HLA-A 1.31E-06 0.2598237 0.927 0.968 0.02505212 0 
ITM2B 1.91E-06 0.57384938 0.47 0.398 0.03652669 0 
GIMAP4 3.50E-06 0.81402745 0.3 0.195 0.06697598 0 
ZFP36L2 4.80E-06 0.59273451 0.517 0.469 0.09179248 0 
ALOX5AP 5.10E-06 0.69693699 0.407 0.31 0.09754789 0 
TNFRSF9 4.95E-33 1.07642307 0.826 0.389 9.48E-29 1 
XCL2 1.07E-16 0.60803282 0.712 0.404 2.05E-12 1 
CRTAM 4.25E-16 0.99822285 0.533 0.245 8.14E-12 1 
RILPL2 1.23E-15 0.9922166 0.489 0.228 2.36E-11 1 
HLA-B 1.60E-15 0.33411267 0.995 0.97 3.07E-11 1 
DUSP2 1.10E-14 0.83589958 0.424 0.176 2.10E-10 1 
XCL1 8.52E-14 0.46022888 0.734 0.45 1.63E-09 1 
CCL4 3.98E-12 0.60327718 0.853 0.576 7.62E-08 1 
HSP90AB1 9.96E-12 0.38190759 0.967 0.764 1.91E-07 1 
PKM 2.52E-11 0.4686157 0.853 0.639 4.82E-07 1 
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HLA-A 1.78E-10 0.29275762 0.995 0.939 3.41E-06 1 
TNFRSF4 5.49E-10 0.55776594 0.446 0.24 1.05E-05 1 
TIGIT 5.62E-10 0.37976571 0.609 0.373 1.08E-05 1 
HLA-C 1.01E-09 0.27079447 0.984 0.954 1.93E-05 1 
REL 1.33E-09 0.75319306 0.413 0.218 2.54E-05 1 
EGR2 2.16E-09 0.7059554 0.386 0.197 4.14E-05 1 
SH2D1A 4.32E-09 0.48700237 0.516 0.31 8.26E-05 1 
CCL4L2 9.95E-09 0.88060279 0.511 0.294 0.00019054 1 
BATF 1.23E-08 0.58404183 0.473 0.276 0.00023584 1 
DTHD1 2.40E-08 0.42006982 0.299 0.123 0.00045953 1 
PRDX1 3.61E-08 0.34959954 0.832 0.599 0.00069079 1 
IL2RG 4.92E-08 0.39393399 0.728 0.588 0.00094089 1 
LTA 5.06E-08 0.33196292 0.75 0.511 0.00096913 1 
PARK7 6.67E-08 0.29438063 0.799 0.581 0.00127583 1 
ARF6 8.12E-08 0.46108803 0.473 0.302 0.00155386 1 
LTB 1.51E-07 0.38868168 0.793 0.589 0.00288359 1 
NFKB2 3.44E-07 0.42787173 0.299 0.143 0.00658557 1 
BCL2A1 3.91E-07 0.58876783 0.255 0.118 0.00747862 1 
HNRNPA1 4.53E-07 0.2933883 0.897 0.732 0.0086627 1 
SERBP1 7.58E-07 0.28475216 0.69 0.466 0.01450354 1 
SRGN 9.83E-07 0.35166247 0.837 0.683 0.01880711 1 
APOBEC3G 1.33E-06 0.45136821 0.516 0.348 0.02549338 1 
SLA 1.66E-06 0.39317139 0.451 0.278 0.03178296 1 
TNFAIP8 2.35E-06 0.4668906 0.505 0.353 0.04489189 1 
RBM25 4.67E-06 0.35696498 0.69 0.529 0.08944149 1 
RBM3 5.00E-06 0.33820706 0.685 0.511 0.09579377 1 
FABP5 2.65E-54 1.36152237 0.907 0.291 5.08E-50 2 
NME1 2.63E-49 0.98345097 0.948 0.357 5.03E-45 2 
NPM1 5.81E-47 0.86380477 0.994 0.729 1.11E-42 2 
HSPD1 1.29E-46 1.10971007 0.919 0.385 2.48E-42 2 
HSPE1 1.24E-45 1.00330887 0.948 0.461 2.37E-41 2 
RAN 1.53E-45 0.88484139 0.994 0.709 2.92E-41 2 
PAICS 2.60E-41 0.74842898 0.669 0.135 4.97E-37 2 
PPIA 9.84E-41 0.68395059 0.994 0.808 1.88E-36 2 
UCK2 8.03E-38 0.67664916 0.459 0.056 1.54E-33 2 
TUBA1B 2.56E-36 0.76953371 0.971 0.512 4.91E-32 2 
NOP16 8.68E-36 0.82137481 0.622 0.14 1.66E-31 2 
SNRPD1 1.44E-35 0.76968624 0.86 0.316 2.76E-31 2 
RPL22L1 2.51E-35 0.78453929 0.727 0.214 4.81E-31 2 
SRM 4.85E-35 0.83229133 0.89 0.361 9.29E-31 2 
ATP1B3 7.26E-35 0.78759301 0.727 0.19 1.39E-30 2 
PDCD5 1.29E-34 0.70914641 0.779 0.221 2.47E-30 2 
RANBP1 1.36E-34 0.68490584 0.843 0.271 2.60E-30 2 
VDAC1 2.33E-34 0.7006048 0.895 0.357 4.46E-30 2 
NOP56 1.32E-33 0.73910075 0.86 0.311 2.53E-29 2 
PPP1R14B 1.34E-33 0.64219362 0.703 0.18 2.57E-29 2 
CCT6A 1.54E-33 0.67395248 0.843 0.283 2.94E-29 2 
MCM6 4.41E-33 0.63187004 0.494 0.085 8.44E-29 2 
LDHB 1.26E-32 0.75652882 0.965 0.548 2.41E-28 2 
EBNA1BP2 1.30E-32 0.63862676 0.715 0.184 2.48E-28 2 
PPA1 2.01E-32 0.70961348 0.849 0.29 3.85E-28 2 
SNRPF 3.40E-32 0.70490929 0.907 0.38 6.50E-28 2 
YWHAQ 7.18E-32 0.69495551 0.61 0.138 1.37E-27 2 
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PFDN2 1.03E-31 0.56047915 0.727 0.201 1.96E-27 2 
PRMT5 2.11E-31 0.59080468 0.372 0.043 4.03E-27 2 
HNRNPAB 5.87E-31 0.52597524 0.576 0.119 1.12E-26 2 
UQCRQ 6.51E-31 0.75554424 0.872 0.356 1.25E-26 2 
NCL 7.69E-31 0.63757274 0.994 0.655 1.47E-26 2 
RPF2 7.76E-31 0.64570924 0.738 0.217 1.48E-26 2 
CDK6 9.01E-31 0.66056551 0.669 0.176 1.73E-26 2 
XCL1 9.59E-31 1.39291227 0.866 0.419 1.84E-26 2 
TIMM17A 1.22E-30 0.52427434 0.512 0.097 2.33E-26 2 
YBX1 1.29E-30 0.73856237 0.907 0.419 2.47E-26 2 
MAGOHB 4.56E-30 0.50357494 0.535 0.106 8.73E-26 2 
PA2G4 9.14E-30 0.69056807 0.884 0.383 1.75E-25 2 
XCL2 1.57E-29 1.31460381 0.837 0.375 3.00E-25 2 
NOLC1 1.85E-29 0.60235638 0.669 0.182 3.55E-25 2 
CCL3 1.95E-29 1.70197601 0.733 0.271 3.73E-25 2 
CCT2 2.56E-29 0.67017831 0.715 0.222 4.91E-25 2 
SNRPE 2.91E-29 0.64765228 0.878 0.346 5.56E-25 2 
GPATCH4 3.83E-29 0.50784405 0.686 0.182 7.33E-25 2 
CCT5 7.72E-29 0.59835511 0.791 0.251 1.48E-24 2 
CKS2 1.06E-28 0.53018166 0.337 0.039 2.03E-24 2 
SLIRP 1.15E-28 0.58150961 0.814 0.266 2.19E-24 2 
CDK4 1.23E-28 0.57925291 0.57 0.132 2.35E-24 2 
HSP90AB1 9.29E-28 0.58531151 0.994 0.76 1.78E-23 2 
GGCT 1.04E-27 0.4640906 0.355 0.047 1.99E-23 2 
PRMT1 1.35E-27 0.51828973 0.622 0.161 2.58E-23 2 
NDUFAB1 1.37E-27 0.59132809 0.738 0.238 2.63E-23 2 
NME2 1.38E-27 0.6052963 0.773 0.251 2.65E-23 2 
CCND2 1.56E-27 0.68045705 0.907 0.419 2.99E-23 2 
NDUFB6 1.57E-27 0.51735916 0.733 0.214 3.01E-23 2 
GZMB 1.89E-27 0.9909016 0.971 0.736 3.61E-23 2 
LTA 2.73E-27 0.9538179 0.907 0.472 5.22E-23 2 
NAMPT 3.42E-27 0.77617256 0.651 0.201 6.54E-23 2 
TUBA1C 3.80E-27 0.58685644 0.791 0.266 7.27E-23 2 
SERBP1 6.64E-27 0.71748807 0.872 0.42 1.27E-22 2 
KPNA2 6.74E-27 0.39366273 0.39 0.06 1.29E-22 2 
DCTPP1 8.02E-27 0.56493559 0.587 0.15 1.54E-22 2 
STOML2 8.86E-27 0.44017558 0.686 0.203 1.70E-22 2 
EEF1E1 9.57E-27 0.51940756 0.61 0.163 1.83E-22 2 
RRP15 1.10E-26 0.35103155 0.605 0.145 2.11E-22 2 
TIMM13 1.70E-26 0.5303417 0.738 0.235 3.26E-22 2 
CCT7 1.73E-26 0.59964155 0.791 0.282 3.32E-22 2 
EIF1AX 2.24E-26 0.50985535 0.523 0.119 4.30E-22 2 
APEX1 2.80E-26 0.42340391 0.634 0.169 5.37E-22 2 
NHP2 3.38E-26 0.63713276 0.849 0.325 6.47E-22 2 
MRPL11 4.01E-26 0.61484268 0.535 0.127 7.67E-22 2 
SNRPB 5.39E-26 0.53557903 0.901 0.377 1.03E-21 2 
AK2 6.01E-26 0.36473889 0.576 0.138 1.15E-21 2 
TIMM8B 6.28E-26 0.6104385 0.64 0.184 1.20E-21 2 
SHMT2 7.17E-26 0.36887882 0.477 0.1 1.37E-21 2 
C1QBP 8.23E-26 0.6036162 0.901 0.401 1.58E-21 2 
IL2RA 9.90E-26 0.51692242 0.831 0.338 1.89E-21 2 
COPRS 1.14E-25 0.39184772 0.355 0.052 2.19E-21 2 
EXOSC4 1.55E-25 0.40007215 0.337 0.045 2.96E-21 2 
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SLC25A5 4.22E-25 0.64154186 0.942 0.525 8.07E-21 2 
CYCS 4.47E-25 0.59958274 0.831 0.353 8.55E-21 2 
GTPBP4 5.78E-25 0.47984145 0.581 0.151 1.11E-20 2 
CCT3 5.87E-25 0.5689834 0.791 0.296 1.12E-20 2 
ATP5PF 5.88E-25 0.55680042 0.837 0.327 1.13E-20 2 
MRPS18C 6.97E-25 0.56052944 0.576 0.155 1.33E-20 2 
CISD1 8.11E-25 0.39900859 0.401 0.071 1.55E-20 2 
MCM2 8.46E-25 0.49961089 0.331 0.047 1.62E-20 2 
IMPDH2 9.75E-25 0.55642404 0.709 0.225 1.87E-20 2 
TUBB 1.05E-24 0.58404915 0.936 0.444 2.00E-20 2 
TXNDC17 1.07E-24 0.49108671 0.686 0.211 2.05E-20 2 
TCP1 1.22E-24 0.57652825 0.68 0.211 2.33E-20 2 
MRPS12 1.66E-24 0.49940156 0.547 0.138 3.18E-20 2 
NUTF2 1.70E-24 0.53234137 0.622 0.18 3.26E-20 2 
PTMA 2.10E-24 0.4500378 1 0.892 4.02E-20 2 
TNFRSF9 2.29E-24 0.6127394 0.866 0.386 4.39E-20 2 
NDUFAF4 2.47E-24 0.40760496 0.471 0.103 4.72E-20 2 
MRPL17 3.36E-24 0.45165506 0.471 0.105 6.43E-20 2 
MRPL15 5.39E-24 0.38077222 0.36 0.058 1.03E-19 2 
MRPL51 5.56E-24 0.48559132 0.698 0.219 1.07E-19 2 
MCM7 7.36E-24 0.42630252 0.401 0.077 1.41E-19 2 
GTF2A2 9.55E-24 0.48172816 0.605 0.172 1.83E-19 2 
HOPX 1.12E-23 0.69492755 0.634 0.198 2.15E-19 2 
STIP1 2.02E-23 0.52594472 0.634 0.192 3.86E-19 2 
LTV1 2.09E-23 0.39379085 0.372 0.064 4.00E-19 2 
RPL7L1 2.62E-23 0.45158025 0.506 0.121 5.02E-19 2 
HELLS 3.45E-23 0.49024224 0.285 0.035 6.60E-19 2 
POMP 3.83E-23 0.53181957 0.919 0.436 7.34E-19 2 
WARS1 4.24E-23 0.42787616 0.686 0.214 8.11E-19 2 
VDAC2 4.33E-23 0.38122541 0.64 0.18 8.28E-19 2 
DHX15 4.36E-23 0.27850256 0.523 0.127 8.35E-19 2 
DTYMK 4.55E-23 0.36770428 0.343 0.055 8.70E-19 2 
TOMM40 4.61E-23 0.39951829 0.471 0.108 8.83E-19 2 
HSPA5 5.88E-23 0.47954167 0.849 0.338 1.12E-18 2 
NIFK 6.16E-23 0.4063055 0.529 0.135 1.18E-18 2 
CBX3 7.53E-23 0.40756638 0.727 0.233 1.44E-18 2 
DDX21 8.06E-23 0.50007764 0.86 0.366 1.54E-18 2 
PUM3 8.82E-23 0.40947963 0.599 0.166 1.69E-18 2 
EIF4A3 1.04E-22 0.42696276 0.698 0.227 1.99E-18 2 
MRPL3 1.20E-22 0.44229846 0.483 0.118 2.30E-18 2 
PSMB5 1.32E-22 0.43087426 0.558 0.151 2.52E-18 2 
GAR1 1.40E-22 0.35317809 0.349 0.058 2.68E-18 2 
DUT 1.46E-22 0.47075538 0.471 0.111 2.79E-18 2 
PGAM1 1.57E-22 0.40834116 0.419 0.087 3.00E-18 2 
PCNA 1.61E-22 0.40096232 0.471 0.111 3.08E-18 2 
SDHB 2.69E-22 0.47714675 0.616 0.19 5.16E-18 2 
POLR2H 2.77E-22 0.44001059 0.564 0.156 5.30E-18 2 
CCDC86 2.90E-22 0.28723641 0.302 0.042 5.55E-18 2 
CHCHD2 3.53E-22 0.50184175 0.953 0.583 6.75E-18 2 
TXN 4.13E-22 0.60633327 0.913 0.47 7.91E-18 2 
MRPL52 5.23E-22 0.50864313 0.779 0.291 1.00E-17 2 
ODC1 5.41E-22 0.49496337 0.599 0.18 1.04E-17 2 
LAG3 5.71E-22 0.46650056 0.581 0.177 1.09E-17 2 
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ZBED2 5.85E-22 0.57627967 0.413 0.09 1.12E-17 2 
HSPA8 7.48E-22 0.55030062 0.988 0.673 1.43E-17 2 
YRDC 7.70E-22 0.42322238 0.302 0.045 1.47E-17 2 
RUVBL2 1.09E-21 0.41676139 0.419 0.09 2.09E-17 2 
MRPS17 1.13E-21 0.39610042 0.331 0.056 2.16E-17 2 
CCT8 1.20E-21 0.52204447 0.709 0.25 2.29E-17 2 
MRPL23 1.23E-21 0.40788195 0.61 0.177 2.36E-17 2 
FKBP1A 1.43E-21 0.42967347 0.587 0.174 2.73E-17 2 
PNP 1.64E-21 0.40495431 0.366 0.071 3.14E-17 2 
PTS 1.75E-21 0.36088132 0.308 0.048 3.35E-17 2 
ZNF593 1.90E-21 0.41263135 0.552 0.155 3.64E-17 2 
TRAP1 2.03E-21 0.30866436 0.349 0.063 3.88E-17 2 
COX20 2.24E-21 0.48865794 0.634 0.2 4.29E-17 2 
COA4 2.86E-21 0.37777509 0.552 0.153 5.48E-17 2 
PSMA2 3.54E-21 0.56815966 0.866 0.414 6.77E-17 2 
TMA16 3.68E-21 0.34243382 0.331 0.056 7.04E-17 2 
PSMD1 3.81E-21 0.34359664 0.529 0.143 7.29E-17 2 
CCL4L2 5.53E-21 1.075962 0.645 0.261 1.06E-16 2 
ABCE1 5.72E-21 0.35854798 0.459 0.11 1.10E-16 2 
SSRP1 5.77E-21 0.45007666 0.564 0.166 1.11E-16 2 
PDIA6 6.68E-21 0.490534 0.901 0.403 1.28E-16 2 
SNRNP25 7.81E-21 0.43211418 0.453 0.111 1.49E-16 2 
MTHFD2 8.54E-21 0.4717169 0.61 0.198 1.63E-16 2 
TXN2 9.78E-21 0.29846936 0.459 0.111 1.87E-16 2 
PRDX4 1.15E-20 0.44095953 0.459 0.116 2.20E-16 2 
SSBP1 1.28E-20 0.52784465 0.826 0.367 2.44E-16 2 
CHORDC1 1.41E-20 0.35584121 0.465 0.116 2.70E-16 2 
PSMG1 1.41E-20 0.44870889 0.314 0.053 2.70E-16 2 
LYPLA1 1.63E-20 0.3760805 0.372 0.076 3.12E-16 2 
RBIS 1.70E-20 0.43903269 0.703 0.238 3.26E-16 2 
HNRNPD 1.71E-20 0.59139954 0.907 0.523 3.28E-16 2 
TKT 1.82E-20 0.36605496 0.372 0.076 3.49E-16 2 
PRDX1 1.93E-20 0.45155461 0.971 0.565 3.70E-16 2 
HMGN1 2.18E-20 0.40664384 0.767 0.282 4.18E-16 2 
SNRPD3 2.19E-20 0.42168568 0.698 0.242 4.19E-16 2 
TOMM22 2.56E-20 0.40991391 0.744 0.279 4.90E-16 2 
CTPS1 2.76E-20 0.37886546 0.453 0.113 5.29E-16 2 
EED 3.04E-20 0.3899639 0.308 0.052 5.82E-16 2 
TXNL1 3.34E-20 0.32258527 0.552 0.158 6.40E-16 2 
POLR3K 3.55E-20 0.31335945 0.413 0.093 6.80E-16 2 
PFDN4 3.78E-20 0.33359137 0.43 0.101 7.23E-16 2 
NOP14 3.86E-20 0.35310925 0.547 0.156 7.38E-16 2 
RBM8A 4.16E-20 0.4677362 0.948 0.494 7.96E-16 2 
MRPL4 4.85E-20 0.4125802 0.471 0.122 9.28E-16 2 
OLA1 4.89E-20 0.34196491 0.413 0.095 9.35E-16 2 
HSPA4 5.75E-20 0.32026626 0.558 0.164 1.10E-15 2 
CCT4 6.05E-20 0.38802344 0.692 0.248 1.16E-15 2 
PSMA1 6.08E-20 0.4629748 0.802 0.33 1.16E-15 2 
APRT 6.13E-20 0.45998542 0.942 0.49 1.17E-15 2 
PPM1G 9.18E-20 0.39220194 0.669 0.232 1.76E-15 2 
CENPX 9.65E-20 0.27515447 0.523 0.143 1.85E-15 2 
SNU13 1.07E-19 0.46984175 0.89 0.435 2.06E-15 2 
PRDX3 1.13E-19 0.33344791 0.5 0.138 2.16E-15 2 
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FARSA 1.19E-19 0.38835296 0.395 0.089 2.28E-15 2 
HNRNPF 1.23E-19 0.37784136 0.721 0.264 2.36E-15 2 
CD82 1.24E-19 0.39673108 0.529 0.153 2.37E-15 2 
SNRPC 1.38E-19 0.46012628 0.831 0.346 2.65E-15 2 
LSM6 1.39E-19 0.38998193 0.552 0.166 2.67E-15 2 
EIF5A 1.50E-19 0.55235496 0.89 0.459 2.87E-15 2 
UFM1 1.66E-19 0.30443484 0.523 0.145 3.17E-15 2 
PSMA5 1.68E-19 0.45072405 0.82 0.341 3.21E-15 2 
NAA20 1.74E-19 0.2802452 0.523 0.148 3.34E-15 2 
BOLA3 1.75E-19 0.40717517 0.57 0.174 3.34E-15 2 
PARK7 2.21E-19 0.4587251 0.948 0.544 4.23E-15 2 
PHB 2.31E-19 0.38648156 0.785 0.308 4.42E-15 2 
SF3B6 2.59E-19 0.44398816 0.68 0.243 4.96E-15 2 
FKBP4 2.72E-19 0.39940165 0.366 0.079 5.20E-15 2 
CHCHD3 2.81E-19 0.25430569 0.39 0.087 5.37E-15 2 
HSP90AA1 3.30E-19 0.396647 0.988 0.671 6.31E-15 2 
AHSA1 3.40E-19 0.38924382 0.552 0.169 6.51E-15 2 
ELOC 3.42E-19 0.44203601 0.709 0.259 6.54E-15 2 
POLR2F 3.71E-19 0.38924071 0.523 0.151 7.11E-15 2 
SIGMAR1 3.76E-19 0.34864755 0.378 0.084 7.20E-15 2 
MACROH2A1 3.79E-19 0.4409161 0.663 0.238 7.25E-15 2 
RPL26L1 4.19E-19 0.31342466 0.401 0.093 8.02E-15 2 
DESI1 5.14E-19 0.39683223 0.419 0.105 9.83E-15 2 
ZNF706 5.70E-19 0.3908907 0.663 0.222 1.09E-14 2 
HDDC2 6.50E-19 0.26488793 0.471 0.124 1.24E-14 2 
TSR1 6.98E-19 0.29223213 0.477 0.129 1.34E-14 2 
SLC25A39 7.67E-19 0.42289267 0.372 0.085 1.47E-14 2 
CCDC124 7.79E-19 0.35744815 0.39 0.09 1.49E-14 2 
LSM2 7.80E-19 0.29690177 0.535 0.158 1.49E-14 2 
BRIX1 8.03E-19 0.32339148 0.39 0.09 1.54E-14 2 
TOMM5 8.23E-19 0.35467544 0.5 0.137 1.58E-14 2 
DNAJA1 8.43E-19 0.4511757 0.849 0.411 1.61E-14 2 
RSL1D1 8.48E-19 0.4863053 0.779 0.335 1.62E-14 2 
WDR43 8.56E-19 0.44634607 0.581 0.188 1.64E-14 2 
HDAC2 8.67E-19 0.29016449 0.453 0.116 1.66E-14 2 
EXOSC8 8.76E-19 0.35505412 0.5 0.143 1.68E-14 2 
MRPL1 8.83E-19 0.35711264 0.424 0.105 1.69E-14 2 
CMSS1 9.99E-19 0.28603469 0.465 0.126 1.91E-14 2 
USP7 1.01E-18 0.30071101 0.453 0.116 1.94E-14 2 
PHB2 1.07E-18 0.36462744 0.634 0.214 2.05E-14 2 
ARPC5L 1.07E-18 0.36865474 0.669 0.235 2.05E-14 2 
MTHFD1L 1.15E-18 0.33860302 0.331 0.066 2.20E-14 2 
IFRD2 1.20E-18 0.33873034 0.343 0.071 2.30E-14 2 
SET 1.23E-18 0.52939939 0.913 0.477 2.35E-14 2 
PDHA1 1.27E-18 0.39110818 0.488 0.14 2.43E-14 2 
TBCA 1.29E-18 0.37780579 0.68 0.238 2.47E-14 2 
MRPL19 1.33E-18 0.36329494 0.36 0.079 2.54E-14 2 
SNRPG 1.69E-18 0.47253656 0.855 0.399 3.24E-14 2 
GNG5 1.78E-18 0.37180106 0.767 0.274 3.40E-14 2 
MMADHC 2.14E-18 0.30044717 0.488 0.134 4.09E-14 2 
NIP7 2.57E-18 0.38149296 0.378 0.089 4.92E-14 2 
ENO1 2.83E-18 0.3791286 0.988 0.783 5.41E-14 2 
DDX39A 2.95E-18 0.34475306 0.75 0.285 5.65E-14 2 
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COX17 3.17E-18 0.41105804 0.767 0.293 6.07E-14 2 
EXOSC3 3.20E-18 0.34478223 0.419 0.106 6.13E-14 2 
MRPS15 3.21E-18 0.36641939 0.541 0.169 6.14E-14 2 
SFXN1 3.41E-18 0.41755822 0.558 0.179 6.53E-14 2 
NDUFB3 3.87E-18 0.36312045 0.686 0.242 7.41E-14 2 
TMX1 4.21E-18 0.28251304 0.39 0.092 8.06E-14 2 
VPS25 4.35E-18 0.30999561 0.349 0.076 8.32E-14 2 
MRPL32 4.52E-18 0.46828376 0.436 0.119 8.64E-14 2 
NUDC 4.61E-18 0.34580831 0.791 0.322 8.82E-14 2 
MRPL12 4.99E-18 0.33731948 0.384 0.092 9.55E-14 2 
CD320 5.08E-18 0.35184832 0.407 0.103 9.72E-14 2 
ANTKMT 5.17E-18 0.2602557 0.32 0.064 9.90E-14 2 
MRPS26 5.18E-18 0.3914229 0.36 0.082 9.92E-14 2 
RRP9 5.21E-18 0.36758523 0.314 0.063 9.97E-14 2 
LSM5 5.31E-18 0.28168784 0.517 0.151 1.02E-13 2 
C19orf48 6.24E-18 0.29169949 0.36 0.081 1.19E-13 2 
AK6 6.25E-18 0.29321782 0.413 0.103 1.20E-13 2 
NUP37 6.75E-18 0.37017991 0.314 0.063 1.29E-13 2 
UQCRHL 7.11E-18 0.30211976 0.471 0.127 1.36E-13 2 
ADRM1 7.85E-18 0.31249827 0.576 0.18 1.50E-13 2 
SYNCRIP 7.97E-18 0.41286943 0.721 0.272 1.53E-13 2 
WDR12 8.12E-18 0.33333559 0.349 0.077 1.55E-13 2 
SRSF1 8.54E-18 0.32067393 0.378 0.089 1.64E-13 2 
TXNL4A 9.02E-18 0.39666329 0.733 0.279 1.73E-13 2 
MAGOH 9.02E-18 0.37486679 0.576 0.185 1.73E-13 2 
ALG3 9.27E-18 0.3476735 0.337 0.072 1.77E-13 2 
EGR2 9.65E-18 0.35601538 0.523 0.163 1.85E-13 2 
ANAPC11 1.15E-17 0.35990462 0.756 0.288 2.20E-13 2 
BATF3 1.15E-17 0.34208928 0.395 0.1 2.20E-13 2 
EIF2B3 1.31E-17 0.44072481 0.331 0.072 2.51E-13 2 
PSMD12 1.44E-17 0.37992227 0.436 0.119 2.75E-13 2 
FAM174C 1.51E-17 0.29503845 0.599 0.2 2.88E-13 2 
POLR3H 1.66E-17 0.30818569 0.297 0.056 3.19E-13 2 
BZW2 1.94E-17 0.33966173 0.355 0.082 3.71E-13 2 
MRPL21 2.15E-17 0.2803219 0.57 0.184 4.11E-13 2 
G3BP1 2.19E-17 0.42157879 0.715 0.277 4.19E-13 2 
IPO7 2.27E-17 0.31566724 0.465 0.132 4.34E-13 2 
NDUFC1 2.38E-17 0.32621993 0.622 0.213 4.56E-13 2 
PRELID1 2.45E-17 0.4218011 0.785 0.354 4.69E-13 2 
TIMMDC1 2.47E-17 0.34043857 0.349 0.079 4.72E-13 2 
MICOS13 2.66E-17 0.38932062 0.744 0.293 5.09E-13 2 
CCL4 2.73E-17 1.10769373 0.878 0.575 5.23E-13 2 
PSMD7 2.82E-17 0.39207206 0.64 0.229 5.40E-13 2 
FBL 2.87E-17 0.31055431 0.727 0.269 5.49E-13 2 
GZMH 2.94E-17 0.47257079 0.779 0.345 5.62E-13 2 
MDH2 3.16E-17 0.28554604 0.622 0.209 6.04E-13 2 
GEMIN6 3.57E-17 0.29507729 0.285 0.053 6.83E-13 2 
EIF2S2 3.73E-17 0.38489601 0.738 0.282 7.14E-13 2 
MTHFD1 3.77E-17 0.28762617 0.302 0.06 7.22E-13 2 
TMX2 4.45E-17 0.31858107 0.297 0.058 8.51E-13 2 
ILF3 4.68E-17 0.36899601 0.669 0.246 8.95E-13 2 
ATP6V0B 4.81E-17 0.38194191 0.523 0.169 9.20E-13 2 
SRP72 5.76E-17 0.31461757 0.448 0.126 1.10E-12 2 
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MRPL33 6.12E-17 0.33053277 0.558 0.182 1.17E-12 2 
IMP4 6.40E-17 0.2854359 0.523 0.164 1.23E-12 2 
STMP1 6.95E-17 0.28848294 0.366 0.087 1.33E-12 2 
EIF3I 7.03E-17 0.43030004 0.773 0.349 1.35E-12 2 
PINX1 7.74E-17 0.3091134 0.32 0.069 1.48E-12 2 
PDCD11 8.39E-17 0.27186049 0.395 0.1 1.61E-12 2 
ATP5F1C 8.56E-17 0.35647913 0.669 0.248 1.64E-12 2 
RPA3 8.64E-17 0.26688166 0.494 0.153 1.65E-12 2 
EIF3J 8.83E-17 0.30636756 0.558 0.179 1.69E-12 2 
MIF 9.77E-17 0.3836307 0.983 0.593 1.87E-12 2 
JTB 9.86E-17 0.36269775 0.657 0.243 1.89E-12 2 
TRMT10C 1.07E-16 0.27914878 0.442 0.122 2.05E-12 2 
MRPS16 1.09E-16 0.32601511 0.477 0.145 2.09E-12 2 
TMEM126A 1.22E-16 0.37129138 0.506 0.163 2.33E-12 2 
RBPJ 1.22E-16 0.39564475 0.605 0.222 2.34E-12 2 
PABPC4 1.25E-16 0.27647064 0.326 0.072 2.39E-12 2 
RPS24 1.34E-16 0.33175317 1 0.924 2.57E-12 2 
GRPEL1 1.39E-16 0.3490031 0.517 0.166 2.66E-12 2 
COPS3 1.40E-16 0.36342811 0.436 0.124 2.67E-12 2 
LDHA 1.45E-16 0.42472898 0.965 0.641 2.77E-12 2 
FAM136A 1.46E-16 0.3014786 0.378 0.095 2.79E-12 2 
GRSF1 1.63E-16 0.30302378 0.355 0.084 3.12E-12 2 
EEF2 1.63E-16 0.29583768 0.826 0.346 3.13E-12 2 
PSMD11 1.76E-16 0.41468723 0.605 0.225 3.36E-12 2 
NCBP2 1.81E-16 0.27702273 0.424 0.116 3.47E-12 2 
MTLN 2.06E-16 0.27105433 0.43 0.118 3.95E-12 2 
SMS 2.17E-16 0.36950267 0.407 0.113 4.16E-12 2 
CALM3 2.22E-16 0.38526432 0.715 0.295 4.26E-12 2 
COX5A 2.34E-16 0.41919555 0.791 0.357 4.49E-12 2 
PSMD14 2.53E-16 0.39972199 0.622 0.233 4.85E-12 2 
SLC35B1 2.63E-16 0.34563397 0.488 0.15 5.03E-12 2 
SNRPA1 2.66E-16 0.37599026 0.61 0.219 5.09E-12 2 
TNFRSF18 3.22E-16 0.38824436 0.581 0.214 6.17E-12 2 
DNAJB11 3.41E-16 0.32885467 0.506 0.163 6.52E-12 2 
NDFIP2 3.43E-16 0.28737006 0.36 0.09 6.56E-12 2 
HMGA1 3.60E-16 0.37639088 0.43 0.127 6.88E-12 2 
SS18L2 3.90E-16 0.34241045 0.407 0.113 7.47E-12 2 
MT1X 3.97E-16 0.3271454 0.448 0.132 7.60E-12 2 
TNFAIP8 4.10E-16 0.34290627 0.727 0.295 7.85E-12 2 
PPA2 4.38E-16 0.26161338 0.297 0.061 8.38E-12 2 
TUFM 4.39E-16 0.28915456 0.605 0.217 8.40E-12 2 
ZBTB32 4.63E-16 0.33380561 0.302 0.066 8.86E-12 2 
PPIL1 4.76E-16 0.32033794 0.273 0.053 9.10E-12 2 
BANF1 5.17E-16 0.34908113 0.727 0.277 9.90E-12 2 
AIMP2 5.25E-16 0.29577828 0.407 0.114 1.00E-11 2 
SEC11C 5.51E-16 0.33100782 0.727 0.285 1.06E-11 2 
MRTO4 5.58E-16 0.30459957 0.448 0.132 1.07E-11 2 
SRSF9 6.82E-16 0.33175287 0.744 0.295 1.31E-11 2 
NAA10 7.66E-16 0.29887618 0.622 0.224 1.47E-11 2 
EIF3E 8.38E-16 0.36230564 0.773 0.327 1.60E-11 2 
UQCRFS1 8.86E-16 0.32265814 0.529 0.174 1.70E-11 2 
PSMA7 8.87E-16 0.42173335 0.953 0.673 1.70E-11 2 
COA6 9.02E-16 0.33505194 0.366 0.095 1.73E-11 2 
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TSR3 9.40E-16 0.33948712 0.506 0.167 1.80E-11 2 
UBE2N 9.63E-16 0.28788431 0.651 0.232 1.84E-11 2 
TFRC 9.88E-16 0.32032154 0.424 0.121 1.89E-11 2 
NDUFC2 1.03E-15 0.31453278 0.669 0.242 1.98E-11 2 
OSTC 1.04E-15 0.34722303 0.628 0.235 1.99E-11 2 
GTF3C6 1.10E-15 0.2704062 0.61 0.216 2.11E-11 2 
DLD 1.20E-15 0.27449294 0.355 0.089 2.29E-11 2 
DENR 1.21E-15 0.31014174 0.43 0.126 2.31E-11 2 
UQCR10 1.25E-15 0.36382932 0.791 0.34 2.40E-11 2 
EIF3B 1.39E-15 0.32987947 0.529 0.172 2.65E-11 2 
SF3B5 1.45E-15 0.33013686 0.75 0.316 2.78E-11 2 
EIF5B 1.47E-15 0.37876905 0.82 0.359 2.81E-11 2 
CAPRIN1 1.52E-15 0.26034428 0.384 0.103 2.92E-11 2 
RBM17 1.60E-15 0.29699388 0.802 0.351 3.06E-11 2 
PPP4C 1.65E-15 0.37932437 0.488 0.161 3.16E-11 2 
YWHAE 1.77E-15 0.36025996 0.698 0.272 3.39E-11 2 
SRSF3 1.79E-15 0.38145162 0.936 0.554 3.43E-11 2 
C1D 1.82E-15 0.3025569 0.314 0.072 3.48E-11 2 
ELP5 1.85E-15 0.28587077 0.326 0.077 3.54E-11 2 
EIF4G1 1.93E-15 0.28955974 0.552 0.187 3.69E-11 2 
ATIC 2.01E-15 0.38026934 0.419 0.122 3.85E-11 2 
CDC123 2.09E-15 0.29619066 0.547 0.187 4.00E-11 2 
UTP11 2.15E-15 0.26181529 0.378 0.1 4.11E-11 2 
HSBP1 2.20E-15 0.25023965 0.442 0.134 4.21E-11 2 
BCL2L1 2.31E-15 0.28950568 0.326 0.077 4.43E-11 2 
DYNLL1 2.58E-15 0.32550855 0.651 0.25 4.94E-11 2 
SNRPD2 2.82E-15 0.33400189 0.994 0.721 5.40E-11 2 
GNL3 3.01E-15 0.2825976 0.622 0.229 5.76E-11 2 
EXOSC5 3.01E-15 0.33788809 0.291 0.066 5.77E-11 2 
IFNG 3.05E-15 0.72110879 0.564 0.224 5.84E-11 2 
GLRX3 3.09E-15 0.30688175 0.5 0.167 5.91E-11 2 
SIAH2 3.14E-15 0.34667008 0.407 0.119 6.00E-11 2 
BOP1 3.34E-15 0.30430136 0.273 0.056 6.39E-11 2 
C12orf45 3.42E-15 0.28808005 0.308 0.071 6.55E-11 2 
ETFA 3.61E-15 0.26864731 0.366 0.097 6.90E-11 2 
METAP2 3.64E-15 0.26736925 0.535 0.184 6.96E-11 2 
PNO1 4.05E-15 0.26591676 0.395 0.11 7.75E-11 2 
HNRNPA1 4.22E-15 0.41070592 0.994 0.709 8.07E-11 2 
DNMT1 4.50E-15 0.33643867 0.552 0.195 8.61E-11 2 
TIMM10 4.72E-15 0.32521244 0.512 0.172 9.04E-11 2 
PSMB6 5.46E-15 0.3598201 0.849 0.419 1.04E-10 2 
MYDGF 5.58E-15 0.28330858 0.657 0.246 1.07E-10 2 
ENY2 6.05E-15 0.30654025 0.628 0.232 1.16E-10 2 
ATP5F1A 6.38E-15 0.3065446 0.756 0.316 1.22E-10 2 
ILF2 6.66E-15 0.34810373 0.651 0.256 1.27E-10 2 
TSTA3 6.83E-15 0.32580269 0.39 0.111 1.31E-10 2 
MRPL41 7.12E-15 0.34158646 0.61 0.233 1.36E-10 2 
COPS9 8.33E-15 0.27369908 0.64 0.243 1.59E-10 2 
MRPL20 8.66E-15 0.41728286 0.744 0.338 1.66E-10 2 
PDIA3 9.06E-15 0.29337781 0.785 0.343 1.73E-10 2 
SEC61B 9.16E-15 0.40468703 0.93 0.488 1.75E-10 2 
MRPS25 9.25E-15 0.28678992 0.407 0.119 1.77E-10 2 
PSMC2 9.43E-15 0.27035539 0.436 0.134 1.81E-10 2 
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JPT1 9.69E-15 0.31597719 0.599 0.225 1.85E-10 2 
CIAO2B 1.09E-14 0.3122099 0.68 0.282 2.09E-10 2 
NIT2 1.10E-14 0.2782726 0.331 0.084 2.11E-10 2 
TMPO 1.23E-14 0.25828659 0.581 0.208 2.35E-10 2 
NDUFS6 1.36E-14 0.33817503 0.692 0.282 2.60E-10 2 
EIF6 1.57E-14 0.27469052 0.64 0.254 3.01E-10 2 
MRPL13 1.99E-14 0.26540464 0.5 0.166 3.82E-10 2 
TUBB4B 2.10E-14 0.29436937 0.703 0.287 4.01E-10 2 
CCDC167 2.15E-14 0.27815728 0.436 0.14 4.11E-10 2 
NOL7 2.19E-14 0.32679062 0.703 0.291 4.20E-10 2 
CBR1 2.26E-14 0.25041618 0.285 0.064 4.33E-10 2 
MANF 2.39E-14 0.29106487 0.448 0.143 4.57E-10 2 
RAB10 2.59E-14 0.2795237 0.407 0.122 4.96E-10 2 
MRPL40 2.67E-14 0.2697203 0.32 0.081 5.11E-10 2 
RPL35 2.71E-14 0.32525361 1 0.945 5.18E-10 2 
ATP5MC3 2.80E-14 0.3644905 0.872 0.462 5.36E-10 2 
NDUFA4 2.91E-14 0.349569 0.907 0.498 5.56E-10 2 
ATP5MPL 2.93E-14 0.3335694 0.785 0.357 5.61E-10 2 
FTSJ3 3.07E-14 0.28880817 0.326 0.084 5.87E-10 2 
NDUFS8 3.11E-14 0.27791693 0.64 0.246 5.95E-10 2 
PSMB2 3.13E-14 0.28110162 0.762 0.324 5.99E-10 2 
PARP1 3.44E-14 0.25382287 0.523 0.184 6.59E-10 2 
CCDC85B 3.54E-14 0.27671778 0.488 0.158 6.77E-10 2 
ARL1 3.67E-14 0.25262642 0.302 0.072 7.03E-10 2 
NDUFA10 3.85E-14 0.27393101 0.506 0.172 7.37E-10 2 
PSMB7 5.20E-14 0.30955754 0.75 0.335 9.96E-10 2 
ATP5F1D 5.21E-14 0.3217707 0.802 0.364 9.97E-10 2 
MRPL47 5.23E-14 0.26097815 0.424 0.13 1.00E-09 2 
DPM2 5.26E-14 0.29906805 0.512 0.176 1.01E-09 2 
EID1 5.49E-14 0.34897846 0.512 0.19 1.05E-09 2 
UQCC2 5.76E-14 0.32581185 0.442 0.148 1.10E-09 2 
TIMM23 5.79E-14 0.37388482 0.407 0.127 1.11E-09 2 
MCTS1 6.17E-14 0.28313883 0.395 0.119 1.18E-09 2 
SNRPA 6.68E-14 0.25401736 0.401 0.121 1.28E-09 2 
CHCHD10 6.81E-14 0.34159155 0.686 0.298 1.30E-09 2 
EIF4G2 6.84E-14 0.31805099 0.733 0.317 1.31E-09 2 
CRTAM 7.47E-14 0.32867279 0.587 0.235 1.43E-09 2 
TMEM147 7.50E-14 0.30902668 0.581 0.222 1.43E-09 2 
PSMA3 8.56E-14 0.3862143 0.733 0.349 1.64E-09 2 
CCDC58 9.34E-14 0.26632811 0.279 0.064 1.79E-09 2 
ID2 9.54E-14 0.37296729 0.791 0.388 1.83E-09 2 
POLR2L 9.89E-14 0.34936379 0.878 0.425 1.89E-09 2 
LAMTOR2 9.92E-14 0.25313361 0.395 0.119 1.90E-09 2 
KARS1 1.04E-13 0.26413471 0.581 0.216 1.99E-09 2 
EPRS1 1.17E-13 0.26004383 0.494 0.171 2.24E-09 2 
SEM1 1.20E-13 0.30430578 0.767 0.343 2.30E-09 2 
PTGES3 1.38E-13 0.30031845 0.797 0.37 2.64E-09 2 
LARP4 1.56E-13 0.34104855 0.401 0.126 2.98E-09 2 
KPNB1 1.63E-13 0.32435251 0.506 0.177 3.12E-09 2 
FKBP11 1.68E-13 0.28924395 0.576 0.221 3.22E-09 2 
RBFA 1.89E-13 0.25426931 0.326 0.087 3.62E-09 2 
TRAPPC4 1.92E-13 0.3109763 0.401 0.126 3.68E-09 2 
EIF3M 1.99E-13 0.31530968 0.767 0.348 3.81E-09 2 
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STRAP 2.02E-13 0.27289395 0.419 0.132 3.87E-09 2 
WDR61 2.05E-13 0.27029851 0.32 0.085 3.93E-09 2 
UQCRH 2.26E-13 0.29079254 0.872 0.422 4.32E-09 2 
MRPL36 2.31E-13 0.3396314 0.343 0.098 4.42E-09 2 
ACP1 2.33E-13 0.29593564 0.552 0.211 4.45E-09 2 
SDHD 2.45E-13 0.27068927 0.395 0.121 4.69E-09 2 
LAGE3 2.54E-13 0.26244088 0.43 0.14 4.86E-09 2 
LSM4 2.81E-13 0.27598349 0.436 0.145 5.39E-09 2 
POLR2I 2.94E-13 0.27488518 0.529 0.193 5.64E-09 2 
PSMB1 3.14E-13 0.31305756 0.855 0.459 6.01E-09 2 
HNRNPA2B1 3.37E-13 0.35460789 0.977 0.683 6.46E-09 2 
VCP 4.30E-13 0.27468675 0.552 0.208 8.24E-09 2 
CALM2 4.54E-13 0.31381608 0.855 0.464 8.69E-09 2 
ACTG1 4.86E-13 0.33443124 1 0.865 9.30E-09 2 
MRPS28 5.21E-13 0.25180179 0.273 0.066 9.96E-09 2 
NASP 5.56E-13 0.3025024 0.657 0.279 1.06E-08 2 
RPS19BP1 5.71E-13 0.26053137 0.506 0.184 1.09E-08 2 
HSPBP1 6.07E-13 0.27369634 0.273 0.066 1.16E-08 2 
MICOS10 6.21E-13 0.32220197 0.628 0.258 1.19E-08 2 
PSMB3 7.30E-13 0.29848396 0.866 0.454 1.40E-08 2 
XRCC5 7.42E-13 0.30783922 0.791 0.37 1.42E-08 2 
H2AZ1 7.96E-13 0.30969897 0.703 0.312 1.52E-08 2 
SLC25A3 8.13E-13 0.29350091 0.826 0.424 1.56E-08 2 
SPCS1 8.23E-13 0.27811461 0.773 0.346 1.58E-08 2 
PDIA4 1.04E-12 0.27249448 0.308 0.085 1.98E-08 2 
ATP5MC1 1.15E-12 0.28931748 0.721 0.322 2.19E-08 2 
XRCC6 1.25E-12 0.28999247 0.756 0.335 2.39E-08 2 
NUDCD2 1.26E-12 0.26930954 0.302 0.081 2.41E-08 2 
SEC61G 1.32E-12 0.34171605 0.878 0.427 2.52E-08 2 
RSL24D1 1.35E-12 0.32994296 0.61 0.256 2.59E-08 2 
VRK1 1.44E-12 0.28080608 0.285 0.074 2.76E-08 2 
UBE2F 1.65E-12 0.27579161 0.349 0.106 3.16E-08 2 
PABPC1 1.93E-12 0.41513807 1 0.826 3.70E-08 2 
GLRX5 1.99E-12 0.29963987 0.349 0.106 3.81E-08 2 
PWP1 2.05E-12 0.28658099 0.5 0.185 3.93E-08 2 
HIGD1A 2.13E-12 0.33828951 0.355 0.11 4.08E-08 2 
ATP5MD 2.65E-12 0.34839166 0.814 0.406 5.08E-08 2 
NOP10 2.83E-12 0.32731169 0.669 0.301 5.42E-08 2 
HEATR1 3.84E-12 0.29922092 0.343 0.106 7.35E-08 2 
PPIH 4.32E-12 0.25008484 0.43 0.148 8.26E-08 2 
ANP32B 4.52E-12 0.25421589 0.686 0.3 8.65E-08 2 
LMNA 4.99E-12 0.38217395 0.413 0.148 9.54E-08 2 
PPP1CC 5.31E-12 0.30528239 0.291 0.081 1.02E-07 2 
MRPL34 7.67E-12 0.26791051 0.308 0.089 1.47E-07 2 
PSMC1 8.42E-12 0.25242557 0.337 0.101 1.61E-07 2 
IER3 8.80E-12 0.26413012 0.285 0.077 1.68E-07 2 
RABGGTB 9.62E-12 0.28495895 0.448 0.163 1.84E-07 2 
EIF4E 1.14E-11 0.26542558 0.343 0.106 2.18E-07 2 
HNRNPDL 1.47E-11 0.26229665 0.971 0.586 2.82E-07 2 
GADD45GIP1 1.56E-11 0.27101856 0.843 0.425 2.98E-07 2 
GUSB 1.90E-11 0.27437405 0.273 0.074 3.64E-07 2 
COX6A1 1.92E-11 0.26981518 0.86 0.43 3.68E-07 2 
ATP5F1B 1.99E-11 0.2817224 0.814 0.415 3.80E-07 2 
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PSMD9 2.60E-11 0.26679821 0.331 0.103 4.97E-07 2 
TNFRSF1B 2.72E-11 0.35929113 0.547 0.229 5.20E-07 2 
GPR171 3.11E-11 0.28181517 0.552 0.233 5.96E-07 2 
ATP5ME 3.12E-11 0.33192119 0.866 0.448 5.98E-07 2 
PKM 3.92E-11 0.32521647 0.965 0.612 7.50E-07 2 
LSM7 4.11E-11 0.26905873 0.663 0.3 7.86E-07 2 
PSMB4 4.37E-11 0.2651322 0.767 0.385 8.36E-07 2 
SDF2L1 4.39E-11 0.2654034 0.657 0.303 8.41E-07 2 
COA3 4.95E-11 0.2750954 0.366 0.124 9.47E-07 2 
C11orf58 5.18E-11 0.25153094 0.651 0.291 9.91E-07 2 
HSPA9 5.38E-11 0.26711413 0.599 0.259 1.03E-06 2 
CNBP 5.84E-11 0.29207271 0.93 0.543 1.12E-06 2 
NDUFB2 7.10E-11 0.26099132 0.814 0.42 1.36E-06 2 
RPS17 2.74E-10 0.27311631 0.988 0.82 5.25E-06 2 
PPIB 2.77E-10 0.29791343 0.953 0.639 5.31E-06 2 
TRMT112 2.94E-10 0.27407156 0.849 0.494 5.64E-06 2 
ATP5MC2 3.06E-10 0.28304271 0.948 0.626 5.85E-06 2 
HNRNPA3 3.22E-10 0.30023387 0.843 0.446 6.16E-06 2 
ITM2A 1.82E-09 0.26510255 0.5 0.221 3.48E-05 2 
BTF3 2.52E-09 0.26049435 0.959 0.725 4.82E-05 2 
COX6C 3.67E-09 0.2603818 0.843 0.457 7.02E-05 2 
HNRNPC 4.25E-09 0.25125859 0.866 0.494 8.13E-05 2 
ATP5F1E 4.47E-09 0.25525418 0.994 0.776 8.57E-05 2 
UQCR11 1.01E-08 0.28020323 0.866 0.493 0.00019371 2 
LGALS1 1.90E-30 1.35099155 0.899 0.276 3.63E-26 3 
IL32 2.38E-28 1.18945591 0.986 0.729 4.55E-24 3 
DPP4 3.29E-26 0.82923132 0.551 0.091 6.29E-22 3 
PFN1 3.56E-21 0.69043123 1 0.895 6.81E-17 3 
S100A6 1.40E-20 0.98652364 0.986 0.635 2.68E-16 3 
IFITM2 4.13E-19 0.89326635 0.971 0.58 7.91E-15 3 
TMSB10 4.30E-19 0.66453429 1 0.932 8.24E-15 3 
FXYD2 5.65E-19 0.77138186 0.275 0.029 1.08E-14 3 
S100A11 4.82E-17 0.92798884 0.797 0.343 9.23E-13 3 
IFITM3 9.52E-16 0.68599878 0.797 0.327 1.82E-11 3 
TXN 1.28E-15 0.80343173 0.928 0.532 2.45E-11 3 
ADAM19 2.10E-15 0.67155978 0.406 0.087 4.02E-11 3 
S100A4 2.71E-15 0.99094598 0.899 0.511 5.18E-11 3 
RPL28 3.78E-14 0.35413019 1 0.979 7.23E-10 3 
ENO1 1.07E-13 0.50708656 1 0.811 2.04E-09 3 
RPS12 6.76E-13 0.30363154 1 0.992 1.29E-08 3 
LTB 3.69E-12 0.66213331 0.942 0.608 7.07E-08 3 
SOS1 5.83E-12 0.45689109 0.435 0.117 1.12E-07 3 
CD226 1.38E-11 0.39220794 0.435 0.119 2.63E-07 3 
FTL 2.38E-11 0.53806564 0.971 0.903 4.55E-07 3 
MIF 2.41E-11 0.61182259 0.942 0.652 4.62E-07 3 
TUBA1B 2.53E-11 0.55492469 0.971 0.577 4.85E-07 3 
ACTB 3.77E-11 0.45457025 1 0.898 7.22E-07 3 
CORO1A 3.85E-11 0.52532743 0.942 0.566 7.37E-07 3 
ACTG1 5.01E-11 0.48081226 1 0.884 9.58E-07 3 
MYL6 7.26E-11 0.44064336 1 0.903 1.39E-06 3 
PSME1 1.16E-10 0.55303825 0.986 0.789 2.23E-06 3 
DOCK2 1.47E-10 0.37607056 0.71 0.28 2.82E-06 3 
MYL12A 1.52E-10 0.5341882 0.942 0.615 2.91E-06 3 
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DEGS1 7.89E-10 0.43052824 0.362 0.104 1.51E-05 3 
PGK1 9.35E-10 0.45856648 0.942 0.535 1.79E-05 3 
TPI1 1.09E-09 0.4726993 1 0.689 2.08E-05 3 
RPS18 1.28E-09 0.31772843 1 0.974 2.46E-05 3 
TYMP 1.59E-09 0.52103169 0.609 0.249 3.03E-05 3 
S100A10 1.81E-09 0.51549207 0.855 0.522 3.47E-05 3 
IFITM1 2.17E-09 0.4047328 0.899 0.543 4.16E-05 3 
VAMP8 2.84E-09 0.36953536 0.609 0.244 5.44E-05 3 
CARD19 3.82E-09 0.39266431 0.348 0.098 7.32E-05 3 
GSTP1 4.98E-09 0.47086202 0.942 0.62 9.54E-05 3 
PSME2 5.21E-09 0.51502358 0.971 0.704 9.97E-05 3 
GRAP2 6.73E-09 0.36011125 0.304 0.077 0.00012884 3 
ATP5MD 7.70E-09 0.48159705 0.855 0.46 0.00014736 3 
RPL32 7.84E-09 0.27468828 1 0.956 0.00015 3 
STX8 8.89E-09 0.36432679 0.406 0.134 0.00017026 3 
LPXN 1.76E-08 0.3856228 0.551 0.222 0.00033633 3 
FLT3LG 2.46E-08 0.50338696 0.391 0.135 0.00047159 3 
PSMA2 3.21E-08 0.44944387 0.87 0.478 0.00061536 3 
GAPDH 4.03E-08 0.39173643 1 0.93 0.0007716 3 
LDHA 4.35E-08 0.44432872 0.928 0.691 0.00083328 3 
PHLDA1 5.57E-08 0.53969519 0.42 0.159 0.00106601 3 
MICOS13 5.93E-08 0.45274389 0.725 0.359 0.00113497 3 
PPIA 6.45E-08 0.41210246 1 0.834 0.00123552 3 
PHPT1 6.94E-08 0.37189057 0.681 0.308 0.00132852 3 
CFL1 7.42E-08 0.42846372 0.986 0.825 0.00142003 3 
H2AZ1 8.82E-08 0.39259598 0.71 0.367 0.00168861 3 
PSMB10 1.06E-07 0.41061258 0.536 0.222 0.00202873 3 
RBM3 1.42E-07 0.48643362 0.826 0.525 0.00272508 3 
HINT1 2.82E-07 0.39120627 0.971 0.693 0.00539324 3 
RPL35 3.63E-07 0.28674569 1 0.953 0.00694717 3 
NQO2 5.13E-07 0.31782187 0.275 0.083 0.00981536 3 
NAA10 5.87E-07 0.40635357 0.594 0.283 0.01123615 3 
CD48 6.24E-07 0.38873636 0.826 0.506 0.01195032 3 
TPM4 1.15E-06 0.36945972 0.58 0.289 0.02209737 3 
NDUFA4 1.19E-06 0.37265193 0.87 0.559 0.02273068 3 
COX17 1.39E-06 0.50393626 0.652 0.372 0.0265907 3 
SAMHD1 1.39E-06 0.25626036 0.406 0.151 0.02667328 3 
BANF1 1.39E-06 0.34676005 0.667 0.347 0.02669692 3 
TMEM205 1.59E-06 0.34134762 0.319 0.11 0.03049209 3 
ANXA2 1.67E-06 0.40857243 0.826 0.477 0.03192435 3 
RBX1 1.90E-06 0.35552265 0.797 0.454 0.03630383 3 
MYH9 2.17E-06 0.31711668 0.522 0.239 0.04148949 3 
COX7B 2.18E-06 0.41328789 0.797 0.496 0.04164692 3 
EMP3 2.27E-06 0.47270246 0.754 0.46 0.04347912 3 
NDUFB3 2.42E-06 0.37704594 0.609 0.312 0.04637423 3 
CCND3 2.44E-06 0.45074178 0.42 0.177 0.04661694 3 
LAMTOR5 2.78E-06 0.28337013 0.667 0.331 0.0531842 3 
LGALS3 2.99E-06 0.49247955 0.507 0.246 0.05723925 3 
LARP1 3.21E-06 0.40317437 0.391 0.164 0.06153132 3 
GBP5 3.62E-06 0.49214541 0.739 0.435 0.06923862 3 
PSMA3 3.92E-06 0.37498142 0.725 0.405 0.07506674 3 
TASOR2 4.18E-06 0.28196247 0.377 0.146 0.08004885 3 
POLR2L 4.37E-06 0.30227942 0.826 0.494 0.08369872 3 
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ATP5ME 4.61E-06 0.35664512 0.812 0.512 0.08824015 3 
IARS1 4.74E-06 0.30963499 0.507 0.242 0.09070206 3 
DNAJB1 7.52E-19 2.78445633 0.485 0.124 1.44E-14 4 
CTLA4 7.63E-18 1.82275801 0.324 0.05 1.46E-13 4 
MXI1 1.98E-16 1.3131949 0.279 0.039 3.79E-12 4 
PDK1 9.81E-13 1.1526276 0.279 0.054 1.88E-08 4 
SAT1 3.11E-12 1.39330145 0.544 0.219 5.95E-08 4 
PELI1 3.82E-11 0.9717616 0.265 0.054 7.31E-07 4 
BNIP3L 5.47E-11 1.44399775 0.324 0.084 1.05E-06 4 
SNX9 7.41E-11 1.2623538 0.309 0.079 1.42E-06 4 
EIF4A2 2.28E-10 1.05583888 0.691 0.432 4.37E-06 4 
PLIN2 3.40E-10 1.74214994 0.353 0.11 6.52E-06 4 
SLC2A3 1.64E-08 1.59346981 0.265 0.073 0.00031366 4 
BACH1 6.18E-08 1.2334436 0.338 0.124 0.00118334 4 
MTRNR2L1 1.33E-07 1.18972366 0.647 0.494 0.00254906 4 
CXCR4 1.67E-07 1.20306245 0.676 0.51 0.00318885 4 
CYTIP 7.73E-07 1.20259955 0.544 0.363 0.01479443 4 
RORA 4.12E-06 0.85740688 0.574 0.385 0.07880731 4 





Table 3-6. Differentially expressed genes (padj<0.1) in biplots showing logFC(LLN/Spleen) 
vs. logFC(Lung/Spleen) and logFC(BM/Spleen) vs. logFC(LLN/Spleen) and 
logFC(BM/Spleen) vs. logFC(Lung/Spleen). 
gene Lung_logFC LLN_logFC BM_logFC LLN vs. Lung Lung vs. BM LLN vs. BM 
ACTB -1.31061 -0.14475 -0.37535 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
ACTG1 -1.04618 0.01087 -0.42567 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
AHNAK 0.83526 0.82090 0.52626 Sig Diff. in LLN NS Sig Diff. in LLN 
ANKRD28 0.86709 0.39852 0.30325 Sig Diff. in Lung Sig Diff. in Lung NS 
ANP32E -0.62827 -0.39657 -0.34317 Sig Diff. in Lung Sig Diff. in Lung NS 
ANXA2 -0.54478 0.16121 -0.23606 Sig Diff. in Lung Sig Diff. in Lung NS 
AP2M1 -0.80208 -0.24230 -0.39447 Sig Diff. in Lung Sig Diff. in Lung NS 
APEX1 -0.66581 -0.44377 -0.45355 Sig Diff. in Lung Sig Diff. in Lung NS 
APOBEC3G -0.77999 -0.44441 -0.19455 Sig Diff. in Lung Sig Diff. in Lung NS 
APOL6 0.16001 0.37683 0.60498 Sig Diff. in LLN NS Sig Diff. in LLN 
APRT -0.60507 0.31108 -0.04820 Sig Diff. in Lung Sig Diff. in Lung NS 
ARF6 -0.40629 -0.57357 -0.49634 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
ARHGDIA -0.43462 -0.36927 -0.46115 NS Sig Diff. in BM Sig Diff. in BM 
ARPC1B -0.56150 -0.13998 -0.42772 Sig Diff. in Lung Sig Diff. in Lung NS 
ARPC2 -0.41005 -0.42729 -0.47312 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
ARPC5L -0.80008 -0.37847 -0.27559 Sig Diff. in Lung Sig Diff. in Lung NS 
ATP1B3 -0.92810 -0.08178 -0.04505 Sig Diff. in Lung Sig Diff. in Lung NS 
ATP5F1A -0.80716 0.07338 -0.08241 Sig Diff. in Lung Sig Diff. in Lung NS 
ATP5F1B -0.54166 -0.13292 -0.54540 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
ATP5F1E -0.32222 0.38935 0.12883 Sig Diff. in LLN NS Sig Diff. in LLN 
ATP5MC3 -0.34797 0.37913 0.17169 Sig Diff. in LLN NS Sig Diff. in LLN 
ATP5MD -0.21686 0.33772 0.11158 Sig Diff. in LLN NS Sig Diff. in LLN 
ATP5ME -0.57271 0.22790 -0.00299 Sig Diff. in Lung Sig Diff. in Lung NS 
ATP5MPL -0.66418 0.20503 -0.07274 Sig Diff. in Lung Sig Diff. in Lung NS 
ATP5PB -0.35833 0.42991 -0.07501 Sig Diff. in LLN NS Sig Diff. in LLN 
ATP5PF -0.65412 0.22563 0.07200 Sig Diff. in Lung Sig Diff. in Lung NS 
ATP6V0E1 -0.53127 -0.08867 -0.00142 Sig Diff. in Lung Sig Diff. in Lung NS 
ATRX 0.01218 -0.65030 -0.13483 Sig Diff. in LLN NS Sig Diff. in LLN 
AZIN1 -0.02527 0.28630 0.31154 Sig Diff. in LLN NS Sig Diff. in LLN 
B2M 0.06951 0.01942 0.32177 NS Sig Diff. in BM Sig Diff. in BM 
B3GALT6 -0.63732 -0.41043 -0.54283 NS Sig Diff. in BM Sig Diff. in BM 
BACH1 1.23531 0.24702 0.27405 Sig Diff. in Lung Sig Diff. in Lung NS 
BATF 0.14618 -0.06566 -0.79547 NS Sig Diff. in BM Sig Diff. in BM 
BCAP31 -0.76481 -0.34652 -0.43790 Sig Diff. in Lung Sig Diff. in Lung NS 
BCL2A1 -0.30290 -0.01507 -0.50781 NS Sig Diff. in BM Sig Diff. in BM 
BNIP3L 1.57940 0.22010 0.29723 Sig Diff. in Lung Sig Diff. in Lung NS 
BST2 -0.70658 0.08005 0.34112 Sig Diff. in Lung Sig Diff. in Lung NS 
BTG1 0.89275 -0.70966 -0.12321 Sig Diff. in LLN NS Sig Diff. in LLN 
C1QBP -0.76573 0.24122 -0.07206 Sig Diff. in Lung Sig Diff. in Lung NS 
CALM3 -0.74353 -0.34866 -0.33672 Sig Diff. in Lung Sig Diff. in Lung NS 
CALR -1.15023 -0.33740 -0.19989 Sig Diff. in Lung Sig Diff. in Lung NS 
CAPNS1 -0.49026 -0.59249 -0.45861 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
CCDC85B -0.78595 -0.24876 -0.17631 Sig Diff. in Lung Sig Diff. in Lung NS 
CCL3 -1.02642 -0.97763 -0.00289 Sig Diff. in Lung Sig Diff. in Lung NS 
CCL4 -1.60002 -0.84786 -0.08291 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
CCL4L2 -1.61812 -1.09489 -0.19317 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
CCL5 -0.30340 -1.01989 0.29366 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
CCND2 -0.70641 0.04670 -0.10775 Sig Diff. in Lung Sig Diff. in Lung NS 
CCNI -0.37584 -1.04345 -0.58016 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
CCT3 -0.69296 -0.10845 -0.47815 Sig Diff. in Lung Sig Diff. in Lung NS 
CCT5 -0.44942 0.18599 -0.16255 Sig Diff. in Lung Sig Diff. in Lung NS 
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CCT6A -0.88863 -0.16645 -0.47656 Sig Diff. in Lung Sig Diff. in Lung NS 
CCT7 -0.69699 0.21915 -0.09938 Sig Diff. in Lung Sig Diff. in Lung NS 
CCT8 -0.69498 0.29784 -0.02320 Sig Diff. in Lung Sig Diff. in Lung NS 
CD226 0.23130 0.32851 0.06901 Sig Diff. in LLN NS Sig Diff. in LLN 
CD27 -0.75279 -0.55924 -0.79564 NS Sig Diff. in BM Sig Diff. in BM 
CD38 0.12582 0.10830 0.77199 NS Sig Diff. in BM Sig Diff. in BM 
CD3D -0.43186 -0.19404 -0.23112 Sig Diff. in Lung Sig Diff. in Lung NS 
CD74 -0.38106 -0.11323 0.36300 Sig Diff. in Lung Sig Diff. in Lung NS 
CD82 -0.83264 -0.53406 -0.69718 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
CD8A -1.06291 -0.61431 -0.37466 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
CDK6 -0.66799 -0.18506 -0.24914 Sig Diff. in Lung Sig Diff. in Lung NS 
CDKAL1 0.48360 0.36539 0.22379 Sig Diff. in LLN NS Sig Diff. in LLN 
CFL1 -0.82120 0.02533 -0.25433 Sig Diff. in Lung Sig Diff. in Lung NS 
CISH -0.71700 -0.15362 -0.47987 Sig Diff. in Lung Sig Diff. in Lung NS 
CLDND1 0.08339 -0.01501 -0.44053 NS Sig Diff. in BM Sig Diff. in BM 
CLIC1 -0.62565 0.01832 -0.30932 Sig Diff. in Lung Sig Diff. in Lung NS 
CLTC 0.17578 0.50664 0.44148 Sig Diff. in LLN NS Sig Diff. in LLN 
COPS6 -0.70463 -0.39234 -0.41164 Sig Diff. in Lung Sig Diff. in Lung NS 
CORO1A -1.46552 0.09127 -0.37267 Sig Diff. in Lung Sig Diff. in Lung NS 
COTL1 -0.76910 -0.36376 -0.55821 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
COX5A 0.16097 0.41174 0.18516 Sig Diff. in LLN NS Sig Diff. in LLN 
COX6B1 -0.11534 0.32378 0.22189 Sig Diff. in LLN NS Sig Diff. in LLN 
COX6C -0.06230 0.37541 0.14366 Sig Diff. in LLN NS Sig Diff. in LLN 
COX7A2 0.12244 0.36250 0.16469 Sig Diff. in LLN NS Sig Diff. in LLN 
COX7B -0.32466 0.39736 0.07514 Sig Diff. in LLN NS Sig Diff. in LLN 
COX7C 0.11498 0.29726 0.06749 Sig Diff. in LLN NS Sig Diff. in LLN 
CRTAM -1.54816 -0.46291 -0.42725 Sig Diff. in Lung Sig Diff. in Lung NS 
CSNK2B -0.07158 0.38604 -0.05962 Sig Diff. in LLN NS Sig Diff. in LLN 
CST7 -0.28723 0.03381 0.55083 NS Sig Diff. in BM Sig Diff. in BM 
CTDSP1 -0.25276 -0.46876 -0.31230 Sig Diff. in LLN NS Sig Diff. in LLN 
CTLA4 1.68468 -0.01545 0.15085 Sig Diff. in Lung Sig Diff. in Lung NS 
CTR9 0.23057 0.40519 0.24188 Sig Diff. in LLN NS Sig Diff. in LLN 
CTSW -0.03903 0.45463 0.70281 NS Sig Diff. in BM Sig Diff. in BM 
CXCR4 1.05646 -0.38967 0.12065 Sig Diff. in Lung Sig Diff. in Lung NS 
CYC1 -0.83454 -0.37887 -0.35186 Sig Diff. in Lung Sig Diff. in Lung NS 
CYCS -0.38574 0.36205 -0.06524 Sig Diff. in LLN NS Sig Diff. in LLN 
DCTPP1 -0.57785 -0.10387 -0.35134 Sig Diff. in Lung Sig Diff. in Lung NS 
DDX21 -0.16072 0.34887 -0.16191 Sig Diff. in LLN NS Sig Diff. in LLN 
DDX39A -0.63308 -0.24269 -0.55303 Sig Diff. in Lung Sig Diff. in Lung NS 
DENND4A 0.54437 0.36702 0.46119 Sig Diff. in LLN NS Sig Diff. in LLN 
DHX9 0.03426 0.37326 0.19430 Sig Diff. in LLN NS Sig Diff. in LLN 
DNAJB1 2.38954 -0.26967 -0.21276 Sig Diff. in Lung Sig Diff. in Lung NS 
DOCK2 0.73461 0.51021 0.33310 Sig Diff. in LLN NS Sig Diff. in LLN 
DPP4 0.35968 0.48737 -0.00002 Sig Diff. in LLN NS Sig Diff. in LLN 
DUSP2 -0.91853 -0.69239 -0.79855 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
EBNA1BP2 -0.80801 0.13937 -0.20262 Sig Diff. in Lung Sig Diff. in Lung NS 
EEF1A1 -0.59228 -0.17585 -0.44740 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
EEF1B2 -0.70136 0.10915 -0.19569 Sig Diff. in Lung Sig Diff. in Lung NS 
EEF1D -0.43941 -0.41826 -0.28191 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
EEF2 0.65083 0.48928 0.12162 Sig Diff. in LLN NS Sig Diff. in LLN 
EGR2 -0.49062 -0.45214 -0.24066 Sig Diff. in Lung Sig Diff. in Lung NS 
EIF2S3 -0.10681 0.31341 -0.11259 Sig Diff. in LLN NS Sig Diff. in LLN 
EIF3D -0.69765 -0.06836 -0.19061 Sig Diff. in Lung Sig Diff. in Lung NS 
EIF3I -0.18966 0.37707 0.01487 Sig Diff. in LLN NS Sig Diff. in LLN 
EIF3K -0.52805 0.11765 0.02365 Sig Diff. in Lung Sig Diff. in Lung NS 
EIF4A2 1.00140 0.11375 0.09053 Sig Diff. in Lung Sig Diff. in Lung NS 
EIF5A -1.63008 -0.62076 -0.88775 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
EIF5B -0.59748 -0.15326 -0.39639 Sig Diff. in Lung Sig Diff. in Lung NS 
EIF6 -0.81013 -0.00372 -0.15484 Sig Diff. in Lung Sig Diff. in Lung NS 
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EMG1 -0.74003 0.13745 -0.28838 Sig Diff. in Lung Sig Diff. in Lung NS 
ENO1 0.04309 0.22235 -0.30647 Sig Diff. in LLN NS Sig Diff. in LLN 
EWSR1 -0.61476 -0.31567 -0.31268 Sig Diff. in Lung Sig Diff. in Lung NS 
FABP5 -1.26296 -0.30919 0.03949 Sig Diff. in Lung Sig Diff. in Lung NS 
FBL -0.85832 -0.37298 -0.42941 Sig Diff. in Lung Sig Diff. in Lung NS 
FTH1 1.18914 0.40238 0.22004 Sig Diff. in LLN NS Sig Diff. in LLN 
FTL 0.58202 0.45882 -0.24073 Sig Diff. in LLN NS Sig Diff. in LLN 
FUNDC2 -0.63858 -0.11944 -0.43075 Sig Diff. in Lung Sig Diff. in Lung NS 
FUS -0.44556 -0.90269 -0.52067 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
GAPDH 0.10007 0.13912 -0.39093 NS Sig Diff. in BM Sig Diff. in BM 
GBP4 -0.79030 -0.47440 0.18401 Sig Diff. in Lung Sig Diff. in Lung NS 
GBP5 0.11684 0.34578 0.61868 NS Sig Diff. in BM Sig Diff. in BM 
GLRX3 -0.65216 -0.02754 -0.25766 Sig Diff. in Lung Sig Diff. in Lung NS 
GNG5 -0.20644 0.35648 0.21859 Sig Diff. in LLN NS Sig Diff. in LLN 
GNLY 1.95739 1.12262 2.54871 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
GPATCH4 -0.72035 0.00489 -0.42588 Sig Diff. in Lung Sig Diff. in Lung NS 
GSTP1 -0.81938 0.32229 -0.04230 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
GTF3A -0.45553 -0.26819 -0.43967 Sig Diff. in Lung Sig Diff. in Lung NS 
GZMA -1.07893 0.34004 0.57098 NS Sig Diff. in BM Sig Diff. in BM 
GZMB -1.95886 0.54771 0.37845 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
GZMH -1.03103 0.09912 0.46166 Sig Diff. in Lung Sig Diff. in Lung NS 
H2AZ1 0.50179 0.53118 0.13881 Sig Diff. in LLN NS Sig Diff. in LLN 
HBS1L 0.73626 0.34699 0.16787 Sig Diff. in LLN NS Sig Diff. in LLN 
HCST -0.06550 0.48641 0.73923 NS Sig Diff. in BM Sig Diff. in BM 
HERC1 0.93576 0.21902 0.50646 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
HINT1 -0.15908 0.26047 -0.04943 Sig Diff. in LLN NS Sig Diff. in LLN 
HLA-A -0.47985 -0.71139 -0.26403 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
HLA-B -0.67124 -0.71253 -0.44889 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
HLA-C -0.63644 -0.75928 -0.36540 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
HLA-E -0.31960 -0.78713 -0.17694 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
HLA-F -0.75799 -0.81832 -0.23381 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
HLA-G -0.18082 -0.56580 -0.18762 Sig Diff. in LLN NS Sig Diff. in LLN 
HNRNPA1 -0.62541 -0.02812 -0.32174 Sig Diff. in Lung Sig Diff. in Lung NS 
HNRNPA2B1 -0.65204 -0.20358 -0.20052 Sig Diff. in Lung Sig Diff. in Lung NS 
HNRNPD -0.87663 -0.31210 -0.24583 Sig Diff. in Lung Sig Diff. in Lung NS 
HNRNPF -0.46190 -0.06079 -0.25886 Sig Diff. in Lung Sig Diff. in Lung NS 
HNRNPL -0.12469 -0.38710 -0.42198 NS Sig Diff. in BM Sig Diff. in BM 
HNRNPM -0.71313 -0.14131 -0.54325 Sig Diff. in Lung Sig Diff. in Lung NS 
HOPX -0.97421 0.00130 0.58938 Sig Diff. in Lung Sig Diff. in Lung NS 
HSP90AB1 -0.89675 -0.10726 -0.61404 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
HSPA1A 1.43595 0.05305 0.05250 Sig Diff. in Lung Sig Diff. in Lung NS 
HSPA1B 1.67366 -0.09932 0.03988 Sig Diff. in Lung Sig Diff. in Lung NS 
HSPA8 -0.35510 0.32796 -0.37827 Sig Diff. in LLN NS Sig Diff. in LLN 
HSPA9 -0.44827 -0.20554 -0.43782 Sig Diff. in Lung Sig Diff. in Lung NS 
HSPD1 -0.78837 -0.03036 -0.06426 Sig Diff. in Lung Sig Diff. in Lung NS 
HSPE1 -0.67918 0.37238 -0.04059 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
HUWE1 0.38210 0.61821 0.31958 Sig Diff. in LLN NS Sig Diff. in LLN 
HYOU1 0.15994 0.41445 0.17504 Sig Diff. in LLN NS Sig Diff. in LLN 
IARS1 0.51821 0.82176 0.09105 Sig Diff. in LLN NS Sig Diff. in LLN 
IFITM1 0.01720 0.43326 0.94453 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
IFITM2 0.41070 0.67792 0.47157 Sig Diff. in LLN NS Sig Diff. in LLN 
IFITM3 0.57811 0.75035 0.86573 Sig Diff. in LLN NS Sig Diff. in LLN 
IL2RG -0.49432 -0.24487 0.00637 Sig Diff. in Lung Sig Diff. in Lung NS 
IL32 -0.22539 0.57851 -0.24807 Sig Diff. in LLN NS Sig Diff. in LLN 
IL7R 1.29303 -0.18652 0.21002 Sig Diff. in Lung Sig Diff. in Lung NS 
ISG15 0.83669 0.19186 1.47310 NS Sig Diff. in BM Sig Diff. in BM 
ITGB7 -0.79439 -0.38214 -0.15621 Sig Diff. in Lung Sig Diff. in Lung NS 
IVNS1ABP 0.57269 0.34712 0.48097 Sig Diff. in LLN NS Sig Diff. in LLN 
JUN 0.08329 -1.20568 -0.36108 Sig Diff. in LLN NS Sig Diff. in LLN 
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JUNB -0.56525 -0.53863 -0.16824 Sig Diff. in LLN NS Sig Diff. in LLN 
KLF6 0.00078 -0.60845 -0.67763 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
KLRB1 -0.32467 -0.77699 0.93647 NS Sig Diff. in BM Sig Diff. in BM 
KLRC1 0.65938 0.51003 0.27583 Sig Diff. in LLN NS Sig Diff. in LLN 
KLRD1 0.54815 -0.04035 0.87855 NS Sig Diff. in BM Sig Diff. in BM 
KMT2E 0.11096 -0.97021 -0.18640 Sig Diff. in LLN NS Sig Diff. in LLN 
LARP7 -0.02601 -0.90544 -0.46214 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
LCK -0.83425 -0.53211 -0.61112 Sig Diff. in Lung Sig Diff. in Lung NS 
LDHA 0.56934 0.53567 0.02623 Sig Diff. in LLN NS Sig Diff. in LLN 
LDHB -1.08627 0.00392 -0.41218 Sig Diff. in Lung Sig Diff. in Lung NS 
LGALS1 -0.19724 0.69949 0.11143 Sig Diff. in LLN NS Sig Diff. in LLN 
LIMD2 -0.74125 -0.34308 0.00612 Sig Diff. in Lung Sig Diff. in Lung NS 
LRBA 0.59498 0.49212 0.42088 Sig Diff. in LLN NS Sig Diff. in LLN 
LTA -2.35551 0.04162 -0.91387 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
LTB -2.01348 -0.15837 -1.05915 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
LYST 0.26521 -0.15626 0.66528 NS Sig Diff. in BM Sig Diff. in BM 
MAGOHB 0.05324 0.47302 0.33450 Sig Diff. in LLN NS Sig Diff. in LLN 
MBNL1 0.42283 0.38290 0.30780 Sig Diff. in LLN NS Sig Diff. in LLN 
MICOS13 -1.06650 0.43123 -0.23925 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
MIF 0.72087 0.65936 0.39976 Sig Diff. in LLN NS Sig Diff. in LLN 
MRPL11 -0.72462 0.07021 -0.04186 Sig Diff. in Lung Sig Diff. in Lung NS 
MRPL14 0.04155 0.44225 0.13787 Sig Diff. in LLN NS Sig Diff. in LLN 
MRPL20 -0.80669 0.26748 -0.06300 Sig Diff. in Lung Sig Diff. in Lung NS 
MRPL23 -0.66531 0.12572 -0.06464 Sig Diff. in Lung Sig Diff. in Lung NS 
MRPL4 -0.71257 -0.08315 -0.38192 Sig Diff. in Lung Sig Diff. in Lung NS 
MRPL52 -0.42754 0.44791 0.23444 Sig Diff. in LLN NS Sig Diff. in LLN 
MRPS18C -0.18716 0.39306 0.32381 Sig Diff. in LLN NS Sig Diff. in LLN 
MRTO4 -0.52172 -0.31108 -0.44912 Sig Diff. in Lung Sig Diff. in Lung NS 
MT-CO1 0.31462 -0.07201 0.27427 NS Sig Diff. in BM Sig Diff. in BM 
MTHFD2 0.14468 0.63140 -0.01770 Sig Diff. in LLN NS Sig Diff. in LLN 
MTRNR2L1 1.26690 -0.08438 0.38006 Sig Diff. in Lung Sig Diff. in Lung NS 
MXI1 1.05870 -0.26484 -0.11948 Sig Diff. in Lung Sig Diff. in Lung NS 
MYH9 0.38681 0.36622 0.31575 Sig Diff. in LLN NS Sig Diff. in LLN 
MYL12A -0.28942 0.38364 0.29460 Sig Diff. in LLN NS Sig Diff. in LLN 
NAA10 -0.57095 0.08507 -0.02835 Sig Diff. in Lung Sig Diff. in Lung NS 
NAA38 0.46882 0.43920 0.45804 Sig Diff. in LLN NS Sig Diff. in LLN 
NCL -0.50368 0.00269 -0.13170 Sig Diff. in Lung Sig Diff. in Lung NS 
NCR3 -0.12864 0.49995 0.39242 Sig Diff. in LLN NS Sig Diff. in LLN 
NDUFA4 -0.62726 0.13659 -0.12560 Sig Diff. in Lung Sig Diff. in Lung NS 
NDUFAB1 -0.45935 0.41021 -0.03881 Sig Diff. in LLN NS Sig Diff. in LLN 
NDUFS6 -0.55274 0.32408 0.17409 Sig Diff. in Lung Sig Diff. in Lung NS 
NFKBIA -0.17187 -0.54703 -0.74540 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
NHP2 -1.02268 0.33750 -0.15759 Sig Diff. in Lung Sig Diff. in Lung NS 
NIBAN1 1.03838 0.45133 0.13235 Sig Diff. in LLN NS Sig Diff. in LLN 
NKG7 -1.05820 0.24678 0.58424 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
NME1 -1.41475 0.37614 -0.17512 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
NOP10 -0.63727 -0.06068 -0.33668 Sig Diff. in Lung Sig Diff. in Lung NS 
NOP16 -0.70075 0.26169 -0.10228 Sig Diff. in Lung Sig Diff. in Lung NS 
NOP53 -0.40259 -0.78571 -0.70108 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
NOP56 -0.81926 -0.17079 -0.38372 Sig Diff. in Lung Sig Diff. in Lung NS 
NPM1 -0.33444 0.49800 -0.02293 Sig Diff. in LLN NS Sig Diff. in LLN 
NSMCE1 -0.67163 0.03037 0.20105 Sig Diff. in Lung Sig Diff. in Lung NS 
OAZ1 -0.40700 -0.30234 -0.25060 Sig Diff. in Lung Sig Diff. in Lung NS 
ODC1 -0.72025 -0.20210 -0.42463 Sig Diff. in Lung Sig Diff. in Lung NS 
OSTC -0.60914 0.15677 -0.10641 Sig Diff. in Lung Sig Diff. in Lung NS 
PA2G4 -0.92720 -0.10056 -0.27620 Sig Diff. in Lung Sig Diff. in Lung NS 
PABPC1 -0.75914 -0.88076 -0.60394 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
PABPC3 -0.33419 -0.59801 -0.31217 Sig Diff. in LLN NS Sig Diff. in LLN 
PARK7 -0.87812 -0.00921 -0.10485 Sig Diff. in Lung Sig Diff. in Lung NS 
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PCBP1 -0.29283 -0.56461 -0.32139 Sig Diff. in LLN NS Sig Diff. in LLN 
PDCD5 -0.22977 0.51564 0.03547 Sig Diff. in LLN NS Sig Diff. in LLN 
PDIA3 -0.74195 0.00739 0.09763 Sig Diff. in Lung Sig Diff. in Lung NS 
PDK1 1.04580 0.14823 0.16484 Sig Diff. in Lung Sig Diff. in Lung NS 
PEBP1 -0.46076 -0.34033 -0.21459 Sig Diff. in Lung Sig Diff. in Lung NS 
PFN1 -1.00385 0.43934 -0.03291 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
PHB -0.89173 -0.06669 -0.18429 Sig Diff. in Lung Sig Diff. in Lung NS 
PIM3 -0.42664 -0.50640 -0.49452 NS Sig Diff. in BM Sig Diff. in BM 
PKM -1.01434 -0.14934 -0.77677 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
PLAAT4 0.10308 -0.41232 0.73711 NS Sig Diff. in BM Sig Diff. in BM 
PLIN2 1.57539 -0.30237 -0.10671 Sig Diff. in Lung Sig Diff. in Lung NS 
PNPLA2 -0.06076 -0.28764 -0.16794 Sig Diff. in LLN NS Sig Diff. in LLN 
PNRC1 -0.03601 -0.82627 -0.02391 Sig Diff. in LLN NS Sig Diff. in LLN 
POLR2L -0.71280 0.22540 0.03709 Sig Diff. in Lung Sig Diff. in Lung NS 
POMP -0.22512 0.32330 -0.01066 Sig Diff. in LLN NS Sig Diff. in LLN 
PPA1 -0.81461 0.25400 -0.13489 Sig Diff. in Lung Sig Diff. in Lung NS 
PPIA -0.73184 0.41439 -0.03645 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
PPIB -0.58458 0.18098 0.15179 Sig Diff. in Lung Sig Diff. in Lung NS 
PPP1CA -1.10251 -0.18838 -0.31226 Sig Diff. in Lung Sig Diff. in Lung NS 
PPP1R15A 0.24079 -0.41989 -0.76896 NS Sig Diff. in BM Sig Diff. in BM 
PRDX1 -1.12471 0.28620 -0.37016 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
PRELID1 -0.82572 -0.02122 -0.15213 Sig Diff. in Lung Sig Diff. in Lung NS 
PRF1 -0.22571 -0.04912 0.80001 NS Sig Diff. in BM Sig Diff. in BM 
PRKDC 0.39673 0.32634 0.20876 Sig Diff. in LLN NS Sig Diff. in LLN 
PRMT1 -0.42848 -0.21116 -0.37144 Sig Diff. in Lung Sig Diff. in Lung NS 
PRR13 -0.61227 -0.12851 -0.32655 Sig Diff. in Lung Sig Diff. in Lung NS 
PSMA3 -0.27867 0.33872 0.05779 Sig Diff. in LLN NS Sig Diff. in LLN 
PSMA4 -0.82387 -0.03679 -0.10331 Sig Diff. in Lung Sig Diff. in Lung NS 
PSMA5 -0.49482 0.27719 0.02510 Sig Diff. in Lung Sig Diff. in Lung NS 
PSMA7 -0.75642 -0.20655 -0.30719 Sig Diff. in Lung Sig Diff. in Lung NS 
PSMB1 -0.78513 0.24449 -0.13426 Sig Diff. in Lung Sig Diff. in Lung NS 
PSMB4 -0.65678 -0.07982 -0.09520 Sig Diff. in Lung Sig Diff. in Lung NS 
PSMB7 -0.80930 0.20033 0.03861 Sig Diff. in Lung Sig Diff. in Lung NS 
PSMB9 -0.59661 -0.23591 0.48184 Sig Diff. in Lung Sig Diff. in Lung NS 
PSMD8 -0.80379 0.03794 -0.26064 Sig Diff. in Lung Sig Diff. in Lung NS 
PSME1 -0.67184 0.19353 0.26653 Sig Diff. in Lung Sig Diff. in Lung NS 
PSME2 -0.93496 0.30263 0.23386 Sig Diff. in Lung Sig Diff. in Lung NS 
PTPN7 -0.92236 -0.37705 -0.39881 Sig Diff. in Lung Sig Diff. in Lung NS 
RAC2 -0.86673 -0.03616 0.00285 Sig Diff. in Lung Sig Diff. in Lung NS 
RACK1 -0.44532 -0.21405 -0.24478 Sig Diff. in Lung Sig Diff. in Lung NS 
RAD23A -0.83421 -0.44825 -0.59167 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
RAN -0.58684 0.18118 -0.23709 Sig Diff. in Lung Sig Diff. in Lung NS 
RANBP1 -0.92501 -0.04219 -0.37993 Sig Diff. in Lung Sig Diff. in Lung NS 
RAPGEF1 0.61797 0.46376 0.52379 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
RASA2 0.24539 0.25351 0.23680 Sig Diff. in LLN NS Sig Diff. in LLN 
RB1 0.42539 0.42610 0.26068 Sig Diff. in LLN NS Sig Diff. in LLN 
RBM17 -0.45015 -0.15257 -0.25153 Sig Diff. in Lung Sig Diff. in Lung NS 
RBM25 -0.55818 -0.85018 -0.47920 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
RBM3 -1.02726 0.31432 -0.50990 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
RHOH -0.48221 -0.18757 -0.44401 Sig Diff. in Lung Sig Diff. in Lung NS 
RILPL2 -1.35277 -0.80471 -1.01454 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
RNF145 0.81153 0.37906 0.08336 Sig Diff. in LLN NS Sig Diff. in LLN 
RNF181 0.25504 0.32847 0.08722 Sig Diff. in LLN NS Sig Diff. in LLN 
RNF213 0.26971 0.45470 0.74342 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
RORA 1.15279 0.00439 0.77457 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
RPF2 -0.41046 -0.09067 -0.65740 NS Sig Diff. in BM Sig Diff. in BM 
RPL10A -0.38061 0.16089 -0.12349 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
RPL12 0.15121 0.28894 -0.01461 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL13A -0.04229 -0.20093 -0.08732 Sig Diff. in LLN NS Sig Diff. in LLN 
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RPL14 0.13078 0.23705 -0.02793 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL18A -0.08878 0.21053 0.03390 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL22L1 -0.20241 0.56722 -0.05854 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL24 -0.00657 0.25165 -0.02330 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL26 0.28279 0.28975 0.16436 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL28 0.15419 0.31763 0.05679 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL3 -0.63162 -0.29585 -0.43860 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
RPL32 -0.20753 0.28456 -0.03452 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL35 -0.15464 0.35335 0.11799 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL35A 0.26651 0.21986 0.16213 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL36 0.32655 0.32059 0.17560 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL37 0.05479 0.28866 0.08036 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL37A -0.07683 0.30988 0.06372 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL4 -0.53240 -0.04699 -0.36041 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
RPL5 -0.70480 0.05005 -0.26702 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
RPL6 -0.56014 0.13667 -0.08052 Sig Diff. in Lung Sig Diff. in Lung NS 
RPL7 -0.22618 0.24077 -0.04011 Sig Diff. in LLN NS Sig Diff. in LLN 
RPL7A -0.36428 0.06092 -0.02396 Sig Diff. in Lung Sig Diff. in Lung NS 
RPLP0 -0.53218 0.04646 -0.30562 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
RPLP2 -0.02832 0.17117 0.04786 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS12 -0.05788 0.19101 -0.11089 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS13 -0.01356 0.27946 0.07959 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS15 0.18105 0.35115 0.24394 Sig Diff. in LLN Sig Diff. in BM Sig Diff. in Both 
RPS15A 0.16888 0.24261 0.15719 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS16 -0.08046 -0.18261 -0.11462 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS18 0.06884 0.31120 -0.02110 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS2 -0.44406 -0.06820 -0.29322 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
RPS21 0.08125 0.32208 0.09288 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS24 0.18441 0.42721 0.22173 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS28 -0.01962 0.20917 0.17534 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS3 -0.00821 0.16014 0.13428 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS5 -0.44856 0.08541 -0.14675 Sig Diff. in Lung Sig Diff. in Lung NS 
RPS6 -0.19787 0.14858 -0.09727 Sig Diff. in LLN NS Sig Diff. in LLN 
RPS7 -0.27492 0.21952 -0.03856 Sig Diff. in LLN NS Sig Diff. in LLN 
RPSA -0.66631 -0.02477 -0.28897 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
RSL1D1 -0.55207 -0.23944 -0.57974 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
S100A11 0.42472 0.77718 0.53574 Sig Diff. in LLN NS Sig Diff. in LLN 
SARAF -0.04052 -0.72523 -0.21850 Sig Diff. in LLN NS Sig Diff. in LLN 
SAT1 1.35478 0.04185 0.43408 Sig Diff. in Lung Sig Diff. in Lung NS 
SDF2L1 -0.80786 0.07631 -0.07444 Sig Diff. in Lung Sig Diff. in Lung NS 
SEC13 -0.42849 -0.32062 -0.71493 NS Sig Diff. in BM Sig Diff. in BM 
SEC16A 0.54186 0.49156 0.16509 Sig Diff. in LLN NS Sig Diff. in LLN 
SEC61B -0.36189 0.38171 0.08242 Sig Diff. in LLN NS Sig Diff. in LLN 
SEC61G -0.30835 0.38332 -0.04053 Sig Diff. in LLN NS Sig Diff. in LLN 
SERBP1 -0.79229 -0.21425 -0.46635 Sig Diff. in Lung Sig Diff. in Lung NS 
SET -1.17052 -0.78006 -0.57054 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
SF3B5 -0.57747 -0.00507 -0.09620 Sig Diff. in Lung Sig Diff. in Lung NS 
SH2D1A -0.88254 0.03804 -0.39170 Sig Diff. in Lung Sig Diff. in Lung NS 
SH3BGRL3 -0.57962 -0.00500 0.07638 Sig Diff. in Lung Sig Diff. in Lung NS 
SH3KBP1 -0.25596 -0.81521 -0.36774 Sig Diff. in LLN NS Sig Diff. in LLN 
SLAMF7 -0.60091 -0.19702 -0.25564 Sig Diff. in Lung Sig Diff. in Lung NS 
SLC25A5 -0.53165 0.05475 -0.36802 Sig Diff. in Lung Sig Diff. in Lung NS 
SLC2A3 1.56145 0.02491 0.23065 Sig Diff. in Lung Sig Diff. in Lung NS 
SLC38A1 0.43367 0.39446 0.01764 Sig Diff. in LLN NS Sig Diff. in LLN 
SLIRP -0.42742 0.47641 0.03055 Sig Diff. in LLN NS Sig Diff. in LLN 
SLK -0.59343 -0.67643 -0.21176 Sig Diff. in LLN NS Sig Diff. in LLN 
SMARCA5 -0.64612 -0.31375 -0.10309 Sig Diff. in Lung Sig Diff. in Lung NS 
SNRPB -0.78906 -0.02842 -0.31606 Sig Diff. in Lung Sig Diff. in Lung NS 
SNRPC -0.89599 -0.06488 -0.18008 Sig Diff. in Lung Sig Diff. in Lung NS 
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SNRPD1 -0.71102 0.09194 -0.17021 Sig Diff. in Lung Sig Diff. in Lung NS 
SNRPD2 -0.67260 0.02589 0.02736 Sig Diff. in Lung Sig Diff. in Lung NS 
SNRPE -0.61559 0.50332 0.10869 Sig Diff. in LLN NS Sig Diff. in LLN 
SNRPF -0.46188 0.40970 0.11759 Sig Diff. in LLN NS Sig Diff. in LLN 
SRM -1.63632 0.14071 -0.14210 Sig Diff. in Lung Sig Diff. in Lung NS 
SRP14 -0.50803 0.11628 0.04655 Sig Diff. in Lung Sig Diff. in Lung NS 
SRP9 -0.57542 0.18136 0.09475 Sig Diff. in Lung Sig Diff. in Lung NS 
SRSF11 0.30887 -0.73468 -0.29490 Sig Diff. in LLN NS Sig Diff. in LLN 
SRSF2 -0.91119 -0.21317 -0.20718 Sig Diff. in Lung Sig Diff. in Lung NS 
SRSF9 -0.58380 0.08944 0.15229 Sig Diff. in Lung Sig Diff. in Lung NS 
SSBP1 -0.37817 0.40933 0.14090 Sig Diff. in LLN NS Sig Diff. in LLN 
SSR2 -0.51557 0.01276 -0.09461 Sig Diff. in Lung Sig Diff. in Lung NS 
SSRP1 -0.96961 -0.57399 -0.53019 Sig Diff. in Lung Sig Diff. in Lung NS 
STAT1 -0.51480 0.15789 0.81674 NS Sig Diff. in BM Sig Diff. in BM 
STOML2 -0.89469 -0.49897 -0.57910 Sig Diff. in Lung Sig Diff. in Lung NS 
STX8 0.14858 0.46802 0.48831 Sig Diff. in LLN NS Sig Diff. in LLN 
SUB1 -0.65577 0.29003 -0.02239 Sig Diff. in Lung Sig Diff. in Lung NS 
SURF4 -0.44511 -0.25198 -0.47517 NS Sig Diff. in BM Sig Diff. in BM 
SYNE2 1.12432 -0.01294 0.65688 NS Sig Diff. in BM Sig Diff. in BM 
SYTL2 1.29477 0.07246 0.60241 Sig Diff. in Lung Sig Diff. in Lung NS 
TALDO1 -0.80963 0.11319 -0.22543 Sig Diff. in Lung Sig Diff. in Lung NS 
TAP1 -0.78197 -0.41800 0.01253 Sig Diff. in Lung Sig Diff. in Lung NS 
TAPBP -0.84179 0.01068 -0.04282 Sig Diff. in Lung Sig Diff. in Lung NS 
TBCB -0.68429 -0.23424 -0.21078 Sig Diff. in Lung Sig Diff. in Lung NS 
TIMM10 -0.04689 0.40264 -0.15367 Sig Diff. in LLN NS Sig Diff. in LLN 
TLE5 -0.63553 -0.37232 0.06761 Sig Diff. in Lung Sig Diff. in Lung NS 
TMBIM6 0.11986 0.46164 0.25061 Sig Diff. in LLN NS Sig Diff. in LLN 
TMED9 -0.77043 -0.61166 -0.33698 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
TMEM123 -0.76862 -0.05006 -0.14053 Sig Diff. in Lung Sig Diff. in Lung NS 
TMSB10 -0.51623 0.52807 0.38073 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
TMSB4X -0.22636 -0.29871 0.00510 Sig Diff. in LLN NS Sig Diff. in LLN 
TNFAIP8 -0.60810 -0.08571 -0.48162 Sig Diff. in Lung Sig Diff. in Lung NS 
TNFRSF4 -1.16747 -0.69332 -1.18729 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
TNFRSF9 -1.61224 -0.52854 -0.87342 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
TNFSF14 -0.63706 -0.65581 -0.56780 Sig Diff. in Lung Sig Diff. in Lung NS 
TOMM22 -1.02745 -0.06679 -0.42089 Sig Diff. in Lung Sig Diff. in Lung NS 
TPM3 -0.48496 0.00468 -0.35156 Sig Diff. in Lung Sig Diff. in Lung NS 
TPT1 -0.20818 -0.34218 -0.07861 Sig Diff. in LLN NS Sig Diff. in LLN 
TRRAP 0.48330 0.57416 0.42880 Sig Diff. in LLN NS Sig Diff. in LLN 
TUBA1B -1.47993 0.31091 -0.30208 Sig Diff. in Both Sig Diff. in Lung Sig Diff. in LLN 
TUBA4A -0.57677 -0.21920 -0.25397 Sig Diff. in Lung Sig Diff. in Lung NS 
TUBB -1.11104 0.14882 -0.29221 Sig Diff. in Lung Sig Diff. in Lung NS 
TUBB4B -0.69182 -0.25073 -0.53655 Sig Diff. in Lung Sig Diff. in Lung NS 
TUFM -0.76060 -0.21428 -0.27790 Sig Diff. in Lung Sig Diff. in Lung NS 
TXN -0.03565 0.99776 0.02653 Sig Diff. in LLN NS Sig Diff. in LLN 
TXNDC17 0.30639 0.47079 0.18039 Sig Diff. in LLN NS Sig Diff. in LLN 
TXNL4A -0.76007 0.01059 -0.10791 Sig Diff. in Lung Sig Diff. in Lung NS 
TXNRD1 0.32622 0.41808 -0.10748 Sig Diff. in LLN NS Sig Diff. in LLN 
TYROBP 0.95382 0.21767 1.29964 NS Sig Diff. in BM Sig Diff. in BM 
U2AF1L4 -0.44927 -0.05084 -0.47197 NS Sig Diff. in BM Sig Diff. in BM 
UQCR10 -0.02378 0.41624 0.19552 Sig Diff. in LLN NS Sig Diff. in LLN 
UQCRQ -0.46143 0.41311 0.05669 Sig Diff. in LLN NS Sig Diff. in LLN 
USP14 0.42329 0.43987 0.17019 Sig Diff. in LLN NS Sig Diff. in LLN 
USP7 -0.68687 -0.17055 -0.27475 Sig Diff. in Lung Sig Diff. in Lung NS 
VIM -0.89546 -0.76054 -0.73719 Sig Diff. in Both Sig Diff. in Both Sig Diff. in Both 
VMA21 0.14041 0.33561 0.33664 Sig Diff. in LLN NS Sig Diff. in LLN 
VPS13B 0.59995 0.42701 0.36401 Sig Diff. in LLN NS Sig Diff. in LLN 
WARS1 -0.88953 0.08925 0.01463 Sig Diff. in Lung Sig Diff. in Lung NS 
WDR1 -0.48150 -0.25899 -0.47321 NS Sig Diff. in BM Sig Diff. in BM 
165 
 
XAF1 0.63580 -0.25021 0.87846 NS Sig Diff. in BM Sig Diff. in BM 
XCL1 -1.03122 0.14843 -0.12593 Sig Diff. in Lung Sig Diff. in Lung NS 
XCL2 -1.51066 -0.00583 -0.12812 Sig Diff. in Lung Sig Diff. in Lung NS 
XIAP -0.10188 -0.59696 -0.31665 Sig Diff. in LLN NS Sig Diff. in LLN 
XPO5 -0.09263 0.45632 0.24752 Sig Diff. in LLN NS Sig Diff. in LLN 
YBX1 -0.94811 -0.28750 -0.51820 Sig Diff. in Lung Sig Diff. in Both Sig Diff. in BM 
YWHAZ -0.13392 0.31356 0.23596 Sig Diff. in LLN NS Sig Diff. in LLN 
ZEB2 0.53891 0.17366 0.78100 NS Sig Diff. in BM Sig Diff. in BM 
ZFP36 -0.45312 -0.91594 -0.23197 Sig Diff. in LLN NS Sig Diff. in LLN 
ZFP36L1 -0.65989 -1.06739 -0.38054 Sig Diff. in LLN NS Sig Diff. in LLN 
ZFP36L2 -0.08351 -1.04108 -0.12970 Sig Diff. in LLN NS Sig Diff. in LLN 
ZMAT2 -0.68039 -0.17947 -0.34276 Sig Diff. in Lung Sig Diff. in Lung NS 





Table 3-7. Information about differentially expressed genes (padj<0.1) highlighted in 
biplots showing logFC(LLN/Spleen) vs. logFC(Lung/Spleen) and logFC(BM/Spleen) vs. 
logFC(LLN/Spleen) and logFC(BM/Spleen) vs. logFC(Lung/Spleen). 
gene protein encoded function tissues in 
which 
padj<0.1 
BATF BATF transcription factor; regulates effector CD8+ T cell 
differentiation; implicated in CD8+ T cell exhaustion 
in chronic viral infection 
BM 
BCL2A1 Bcl2A1/Bfl-1 NF-kB target gene; promotes survival by sequestering 
pro-apoptotic BCL2 proteins 
BM 
BNIP3L BNIP3L/NIX pro-apoptotic gene of Bcl-2 family Lung 
CCL3 CCL3/MIP-α chemokine; involved in recruitment of 
polymorphonuclear leukocytes; shown to be to be 
crucial in suppressing chronic viral infection 
Lung 
CCL4 CCL4/MIP-1β chemokine; involved in recruitment of NK cells, 
monocytes, and other immune cells; shown to be to be 
crucial in suppressing chronic viral infection 
LLN, Lung 
CCL4L2 CCL4L2 chemokine similar to CCL4 LLN, Lung 
CCL5 CCL5/RANTES chemokine; involved in recruitment monocytes, T 
cells, and eosinophils into inflammatory sites;  shown 
to be to be crucial in suppressing chronic viral 
infection 
LLN, Lung 
CD226 PTA1/DNAM-1 member of immunoglobulin superfamily; mediates 
cellular adhesion through binding of CD112 and 
CD155; promotes the migration, activation, 
proliferation, and differentiation of CD8 + T cells 
LLN 
CD27 CD27 member of the TNF-receptor superfamily; co-
stimulatory molecule involved in T cell activation and 
long-term maintenance of T cell memory 
BM 
CD38 CD38 involved in modulation of antigen-mediated T cell 
responses; often used as T cell activation marker 
BM 
CD74 CD74/HLADG MHC class II invariant chain; involved in antigen 
presentation; high-affinity receptor for cytokine MIF 
that promotes pro-survival and proliferative pathways; 
expressed by a small subset of T cells with effector 
memory phenotype regulates T cell development 
Lung 
CD82 CD82/KAI1 membrane glycoprotein member of tetraspanin 
superfamily, involved in T cell adhesion to antigen 
presenting cells and adhesion-dependent signaling 
through LFA-1 during T cell activation 
BM, Lung 
CRTAM CRTAM member of immunoglobulin superfamily; mediates 
cellular adhesion and tissue retention; part of core 
tissue-resident memory T cell signature 
Lung 
CTLA4 CTLA4/CD152 member of immunoglobulin superfamily; CD28 
homologue; immune checkpoint expressed on 
regulatory T cells and activated conventional T cells 
as negative regulator of T cell function and 
proliferation 
Lung 









GNLY GNLY antimicrobial peptide found in granules of cytotoxic 
immune cells, including cytotoxic T cells and NK 
cells 
BM, Lung 
GZMA GZMA serine protease found in granules of cytotoxic immune 
cells, including cytotoxic T cells and NK cells 
BM 
GZMB GZMB serine protease found in granules of cytotoxic immune 
cells, including cytotoxic T cells and NK cells 
LLN, Lung 
GZMH GZMH serine protease found in granules of cytotoxic immune 
cells, including cytotoxic T cells and NK cells 
Lung 
HOPX HOPX homeodomain protein; associated with CD8+ cytokine 
response transcription profile 
Lung 
IFITM1 IFITM1/CD225 IFN-induced gene; inhibits viral entry and plays a role 
in antiproliferative action of IFN-γ 
BM, LLN 
IFITM2 IFITM2 IFN-induced gene; inhibits viral entry LLN 
IFITM3 IFITM3 IFN-induced gene; inhibits viral entry LLN 
IL2RG IL2RG/CD132 cytokine receptor subunit for IL-2, -4, -7. -9, -15, and 
-21 
Lung 
IL32 IL-32 cytokine; induces production of pro-inflammatory 
cytokines, such as IL-8 and TNF-α by other immune 
cells 
LLN 
IL7R IL7R receptor for IL-7 Lung 
ITGB7 ITGB7 integrin beta-7; pairs with ITGA4 (CD49d) and 
ITGAE (CD103) to promote cell adhesion 
Lung 
KLF6 KLF6 transcription factor; identified in tissue-specific 
transcription signature  
BM, LLN 
KLRB1 KLRB1/CD161 lectin-like receptor; expressed on NK cells, Th17 
cells, MAIT cells, and polyfunctional memory CD8+ 
T cells. 
BM 
KLRC1 KLRC1/NKG2A/CD159A lectin-like receptor; inhibitory receptor that regulates 
anti-viral responses on CD8+ T cells and NK cells 
LLN 
KLRD1 KLRD1/CD94 lectin-like receptor; expressed on NK cells and CD8+ 
T cells as heterodimer with KLRK1 
BM 
LGALS1 galectin-1 expressed by CD8+ effector T cells induced by viral 
infection; induces apoptosis; involved in cell 
adhesion; identified in tissue-specific transcription 
signature 
LLN 
LTB lymphotoxin-beta/TNF-C member of the TNF family; cytokine with cytotoxic 
capabilities involved in effector T cell response  
BM, Lung 
MIF MIF inflammatory cytokine that modulates T cell 
activation 
LLN 
NCR3 NCR3/CD337/NKp30 member of natural cytotoxicity receptor family; 
activating NK receptor expressed on NK cells and 
CD8+ T cells with cytotoxic capacity 
LLN 
NFKBIA IκBα inhibitor of NF-κB transcription factor BM, LLN 
NKG7 NKG7 involved in NK cell and CD8+ T cell degranulation BM, Lung 
NME1 NME1 marker of TCR-mediated T cell activation LLN, Lung 
PA2G4 PA2G4/EBP1 negative regulator of apoptosis Lung 
PDCD5 PDCD5 positive regulator of apoptosis LLN 
PPIA PPIA/CypA involved in regulation of inflammation and apoptosis; 
inhibits viral replication of influenza virus 
LLN, Lung 





PRF1 perforin pore-forming polymerizing protein found in granules 
of cytotoxic immune cells, including cytotoxic T cells 
and NK cells 
BM 
RORA RORα transcription factor; involved in regulation of the 
differentiation, development, and function of immune 
cells, including CD8+ effector T cells 
BM, Lung 
SLAMF7 SLAMF7/CD319 type I transmembrane glycoprotein; involved in 
degranulation and cytotoxicity of CD8+ T cells 
Lung 
STAT1 STAT1 transcription factor; activated by various ligands, 
including type I and type II interferons; regulate T cell 
activation, proliferation, differentiation, and function; 
essential for protection again viral infections 
BM 
STOML2 STOML2/SLP-2 involved in antigen-receptor-mediated T cell 
activation 
Lung 
TNFAIP8 TNFAIP8 TNF-α-induced protein; activates NF-κB; involved in 
regulation of cell survival and proliferation 
Lung 
TNFRSF4 TNFRSF4/CD134/OX40 member of TNFR superfamily; expressed on antigen-
stimulated T cells and other immune cells; provides 
costimulatory signals to T cells to promote survival 
and proliferation and regulates effector function 
BM, LLN, 
Lung 
TNFRSF9 TNFRSF9/CD137/4-1BB member of TNFR superfamily; expressed on antigen-
stimulated T cells and other immune cells; provides 
costimulatory signals to T cells to promote survival 
and proliferation and regulates effector function 
BM, Lung 
TNFSF14 TNFSF14/CD258/LIGHT secreted protein of TNF superfamily; expressed on 
activated T cells and other immune cells; provides 
costimulatory signals to T cells to regulate activation, 
proliferation,  survival, and effector function 
Lung 
XAF1 XAF1 positive regulator of apoptosis BM 
XCL1 XCL1/lymphotactin chemokine; produced primarily by activated CD8+T 
cells and NK cells 
Lung 





Table 3-8. Differentially expressed genes (padj<0.1) between Flu and CMV peptide-
responsive CD69+ IFN-g+ CD8+ T cells in all sites. 
BM 
gene p value avg_logFC pct.1 pct.2 p adj 
TNFRSF9 7.44E-10 -1.16564576 0.241 0.603 1.42E-05 
FABP5 1.06E-09 -1.33670895 0.198 0.56 2.02E-05 
ITM2A 8.95E-08 -0.76870155 0.138 0.466 0.00171391 
SIAH2 1.30E-07 -0.7948818 0.043 0.302 0.00248529 
SRM 3.13E-07 -0.69894713 0.284 0.612 0.00599804 
NAMPT 4.33E-07 -0.90819553 0.095 0.371 0.00828103 
IFITM1 5.40E-07 0.79615833 0.802 0.629 0.01033286 
GZMH 5.83E-07 -0.69548455 0.397 0.733 0.01115358 
DUSP4 1.64E-06 -0.51419087 0.06 0.31 0.03142388 
RGCC 1.96E-06 -0.68110346 0.129 0.405 0.03748053 
YWHAQ 2.19E-06 -0.64935081 0.112 0.379 0.04197039 
RPS27 3.87E-06 0.36527413 1 1 0.07414496 
EGR2 4.43E-06 -0.72214951 0.103 0.362 0.08469963 
RPL41 4.72E-06 0.27048537 0.983 0.966 0.09028246 
 
Spleen 
gene p value avg_logFC pct.1 pct.2 p adj 
TNFRSF4 2.62E-06 -0.81018689 0.336 0.67 0.05012068 
 
Blood, Lung, and LLN 





Figure 3-15. Cytokine production by antigen-responding T cells following stimulation with 
Flu and CMV CD8 peptide pools.  
(A) Diagram outlining supernatant samples collected following in vitro stimulation with Flu or 
CMV CD8 peptide pools of single-cell suspensions from the blood, BM, spleen, lung, and LLN 
of 12 individual donors. (B) Heatmaps showing cytokine production profiles across multiple 
tissue sites within individual donors for five representative donors. Color intensity of each cell 
represents cytokine concentration normalized to DMSO negative control and max absolute 
scaled per row within each donor, with values ranging from -1 to 1 across all analytes. (C) 
Pairwise comparisons of log(x+1) normalized cytokine levels in supernatants from following in 
vitro stimulation of single-cell suspensions from blood (n=6), BM (n=7), spleen (n=9), lung 
(n=8), and LLN (n=10) with Flu (red) or CMV (blue) peptide pools. No comparison shown was 
statistically significant. (D) Cytokine levels in blood, BM, spleen, lung, LLN supernatant 
samples. Statistical significance was calculated using one-way ANOVA followed by Tukey’s 
multiple comparisons test indicated by ****, p £ 0.0001; ***, p £ 0.001; **, p £ 0.01; *, p £ 










 Understanding the heterogeneity of the anti-viral immune response in humans requires 
studying virus-specific T cells in tissue sites where they function and persist. Here, we examined 
the factors that shape the distribution, subset differentiation, clonal repertoire, and function of 
anti-viral T cell immune responses to prevalent viruses—Flu and CMV. We found that the 
overall frequency, clonal expansion, tissue distribution, and TCR repertoire of virus-specific 
CD8+ T cells is determined primarily by the virus type. However, the differentiation and subset 
delineation of virus-specific T cells was shaped by multiple factors—including tissue site, age, 
and sex. Moreover, the establishment of virus-specific TRM was also a feature of both virus 
specificity and tissue site. Transcriptional and functional analysis revealed that virus-specific T 
cell responses are highly correlated to the tissue. Together, our results elucidate the role of 
multiple factors in shaping the functional maintenance of anti-viral T cell responses throughout 
the human body, important for targeting, monitoring, and predicting immune responses to 
existing and emerging viruses. 
 Our tissue resource enables assessment of virus-specific T cells across sites (lungs, 
intestines, BM, spleen, and LNs) and between different virus types. Here, we focused on two 
ubiquitous viruses, influenza A as a prevalent acute respiratory virus for which individuals have 
multiple exposures over their lifetimes, and CMV as a prevalent persisting virus. Our analyses 
reveal that virus type plays a crucial role in determining the tissue distribution, subset 
differentiation, and clonal features of virus-specific T cells. While T cells specific for both virus 
types could be found in blood and multiple sites (except intestines), Flu-specific T cells exhibited 
biased distribution and functional maintenance in the lungs and LLN consistent with virus 
tropism, while CMV-specific T cells were present in higher frequencies in multiple sites, 
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particularly in the BM, consistent with CMV establishing persistent infection in hematopoietic 
cells 198. In all donors examined, Flu-specific T cells were maintained as TRM in lungs (and to a 
lesser extent in LLN and spleen) consistent with lung TRM establishment to influenza infection in 
mice 181, 333, 334, 352. By contrast, CMV-specific T cells were predominantly circulating TEM and 
TEMRA cells, likely due to the systemic nature of CMV infection, and/or the effects of persistent 
stimulation, as observed in studies in blood 205, 208. Furthermore, TCR repertoire analysis showed 
distinct Vb gene usage, and a lack of substantial clonal overlap between CMV- and Flu-specific 
T cells, suggesting that cross-reactivity between virus-specific T cell clones is not extensive. 
Together, these data demonstrate the critical role that virus plays in long-term maintenance of 
anti-viral immunity.  
 The acquisition of multiple sites from individual donors allows us to assess the role of 
tissue localization in shaping the characteristics of virus-specific T cells. As shown here, tissue is 
a major determinant of the subset composition, phenotype, and function of virus-specific T cells. 
The tissue environment itself can bias the subset distribution. For example, BM contains more 
TEMRA cells than other sites, while lungs and intestines containing predominant TRM populations 
28, 80, 316, thus influencing the phenotype of virus-specific cells in these sites. We also found major 
associations in the functional response profile of virus-specific T cells with the tissue site. Upon 
stimulation with virus-specific peptide epitopes, Flu- and CMV-specific CD8+ T cells shared 
transcriptomic profiles consistent with activated human CD8+ T cells 27, but these profiles 
segregated primarily based on tissue site, while BM was the only site with differences based on 
virus specificity. Accordingly, multiplexed quantification of cytokine production revealed a 
tissue-driven segregation of anti-viral T cell function, with CMV-specific influences within the 
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BM. These results indicate compartmentalized functional maintenance of anti-viral T cell 
memory that may be uniquely adapted to mediate protection in situ.  
Age was highly associated with virus-specific T cell maintenance in specific sites. While 
the site-specific subset composition of Flu- and CMV-specific T cells did not alter over age (18-
78yrs) in most sites, Flu-specific TRM declined in LLN with age, and CMV-specific TRM 
increased slightly with age. We propose that dynamic events occurring in certain sites—such as 
the replenishment of lung memory T cells from LLN for Flu-specific T cells, and the activation 
and differentiation of CMV-specific T cells in the BM due to virus reactivation—results in 
compartmentalization of age-associated effects. However, when comparing Flu-specific T cells 
in adult versus pediatric tissues, there was a striking difference in the subset composition; there 
was a significantly higher proportion of TCM and lower frequency of TRM in the lungs and LLN 
of children compared to adults. These results suggest that repeated infections and/or prolonged 
persistence is necessary for full TRM development. The stark differences in anti-viral immune 
responses in children compared to adults have been identified with antibody and T cell responses 
to SARS-CoV-2 142, 353, suggesting intrinsic developmental differences. Dissecting these and 
other features of pediatric immunity due to the tissue environment are important for promoting 
optimal protection at this critical life stage.   
Our findings also reveal that biological sex plays a role in shaping maintenance of tissue 
immunity to viruses. Notably, females have higher frequencies of CMV-specific T cells 
compared to males, particularly in the lung. Moreover, females have higher frequencies of virus-
specific TEMRA, while males have higher frequencies of TEM within lung, spleen, and LLN; males 
also had higher frequencies of Flu-specific lung TRM compared to females. Together, these 
findings suggest that virus-driven T cell differentiation in females is more skewed to terminal 
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effector generation—a result consistent with mouse studies showing biased generation of short 
lived effector cells following infection of female compared to male mice 354. Human studies 
found that female T cells exhibited elevated proliferation, production of pro-inflammatory 
cytokines, and cytotoxic T cell activity when stimulated compared to male T cells 355-357, 
consistent with TEMRA functional profiles 27, 358. The mechanisms underlying these sex-associated 
differences will be important to define in future studies for optimizing vaccines and therapies 
specific to males and females. 
There are limitations to this study. This study uses human samples from diverse donors to 
profile multiple aspects of anti-viral immunity. To measure virus-specific T cells responses, we 
purified T cells from tissue digests using highly optimized protocols; however, lymphocyte 
isolation from tissues is not quantitative 359 and more precise assessment of frequencies within a 
site will require methods for detection of rare antigen-specific T cells by imaging. To define 
further the role of virus, tissue, age, and sex, continued assessment of virus-specific T cells in 
more donors and across more virus specificities is needed. While we were able to stratify donors 
based on age and sex, a larger cohort would allow examination of other factors, such as BMI, 
comorbidities, race, and ethnicity. As with all human studies, inter-individual variation cannot be 
fully controlled. Finally, longitudinal assessment of virus-specific T cells was done between 
individuals and not within individuals, due to limitation of tissue sampling.   
In summary, our study provides a comprehensive view of virus-specific T cell memory in 
humans and the different factors which impact its generation and maintenance (Figure 3-16). 
These findings provide a foundation for defining predictive models that can be leveraged to 




Figure 3-16. Graphical summary of findings. 





Chapter 4: SARS-CoV-2 infection generates tissue-localized 
immunological memory in humans 
ABSTRACT: 
 Adaptive immune responses to SARS-CoV-2 infection have been extensively 
characterized in blood; however, most functions of protective immunity must be accomplished in 
tissues. In this study, we examine SARS-CoV-2 seropositive organ donors (ages 10 – 74) and 
show that CD4+ T, CD8+ T, and B cell memory generated in response to infection is present in 
bone marrow, spleen, lung, and multiple lymph nodes (LNs) for up to 6 months post-infection. 
Lungs and lung-associated LNs were the most prevalent sites for SARS-CoV-2 specific memory 
T and B cells, with significant correlations between circulating and tissue-resident memory T and 
B cells in all sites. We further identified SARS-CoV-2-specific germinal centers in the lung-
associated LNs up to 6 months post-infection. SARS-CoV-2-specific follicular helper T cells 
were also abundant in lung-associated LNs and lungs. Together, the results indicate local tissue 
coordination of cellular and humoral immune memory against SARS-CoV-2 for site-specific 
protection against future infectious challenges. 
 
 
Chapter expanded from:  
Poon, M.M.L.,† Rybkina, K., †  Kato, Y., †  Kubota, M., Matsumoto, R., Bloom, N.I., Zhang, Z., 
Hastie, K.M., Grifoni, A., Weiskopf, D., Wells, S.B.,  Ural, B.B., Lam, N., Szabo, P.A., Dogra, 
P., Lee, Y.S., Gray, J.I.,  Bradley, M.C., Brusko, M.A., Brusko, T.M., Saphire, E.O., Connors, 
T.J., Sette, A., Crotty, S., Farber, D.L. (2021) SARS-CoV-2 infection generates tissue-localized 
immunological memory in humans. Science Immunology. doi: 10.1126/sciimmunol.abl9105 
 





Ending the global COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 
depends on the establishment of immunological memory. SARS-CoV-2 infects the respiratory 
tract and induces adaptive immune responses, resulting in virus-specific T and B lymphocytes 
mediating viral clearance at the infection site and inhibiting viral dissemination through T cell 
effector functions and antibodies.  It is now well-documented that mild and severe infection 
generates circulating virus-specific T cells and antibodies detectable in peripheral blood for up to 
a year or more 212, 222, 224, 229, 235, 360-362. Moreover, the presence of neutralizing antibodies specific 
for the viral Spike (S) protein correlates with protection for SARS-CoV-2 vaccines 363, 364. 
However, the emergence of viral variants with potential for immune evasion 365-369 and 
variability in vaccination rates among populations enable ongoing SARS-CoV-2 spread. An 
understanding of the breadth and functional potential of virus-specific T and B cell memory is 
needed for developing improved strategies to protect against continually evolving strains. 
A major limitation in studying human immune responses is that sampling is largely 
confined to peripheral blood, while adaptive immune responses are generated and carry out their 
protective functions in a range of tissues. Memory cells are also maintained in diverse tissues—
including infection sites and lymphoid organs (reviewed in 337, 339). Virus-specific memory CD4+ 
and CD8+ T cells comprise heterogeneous subsets of circulating subsets and non-circulating 
tissue-resident memory cells (TRM) in various sites 329, 330. In mouse models, TRM in the lung 
mediate optimal protective responses to respiratory infection 181, 332, 333, and this localized 
protection also involves responses in lung-associated lymph nodes (LNs) 331, 334.  In humans, the 
majority of T cells in adults are memory. The subset composition of human T cell memory is 
specific to the tissue site; in mucosal, exocrine, and barrier sites TRM predominate, while 
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lymphoid sites contain circulating effector and central memory (TEM, TCM) along with TRM 
subsets 137, 329, 370. All types of memory T cells in tissues express gene expression signatures 
distinct from memory T cells in peripheral blood 27, suggesting that they are differentially 
maintained compared to circulation. In SARS-CoV-2 infection, activated TEM and TRM were 
identified in the airways of severe COVID-19 240, 241, although the distribution and functional 
capacity of SARS-CoV-2-specific memory T cells across tissues remain uncharacterized. 
The generation of memory B cells following an infection occurs in secondary lymphoid 
organs (LN, spleen) and requires virus-specific follicular helper T cells (TFH) which promote B 
cell differentiation, survival, and somatic hypermutation in germinal centers (GC) 72. Memory B 
cells can persist in multiple sites, and exhibit tissue-resident phenotypes 371. In mouse respiratory 
infection models, resident memory B cells (BRM) in lung and lung-associated LNs can be 
important for protection 372.  In human lymphoid and mucosal sites, memory B cells are the 
predominant subset, while naïve B cells prevail in circulation 373. SARS-CoV-2 infection elicits 
generation of S-, receptor-binding domain (RBD), and nucleocapsid (N)-specific memory B cells 
detectable in peripheral blood 212, 224, 229; however, the distribution and maintenance of SARS-
CoV-2-specific memory B cells and GC B cells in tissues following natural infection have not 
been reported. Moreover, the relationship between human B and T cell memory in tissues is 
largely unexplored.   
The use of physiologically healthy tissues from organ donors has enabled study of human 
immune cells across multiple sites 23, 28, 337. Investigating tissue immunity to SARS-CoV-2 is 
particularly challenging, as previously infected, but unvaccinated donors are required.  Here, we 
present a novel investigation of SARS-CoV-2-specific memory T and B cell populations in 
lymphoid and mucosal sites of previously infected, seropositive organ donors, which we 
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identified in bone marrow (BM), spleen, lung, and LNs up to 6 months post-infection. Lung and 
lung-associated LNs were the most prevalent sites for SARS-CoV-2 specific memory T and B 
cells, with a proportion exhibiting tissue-resident profiles. We also detected virus-specific GC B 
cells in lung-associated LNs along with TFH, suggesting ongoing generation of humoral 
immunity. Together, our results reveal local coordination of cellular and humoral memory 





Organ donor cohorts for analysis of SARS-CoV-2-specific immune responses in tissues 
 We have established a human tissue resource for obtaining multiple tissues from organ 
donors through collaborations with the organ procurement organizations 23, 28, 337. Use of organ 
donor tissue allows for rapid isolation of live immune cells for functional analysis, thus enabling 
assessment of immune responses in multiple sites within an individual. We identified 4 organ 
donors ages 10-74 years with previous SARS-CoV-2 infection (Figure 4-1A) who died of non-
infectious-related causes and were SARS-CoV-2 PCR negative at the time of organ procurement. 
Previous SARS-CoV-2 infection history was based on post-procurement testing for antibodies to 
N protein (see methods) and/or a confirmed history of COVID-19 2-6 months previously (Table 
4-1). Controls were pre-pandemic seronegative organ donors procured prior to November 2019 
who also died of non-infectious causes (Table 4-1).   
All seropositive donors had detectable serum IgG to N, S, and RBD, along with SARS-
CoV-2 neutralizing antibodies, consistent with antibody responses generated from acute 
infection 221, 374, while serum from pre-pandemic organ donors lacked antibodies to SARS-CoV-
2 (Figure 4-1B, C). Using this cohort, we examined SARS-CoV-2 specific T and B cell 
responses across blood, BM, spleen, lung, lung-associated LNs, and gut-associated LNs (iliac 





Figure 4-1. SARS-CoV-2-specific CD4+ and CD8+ T cells in blood and tissues of previously 
infected organ donors. 
(A) SARS-CoV-2 seropositive donors and tissues used from each donor for this study. (B) Anti-
SARS-CoV-2 antibody reactivities for seropositive and seronegative donors. Graphs show 
endpoint titers (ET) of IgG specific for SARS-CoV-2 Spike, RBD, and Nucleocapsid. (C) SARS-
CoV-2 Spike pseudovirus (PSV) neutralizing titers for seropositive and seronegative donors. 
Serology statistical analyses were performed using Mann-Whitney U test. * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001; **** p ≤ 0.0001. (D) Identification of SARS-CoV-2-specific CD4+ T cells 
using the activation-induced marker (AIM) assay. Mononuclear cells isolated from blood, bone 
marrow (BM), spleen, lung, and lung-associated lymph node (LLN) were stimulated with SARS-
CoV-2 peptide pools (See Materials and Methods) and responding CD4+ T cells were identified 
based on induction of OX40, 4-1BB, and CD40L as shown in representative flow cytometry 
plots from D498 reactive to MP _S. SARS-CoV-2-specific CD4+ T cells were defined based on 
combined gates CD40L+4-1BB+ (left), OX40+4-1BB+ (middle), or CD40L+OX40+ (right) of total 
CD4+ T cells for each stimulation condition and tissue site (see Figure 4-2 for gating strategy). 
(E) AIM assay for detection of SARS-CoV-2-specific CD8+ T cells in blood, BM, lung, LLN, 
and gut-associated lymph node (GLN), showing induction of 4-1BB and CD25 in representative 
flow cytometry plots from D495 reactive to MP_S. AIM+ CD8+ T cells were defined based on 
frequency 4-1BB+CD25+ from total CD8+ T cells for each stimulation condition and tissue site 
(see Figure 4-2 for gating strategy). (F) SARS-CoV-2 epitope specific CD4+T cells identified 
following stimulation with MP_S (left) and MP_CD4_R (right) peptide megapools (MPs) from 
indicated tissues sites of seropositive and seronegative donors. (G) Total SARS-CoV-2-specific 
CD4+ T cells in each site from individual donors based on responses to all epitopes. (H) SARS-
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CoV-2 epitope specific CD8+ T cells identified following stimulation with MP_S (left), 
MP_CD8_A (middle), and MP_CD8_B (right) peptide MPs from indicated sites of seropositive 
and seronegative donors. (I) Total SARS-CoV-2-specific CD8+ T cells in each site from 
individual donors based on compiled responses to all epitopes. n=4 SARS-CoV-2 seropositive 
donors (n=4 for blood, lung, LLN; n=3 for spleen and GLN; n=2 for BM). n=10 for seronegative 
donors (n=4 for BM, LLN, and GLN; n=3 for blood, spleen, and lung). Statistical analysis was 
performed using one-way ANOVA, corrected for multiple comparisons by false discovery rate 
(FDR) using two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. * q ≤ 0.05; 
** q ≤ 0.01; *** q ≤ 0.001; **** q ≤ 0.0001. Datasets were log-transformed before statistical 
analysis. ET, endpoint titer; RBD, receptor-binding domain; PSV, pseudovirus; AIM, activation-










Table 4-1. Information about donors in this study. 
Donor Age Sex Ethnicity/race Cause of death Estimated time post-infection 
SARS-CoV-2 seropositive donors 
HDL113 10 M Hispanic/Latino Anoxia: asphyxiation Unknown 
D492 74 M Hispanic/Latino Cerebrovascular/ stroke > 2 months 
D495 42 M Black or African American 
Anoxia: 
cardiovascular Unknown 
D498 71 M White Cerebrovascular/ stroke > 6 months 
SARS-CoV-2 seronegative controls 
D210 37 M Hispanic/Latino Head trauma  
D303 64 M Asian Anoxia: cardiovascular 
 




D321 17 F White Anoxia: cardiovascular 
 
D340 23 M Black or African American Head trauma 
 
D341 49 M White Cerebrovascular/ stroke 
 
D342 59 M Hispanic/Latino Anoxia  
D372 68 M Hispanic/Latino Cerebrovascular/ stroke 
 
D426 43 F Hispanic/Latino Anoxia  




D451 54 F White Cerebrovascular/ stroke 
 
D453 67 F White Head trauma  






SARS-CoV-2-specific T cells in lung and lymphoid tissues 
SARS-CoV-2-specific T cells in different sites from seropositive and seronegative organ 
donors were measured based on expression of T cell receptor-dependent activation-induced 
markers (AIMs) following stimulation with SARS-CoV-2-specific peptide megapools (MPs), 
which enable simultaneous presentation of a large number of virus-specific epitopes 222, 375, 376. 
Mononuclear cells from each site were stimulated for 24 hours in vitro with four different SARS-
CoV-2 specific MPs (see Figure 4-2 and Materials and Methods): MP_S (containing overlapping 
peptides representing the entirety of S), MP_CD4_R (containing predicted HLA class II viral 
epitopes minus S), MP_CD8_A and MP_CD8_B (each containing predicted HLA class I 
epitopes from all viral proteins)222. SARS-CoV-2-specific CD4+ T cells were identified based on 
co-expression of 2 or more of the following three AIMs (OX40, 4-1BB, and/or CD40L) (Figure 
4-1D, 4-3A), while virus-reactive CD8+ T cells were identified based on co-expression of CD25 
and 4-1BB (Figure 4-1E, 4-3B). Quantification of SARS-CoV-2- specific CD4+ and CD8+ T cell 
responses was based on DMSO-background-subtracted frequencies of AIM+ CD4+ and CD8+ T 
cells (Figure 4-1F, H). 
For CD4+ T cells, significant responses to S protein were found in all sites examined 
(blood, BM, spleen, lung, lung-associated LNs, and gut-associated LNs) relative to pre-pandemic 
control samples (Figure 4-1F, left panel). For non-S SARS-CoV-2 epitopes, there were 
significant CD4+ T cell frequencies in the BM, lung-associated LNs, and gut-associated LNs 
(Figure 4-1F, right panel). Total SARS-CoV-2-specific CD4+ T cell responses largely reflected 
the pattern observed with S-specific responses (Figure 4-1F, G). SARS-CoV-2-specific CD8+ T 
cell frequencies were generally lower in magnitude than for CD4+ T cells and more variable 
between donors (Figure 4-1G-I). Significant SARS-CoV-2-specific CD8+ T cell frequencies 
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above controls were observed for lung- and gut-associated LNs for class I epitopes (Figure 4-1H, 
I).  Comparing across all donors and sites, CD4+ T cells responding to S protein epitopes were 
the predominant SARS-CoV-2-specific T cells across tissue sites for all individuals (Figure 4-1F, 
G, 4-3C). While the distribution patterns of SARS-CoV-2-specific T cell responses across tissue 
sites varied between donors (Figure 4-1, 4-4), the lung and lung-associated LNs were most 
consistently the dominant sites for virus-specific CD4+ and CD8+ T cells (Figure 4-3D). These 
results indicate that SARS-CoV-2 infection generates virus-specific T cell responses across 
blood, multiple lymphoid sites, and lungs, with higher frequencies localized in lung tissue and 




Figure 4-2. T cell flow cytometry gating strategy.  
Gating strategy to define SARS-CoV-2-specific TFH, CD4+ T cells, CD8+ T cells, and T cell 
subsets. TCM, central memory T cell; TEM, effector memory T cell; TEMRA, terminally 













Figure 4-3. SARS-CoV-2 peptide-pool-responding CD4+ and CD8+ T cells across 
seropositive donors and tissue sites.  
(A) Representative flow cytometry plots of SARS-CoV-2-specific CD4+T cells from D498 
reactive to MP_CD4_R. SARS-CoV-2-specific CD4+ T cells were defined based on combined 
gates CD40L+4-1BB+ (left), OX40+4-1BB+ (middle), or CD40L+OX40+ (right) of total CD4+T 
cells for each stimulation condition and tissue site (see Figure S1 for gating strategy). (B) 
Representative flow cytometry plots of SARS-CoV-2-specific CD8+ T cells from D495 reactive 
to MP_CD8_A and MP_CD8_B. SARS-CoV-2-specific CD8+ T cells were defined based on 
frequency of 4-1BB+CD25+ of total CD8+T cells for each stimulation condition and tissue site 
(see Figure S1 for gating strategy). (C, D) Heatmap showing DMSO background-subtracted 
frequencies of SARS-CoV-2-specific CD4+ T cells (S, R) and CD8+ T cells (S, A, and B) in 
blood and tissues sites for individual donors identified based on the expression of AIMs 
following 24 hr in vitro stimulation with peptide megapools (MPs) MP_S, MP_CD4_R, 
MP_CD8_A, and MP_CD8_B. Color intensity of each cell is based on either (C) absolute 
frequencies or (D) row normalization of (min-max scaled) values. Blank cells indicate no 











Figure 4-4. SARS-CoV-2-specific CD4+ and CD8+ T cells in blood and tissues of individual 
seropositive donors.  
(A, B) Frequencies of SARS-CoV-2 specific (A) CD4+ T cells and (B) CD8+ T cells in tissues 
sites of individual donors. Tissues are ordered from highest to lowest frequency of SARS-CoV-2 
specific T cells for each donor. SARS-2, SARS-CoV-2; BM, bone marrow; LLN, lung-










SARS-CoV-2-specific T cells are maintained in tissues as circulating and resident memory 
subsets 
We analyzed the subset distribution of SARS-CoV-2-specific T cells based on coordinate 
expression of CD45RA and CCR7, defining central memory T cells (TCM; CD45RA-CCR7+), 
effector memory T cells (TEM; CD45RA-CCR7-), terminally differentiated effector T cells 
(TEMRA; CD45RA+CCR7-), and naïve or stem-like memory cells (CD45RA+CCR7+)78, 127. Each 
tissue has a distinct T cell subset composition that is conserved between individuals as we 
previously determined 26, 28, 137; T cell phenotypes for each site and for SARS-CoV-2-specific T 
cells are shown in representative flow cytometry plots (Figure 4-5A). The majority of SARS-
CoV-2-specific CD4+ T cells are maintained as TEM (≥75%) in the blood and lung, and as TEM or 
TCM (≥80%) in lymphoid sites (Figure 4-5B). For SARS-CoV-2 specific CD8+ T cells, the 
majority were maintained as TEM and TEMRA cells (≥50%) for all sites; the proportion of TEMRA 
was higher than TEM for BM, spleen, and lung, while TEM were more prevalent than TEMRA for 
LNs (Figure 4-5C). Donors D495 and D498 had a particularly high proportion of SARS-CoV-2-
specific CD8+ TEMRA cells in the lung, while the pediatric donor (HDL113) harbored more 
SARS-CoV-2-specific CD45RA+CCR7+ CD8+ T cells in the lung and lung-associated LN 
(Figure 4-5C).  
We also analyzed co-expression of residency markers CD69 and CD103 by SARS-CoV-
2-specific T cells (assessment of CD69 alone as a TRM marker was confounded due to CD69 
upregulation by TCR-stimulated T cells). Virus-specific CD69+CD103+ memory CD4+ and CD8+ 
T cells (TRM) were mostly confined to the lung, while lower frequencies of SARS-CoV-2-
specific CD8+ TRM were also detected in LNs (Figure 4-5D, E). Together, these results show that 
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SARS-CoV-2 specific T cells are maintained across diverse tissue sites as memory T cells, with 




Figure 4-5. SARS-CoV-2-specific T cells are maintained as memory subsets in diverse 
tissues of seropositive donors.  
(A) Subset phenotypes of total (grey contour) and SARS-CoV-2-specific (red dots) CD4+ (top 
row) and CD8+ (bottom row) T cells based on CD45RA and CCR7 expression 
(CD45RA+CCR7+; CD45RA+CCR7+, TCM; CD45RA+CCR7-, TEM; CD45RA+CCR7-, 
TEMRA) shown in representative flow cytometry plots. (B) T cell subset delineation of SARS-
CoV-2-specific CD4+ T cells in blood and indicated tissues of seropositive organ donors. (C) T 
cell memory subset delineation of SARS-CoV-2-specific CD8+ T cells in blood and indicated 
tissues of seropositive organ donors. (D) Expression of tissue residency markers CD69 and 
CD103 by SARS-CoV-2-specific CD4+ T cells in indicated sites of seropositive donors. (E) 
Expression of tissue residency markers CD69 and CD103 by SARS-CoV-2-specific CD8+ T 
cells in indicated sites of seropositive donors. Memory subset differentiation and residency 
marker analysis was conducted on tissue sites for which number of SARS-CoV-2-specific T cells 
was ≥ 5 based on AIM assays. SARS-CoV-2-specific CD8+ T cells in the blood were not 
detected above this threshold. n=4 SARS-CoV-2 seropositive donors (n=4 for blood, lung, LLN; 
n=3 for spleen and GLN; n=2 for BM). n=10 for seronegative donors (n=4 for BM, LLN, and 
GLN; n=3 for blood, spleen, and lung). Statistical analysis was performed using one-way 
ANOVA, corrected for multiple comparisons by FDR using two-stage linear step-up procedure 
of Benjamini, Krieger, and Yekutieli. No comparisons were statistically significant. Datasets 
were log-transformed before statistical analysis. SARS-2, SARS-CoV-2; TCM, central memory 
T cell; TEM, effector memory T cell, TEMRA, terminally-differentiated effector T cell; Bld, 










Tissue specificity and heterogeneity of functional responses to SARS-CoV-2 
The functional responses of SARS-CoV-2-responding cells from different sites were 
assessed by multiplex quantification of 50 immune mediators from culture supernatants of 
peptide-stimulated mononuclear cells as in Figure 4-1. Blood and tissues exhibited distinct 
immune mediator production profiles, and the magnitude of responses varied between donors 
(Figure 4-6, 4-7, 4-8A). Importantly, there was heterogeneity between individuals in the 
distribution of functional responses across sites. In particular, SARS-CoV-2-specific functional 
responses were primarily located in the lung for donor D492, in the lung-associated LN and 
blood for donor D495, while D498 and HDL113 exhibited a broad functional response across 
multiple sites (Figure 4-6A). Interestingly, for both elderly donors (D492 and D498), lung-
associated LN responses were much weaker compared to other tissue sites, even when the 
frequency AIM+ CD4+ and CD8+ T cells in the lung-associated LN were high relative to other 
tissue sites (Figure 4-4 and 4-6A). Overall, these data show that virus-specific functional 
responses are differentially maintained across sites and individuals.  
Tissue-specific functional profiles were apparent in the profile of soluble mediators 
produced in response to stimulation with SARS-CoV-2 peptide pools (Figure 4-6B, C, 4-7, and 
4-8A). Immune mediators varied significantly between tissue sites, both when assessing absolute 
concentrations and DMSO-background-subtracted concentrations (Figure 4-6B, 4-7, and 4-9), 
while functional profiles among peptide pool stimulations within the same tissue were similar 
(Figure 4-8B). Importantly, the functional responses in the LN were the most diverse and 
included Type 1 proinflammatory cytokines and cytolytic mediators (IFN-γ, TNF-a, granzyme 
B, perforin, GM-CSF), Type 2 cytokines (IL-5, IL-9, IL-13), and Type 3 cytokines (IL-17A, IL-
17F, G-CSF) –most at increased levels compared to other sites (Figure 4-6B, C). The functional 
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response in the lung was distinct from other sites and included proinflammatory profiles (TNF-a, 
perforin, granzyme, IL-12, IL-17A, G-CSF), IL-10 associated with regulation of inflammation 
during respiratory infections 377, and higher levels of IL-6 and the homeostatic cytokine IL-15 
compared to other sites (Figure 4-6B, C). BM responses were mostly TNF-a, perforin, granzyme 
B, and IL-10, while blood responses were similar to BM (Figure 4-6B, C). Comparing the 
immune mediator milieu between sites reveals that certain cytokines are produced across sites, 
while others are distinct to specific sites (Figure 4-6C). Together, these results indicate that 
SARS-CoV-2-specific memory T cells in different sites exhibit distinct functional responses to 




Figure 4-6. Heterogeneity and tissue specificity of functional responses to SARS-CoV-2 
epitopes.  
(A) Profiles of immune mediators produced for multiple tissue sites within SARS-CoV-2 
seropositive donors following stimulation with peptide MPs MP_S (S), MP_CD4_R (R), 
MP_CD8_A (A), and MP_CD8_B (B), shown as a heatmap. The color intensity of each cell 
represents DMSO-background-subtracted analyte concentration (max absolute scaled per 
column) within each donor (See Materials and Methods). (B) Concentration of indicated immune 
mediators measured within supernatants from in vitro stimulations of blood, BM, spleen, lung, 
LLN, and GLN mononuclear cells with SARS-CoV-2 MPs for which SARS-CoV-2-specific T 
cells were identified based on DMSO-background-subtracted frequencies of AIM+ CD4+ and 
CD8+ T cells. Statistical analysis was performed using one-way ANOVA, corrected for multiple 
comparisons by Tukey’s multiple comparisons test. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001, 
****, p ≤ 0.0001. (C) Immune mediator milieu for each site. Heatmap showing log (Mean x + 1) 
pg/mL levels of immune mediators averaged across donors and stimulation conditions for each 
tissue site, derived from samples for which significant frequencies of SARS-CoV-2-specific T 
cells were identified above background in Figure 4-1. BL, blood; BM, bone marrow; SP, spleen; 









Figure 4-7. Cytokine, chemokine, and growth factor production following stimulation with 
SARS-CoV-2 antigens across tissue sites.  
Concentration of indicated cytokines, chemokines, and growth factors measured within 
supernatants from in vitro stimulations of blood, BM, spleen, lung, lung-associated LN, and gut-
associated LN mononuclear cells with SARS-CoV-2 MPs for which SARS-CoV-2-specific T 
cells were identified based on DMSO background-subtracted frequencies of AIM+ CD4+ and 
CD8+ T cells. Statistical analysis was performed using one-way ANOVA, corrected for multiple 
comparisons by Tukey’s multiple comparisons test. *, p £ 0.05; **, p £ 0.01; ***, p £ 0.001, 














Figure 4-8. Immune mediator production profiles by tissue site and by peptide pool. 
(A) Heatmap showing log (Mean x + 1) pg/mL levels of immune mediators averaged across 
donors and stimulation conditions for each tissue site, derived from samples for which significant 
frequencies of SARS-CoV-2-specific T cells were identified above background in Figure 4-1. 
(B) Heatmap showing log (Mean x + 1) pg/mL levels of immune mediators averaged across 
donors for each stimulation condition and tissue site for which significant frequencies of SARS-
CoV-2-specific T cells were identified above background in Figure 4-1. BM, bone marrow; 











Figure 4-9. Background-subtracted concentrations of cytokines, chemokines, and growth 
factors produced after stimulation with SARS-CoV-2 antigens.  
DMSO-background subtracted concentration of indicated cytokines, chemokines, and growth 
factors measured within supernatants from in vitro stimulations of blood, BM, spleen, lung, lung-
associated LN, and gut-associated LN mononuclear cells with SARS-CoV-2 MPs for which 
SARS-CoV-2-specific T cells were identified above background in Figure 4-1. Statistical 
analysis was performed using one-way ANOVA, corrected for multiple comparisons by Tukey’s 
multiple comparisons test. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001, ****, p ≤ 0.0001. BM, bone 









SARS-CoV-2-specific memory B cells and resident phenotypes in tissues 
To characterize the nature of memory B cell responses to SARS-CoV-2 in tissues, we 
used fluorescently-labeled, biotinylated, and multimerized probes of full-length S and RBD 
proteins to detect antigen-binding B cells among IgM+, IgG+, or IgA+ memory B cells (Figure 4-
10A), as previously described 229. SARS-CoV-2 specific memory B cells were detected at 
frequencies substantially higher in seropositive donors than seronegative donors in all tissues 
examined, including lungs, BM, spleen, lung-associated LNs, and gut-associated LNs (Figure 4-
11A, B). Notably, IgG+ was the dominant isotype of SARS-CoV-2-specific memory B cells in 
almost all samples, though IgM+ and IgA+ memory B cells were present (Figure 4-11C). For 
D498, while few SARS-CoV-2-specific memory B cells were IgM+ in the LNs, >40% were IgM+ 
in the BM and spleen. For D495, while almost no IgA+ SARS-CoV-2-specific memory B cells 
were found in the lung, ~25% were IgA+ in gut-associated LNs (Figure 4-11C). SARS-CoV-2-
specific memory B cells were present at significantly higher frequencies in lung and lung-
associated LNs than in the spleen or gut-associated LNs (Figure 4-11B, D). The highest 
proportion of SARS-CoV-2-specific IgG+ memory B cells were found in the lung and lung-
associated LNs (Figure 4-11D).  
Memory B cells can persist as tissue-resident cells (BRM) in lymphoid or non-lymphoid 
tissues, identified by CD69 expression 372, 373, 378. In tissues of seropositive and seronegative 
donors, we detected significant populations (>50-75%) of CD69+ B cells comprising >50% of 
total B cells in the lung and LNs, while BM and spleen contained much lower frequencies (0-
10%) of CD69-expressing B cells (Figure 4-10B, C). Importantly, substantial frequencies of 
SARS-CoV-2 specific memory B cells exhibited CD69 expression indicative of tissue resident 
profiles in lungs (50-80%) and LNs (20-40%) (Figure 4-11E, F). By contrast, negligible 
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frequencies (<3%) of CD69+ SARS-CoV-2 S/RBD-specific memory B cells were detected in the 
BM of organ donors (Figure 4-11E, F), and in previously collected peripheral blood samples 
from convalescent COVID-19 individuals (Figure 4-10D-I), consistent with previous analysis of 
polyclonal B cells in these sites 373. Together, these results provide direct evidence for human 
antigen-specific BRM in lungs and LNs that are distinct from corresponding populations in blood. 
Thus, SARS-CoV-2 infection leads to the preferential formation and/or retention of antigen-
specific B cell memory within lungs and lung-associated LNs, with CD69+ tissue-resident cells 





Figure 4-10. Tissue memory and germinal center B cell responses following natural 
exposure to SARS-CoV-2.  
(A) Gating strategies to define Spike and/or RBD(S/RBD)-specific germinal center (GC) and 
memory B cells. (B) CD69 expression patterns on total memory B cells (CD27+ and/or IgD- non-
GC B cells) found in different tissues. Percentages of CD69+ cells are indicated. (C) Frequency 
(percentage of total memory B cells that are CD69+. (D-I) Memory B cells in blood from 
separate COVID-19 convalescent donors (n=6; 43-120 days post-symptom onset) were analyzed 
by flow cytometry. (D) Spike (left panel) and RBD (right panel) staining on memory B cells in 
blood. (E) Spike/RBD-specific memory B cells as a frequency of total B cells in blood. (F) CD69 
expression patterns on S/RBD-specific memory B cells in blood. Percentages of CD69+ cells are 
indicated. (G) Frequency of S/RBD-specific memory B cells that are CD69+ in blood. (H) CD69 
expression patterns on total memory B cells in blood. (I) Frequency of total memory B cells that 
are CD69+ in blood. (J) Spike (upper panel) and RBD (lower panel) staining on GC B cells. BM, 











Figure 4-11. SARS-CoV-2-specific memory B cells in tissues.  
(A) Representative flow cytometry plots showing staining patterns of probes for SARS-CoV-2 
Spike (upper panel) and RBD (lower panel) on memory B cells, defined here as 
CD19+CD20+IgD- non-GC B cells (see Figure 4-10A for gating). Memory B cells in BM, spleen, 
lung, LLN, and GLN from a SARS-CoV-2 Spike seropositive donor (D498) and memory B cells 
in lung from a seronegative donor (D340). Percentages are indicated. (B) SARS-CoV-2-specific 
memory B cells in tissues. Graph shows frequency of memory B cells specific to Spike and/or 
RBD (S/RBD) in indicated sites expressed as a percentage of CD19+CD20+ total B cells. (C) 
Fraction of SARS-CoV-2 S/RBD-specific memory B cells that belong to indicated Ig isotypes. 
(D) Frequency (percentage) of IgG+ memory B cells that are specific to S/RBD. (E) 
Representative flow cytometry plots showing CD69 expression on memory B cells specific to 
S/RBD. Percentages are indicated. (F) Frequency (percentage) of SARS-CoV-2 S/RBD-specific 
memory B cells that are CD69+. n=4 Seropositive donors (n=4 for lung, LLN, GLN; n = 3 for 
spleen; n = 2 for BM). n=7 Seronegative donors (n = 4 for lung, spleen; n = 5 for LLN, GLN, 
BM). Statistical analysis was performed using one-way ANOVA, corrected for multiple 
comparisons by FDR using two-stage linear step-up procedure of Benjamini, Krieger, and 
Yekutieli. * q ≤ 0.05; ** q ≤ 0.01; *** q ≤ 0.001; **** q ≤ 0.0001. For (B) and (D), datasets 
were log-transformed before statistical analysis. S/RBD, SARS-CoV-2 Spike and/or RBD; RBD, 
receptor-binding domain; BM, bone marrow; LLN, lung-associated lymph node; GLN, gut-










SARS-CoV-2-specific GC B cells and TFH cells in LNs 
GCs within lymphoid organs are important microanatomical sites in which activated B 
cells receive cognate help from TFH to undergo somatic hypermutation to evolve higher affinity 
antibody recognition of pathogens 379. While previous studies have demonstrated affinity 
matured SARS-CoV-2-specific memory B cells in blood 212, BM plasma cells 380, and circulating 
virus-specific TFH cells 160, which all indicate GC responses in COVID-19 213, direct evidence of 
SARS-CoV-2 antigen-specific GCs (and S-specific GC B cells, in particular) is lacking. We 
identified GC B cells by assessing co-expression of Bcl6 (a transcription factor required for GC 
B cell differentiation 381) and Ki67 (a marker of active cellular proliferation) among total CD19+ 
B cells (Figure 4-10A). The frequency of GC B cells (Bcl6+Ki67+CD19+ B cells) trended higher 
in lung-associated LNs of seropositive donors than seronegative donors (Figure 4-12A, B; q = 
0.053). SARS-CoV-2-specific GC B cells identified based on binding to S and RBD proteins 
were identified in lung-associated LNs of 3 out of 4 seropositive donors and in gut-associated 
LNs of one donor (Figure 4-12C, D and Figure 4-10J). Virus-specific GC B cells were not 
detected in BM, spleen, or lung of seropositive donors, nor in any tissues of seronegative donors 
(Figure 4-12C, D). These results provide direct evidence that SARS-CoV-2-specific GC 
responses are induced by SARS-CoV-2 infection and are maintained in lung-associated LNs 
following resolution of infection. Additionally, long-lasting GCs can even be generated in human 
gut-associated LNs.  
TFH cells can be identified by co-expression of CXCR5 and PD-1 71. TFH-phenotype cells 
(CXCR5+PD-1+CD4+ T cells) were found at low frequencies (5-10%) in lymphoid sites (spleen, 
lung-associated LNs, gut-associated LNs) and in even lower frequencies in BM and most lungs 
of seronegative and seropositive donors (Figure 3-13), demonstrating the relative rarity of this 
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population among total T cells. However, SARS-CoV-2-specific TFH cells (identified by AIMs 
as in Figure 3-1) were found in multiple sites of seropositive donors, comprising 20-50% of 
SARS-CoV-2-reactive CD4+ T cells in LNs, and lower but significant frequencies in lung, spleen 
and BM (Figure 3-12E-G). In one seropositive donor, over 80% of virus-specific CD4+ T cells in 
the lung were TFH, representing ~4% of non-naïve SARS-CoV-2-specific CD4+ T cells, 
consistent with the higher overall frequency of TFH cells in the lungs of that donor (Figure 3-12F, 
G and 3-13). Together, the SARS-CoV-2-specific GC B cell and TFH data indicated robust GC 
responses to SARS-CoV-2 infection, distributed among lymphoid tissues and sites of viral 





Figure 4-12. SARS-CoV-2-specific germinal center B cells and follicular helper T cells in 
seropositive donors.  
(A) Bcl6+Ki67+ germinal center (GC) B cells in different tissues, shown in representative flow 
cytometry plots from seropositive donor D498. See Figure 3-10 for gating strategy. (B) 
Frequency of Bcl6+Ki67+ GC B cells in tissue sites of seropositive and seronegative donors 
expressed as a percentage of total CD19+CD20+ total B cells. (C) GC B cells in the LLN for each 
donor shown in representative flow cytometry plots. GC B cells specific to S/RBD are depicted 
in red. (D) Frequency of S/RBD-specific GC B cells as a percentage of total B cells. (E) TFH 
phenotype and frequency among NN CD4+ T cells per tissue as depicted by the rectangle gate, 
shown in representative flow cytometry plots from seropositive donor D498 (lung, LLN, spleen, 
BM) and D495 (GLN); see Materials and Methods for gating strategy. SARS-CoV-2-specific 
NN CD4+ T cells are highlighted in orange. (F) Frequency of CXCR5+PD-1+ TFH cells per tissue 
as percentage of SARS-CoV-2-specific CD4+ T cells. (G) Frequency of SARS-CoV-2-specific 
TFH cells per tissue as percentage of total NN CD4+ T cells. Statistical analysis was performed on 
log-transformed datasets using one-way ANOVA, corrected for multiple comparisons by FDR 
using two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. * q £ 0.05, ** q £ 
0.01; **** q £ 0.0001. SARS-2, SARS-CoV-2; S/RBD, SARS-CoV-2 Spike and/or RBD; GC, 
germinal center; BM, bone marrow; LLN, lung-associated lymph node; GLN, gut-associated 










Figure 4-13. Follicular helper T cell responses across tissue sites.  










Coordinated adaptive immunity across tissues 
The identification of SARS-CoV-2-specific memory T and B cells in multiple tissues, 
along with TFH and GC B cells in LNs, suggested site-directed coordination of cellular and 
humoral immunity. In order to identify potential associations between SARS-CoV-2-specific 
lymphocyte populations across sites, we performed an exploratory correlation analysis (Figure 3-
14 and 3-15). The frequencies of S-specific CD4+ and CD8+ T cells (but not total SARS-CoV-2-
specific T cells, Figure 3-15A) were positively correlated across tissue sites (p=0.0116; Figure 3-
14A). Significant associations also emerged between SARS-CoV-2-specific B and T cells 
(Figure 3-14B-F and 3-15B-K)). SARS-CoV-2-specific CD4+ T cell frequencies correlated 
positively with S/RBD-specific memory B cells across all tissues (p=0.0009), as well as IgG+ 
(p=0.0009) and IgA+ (p=0.0203) subpopulations (Figure 3-14B, C and 3-15D, E). For tissue-
resident SARS-CoV-2-specific lymphocytes, CD69+CD103+ CD8+ TRM cells correlated with 
CD69+ BRM – both as frequencies of total lymphocytes (p=0.0069) and as fractions within their 
respective antigen-specific populations (p=0.01) (Figure 3-14E and 3-15J). Positive correlations 
were also observed between CD4+ TRM and BRM across all tissues (p=0.0198; Figure 3-15I). For 
follicular responses, S/RBD-specific memory B cells correlated with SARS-CoV-2-specific TFH 
cells across tissues (p=0.0236; Figure 3-14F and 3-15K). 
Given that lung and lung-associated LNs contained the highest frequencies of SARS-
CoV-2-specific lymphocytes, we performed a targeted correlation matrix analysis to identify 
potential associations within and between these sites (Figure 3-14G). SARS-CoV-2-specific TFH 
cells in the lung-associated LNs were significantly associated with lung memory B cells, while 
SARS-CoV-2-specific CD4+ T cell frequencies positively correlated with SARS-CoV-2-specific 
GC B cells lung-associated LNs. Conversely, certain LN and lung populations were inversely 
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correlated. In particular, the amount of S/RBD-specific GC B cells in the lung-associated LNs 
negatively correlated with S-specific CD4+ T cells in the lung. Similarly, S/RBD-specific 
memory B cell frequencies in the lung-associated LNs negatively correlated with SARS-CoV-2-
specific and S-specific CD8+ T cell frequencies in the lung. Similar correlations were observed 
when including blood and plasma antigen-specific lymphocyte populations in correlation matrix 
analyses (Figure 3-16). Together, these results suggest opposing or compensatory effects of 






Figure 4-14. SARS-CoV-2-specific adaptive immune relationships.  
 (A) Correlation between SARS-CoV-2 Spike-specific CD4+ T cells as frequency of total CD4+ 
T cells and Spike-specific CD8+ T cells as frequency of total CD8+ T cells. (B) Correlation 
between the frequency of SARS-CoV-2-specific CD4+ T cells and SARS-CoV-2 S/RBD-specific 
memory B cells. (C) Correlation between SARS-CoV-2-specific CD4+ T cells and IgG+ SARS-
CoV-2 S/RBD-specific memory B cells. (D) Correlation between SARS-CoV-2-specific CD8+ T 
cells and SARS-CoV-2 S/RBD-specific memory B cells within lymphoid tissues. (E) Correlation 
between SARS-CoV-2-specific CD69+CD103+ CD8+ TRM cells and CD69+ SARS-CoV-2 
S/RBD-specific BRM. (F) Correlation between SARS-CoV-2-specific PD-1+CXCR5+ TFH cells 
as frequency of NN CD4+ T cells and SARS-CoV-2 S/RBD-specific memory B cells as 
frequency of total memory B cells. (G) Correlogram of SARS-CoV-2-specific lung and LLN 
lymphocyte populations. Pearson R coefficients are shown from blue (−1.0) to red (1.0); R 
values are indicated by color and circle size. SARS-CoV-2-specific lymphocyte frequencies are 
depicted as a percentage of the parent population (%) or as counts per million PBMCs (/M); 
SARS-CoV-2-specific TFH cells are a percentage of total NN CD4+ T cells. Statistical analysis 
was performed on datasets using Pearson correlation. *, p £ 0.05; **, p £ 0.01; ***, p £ 0.001. 
SARS-2, SARS-CoV-2; S/RBD, SARS-CoV-2 Spike and/or RBD; BM, bone marrow; LLN, 
lung-associated lymph node; GLN, gut-associated lymph node; TFH, follicular helper T cell; 
GCB, germinal center B cell; MB, memory B cell; TRM, CD69+CD103+ resident memory T cell; 








Figure 4-15. SARS-CoV-2-specific immune memory relationships across organs.  
(A) Correlation between SARS-CoV-2-specific CD4+ T cells as frequency of total CD4+ T cells 
and SARS-CoV-2-specific CD8+ T cells as frequency of total CD8+ T cells. (B) Correlation 
between SARS-CoV-2-specific CD4+ T cells as frequency of total CD4+ T cells and SARS-CoV-
2 S/RBD-specific memory B cells as frequency of total memory B cells within lymphoid tissues. 
(C) Correlation between SARS-CoV-2-specific CD8+ T cells as frequency of total CD8+ T cells 
and SARS-CoV-2 S/RBD-specific memory B cells as frequency of total memory B cells in lung 
and lymphoid tissues. (D) Correlation between SARS-CoV-2-specific CD4+ T cells as frequency 
of total CD4+ T cells and IgA+ SARS-CoV-2 S/RBD-specific memory B cells as frequency of 
total memory B cells. (E) Correlation between SARS-CoV-2-specific CD4+ T cells as frequency 
of total CD4+ T cells and IgM+ SARS-CoV-2 S/RBD-specific memory B cells as frequency of 
total memory B cells. (F) Correlation between SARS-CoV-2-specific CD8+ T cells as frequency 
of total CD8+ T cells and IgG+ SARS-CoV-2 S/RBD-specific memory B cells as frequency of 
total memory B cells. (G) Correlation between SARS-CoV-2-specific CD8+ T cells as frequency 
of total CD8+ T cells and IgA+ SARS-CoV-2 S/RBD-specific memory B cells as frequency of 
total memory B cells. (H) Correlation between SARS-CoV-2-specific CD8+ T cells as frequency 
of total CD8+ T cells and IgM+ SARS-CoV-2 S/RBD-specific memory B cells as frequency of 
total memory B cells. (I) Correlation between SARS-CoV-2-specific CD69+ CD103+ CD4+ 
tissue-resident memory T cells (TRM) as frequency of total CD4+ T cells and CD69+ SARS-CoV-
2 S/RBD-specific tissue-resident memory B cells (BRM) as frequency of total memory B cells. (J) 
Correlation between SARS-CoV-2-specific CD69+ CD103+ CD8+ TRM as frequency of SARS-
CoV-2-specific CD8+ T cells and CD69+ SARS-CoV-2 S/RBD-specific BRM  as frequency of 
SARS-CoV-2 S/RBD-specific memory B cells. (K) Correlation between SARS-CoV-2-specific 
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PD-1+ CXCR5+ TFH cells as frequency of total CD4+ T cells and SARS-CoV-2 S/RBD-specific 
memory B cells as frequency of total memory B cells. Statistical analyses were performed using 
Pearson correlation on log-transformed values (A-I, K) or absolute frequencies (J). SARS-2, 
SARS-CoV-2; S/RBD, SARS-CoV-2 Spike and/or RBD; BM, bone marrow; LLN, lung-











Figure 4-16. Correlogram of SARS-CoV-2-specific, blood, lung and lung-associated LN 
lymphocyte populations.  
Pearson R coefficients are shown from blue (−1.0) to red (1.0); R values are indicated by color 
and circle size. SARS-CoV-2-specific lymphocyte frequencies are depicted as a percentage of 
the parent population (%) or as counts per million PBMCs (/M); TFH cells are a percentage of 
NN CD4+ T cells. Plasma antibody titers are depicted as ELISA endpoint titer. Statistical 
analysis was performed on datasets using Pearson correlation. *, p £ 0.05; **, p £ 0.01; ***, p £ 
0.001. LLN, lung-associated lymph node; TFH, follicular helper T cell; GCB, germinal center B 
cell; MB, memory B cell; TRM, CD69+CD103+ resident memory T cell; BRM, CD69+ resident 
memory B cell; S+, Spike-protein-specific; S2+, SARS-CoV-2-specific; PSV, pseudovirus; 













Immunological memory is maintained by heterogeneous subsets of virus-specific T and B 
cells in non-lymphoid tissue sites of infection and multiple lymphoid organs. A comprehensive 
assessment of memory responses is therefore difficult to accomplish in humans. Here, we reveal 
the cellular complexity and functional diversity of SARS-CoV-2-specific memory T and B cells 
in lymphoid and mucosal tissues of previously infected organ donors up to 6 months post-
infection (see Figure 4-17 for summary schematic). SARS-CoV-2-specific CD4+ T, CD8+ T, and 
B cells predominantly localized in the lung and lung-associated LNs and were maintained as 
memory cell populations. Tissue-resident T and B cells, known to participate in protection 
against secondary viral infections, were found most abundantly in the lung and were correlated 
across multiple sites. Moreover, SARS-CoV-2-specific GC B cells and TFH cells were discovered 
in lung-associated LNs, suggesting persisting GC responses months after resolution of infection. 
Together, these results indicate that the maintenance of SARS-CoV-2-specific immune memory 
is characterized by localized, ongoing coordination of cellular and humoral immunity within 
tissues.  
SARS-CoV-2-specific memory T and B cells were found throughout the body and 
localized preferentially to lung and lung-associated LNs, providing direct evidence that those 
sites are key locations for establishment of immune memory after SARS-CoV-2 infection. Gut-
associated LNs in some donors were also significant sites for SARS-CoV-2-specific memory T 
and B cells (particularly TRM and BRM), which could be due to the gut being a major site for 
SARS-CoV-2 replication in some cases 212, 382. The low frequency of SARS-CoV-2-specific 
memory T or B cells in the spleen further suggests that virus infection is generally limited to 
mucosal sites of entry. Our results show a proportion of SARS-CoV-2-specific memory T cells 
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in the lung were TRM, consistent with findings in airways of severe COVID-19 and surgical lung 
samples from previously infected patients 240-242. Additionally, we show that the majority of the 
SARS-CoV-2-specific memory B cells were resident.. In mouse models of influenza infection, 
localization and tissue residence of T and B cells to the lung and lung-associated LNs is 
correlated with optimal protective responses 331, 333, 372. Therefore, tissue localized and resident 
memory T and B cells in the lung are likely important for site-specific protection and could be 
targets for site-specific boosting in vaccination.    
SARS-CoV-2-specific memory CD4+ T cells were identified at significantly higher 
frequencies than CD8+ T cells across tissue sites, reflecting previous studies of peripheral blood 
showing that CD4+ responses are more robust than CD8+ responses months after resolution of 
infection 222, 226. In addition, SARS-CoV-2-specific T cells exhibited tissue-specific functional 
profiles, with cytotoxic proinflammatory, regulatory, and tissue repair functions variably 
manifested across different sites. In the lung-associated LNs, memory T cells exhibited broad 
proinflammatory, helper, and regulatory functional profiles. SARS-CoV-2-specific lung T cells 
produced higher levels of IL-10 compared to other sites, consistent with a role for T cell-derived 
IL-10 in regulating lung inflammation in mice 377. We previously showed in paired airway and 
blood samples of severe COVID-19 patients that the cytokine and chemokine profile in airway 
washes was distinct from that in plasma 240. Here, we further demonstrate that the functional 
responses of virus-specific T cells are tissue-specific – not only at the site of infection, but also 
across numerous lymphoid tissues. Together, these results suggest that T cells in tissues mediate 
responses that are functionally adapted to the tissue site, resulting in heterogeneity of immune 
memory stored throughout the body.   
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SARS-CoV-2-specific memory B cells were distributed across multiple sites. While 
frequencies were highest in lung and LNs, there were also significant frequencies in BM. In all 
sites, virus-specific memory B cells exhibited a predominantly IgG+ memory phenotype. The 
finding of S/RBD-specific BRM in lung and lymphoid sites was notable, as was the low frequency 
of IgA+ SARS-CoV-2-specific memory B cells in mucosal tissue and associate LNs.   
Our results directly demonstrate ongoing, persistent GC responses in LNs following 
resolution of SARS-CoV-2 infection—including at least one example 6 months post-infection. 
Despite a report of potentially impaired GC responses in fatal COVID-19 383, our data show 
coordinated TFH and GC B cells in the lung-associated LNs to non-fatal SARS-CoV-2 infection. 
These results provide evidence of ongoing GC reactions following resolution of infection, 
consistent with reports of prolonged evolution of humoral responses in peripheral blood up to 6 
months following SARS-CoV-2 infection 212, 384. GC B cells were detected in donors spanning a 
broad age range—from 10-74 years, providing compelling evidence that the ability to establish 
robust GC responses to novel pathogens can be maintained with age.  
These results also indicate ongoing interaction and coordination between T and B cells 
within LNs, which we also found related to memory populations in the lung. Significant 
correlations were also found between SARS-CoV-2-specific memory B and T cell populations 
across tissue sites, consistent with correlations between virus-specific T and B cell responses in 
peripheral blood of previously infected individuals 224, 229. We also identified potential inverse 
correlations between frequencies of virus-specific CD8+T cells in the lung and memory B cells in 
the lung-associated LN, suggesting that lung responses in situ can impact the magnitude or 
requirement for humoral responses in the associated LN. Together, these findings suggest that 
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dynamic coordination of adaptive immune responses across the body is a feature of anti-viral 
immunity to SARS-CoV-2.  
This work has certain limitations. Namely, our study focuses on four seropositive donors 
across seven decades of life to provide a representative profile of tissue-specific anti-viral 
immune responses. In addition to the challenges of obtaining live cells for immunological studies 
from organ donors, the findings here also depended on SARS-CoV-2 seropositive donors who 
had not been vaccinated, thus limiting the size of the donor pool and the timeframe of collection 
(prior to December 2020). The consistency in cell type and site-specific trends and correlations 
across all profiled donors, as well as corroboration of larger scale blood studies, demonstrates 
how this project provides new insights into tissue-specific immune memory maintenance and 
persistence of humoral and cellular responses following SARS-CoV-2 infection. 
In conclusion, we reveal here that immunological memory from SARS-CoV-2 infection 
is maintained as heterogeneous subsets across multiple sites, with active and preferential 
maintenance in lung and associated LNs, as well as site-specific functional adaptations. These 
findings support the development of site-specific strategies for monitoring immune memory to 




Figure 4-17. Graphical representation of study workflow and SARS-CoV-2-specifc 
lymphocyte frequencies across human tissues.  
Schematic diagram illustrating donors and tissues utilized (top left) and experimental workflow 
(top right) for this study. (Bottom panel) Visual representation of presence (GC B cells) and 
frequency (memory B cells, CD4+ T cells and CD8+ T cells) of SARS-CoV-2-specific 
lymphocytes found across all donors used in this study. SARS-2, SARS-CoV-2; BM, bone 
marrow; LLN, lung-associated lymph node; GLN, gut-associated lymph node; GC, germinal 










Chapter 5: Conclusions 
Anti-viral adaptive immune memory is stored in diverse sites, particularly within 
lymphoid tissues and at tissue sites of infection. Yet, most knowledge about human anti-viral 
immunity is based on studies of peripheral blood samples or inferred from animal studies. These 
studies have provided tremendous insights. Mouse models of infection by various acute and 
persistent viruses have demonstrated that virus-specific TRM reside in tissue sites of infection 
long-term and provide optimum protection again re-infection 184-186, 385-390. In humans, have been 
largely non-antigen-specific TRM exhibiting phenotypes and transcriptional profiles homologous 
to mouse TRM have been identified outside circulation and in nonlymphoid tissues142, 177, 178, 183, 
391. Additionally, circulating virus-specific memory T cells with function capacity have been 
identified in acute and persistent viral infection and post-infection in humans 157, 174, 205, 206, 208, 209, 
221, 222, 225, 226, 230, 297, 312, 362, 392, 393. However, in order to better understand the tissue-wide 
dynamics of human anti-viral immunity and the factors that shape it, it is paramount to look 
within the tissues and examine how the immune system response to various viral challenge. The 
work presented in this thesis demonstrates the persistence of anti-viral adaptive immune 
responses in diverse tissue sites, offering insights into the distribution, phenotype, clonality, and 
functional capacity of virus-specific lymphocytes. 
Our work revealed that the tissue distribution of virus-specific T cells is shaped by the 
tissue tropism of the virus. Persistent immune protection against systemic persistent virus CMV 
is characterized by dissemination of CMV-specific CD8+ T cells in multiple sites – blood, BM, 
spleen, lung, and LNs, with substantial frequencies observed in the BM, which is a known site of 
latency for the virus. In contrast, virus-specific CD8+ T cells against acute respiratory virus Flu, 
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as well as virus-specific CD4+ T, CD8+ T, and B cells against acute respiratory virus SARS-
CoV-2 are preferentially localized within the lung tissue site of infection and associated LN site.  
The maintenance of T cell subsets within various tissue sites depends on the tissue 
environment, as well as characteristics of the virus. Overall, the T cell subset differentiation of 
antigen-specific T cells in various tissues mirrors the compartmentalization of bulk T cell 
populations previously reported by our laboratory, with CD8+ T cells in adult donors being 
primarily CCR7- TEM and TEMRA populations, while CD4+ T cells are mostly TEM in mucosal sites 
and TCM/TEM in lymphoid sites 26, 28. Within each tissue site, the virus shapes the memory T cell 
subset pool. CMV-specific CD8+ T cells are predominantly TEMRA in multiple sites and TEM in 
LNs. There were significantly higher frequencies of CMV-specific TEMRA in blood, spleen, and 
lung and significantly higher frequencies of CMV-specific circulating CD69- TEM in the lung 
than Flu-specific CD8+ T cells, reflecting the systemic nature of CMV infection, which requires 
ongoing circulating immune surveillance. In contrast, Flu-specific CD8+ T cells are maintained 
primarily as TEM in lymphoid and mucosal sites with a fraction also found as TEMRA in the BM. 
Looking at characteristics of tissue residency, we found higher frequencies of Flu-specific TRM  
than CMV-specific TRM  in spleen, lung, and LLN, in line with the lung tropism of respiratory 
Flu infection. Similarly, SARS-CoV-2 seropositive donors harbored virus-specific CD4+ and 
CD8+ TRM  in the lung and CD8+ TRM  in LNs against the respiratory virus, but not in circulation 
or in spleen and BM.  
Examining the effects of biological characteristics of individuals on the maintenance of 
anti-viral immunity, we showed that age and sex play a role in shaping immune memory. In the 
comparison of CMV and Flu responses in adult donors over age, we found that age-associated 
effects are observed in certain tissues, but not throughout the entire body. For example, there was 
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an increase in frequency of Flu-specific TEMRA in the BM and a decrease in frequency of Flu-
specific TRM in LLN with age. For both elderly SARS-CoV-2 seropositive donors examined, 
LLN functional responses were much weaker compared to other tissue sites, even when there 
were substantial frequencies AIM+ CD4+ and CD8+ T cells in the LLN. When comparing adults 
and pediatric donors, we demonstrated that, in lung and LLN, Flu-specific CD8+ T cells in 
pediatric donors were maintained at higher frequencies as CCR7+ CD45RA- TCM and lower 
frequencies as CD69+ CD103+ TRM compared to adult donors. These findings demonstrate that 
effects of aging play a role in the maintenance of anti-viral immune response, whether it be due 
to intrinsic effects of aging tissue or accumulated exposures to viral antigens. Our studies also 
indicate that sex plays a role in shaping the virus-specific T cell compartment within tissue sites, 
though more studies are required to fully elucidate the mechanisms underlying these 
observations.  
While the phenotypic characteristics of anti-viral immune memory is shaped by a 
multitude of factors, our work demonstrates that the functional immune response is primarily 
determined by the tissue. In the studies presented in the thesis, stimulation of T cells by antigens 
specific for all three viruses studied resulted in functional profiles defined by the cells’ tissue of 
origin. Through profiling of immune mediators in cell culture supernatants, as well as 
transcriptional profiles through scRNA-seq, we showed that virus-specific responses largely 
correlated to the tissue, with the exception of a subset of BM CMV-specific T cells whose 
functional responses appeared to be defined in part by virus-driven influences. 
These results provide insights into how anti-viral immune memory responses are 
maintained, not only in circulation, but also within tissue sites, to provide protection against 
prevalent viruses. While heterogeneity exists among individuals with regards to adaptive 
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immune memory against viruses, work presented in this thesis reveals how factors, such as 
tissue, virus, age, and sex play important roles in governing how anti-viral immune memory is 
maintained in tissues. To define further the contribution of these various factors, continued 
assessment of virus-specific adaptive immune responses in more donors and across more virus 
specificities is needed, as well as further examination of other factors, such as BMI, 
comorbidities, ethnicity, etc. Our work provides improved understanding of the determinants of 
tissue-localized anti-viral immunity and has major implications for defining predictive models 
and site-specific strategies that can be leveraged for the development of individualized vaccines 
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Appendix A: Scripts in Python and R 
Visualization of Flu- and CMV-specific T cell subsets 
import pandas as pd 
import os  
import matplotlib.pyplot as plt 
import seaborn as sns 
import numpy as np 
import matplotlib as mpl 
 





data = pd.read_csv("09252020_adult compiled freqs for python.csv") 
data 
 
pal = {"Flu":"red","CMV":"blue"} 
 
fig, ax = plt.subplots(figsize = (8,5)) 
ax = sns.boxplot(x="Tissue", y="% multimer+ of CD8+ T cells", hue="Virus",  
                 fliersize = 2, data=data, palette = pal,  
                 hue_order = ['Flu', 'CMV']) 
ax = sns.stripplot(x='Tissue', y='% multimer+ of CD8+ T cells', hue="Virus",  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 







handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 





















C = C.sort_values(by=['AGE']) 
F=flu.loc[:,sel_columns] 
F.head(5) 















c_y_axis_labels = C["AGE"] 




g = sns.heatmap(C_norm, annot=C_freq, linewidths=.5, linecolor = 'lightgrey',  
                cmap='Blues', yticklabels=c_y_axis_labels) 




cbar = ax.collections[0].colorbar 






g = sns.heatmap(F_norm, annot=F_freq, linewidths=.5, linecolor = 'lightgrey',  
                cmap='Reds', yticklabels=f_y_axis_labels) 
g.set_yticklabels(g.get_yticklabels(), rotation = 0, fontsize=14) 
g.set_ylabel('Age',fontsize=20) 
g.set_xticklabels(x_axis, fontsize=16) 
ax.set_title('Influenza A',fontsize=25, weight='bold',pad=20) 
cbar = ax.collections[0].colorbar 
cbar.set_label(label='Row normalized value', fontsize=15) 
plt.savefig("09262020_flufreqheatmap_normalized.pdf",bbox_inches='tight') 
 
#Figure 3-4C, 3-6B, 3-7A 
 
data = pd.read_csv("08252021_CD69-TEM freqs for python.csv") 
data 
 
pal = {"Flu":"red", "CMV":"blue"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
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ax = sns.boxplot(x="Tissue", y="% TEM of CD8+ multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jej"], hue="Virus", hue_order=["Flu","CMV"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEM of CD8+ multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jej"], hue="Virus", hue_order=["Flu","CMV"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 
plt.savefig("08252021_CD69-TEM freq.pdf", dpi = 600) 
plt.show() 
 
data = pd.read_csv("03182021_TEM freqs for python.csv") 
data 
 
pal = {"Flu":"red", "CMV":"blue"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% TEM of CD8+ multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jej"], hue="Virus", hue_order=["Flu","CMV"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEM of CD8+ multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jej"], hue="Virus", hue_order=["Flu","CMV"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 
plt.savefig("03182021_TEM freq.pdf", dpi = 600) 
plt.show() 
 
data = pd.read_csv("03182021_TEMRA freqs for python.csv") 
data 
 
pal = {"Flu":"red", "CMV":"blue"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% TEMRA of CD8+ multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jej"], hue="Virus", hue_order=["Flu","CMV"], 
                 fliersize = 0, data=data, palette = pal) 
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ax = sns.stripplot(x="Tissue", y="% TEMRA of CD8+ multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jej"], hue="Virus", hue_order=["Flu","CMV"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 
plt.savefig("03182021_TEMRA freq.pdf", dpi = 600) 
plt.show() 
 
data = pd.read_csv("03182021_CD57 freqs for python.csv") 
data 
 
pal = {"Flu":"red", "CMV":"blue"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% CD57 of CD8+ multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jej"], hue="Virus", hue_order=["Flu","CMV"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% CD57 of CD8+ multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jej"], hue="Virus", hue_order=["Flu","CMV"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 




data = pd.read_csv("03182021_TRM of TEM freqs for python.csv") 
data 
 
pal = {"Flu":"red", "CMV":"blue"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% TRM of CD8+ multimer+ TEM", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jej"], hue="Virus", hue_order=["Flu","CMV"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TRM of CD8+ multimer+ TEM", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jej"], hue="Virus", hue_order=["Flu","CMV"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 
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handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 




#Figure 3-4D,E 3-6D, 3-7C 
































y=LG_CMV['CD69+/CD103+ TRM of TEM'] 
f,ax=plt.subplots(figsize=(8,4)) 
g = sns.regplot(x,y, scatter_kws={"color":"b","s":20}, line_kws={"color":"b","lw":"1"}) 
g.set(ylim=(-20, 100)) 






















data = pd.read_csv("08162021_HLA comp CD8 CD69- TEM CMV for python.csv") 
data 
 
pal = {"A2":"darkslateblue", "multiple":"lightgrey"} 
 
fig, ax = plt.subplots(figsize = (5,5)) 
ax = sns.boxplot(x="Tissue", y="% TEM of CMV-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEM of CMV-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 





data = pd.read_csv("08162021_HLA comp CD8 CD69- TEM flu for python.csv") 
data 
 
pal = {"A2":"darkslateblue", "multiple":"lightgrey"} 
 
fig, ax = plt.subplots(figsize = (5,5)) 
ax = sns.boxplot(x="Tissue", y="% TEM of Flu-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEM of Flu-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                   dodge= True, data=data, palette = pal, edgecolor = "k", 
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handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 




data = pd.read_csv("08162021_HLA comp CD8 TEMRA CMV for python.csv") 
data 
 
pal = {"A2":"darkslateblue", "multiple":"lightgrey"} 
 
fig, ax = plt.subplots(figsize = (5,5)) 
ax = sns.boxplot(x="Tissue", y="% TEMRA of CMV-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEMRA of CMV-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 





data = pd.read_csv("08162021_HLA comp CD8 TEMRA flu for python.csv") 
data 
 
pal = {"A2":"darkslateblue", "multiple":"lightgrey"} 
 
fig, ax = plt.subplots(figsize = (5,5)) 
ax = sns.boxplot(x="Tissue", y="% TEMRA of Flu-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEMRA of Flu-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                   dodge= True, data=data, palette = pal, edgecolor = "k", 











handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 





data = pd.read_csv("08162021_HLA comp CD8 TRM CMV for python.csv") 
data 
 
pal = {"A2":"darkslateblue", "multiple":"lightgrey"} 
 
fig, ax = plt.subplots(figsize = (5,5)) 
ax = sns.boxplot(x="Tissue", y="% TRM of CMV-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TRM of CMV-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 





data = pd.read_csv("08162021_HLA comp CD8 TRM flu for python.csv") 
data 
 
pal = {"A2":"darkslateblue", "multiple":"lightgrey"} 
 
fig, ax = plt.subplots(figsize = (5,5)) 
ax = sns.boxplot(x="Tissue", y="% TRM of flu-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TRM of flu-multimer+", order=["Blood","BM","Spleen","Lung","LLN"], 
hue="HLA", hue_order=["A2","multiple"], 
                   dodge= True, data=data, palette = pal, edgecolor = "k", 











handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 




data = pd.read_csv("09292020_ped compiled freqs for python.csv") 
data 
 
pal = {"Pediatric":"crimson", "Adult":"lightgrey"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% multimer+ of CD8+ T cells", order=["Spleen","Lung","LLN","MLN"], 
hue="Age", hue_order=["Pediatric","Adult"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% multimer+ of CD8+ T cells", order=["Spleen","Lung","LLN","MLN"], 
hue="Age", hue_order=["Pediatric","Adult"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 







handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 




mpl.rcParams['pdf.fonttype'] = 42 
 




fig, ax = plt.subplots(figsize = (5,5)) 
ax = sns.boxplot(x="Tissue", y="% multimer+ of CD8+ T cells", order=["Spleen","Lung","LLN","MLN"], 
hue="Age", hue_order=["Pediatric"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% multimer+ of CD8+ T cells", order=["Spleen","Lung","LLN","MLN"], 
hue="Age", hue_order=["Pediatric"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:0], labels[0:0]) 





data = pd.read_csv("03042021_sex comp CMV freqs for python.csv") 
data 
 
pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% CMV multimer+ of CD8+ T cells", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% CMV multimer+ of CD8+ T cells", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 





data = pd.read_csv("03042021_sex comp flu freqs for python.csv") 
data 
 
pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% Flu multimer+ of CD8+ T cells", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% Flu multimer+ of CD8+ T cells", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                  dodge= True, data=data, palette = pal, edgecolor = "k", 










handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 








data = pd.read_csv("03042021_sex comp CMV TEM freqs for python.csv") 
data 
 
pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% TEM of CD8+ CMV-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEM of CD8+ CMV-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 





data = pd.read_csv("03042021_sex comp flu TEM freqs for python.csv") 
data 
 
pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% TEM of CD8+ Flu-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
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ax = sns.stripplot(x="Tissue", y="% TEM of CD8+ Flu-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 








handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 




data = pd.read_csv("03042021_sex comp CMV TEMRA freqs for python.csv") 
data 
 
pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% TEMRA of CD8+ CMV-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEMRA of CD8+ CMV-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 








handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 





data = pd.read_csv("03042021_sex comp flu TEMRA freqs for python.csv") 
data 
 
pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 





                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEMRA of CD8+ Flu-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 








handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 




data = pd.read_csv("03042021_sex comp CMV TRM freqs for python.csv") 
data 
 
pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% CD69+/CD103+ TRM of CD8+ CMV-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% CD69+/CD103+ TRM of CD8+ CMV-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 





data = pd.read_csv("03042021_sex comp flu TRM freqs for python.csv") 
data 
 
pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
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ax = sns.boxplot(x="Tissue", y="% CD69+/CD103+ TRM of CD8+ Flu-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% CD69+/CD103+ TRM of CD8+ Flu-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 




data = pd.read_csv("03042021_sex comp CMV TRM freqs of total mult for python.csv") 
data 
 
pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% CD69+/CD103+ TRM of CD8+ CMV-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% CD69+/CD103+ TRM of CD8+ CMV-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 








handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 





data = pd.read_csv("03042021_sex comp flu TRM freqs of total mult for python.csv") 
data 
 




fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% CD69+/CD103+ TRM of CD8+ Flu-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% CD69+/CD103+ TRM of CD8+ Flu-multimer+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 




data = pd.read_csv("05102021_sex comp CD8 TEM freqs for python.csv") 
data 
 
pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% TEM of CD8+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEM of CD8+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 
plt.savefig("05102021_sex comp CD8 TEM freq.pdf", dpi = 600) 
plt.show() 
 





pal = {"Male":"green", "Female":"orange"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="% TEMRA of CD8+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="% TEMRA of CD8+", 
order=["Blood","BM","Spleen","Lung","LLN","ILN","MLN","Jejunum"], hue="Sex", 
hue_order=["Male","Female"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 
plt.savefig("05102021_sex comp CD8 TEMRA freq.pdf", dpi = 600) 
plt.show() 
 
#Figure 3-10C, D 
 
data = pd.read_csv("03182021_shannon entropy for python.csv") 
data 
 
pal = {"Flu":"white", "CMV":"grey"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="Shannon entropy", order=["Blood","BM","Spleen","Lung","LLN","MLN"], 
hue="Virus", hue_order=["Flu","CMV"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="Shannon entropy", order=["Blood","BM","Spleen","Lung","LLN","MLN"], 
hue="Virus", hue_order=["Flu","CMV"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 









pal = {"Flu":"white", "CMV":"grey"} 
 
fig, ax = plt.subplots(figsize = (6,5)) 
ax = sns.boxplot(x="Tissue", y="Clonality", order=["Blood","BM","Spleen","Lung","LLN","MLN"], hue="Virus", 
hue_order=["Flu","CMV"], 
                 fliersize = 0, data=data, palette = pal) 
ax = sns.stripplot(x="Tissue", y="Clonality", order=["Blood","BM","Spleen","Lung","LLN","MLN"], hue="Virus", 
hue_order=["Flu","CMV"],  
                   dodge= True, data=data, palette = pal, edgecolor = "k", 









handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles[0:2], labels[0:2]) 









CMV_spleen_D421 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/04182019 D434_D421/For Mei Mei/D421-spleen-CMV-tet-exvivo-nostim.txt", header = T, 
stringsAsFactors = FALSE) 
CMV_LLN_D421 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/04182019 D434_D421/For Mei Mei/D421-LLN-CMV-tet-exvivo-nostim.txt", header = T, 
stringsAsFactors = FALSE) 
CMV_lung_D421 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/04182019 D434_D421/For Mei Mei/D421-lung-CMV-tet-exvivo-nostim.txt", header = T, 
stringsAsFactors = FALSE) 
 
#434 
CMV_spleen_D434 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/04182019 D434_D421/For Mei Mei/D434-spleen-CMV-tet-exvivo-nostim.txt", header = T, 
stringsAsFactors = FALSE) 
CMV_LLN_D434 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/04182019 D434_D421/For Mei Mei/D434-LLN-CMV-tet-exvivo-nostim.txt", header = T, 
stringsAsFactors = FALSE) 
CMV_lung_D434 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/04182019 D434_D421/For Mei Mei/D434-lung-CMV-tet-exvivo-nostim.txt", header = T, 
stringsAsFactors = FALSE) 
flu_spleen_D434 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/04182019 D434_D421/For Mei Mei/D434-spleen-flu-tet-exvivo-nostim.txt", header = T, 
stringsAsFactors = FALSE) 
flu_LLN_D434 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/04182019 D434_D421/For Mei Mei/D434-LLN-flu-tet-exvivo-nostim.txt", header = T, stringsAsFactors 
= FALSE) 
flu_lung_D434 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 




CMV_blood_D438 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-blood-CMVtet.txt", header = T, stringsAsFactors = 
FALSE) 
CMV_blood_D438$VEnd <- NA 
CMV_blood_D438=CMV_blood_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
CMV_BM_D438 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-BM-CMVtet.txt", header = T, stringsAsFactors = FALSE) 
CMV_BM_D438$VEnd <- NA 
CMV_BM_D438=CMV_BM_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
CMV_spleen_D438= read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-spleen-CMVtet.txt", header = T, stringsAsFactors = 
FALSE) 
CMV_spleen_D438$VEnd <- NA 
CMV_spleen_D438=CMV_spleen_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
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CMV_LLN_D438 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-LLN-CMVtet.txt", header = T, stringsAsFactors = FALSE) 
CMV_LLN_D438$VEnd <- NA 
CMV_LLN_D438=CMV_LLN_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
CMV_lung_D438 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-lung-CMVtet.txt", header = T, stringsAsFactors = FALSE) 
CMV_lung_D438$VEnd <- NA 
CMV_lung_D438=CMV_lung_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
CMV_MLN_D438 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-MLN-CMVtet.txt", header = T, stringsAsFactors = 
FALSE) 
CMV_MLN_D438$VEnd <- NA 
CMV_MLN_D438=CMV_MLN_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_blood_D438 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-blood-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_blood_D438$VEnd <- NA 
flu_blood_D438=flu_blood_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_BM_D438 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-BM-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_BM_D438$VEnd <- NA 
flu_BM_D438=flu_BM_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_spleen_D438= read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-spleen-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_spleen_D438$VEnd <- NA 
flu_spleen_D438=flu_spleen_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_LLN_D438 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-LLN-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_LLN_D438$VEnd <- NA 
flu_LLN_D438=flu_LLN_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_lung_D438 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-lung-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_lung_D438$VEnd <- NA 
flu_lung_D438=flu_lung_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_MLN_D438 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-MLN-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_MLN_D438$VEnd <- NA 
flu_MLN_D438=flu_MLN_D438[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
#447 
CMV_blood_D447 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-blood-flutet.txt", header = T, stringsAsFactors = FALSE) 
CMV_blood_D447$VEnd <- NA 
CMV_blood_D447=CMV_blood_D447[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
CMV_BM_D447 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-BM-flutet.txt", header = T, stringsAsFactors = FALSE) 




                                  "JStart","incidence","convergence","occurrences")] 
CMV_spleen_D447= read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-spleen-flutet.txt", header = T, stringsAsFactors = FALSE) 
CMV_spleen_D447$VEnd <- NA 
CMV_spleen_D447=CMV_spleen_D447[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
CMV_LLN_D447 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-LLN-flutet.txt", header = T, stringsAsFactors = FALSE) 
CMV_LLN_D447$VEnd <- NA 
CMV_LLN_D447=CMV_LLN_D447[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
CMV_lung_D447 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D438-lung-flutet.txt", header = T, stringsAsFactors = FALSE) 
CMV_lung_D447$VEnd <- NA 
CMV_lung_D447=CMV_lung_D447[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_blood_D447 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D447-blood-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_blood_D447$VEnd <- NA 
flu_blood_D447=flu_blood_D447[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_BM_D447 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D447-BM-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_BM_D447$VEnd <- NA 
flu_BM_D447=flu_BM_D447[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_spleen_D447= read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D447-spleen-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_spleen_D447$VEnd <- NA 
flu_spleen_D447=flu_spleen_D447[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_LLN_D447 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D447-LLN-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_LLN_D447$VEnd <- NA 
flu_LLN_D447=flu_LLN_D447[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_lung_D447 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/08202019_D438_D447_multimer sort/D447-lung-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_lung_D447$VEnd <- NA 
flu_lung_D447=flu_lung_D447[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 




CMV_BM_D457 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/09242019_D457_multimer sort/D457-BM-CMVtet.txt", header = T, stringsAsFactors = FALSE) 
CMV_BM_D457$VEnd <- NA 
CMV_BM_D457=CMV_BM_D457[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
CMV_spleen_D457= read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/09242019_D457_multimer sort/D457-spleen-CMVtet.txt", header = T, stringsAsFactors = FALSE) 
CMV_spleen_D457$VEnd <- NA 
CMV_spleen_D457=CMV_spleen_D457[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
CMV_LLN_D457 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/09242019_D457_multimer sort/D457-LLN-CMVtet.txt", header = T, stringsAsFactors = FALSE) 
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CMV_LLN_D457$VEnd <- NA 
CMV_LLN_D457=CMV_LLN_D457[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
CMV_lung_D457 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/09242019_D457_multimer sort/D457-lung-CMVtet.txt", header = T, stringsAsFactors = FALSE) 
CMV_lung_D457$VEnd <- NA 
CMV_lung_D457=CMV_lung_D457[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
 
flu_BM_D457 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/09242019_D457_multimer sort/D457-BM-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_BM_D457$VEnd <- NA 
flu_BM_D457=flu_BM_D457[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_spleen_D457= read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/09242019_D457_multimer sort/D457-spleen-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_spleen_D457$VEnd <- NA 
flu_spleen_D457=flu_spleen_D457[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_LLN_D457 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/09242019_D457_multimer sort/D457-LLN-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_LLN_D457$VEnd <- NA 
flu_LLN_D457=flu_LLN_D457[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
flu_lung_D457 = read.table("/Volumes/CCTI_Labs/CCTI_USERS/Mei Mei Li/Antiviral immunity/TCR 
sequencing/09242019_D457_multimer sort/D457-lung-flutet.txt", header = T, stringsAsFactors = FALSE) 
flu_lung_D457$VEnd <- NA 
flu_lung_D457=flu_lung_D457[, c("count","freq","cdr3nt","cdr3aa","v","d","j","VEnd","DStart","DEnd", 
                                  "JStart","incidence","convergence","occurrences")] 
 
 
D421_master_df <- list(CMV_spleen_D421,CMV_LLN_D421,CMV_lung_D421) 
 
D434_master_df <- list(CMV_spleen_D434,flu_spleen_D434, CMV_LLN_D434, 
flu_LLN_D434,CMV_lung_D421, flu_lung_D434) 
 
D438_master_df <-list(CMV_blood_D438, flu_blood_D438, CMV_BM_D438, flu_BM_D438, 
CMV_spleen_D438, flu_spleen_D438, CMV_LLN_D438, flu_LLN_D438, CMV_lung_D438, flu_lung_D438, 
CMV_MLN_D438, flu_MLN_D438) 
 
D447_master_df <- list(CMV_blood_D447, flu_blood_D447, CMV_BM_D447, flu_BM_D447, 
CMV_spleen_D447, flu_spleen_D447 ,CMV_LLN_D447, flu_LLN_D447, CMV_lung_D447, flu_lung_D447) 
 
D457_master_df <- list(CMV_BM_D457, flu_BM_D457, CMV_spleen_D457, flu_spleen_D457, 
CMV_LLN_D457, flu_LLN_D457, CMV_lung_D457, flu_lung_D457) 
 
 
colummns <- c ("Umi.count",                "Umi.proportion",        
               "Read.count",               "Read.proportion",          
               "CDR3.nucleotide.sequence", "CDR3.amino.acid.sequence", 
               "V.gene",                   "J.gene",                   
               "D.gene",                   "V.end",                    
               "J.start",                  "D5.end",                   
               "D3.end",                   "VD.insertions",            




D421_mod_df <- list() 
 
for (i in seq(1,3)) { 
  df <-  as.data.frame(D421_master_df[[i]]) 
  df["Umi.count"] <- FALSE 
  df["Umi.proportion"] <- FALSE 
  df <- df[,c(15,16,1,2,3,4,5,7,6,8,11,9,10,12,13,14)] 
  colnames(df) <- colummns 
  D421_mod_df[i] <- list(df) 
} 
 
D434_mod_df <- list() 
 
for (i in seq(1,6)) { 
  df <-  as.data.frame(D434_master_df[[i]]) 
  df["Umi.count"] <- FALSE 
  df["Umi.proportion"] <- FALSE 
  df <- df[,c(15,16,1,2,3,4,5,7,6,8,11,9,10,12,13,14)] 
  colnames(df) <- colummns 
  D434_mod_df[i] <- list(df) 
} 
 
D438_mod_df <- list() 
 
for (i in seq(1,12)) { 
  df <-  as.data.frame(D438_master_df[[i]]) 
  df["Umi.count"] <- FALSE 
  df["Umi.proportion"] <- FALSE 
  df <- df[,c(15,16,1,2,3,4,5,7,6,8,11,9,10,12,13,14)] 
  colnames(df) <- colummns 
  D438_mod_df[i] <- list(df) 
} 
 
D447_mod_df <- list() 
 
for (i in seq(1,10)) { 
  df <-  as.data.frame(D447_master_df[[i]]) 
  df["Umi.count"] <- FALSE 
  df["Umi.proportion"] <- FALSE 
  df <- df[,c(15,16,1,2,3,4,5,7,6,8,11,9,10,12,13,14)] 
  colnames(df) <- colummns 
  D447_mod_df[i] <- list(df) 
} 
 
D457_mod_df <- list() 
 
for (i in seq(1,8)) { 
  df <-  as.data.frame(D457_master_df[[i]]) 
  df["Umi.count"] <- FALSE 
  df["Umi.proportion"] <- FALSE 
  df <- df[,c(15,16,1,2,3,4,5,7,6,8,11,9,10,12,13,14)] 
  colnames(df) <- colummns 
  D457_mod_df[i] <- list(df) 
} 
 
names(D421_mod_df) <- c("CMV_spleen_D421","CMV_LLN_D421","CMV_lung_D421") 
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names(D434_mod_df) <- c('CMV_spleen_D434','flu_spleen_D434', 'CMV_LLN_D434',  
                        'flu_LLN_D434','CMV_lung_D421', 'flu_lung_D434') 
names(D438_mod_df) <- c('CMV_blood_D438', 'flu_blood_D438', 'CMV_BM_D438', 'flu_BM_D438', 
                        'CMV_spleen_D438', 'flu_spleen_D438', 'CMV_LLN_D438', 'flu_LLN_D438', 
                        'CMV_lung_D438', 'flu_lung_D438', 'CMV_MLN_D438', 'flu_MLN_D438') 
 
names(D447_mod_df) <- c('CMV_blood_D447', 'flu_blood_D447', 'CMV_BM_D447', 'flu_BM_D447',  
                        'CMV_spleen_D447', 'flu_spleen_D447' ,'CMV_LLN_D447', 'flu_LLN_D447', 
                        'CMV_lung_D447', 'flu_lung_D447') 
 
names(D457_mod_df) <- c('CMV_BM_D457', 'flu_BM_D457','CMV_spleen_D457', 'flu_spleen_D457', 
                        'CMV_LLN_D457', 'flu_LLN_D457', 'CMV_lung_D457', 'flu_lung_D457')       
       
 
vis.top.proportions(D434_mod_df, .head=c(3,10,50,100, 1000)) 
vis.top.proportions(D438_mod_df, .head=c(3,10,50,100, 1000)) 
vis.top.proportions(D447_mod_df, .head=c(3,10,50,100, 1000)) 
vis.top.proportions(D457_mod_df, .head=c(3,10,50,100, 1000)) 
 




cosine_similarity = cosine.sharing(shared) 
cosine_similarity 
heatmap(cosine_similarity, symm = TRUE) 
 




cosine_similarity = cosine.sharing(shared) 
cosine_similarity 
heatmap(cosine_similarity, symm = TRUE) 
 




cosine_similarity = cosine.sharing(shared) 
cosine_similarity 
heatmap(cosine_similarity, symm = TRUE) 
 




cosine_similarity = cosine.sharing(shared) 
cosine_similarity 
heatmap(cosine_similarity, symm = TRUE) 
 








heatmap(cosine_similarity, symm = TRUE) 
 
##These are the functions used to calculate clonality and shannon entropy, obtained from Michelle Miron 
 
shannon.entropy <- function(p){ 
  if (min(p) < 0 || sum(p) <= 0) 
    return(NA) 
  p.norm <- p[p>0]/sum(p) 
  -sum(log2(p.norm)*p.norm) 
} 
 
Clonality <- function(p) { 
  x = p[p>0] / sum(p) 
  l = length(x) 
  entropy = shannon.entropy(p) 
  maxentropy = -log2(1/l) 




(written with help from Michelle Miron) 













df = read.csv("/Users/ml3828/Desktop/03022021_vgeneusage.csv", row.names = 1) 
 
 
feature_scale <- function(row) { 
  newrow <-(row-min(row))/(max(row)-min(row)) 




percent_scale <- function(row) { 
  newrow <-(row)/(sum(row)) 
  return(newrow) 
} 
 
df_feature1 <- apply(df,1,percent_scale) 
 
dat <- reshape2::melt(df_feature1) 
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string1 <- as.character(dat$Var2) 
dat$Var2 <-  as.character(dat$Var2) 
conditions1 <- data.frame( 
  Tissue = unlist(gsubfn::strapplyc(dat$Var2,"blood|BM|LLN|lung|spleen|MLN",simplify = TRUE)), 
  Virus = unlist(gsubfn::strapplyc(dat$Var2,"CMV|flu",simplify = TRUE)) 
) 
   
dat2 <- cbind(dat,conditions1) 
 
### PCA analysis 
library(factoextra) 
#df_feature <-subset(df_feature, select=-c(D383_Spl_CD8_TMEM_1)) 
res.pca <- prcomp(t(df_feature1), scale = F) 
 
conditions_pca <- data.frame( 
  Tissue = unlist(gsubfn::strapplyc(rownames(res.pca$x),"blood|BM|LLN|lung|spleen|MLN",simplify = TRUE)), 
  Virus = unlist(gsubfn::strapplyc(rownames(res.pca$x),"CMV|flu",simplify = TRUE)), 




mylabelpca1 <- cbind(rownames(res.pca$x),conditions_pca) 
 
 
Tissue1 <- as.factor(mylabelpca1$Tissue) 
Tissue1.plot <- fviz_pca_ind(res.pca, 
                            geom = c("point"), 
                            col.ind = Tissue1, # color by Lineage 
                            palette = c("#f69420","#ea028c","#795ba7","#00acee","#33b44e","#ffdc0e"), 
                            addEllipses = TRUE, # Concentration ellipses 
                            ellipse.type = "confidence", 
                            legend.title = "Groups", 
                            repel = TRUE, 




Virus1 <- as.factor(mylabelpca1$Virus) 
Virus1.plot <- fviz_pca_ind(res.pca, 
                              geom = c("point"), 
                              palette = c("blue","red"), 
                              col.ind = Virus1, # color by Lineage 
                              addEllipses = TRUE, # Concentration ellipses 
                              ellipse.type = "confidence", 
                              legend.title = "Groups", 
                              repel = TRUE, 




Donor1 <- as.factor(mylabelpca1$Donor) 
Donor1.plot <- fviz_pca_ind(res.pca, 
                           geom = c("point"), 
                           palette = c("#f9c1a3","#eeb6d3","#b8b3d9","#acd7a0","#95d8e6"), 
                           col.ind = Donor1, # color by Lineage 
                           addEllipses = TRUE, # Concentration ellipses 
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                           ellipse.type = "confidence", 
                           legend.title = "Groups", 
                           repel = TRUE, 





grid.pca <- grid.arrange(Tissue1.plot, 
                         Virus1.plot,Donor1.plot,nrow=2) 
getwd() 
file2 <- paste(wd,"/",dates,"vb.pca.pdf", sep ="") 
pdf(file2, 
    width = 7, 
    height = 6) 
grid.arrange(Tissue1.plot, 
             Virus1.plot,Donor1.plot,nrow=2) 











#filter for protein coding 
proteins <- read.table("~/Downloads/protein_coding.csv", header=T, sep=",") 
umi.counts <- read.table("~/Dropbox/Maya_New/Maya_matrix.csv",header = T,row.names = 1,sep=",") 
umi.counts <- subset(umi.counts, rownames(umi.counts) %in% proteins$Gene) 
meta <- read.table("~/Dropbox/Maya_New/Maya_new_meta.csv",header = T,sep=",",row.names=1) 
meta <- cbind(meta,data.frame(str_split_fixed(meta$Identity, "_", 3))) 
meta$ID <- rownames(meta) 
colnames(meta) <- c(colnames(meta)[1:4],"Tissue","Virus","Cell","ID") 
meta <- subset(meta, meta$Identity != "EMPTY") 
umi.counts <- subset(umi.counts, select=colnames(umi.counts) %in% meta$ID) 
 
# Seurat object creation and general filtering 
tcell <- CreateSeuratObject(counts = umi.counts, project = "All_Plates", names.delim = "", meta.data = meta) 
tcell@meta.data[["orig.ident"]] <- tcell@meta.data[["Identity"]] 
tcell <- subset(tcell, subset = Identity !=  "EMPTY") 
tcell[["percent.mt"]] <- PercentageFeatureSet(tcell, pattern = "^MT-") 
# Visualize QC metrics as a violin plot 
VlnPlot(tcell, features = c("nFeature_RNA", "nCount_RNA", "percent.mt"), ncol = 3) 
plot1 <- FeatureScatter(tcell, feature1 = "nCount_RNA", feature2 = "percent.mt") 
plot2 <- FeatureScatter(tcell, feature1 = "nCount_RNA", feature2 = "nFeature_RNA") 
plot1 + plot2 
#Filter 
tcell <- subset(tcell, subset = nFeature_RNA > 200 & percent.mt < 10) 
tcell <- SetIdent(object = tcell, value = tcell@meta.data[["Identity"]]) 
VlnPlot(tcell, features = c("nFeature_RNA", "percent.mt"), ncol = 2) 
 
#just CD8 
tcell <- subset(tcell, subset = Cell ==  "CD8") 
#CD8 outliers from PCA 
tcell <- subset(tcell, subset = ID !="DM037_CGTGTCTA" & ID !="DM037_CTAGCTGT" 
                & ID != "DM035_CTGTGTAC") 
#just CD4 
tcell <- subset(tcell, subset = Cell ==  "CD4") 
 
#Normalize by log 
tcell <- NormalizeData(tcell, normalization.method = "LogNormalize", scale.factor = 10000)                 
#scale data for PCA etc 
all.genes <- rownames(tcell) 
tcell <- ScaleData(tcell, features = all.genes) #,vars.to.regress = "percent.mt") 
tcell <- FindVariableFeatures(tcell, selection.method = "vst") 
tcell <- RunPCA(tcell, features = VariableFeatures(object = tcell)) 
DimPlot(tcell, reduction = "pca", group.by = "Identity", pt.size=2.5) 
 
#Find HVG 




VizDimLoadings(tcell, dims = 1:2, reduction = "pca") 
# Identify the 10 most highly variable genes 
top10 <- head(VariableFeatures(tcell), 10) 
# plot variable features with and without labels 
LabelPoints(plot = VariableFeaturePlot(tcell), points = top10, repel = TRUE) 
 
#Visualizing key genes 
FeaturePlot(tcell, features = c("CCL4","IFNG","GZMB","CCL3","FABP5","DNAJB1"), pt.size=2) 
FeaturePlot(tcell, features = c("CCL4","IFNG","GZMB","FABP5","SCGB1A1","IL2"), pt.size=2) 
#CD8 HVG 
FeaturePlot(tcell, features = 
c("CCL4","XCL1","CCL4L2","XCL1","XCL2","GZMB","IFNG","DNAJB1","GNLY"), pt.size=2) 
#CD4 HVG 
FeaturePlot(tcell, features = c("CCL4","IFNG","CCL4L2","IL2","FABP5","CCL3","IL22","XCL1","CXCL10"), 
pt.size=2) 
#Tmem signature 
FeaturePlot(tcell, features = c("CXCR6","ITGA1","ITGAE","CX3CR1","PDCD1","CRTAM"), pt.size=2) 
#PCA variance  
pca = tcell@reductions[["pca"]] 
eigValues = (pca@stdev)^2  ## EigenValues 
varExplained = eigValues / sum(eigValues) 
varExplained 
mat <- Seurat::GetAssayData(tcell, assay = "RNA", slot = "scale.data") 
pca <- tcell[["pca"]] 
# Get the total variance: 
total_variance <- sum(matrixStats::rowVars(mat)) 
eigValues = (pca@stdev)^2  ## EigenValues 
varExplained = eigValues / total_variance 
varExplained 
 
#determining the best PC # for UMAP 
PCAcoord <- tcell[['pca']]@cell.embeddings[,1:2] 
ElbowPlot(tcell, ndims=50) 
DimHeatmap(tcell, dims = c(1:3, 10:18), cells = 500, balanced = TRUE) 
tcell <- JackStraw(tcell, num.replicate = 100) 
tcell <- ScoreJackStraw(tcell, dims = 1:20) 
JackStrawPlot(tcell, dims = 1:20) 
 
#creating UMAP 
tcell <- RunUMAP(tcell, dims = 1:15) 
DimPlot(tcell, reduction = "umap", group.by = "Tissue", cols = "Set2",pt.size=3) 
DimPlot(tcell, reduction = "umap", group.by = "Identity", pt.size=3) 
DimPlot(tcell, reduction = "umap", group.by = "Virus", pt.size=3, cols= c("blue","red")) 
tcell <- FindNeighbors(tcell, dims = 1:15) 
# Findings clusters in the UMAP 
tclust <- FindClusters(tcell, resolution = 0.5) 
DimPlot(tclust, reduction = "umap", pt.size=3, cols = "Set1") 
#Finding markers per cluster 
tclust.markers <- FindAllMarkers(tclust, only.pos = TRUE, min.pct = 0.25, logfc.threshold = 0.25) 
toptclust <- tclust.markers %>% group_by(cluster) %>% top_n(n = -5, wt = p_val_adj) 
DoHeatmap(tclust, features = toptclust$gene, size = 3, label =F, group.colors = c( "#E41A1C", "#377EB8", 
"#4DAF4A", "#984EA3", "#FF7F00"), raster=F) 
#write.table(56dtclust@meta.data, file='Cell_Cluster.csv', quote=FALSE, sep=',', col.names = T) 
fullmeta <- tclust@meta.data 




#UMAP Cluster Markers 
#Cluster0 
FeaturePlot(tcell, features = c("CCL5", "KLRB1", "IFITM1", "ANXA1", "IL7R", "STAT1", "IRF1", "TPT1", 
"XAF1"), pt.size=0.25) 
#Cluster1 
FeaturePlot(tcell, features = c("XCL2", "XCL1", "CCL4", "EGR2", "BATF", "NFKB2", "TNFRSF9", "TNFRSF4", 
"IL2RG", "CRTAM", "TIGIT", "BCL2A1"), pt.size=0.25) 
#Cluster2 
FeaturePlot(tcell, features = c("NME1", "GZMB", "IL2RA", "IFNG", "DDX21", "ABCE1", "ILF3", "BANF1", 
"UBE2N", "HNRNPA2B1"), pt.size=0.25) 
#Cluster3 
FeaturePlot(tcell, features = c("IFITM2", "IFITM3", "IFITM1", "IL32", "LTB", "MIF", "CD226", "LGALS1"), 
pt.size=0.25) 
#Cluster4 + GZMH 
FeaturePlot(tcell, features = c("CTLA4", "CXCR4", "BNIP3L","GZMH"), pt.size=1) 
 
FeaturePlot(tcell, features = c("NME1"), pt.size=2) 
FeaturePlot(tcell, features = c("GZMB"), pt.size=2) 
FeaturePlot(tcell, features = c("IL2RA"), pt.size=2) 
FeaturePlot(tcell, features = c("IL7R"), pt.size=2) 
FeaturePlot(tcell, features = c("CCL5"), pt.size=2) 
FeaturePlot(tcell, features = c("IFITM1"), pt.size=2) 
FeaturePlot(tcell, features = c("STAT1"), pt.size=2) 
FeaturePlot(tcell, features = c("XCL1"), pt.size=2) 
FeaturePlot(tcell, features = c("XCL2"), pt.size=2) 
FeaturePlot(tcell, features = c("CCL4"), pt.size=2) 
FeaturePlot(tcell, features = c("TNFRSF9"), pt.size=2) 
FeaturePlot(tcell, features = c("TNFRSF4"), pt.size=2) 
FeaturePlot(tcell, features = c("CRTAM"), pt.size=2) 
FeaturePlot(tcell, features = c("LGALS1"), pt.size=2) 
FeaturePlot(tcell, features = c("KLRB1"), pt.size=2) 
 
# find all markers between BM groups 
cluster1.markers <- FindMarkers(tclust,ident.1 = 0, ident.2 = 2, min.pct = 0.25) 
top1 <- cluster1.markers %>% top_n(n = -50, wt = p_val_adj) 
DoHeatmap(tclust, features = rownames(top1), cells = WhichCells(tclust,idents=c(0,2)),size = 3, label =F) 
#write.table(tclust.markers, "Cluster_MarkersCD4.csv", quote=F, sep = ",") 
 
# overall markers for CD8 or CD4 
tcell.markers <- FindAllMarkers(tcell, only.pos = T, min.pct = 0.25, logfc.threshold = 0.25) 
tcell.markers %>% group_by(cluster) %>% top_n(n = -2, wt = p_val_adj) 
top10 <- tcell.markers %>% group_by(cluster) %>% top_n(n = -5, wt = p_val_adj) 
DoHeatmap(tcell, features = top10$gene, size = 3, label =F,, raster=F) 
 
filtmarkers <- tcell.markers %>% group_by(cluster) %>% top_n(n = -200, wt = p_val_adj) 
filtmarkers <- subset(filtmarkers,filtmarkers$p_val_adj<0.05) 
#write.table(filtmarkers, "MarkersCD4.csv", quote=F, sep = ",") 
 
###################### LFC Ratio Analysis ################################### 
tcell <- SetIdent(object = tcell, value = tcell@meta.data[["Tissue"]]) 
lungspleen.markers <- FindMarkers(tcell, ident.1 = c("lung"),  
                                  ident.2 = c("spleen"), min.pct = 0,logfc.threshold = 0, min.cells.feature = 1,min.cells.group = 
3) 
DoHeatmap(tcell, features = rownames(lungspleen.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("spleen","lung"))) + NoLegend() 
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sig_lungspleen <- subset(lungspleen.markers,p_val_adj < 0.1) 
#write.table(lungspleen.markers, "LungSpleenDiff_CD4.csv", quote=F, sep = ",") 
 
llnspleen.markers <- FindMarkers(tcell, ident.1 = c("LLN"),  
                                 ident.2 = c("spleen"), min.pct = 0,logfc.threshold = 0, min.cells.feature = 1,min.cells.group = 3) 
DoHeatmap(tcell, features = rownames(llnspleen.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("spleen","LLN"))) + NoLegend() 
sig_llnspleen <- subset(llnspleen.markers,p_val_adj < 0.1) 
#write.table(llnspleen.markers, "LLNSpleenDiff_CD4.csv", quote=F, sep = ",") 
 
BMspleen.markers <- FindMarkers(tcell, ident.1 = c("BM"),  
                                ident.2 = c("spleen"), min.pct = 0,logfc.threshold = 0, min.cells.feature = 1,min.cells.group = 3) 
DoHeatmap(tcell, features = rownames(BMspleen.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("spleen","BM"))) + NoLegend() 
sig_BMspleen <- subset(BMspleen.markers,p_val_adj < 0.1) 
#write.table(BMspleen.markers, "BMSpleenDiff_CD4.csv", quote=F, sep = ",") 
 
#### union of rownames from Lung, Spleen, LLN, BM 
lfcspleen <- merge(lungspleen.markers, llnspleen.markers, by="row.names") 
rownames(lfcspleen) <- lfcspleen$Row.names 
lfcspleen <- merge(lfcspleen, BMspleen.markers, by="row.names") 
rownames(lfcspleen) <- lfcspleen$Row.names 
lfcspleen <- lfcspleen[,c(4,9,14)] 
colnames(lfcspleen) <- c("lung_logFC","lln_logFC","BM_logFC") 
lfcspleen$keyLLN <- ifelse(rownames(lfcspleen) %in% rownames(sig_lungspleen), "Sig Diff. in Lung", 
                           ifelse(rownames(lfcspleen) %in% rownames(sig_llnspleen) , "Sig Diff. in LLN","NS")) 
lfcspleen[which(rownames(lfcspleen) %in% rownames(sig_lungspleen) & 
                  rownames(lfcspleen) %in% rownames(sig_llnspleen), arr.ind=TRUE), 4] <- "Sig Diff. in Both" 
lfcspleen$keyBM <- ifelse(rownames(lfcspleen) %in% rownames(sig_lungspleen), "Sig Diff. in Lung", 
                          ifelse(rownames(lfcspleen) %in% rownames(sig_BMspleen) , "Sig Diff. in BM","NS")) 
lfcspleen[which(rownames(lfcspleen) %in% rownames(sig_lungspleen) & 
                  rownames(lfcspleen) %in% rownames(sig_BMspleen), arr.ind=TRUE), 5] <- "Sig Diff. in Both" 
lfcspleen$keyLLNBM <- ifelse(rownames(lfcspleen) %in% rownames(sig_llnspleen), "Sig Diff. in LLN", 
                             ifelse(rownames(lfcspleen) %in% rownames(sig_BMspleen) , "Sig Diff. in BM","NS")) 
lfcspleen[which(rownames(lfcspleen) %in% rownames(sig_llnspleen) & 
                  rownames(lfcspleen) %in% rownames(sig_BMspleen), arr.ind=TRUE), 6] <- "Sig Diff. in Both" 
#write.table(lfcspleen, "DE_SpleenLFC_CD8.csv", quote=F, sep = ",") 
 
####### lung LLN 
ggplot(lfcspleen %>% arrange(match(keyLLN, c("NS","Sig Diff. in Lung","Sig Diff. in LLN", "Sig Diff. in 
Both"))), aes(x=lung_logFC, y=lln_logFC)) + 
  geom_hline(yintercept=0) +geom_vline(xintercept = 0)+geom_point(aes(color=keyLLN, shape=keyLLN), size=2) 
+ 
  labs(x="LFC(Lung/Spleen)", y="LFC(LLN/Spleen)")+ 
  scale_color_manual(breaks=c("Sig Diff. in Both","Sig Diff. in Lung","Sig Diff. in LLN", "NS"), 
                     values = c("NS" = "gray","Sig Diff. in Lung" = "blue","Sig Diff. in LLN" = "red", "Sig Diff. in Both" = 
"green"))+ 
  scale_shape_manual(breaks=c("Sig Diff. in Both","Sig Diff. in Lung","Sig Diff. in LLN", "NS"), 
                     values = c(16,17,17,16)) + theme(legend.title = element_blank()) + 
  guides(colour = guide_legend(override.aes = list(size=2))) + xlim(-2.7,2.7)+ylim(-2.6,2.6) #xlim(-2.7,2.7)+ylim(-
2,2)# + xlim(-2.5,2.5)+ylim(-2.6,2.6) 
 
####### BM lung 
ggplot(lfcspleen %>% arrange(match(keyBM, c("NS","Sig Diff. in Lung","Sig Diff. in BM", "Sig Diff. in Both"))), 
       aes(x=lung_logFC, y=BM_logFC)) +geom_hline(yintercept=0) +geom_vline(xintercept = 0)+ 
geom_point(aes(color=keyBM, shape=keyBM), size=2) + 
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  labs(x="LFC(Lung/Spleen)", y="LFC(BM/Spleen)")+ 
  scale_color_manual(breaks=c("Sig Diff. in Both","Sig Diff. in Lung","Sig Diff. in BM", "NS"), 
                     values = c("NS" = "gray","Sig Diff. in Lung" = "blue","Sig Diff. in BM" = "red", "Sig Diff. in Both" = 
"green"))+ 
  scale_shape_manual(breaks=c("Sig Diff. in Both","Sig Diff. in Lung","Sig Diff. in BM", "NS"), 
                     values = c(16,17,17,16)) + theme(legend.title = element_blank()) + 
  guides(colour = guide_legend(override.aes = list(size=2))) + xlim(-2.7,2.7)+ylim(-2.6,2.6)# + xlim(-
2.5,2.5)+ylim(-2.6,2.6) 
 
####### BM LLN 
ggplot(lfcspleen %>% arrange(match(keyLLNBM, c("NS","Sig Diff. in LLN","Sig Diff. in BM", "Sig Diff. in 
Both"))), 
       aes(x=lln_logFC, y=BM_logFC)) +geom_hline(yintercept=0) +geom_vline(xintercept = 0)+ 
geom_point(aes(color=keyLLNBM, shape=keyLLNBM), size=2) + 
  labs(x="LFC(LLN/Spleen)", y="LFC(BM/Spleen)")+ 
  scale_color_manual(breaks=c( "Sig Diff. in Both","Sig Diff. in LLN","Sig Diff. in BM","NS"), 
                     values = c("NS" = "gray","Sig Diff. in LLN" = "blue","Sig Diff. in BM" = "red", "Sig Diff. in Both" = 
"green"))+ 
  scale_shape_manual(breaks=c( "Sig Diff. in Both","Sig Diff. in LLN","Sig Diff. in BM","NS"), 
                     values = c(16,17,17,16)) + theme(legend.title = element_blank()) + 




###################### CD8 DE Analyses ###################################### 
 
spleenCD8.markers <- FindMarkers(tcell, ident.1 = c("spleen_flu_CD8"),  
                                 ident.2 = c("spleen_CMV_CD8"), min.pct = 0,logfc.threshold = 0, min.cells.feature = 
1,min.cells.group = 3) 
DoHeatmap(tcell, features = rownames(spleenCD8.markers)[1:50], size = 3,angle=0,raster=FALSE, 
          cells = WhichCells(tcell,idents=c("spleen_flu_CD8","spleen_CMV_CD8"))) + NoLegend() 
sig_spleenCD8 <- subset(spleenCD8.markers,spleenCD8.markers$p_val_adj < 0.1) 
#write.table(spleenCD8.markers, "ALLspleenDiffCD8.csv", quote=F, sep = ",") 
 
bloodCD8.markers <- FindMarkers(tcell, ident.1 = c("blood_flu_CD8"),  
                                ident.2 = c("blood_CMV_CD8"), min.pct = 0,logfc.threshold = 0, min.cells.feature = 
1,min.cells.group = 3) 
DoHeatmap(tcell, features = rownames(bloodCD8.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("blood_flu_CD8","blood_CMV_CD8"))) + NoLegend() 
sig_bloodCD8 <- subset(bloodCD8.markers,p_val_adj < 0.1) 
write.table(bloodCD8.markers, "ALLbloodDiffCD8.csv", quote=F, sep = ",") 
 
lungCD8.markers <- FindMarkers(tcell, ident.1 = c("lung_flu_CD8"),  
                               ident.2 = c("lung_CMV_CD8"),min.pct = 0,logfc.threshold = 0, min.cells.feature = 
1,min.cells.group = 3) 
DoHeatmap(tcell, features = rownames(lungCD8.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("lung_flu_CD8","lung_CMV_CD8"))) + NoLegend() 
sig_lungCD8 <- subset(lungCD8.markers,p_val_adj < 0.1) 
#write.table(lungCD8.markers, "ALLlungDiffCD8.csv", quote=F, sep = ",") 
 
BMCD8.markers <- FindMarkers(tcell, ident.1 = c("BM_flu_CD8"),  
                             ident.2 = c("BM_CMV_CD8"), min.pct = 0,logfc.threshold = 0, min.cells.feature = 
1,min.cells.group = 3) 
DoHeatmap(tcell, features = rownames(BMCD8.markers)[1:15], size = 3,angle=0, raster=F, 
          cells = WhichCells(tcell,idents=c("BM_flu_CD8","BM_CMV_CD8"))) + NoLegend() 
sig_BMCD8 <- subset(BMCD8.markers,p_val_adj < 0.1) 
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#write.table(BMCD8.markers, "ALLBMDiffCD8.csv", quote=F, sep = ",") 
 
LLNCD8.markers <- FindMarkers(tcell, ident.1 = c("LLN_flu_CD8"),  
                              ident.2 = c("LLN_CMV_CD8"), min.pct = 0,logfc.threshold = 0, min.cells.feature = 
1,min.cells.group = 3) 
DoHeatmap(tcell, features = rownames(LLNCD8.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("LLN_flu_CD8","LLN_CMV_CD8"))) + NoLegend() 
sig_LLNCD8 <- subset(LLNCD8.markers,p_val_adj < 0.1) 





combn(allsig, 2, function(x) intersect(x[[1]], x[[2]]), simplify = F) 
tb <- table(unlist(allsig)) 
tb[tb>1] 
 
###################### CD4 DE Analyses ###################################### 
 
spleenCD4.markers <- FindMarkers(tcell, ident.1 = c("spleen_flu_CD4"),  
                                 ident.2 = c("spleen_CMV_CD4"), min.pct = 0.25) 
DoHeatmap(tcell, features = rownames(spleenCD4.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("spleen_flu_CD4","spleen_CMV_CD4"))) + NoLegend() 
 
sig_spleenCD4 <- subset(spleenCD4.markers,spleenCD4.markers$p_val_adj < 0.1) 
#write.table(spleenCD4.markers, "SpleenDiffCD4.csv", quote=F, sep = ",") 
 
bloodCD4.markers <- FindMarkers(tcell, ident.1 = c("blood_flu_CD4"),  
                                ident.2 = c("blood_CMV_CD4"), min.pct = 0.25) 
DoHeatmap(tcell, features = rownames(bloodCD4.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("blood_flu_CD4","blood_CMV_CD4"))) + NoLegend() 
sig_bloodCD4 <- subset(bloodCD4.markers,p_val_adj < 0.1) 
#write.table(bloodCD4.markers, "BloodDiffCD4.csv", quote=F, sep = ",") 
 
lungCD4.markers <- FindMarkers(tcell, ident.1 = c("lung_flu_CD4"),  
                               ident.2 = c("lung_CMV_CD4"), min.pct = 0.25) 
DoHeatmap(tcell, features = rownames(lungCD4.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("lung_flu_CD4","lung_CMV_CD4"))) + NoLegend() 
sig_lungCD4 <- subset(lungCD4.markers,p_val_adj < 0.1) 
#write.table(lungCD4.markers, "LungDiffCD4.csv", quote=F, sep = ",") 
 
BMCD4.markers <- FindMarkers(tcell, ident.1 = c("BM_flu_CD4"),  
                             ident.2 = c("BM_CMV_CD4"), min.pct = 0.25) 
DoHeatmap(tcell, features = rownames(BMCD4.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("BM_flu_CD4","BM_CMV_CD4"))) + NoLegend() 
sig_BMCD4 <- subset(BMCD4.markers,p_val_adj < 0.1) 
#write.table(BMCD4.markers, "BMDiffCD4.csv", quote=F, sep = ",") 
 
LLNCD4.markers <- FindMarkers(tcell, ident.1 = c("LLN_flu_CD4"),  
                              ident.2 = c("LLN_CMV_CD4"), min.pct = 0.25) 
DoHeatmap(tcell, features = rownames(LLNCD4.markers)[1:50], size = 3,angle=0, 
          cells = WhichCells(tcell,idents=c("LLN_flu_CD4","LLN_CMV_CD4"))) + NoLegend() 
sig_LLNCD4 <- subset(LLNCD4.markers,p_val_adj < 0.1) 







combn(allsig, 2, function(x) intersect(x[[1]], x[[2]]), simplify = F) 
tb <- table(unlist(allsig)) 
tb[tb>1] 
 
###################### CD8 Cross-Tissue Flu Analyses ###################################### 
 
#just flu CD8 
tdiff <- subset(tcell, subset = Cell ==  "CD8" & Virus == "flu") 
#Normalize by log 
tdiff <- NormalizeData(tdiff, normalization.method = "LogNormalize", scale.factor = 10000)                 
#scale data for PCA etc 
all.genes <- rownames(tdiff) 
tdiff <- ScaleData(tdiff, features = all.genes) #,vars.to.regress = "percent.mt") 
 
bloodCD8.markers <- FindMarkers(tdiff, ident.1 = c("blood_flu_CD8"),  
                                ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(bloodCD8.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_bloodCD8 <- subset(bloodCD8.markers,p_val_adj < 0.1) 
#write.table(bloodCD8.markers, "BloodFluCD8.csv", quote=F, sep = ",") 
 
BMCD8.markers <- FindMarkers(tdiff, ident.1 = c("BM_flu_CD8"),  
                             ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(BMCD8.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_BMCD8 <- subset(BMCD8.markers,p_val_adj < 0.1) 
#write.table(BMCD8.markers, "BMFluCD8.csv", quote=F, sep = ",") 
 
LLNCD8.markers <- FindMarkers(tdiff, ident.1 = c("LLN_flu_CD8"),  
                              ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(LLNCD8.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_LLNCD8 <- subset(LLNCD8.markers,p_val_adj < 0.1) 
#write.table(LLNCD8.markers, "LLNFluCD8.csv", quote=F, sep = ",") 
 
lungCD8.markers <- FindMarkers(tdiff, ident.1 = c("lung_flu_CD8"),  
                               ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(lungCD8.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_lungCD8 <- subset(lungCD8.markers,p_val_adj < 0.1) 
#write.table(lungCD8.markers, "lungFluCD8.csv", quote=F, sep = ",") 
 
spleenCD8.markers <- FindMarkers(tdiff, ident.1 = c("spleen_flu_CD8"),  
                                 ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(spleenCD8.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_spleenCD8 <- subset(spleenCD8.markers,p_val_adj < 0.1) 
#write.table(spleenCD8.markers, "spleenFluCD8.csv", quote=F, sep = ",") 
 
###################################### CD8 CMV ######################################## 
 
#just CMV CD8 
tdiff <- subset(tcell, subset = Cell ==  "CD8" & Virus == "CMV") 
#Normalize by log 
tdiff <- NormalizeData(tdiff, normalization.method = "LogNormalize", scale.factor = 10000)                 
#scale data for PCA etc 
all.genes <- rownames(tdiff) 




bloodCD8.markers <- FindMarkers(tdiff, ident.1 = c("blood_CMV_CD8"),  
                                ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(bloodCD8.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_bloodCD8 <- subset(bloodCD8.markers,p_val_adj < 0.1) 
write.table(bloodCD8.markers, "BloodCMVCD8.csv", quote=F, sep = ",") 
 
BMCD8.markers <- FindMarkers(tdiff, ident.1 = c("BM_CMV_CD8"),  
                             ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(BMCD8.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_BMCD8 <- subset(BMCD8.markers,p_val_adj < 0.1) 
write.table(BMCD8.markers, "BMCMVCD8.csv", quote=F, sep = ",") 
 
LLNCD8.markers <- FindMarkers(tdiff, ident.1 = c("LLN_CMV_CD8"),  
                              ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(LLNCD8.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_LLNCD8 <- subset(LLNCD8.markers,p_val_adj < 0.1) 
write.table(LLNCD8.markers, "LLNCMVCD8.csv", quote=F, sep = ",") 
 
lungCD8.markers <- FindMarkers(tdiff, ident.1 = c("lung_CMV_CD8"),  
                               ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(lungCD8.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_lungCD8 <- subset(lungCD8.markers,p_val_adj < 0.1) 
write.table(lungCD8.markers, "lungCMVCD8.csv", quote=F, sep = ",") 
 
spleenCD8.markers <- FindMarkers(tdiff, ident.1 = c("spleen_CMV_CD8"),  
                                 ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(spleenCD8.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_spleenCD8 <- subset(spleenCD8.markers,p_val_adj < 0.1) 
write.table(spleenCD8.markers, "spleenCMVCD8.csv", quote=F, sep = ",") 
 
###################### CD4 Cross-Tissue Flu Analyses ###################################### 
 
#just flu CD4 
tdiff <- subset(tcell, subset = Cell ==  "CD4" & Virus == "flu") 
#Normalize by log 
tdiff <- NormalizeData(tdiff, normalization.method = "LogNormalize", scale.factor = 10000)                 
#scale data for PCA etc 
all.genes <- rownames(tdiff) 
tdiff <- ScaleData(tdiff, features = all.genes) #,vars.to.regress = "percent.mt") 
 
bloodCD4.markers <- FindMarkers(tdiff, ident.1 = c("blood_flu_CD4"),  
                                ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(bloodCD4.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_bloodCD4 <- subset(bloodCD4.markers,p_val_adj < 0.1) 
write.table(bloodCD4.markers, "BloodFluCD4.csv", quote=F, sep = ",") 
 
BMCD4.markers <- FindMarkers(tdiff, ident.1 = c("BM_flu_CD4"),  
                             ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(BMCD4.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_BMCD4 <- subset(BMCD4.markers,p_val_adj < 0.1) 
write.table(BMCD4.markers, "BMFluCD4.csv", quote=F, sep = ",") 
 
LLNCD4.markers <- FindMarkers(tdiff, ident.1 = c("LLN_flu_CD4"),  
                              ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(LLNCD4.markers)[1:50], size = 3,angle=0) + NoLegend() 
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sig_LLNCD4 <- subset(LLNCD4.markers,p_val_adj < 0.1) 
write.table(LLNCD4.markers, "LLNFluCD4.csv", quote=F, sep = ",") 
 
lungCD4.markers <- FindMarkers(tdiff, ident.1 = c("lung_flu_CD4"),  
                               ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(lungCD4.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_lungCD4 <- subset(lungCD4.markers,p_val_adj < 0.1) 
write.table(lungCD4.markers, "lungFluCD4.csv", quote=F, sep = ",") 
 
spleenCD4.markers <- FindMarkers(tdiff, ident.1 = c("spleen_flu_CD4"),  
                                 ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(spleenCD4.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_spleenCD4 <- subset(spleenCD4.markers,p_val_adj < 0.1) 
write.table(spleenCD4.markers, "spleenFluCD4.csv", quote=F, sep = ",") 
 
###################################### CD4 CMV ######################################## 
 
#just CMV CD4 
tdiff <- subset(tcell, subset = Cell ==  "CD4" & Virus == "CMV") 
#Normalize by log 
tdiff <- NormalizeData(tdiff, normalization.method = "LogNormalize", scale.factor = 10000)                 
#scale data for PCA etc 
all.genes <- rownames(tdiff) 
tdiff <- ScaleData(tdiff, features = all.genes) #,vars.to.regress = "percent.mt") 
 
bloodCD4.markers <- FindMarkers(tdiff, ident.1 = c("blood_CMV_CD4"),  
                                ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(bloodCD4.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_bloodCD4 <- subset(bloodCD4.markers,p_val_adj < 0.1) 
write.table(bloodCD4.markers, "BloodCMVCD4.csv", quote=F, sep = ",") 
 
BMCD4.markers <- FindMarkers(tdiff, ident.1 = c("BM_CMV_CD4"),  
                             ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(BMCD4.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_BMCD4 <- subset(BMCD4.markers,p_val_adj < 0.1) 
write.table(BMCD4.markers, "BMCMVCD4.csv", quote=F, sep = ",") 
 
LLNCD4.markers <- FindMarkers(tdiff, ident.1 = c("LLN_CMV_CD4"),  
                              ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(LLNCD4.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_LLNCD4 <- subset(LLNCD4.markers,p_val_adj < 0.1) 
write.table(LLNCD4.markers, "LLNCMVCD4.csv", quote=F, sep = ",") 
 
lungCD4.markers <- FindMarkers(tdiff, ident.1 = c("lung_CMV_CD4"),  
                               ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(lungCD4.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_lungCD4 <- subset(lungCD4.markers,p_val_adj < 0.1) 
write.table(lungCD4.markers, "lungCMVCD4.csv", quote=F, sep = ",") 
 
spleenCD4.markers <- FindMarkers(tdiff, ident.1 = c("spleen_CMV_CD4"),  
                                 ident.2 = NULL, min.pct = 0.25) 
DoHeatmap(tdiff, features = rownames(spleenCD4.markers)[1:50], size = 3,angle=0) + NoLegend() 
sig_spleenCD4 <- subset(spleenCD4.markers,p_val_adj < 0.1) 




Multiplex cytokine assay analysis 
 
Analysis of Flu- and CMV-specific responses 
 
import pandas as pd 
import os  
import matplotlib.pyplot as plt 
import seaborn as sns 
import numpy as np 
import phenograph 
import umap 
import matplotlib as mpl 
 
from matplotlib import colors as mcolors 
from openTSNE import TSNE 
from openTSNE.callbacks import ErrorLogger 
from sklearn.preprocessing import MinMaxScaler 
from sklearn.preprocessing import StandardScaler 
from sklearn.preprocessing import MaxAbsScaler 
from scipy.stats import zscore 
 
pd.set_option("max_columns", 50) 







D296=pd.read_csv("D296_deltaDMSO.csv", header=0, index_col=0) 
D296_sel_data = D296.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D296_sel_data) 
D296_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D296_sel_data 
 
g = sns.clustermap(D296_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 






D309=pd.read_csv("D309_deltaDMSO.csv", header=0, index_col=0) 
D309_sel_data = D309.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D309_sel_data) 
D309_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D309_sel_data 
 
g = sns.clustermap(D309_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
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                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 






D353=pd.read_csv("D353_deltaDMSO.csv", header=0, index_col=0) 
D353_sel_data = D353.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D353_sel_data) 
D353_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D353_sel_data 
 
g = sns.clustermap(D353_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 






D399=pd.read_csv("D399_deltaDMSO.csv", header=0, index_col=0) 
D399_sel_data = D399.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D399_sel_data) 
D399_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D399_sel_data 
 
g = sns.clustermap(D399_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 






D435=pd.read_csv("D435_deltaDMSO.csv", header=0, index_col=0) 
D435_sel_data = D435.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D435_sel_data) 
D435_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D435_sel_data 
 
g = sns.clustermap(D435_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
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                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 






D438=pd.read_csv("D438_deltaDMSO.csv", header=0, index_col=0) 
D438_sel_data = D438.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D438_sel_data) 
D438_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D438_sel_data 
 
g = sns.clustermap(D438_sel_data, figsize= (20, 5), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 






D444=pd.read_csv("D444_deltaDMSO.csv", header=0, index_col=0) 
D444_sel_data = D444.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D444_sel_data) 
D444_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D444_sel_data 
 
g = sns.clustermap(D444_sel_data, figsize= (20, 5), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 






D457=pd.read_csv("D457_deltaDMSO.csv", header=0, index_col=0) 
D457_sel_data = D457.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D457_sel_data) 
D457_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D457_sel_data 
 
g = sns.clustermap(D457_sel_data, figsize= (20, 5), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 
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D487=pd.read_csv("D487_deltaDMSO.csv", header=0, index_col=0) 
D487_sel_data = D487.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D487_sel_data) 
D487_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D487_sel_data 
 
g = sns.clustermap(D487_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 






D495=pd.read_csv("D495_deltaDMSO.csv", header=0, index_col=0) 
D495_sel_data = D495.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D495_sel_data) 
D495_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D495_sel_data 
 
g = sns.clustermap(D495_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 






HDL094=pd.read_csv("HDL094_deltaDMSO.csv", header=0, index_col=0) 
HDL094_sel_data = HDL094.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(HDL094_sel_data) 
HDL094_sel_data = pd.DataFrame(scale, columns = dat_cols) 
HDL094_sel_data 
 
g = sns.clustermap(HDL094_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 








HDL113=pd.read_csv("HDL113_deltaDMSO.csv", header=0, index_col=0) 
HDL113_sel_data = HDL113.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(HDL113_sel_data) 
HDL113_sel_data = pd.DataFrame(scale, columns = dat_cols) 
HDL113_sel_data 
 
g = sns.clustermap(HDL113_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, vmin=-1, vmax=1, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 







Analysis of SARS-CoV-2-specific responses 
 
import pandas as pd 
import os  
import matplotlib.pyplot as plt 
import seaborn as sns 
import numpy as np 
import phenograph 
import umap 
import matplotlib as mpl 
 
from matplotlib import colors as mcolors 
from openTSNE import TSNE 
from openTSNE.callbacks import ErrorLogger 
from sklearn.preprocessing import MinMaxScaler 
from sklearn.preprocessing import StandardScaler 
from sklearn.preprocessing import MaxAbsScaler 
from scipy.stats import zscore 
 
pd.set_option("max_columns", 50) 








D492=pd.read_csv("D492_deltaDMSO_noflu.csv", header=0, index_col=0) 
D492_sel_data = D492.loc[:,dat_cols] 
mas = MaxAbsScaler() 
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scale = mas.fit_transform(D492_sel_data) 
D492_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D492_sel_data 
 
g = sns.clustermap(D492_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 







D495_24=pd.read_csv("D495_24_deltaDMSO_noflu.csv", header=0, index_col=0) 
D495_24_sel_data = D495_24.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D495_24_sel_data) 
D495_24_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D495_24_sel_data 
 
g = sns.clustermap(D495_24_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 







D495_6=pd.read_csv("D495_6_deltaDMSO_noflu.csv", header=0, index_col=0) 
D495_6_sel_data = D495_6.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D495_6_sel_data) 
D495_6_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D495_6_sel_data 
 
g = sns.clustermap(D495_6_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 







D498_24=pd.read_csv("D498_24_deltaDMSO_noflu.csv", header=0, index_col=0) 
D498_24_sel_data = D498_24.loc[:,dat_cols] 
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mas = MaxAbsScaler() 
scale = mas.fit_transform(D498_24_sel_data) 
D498_24_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D498_24_sel_data 
 
g = sns.clustermap(D498_24_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 









D498_6=pd.read_csv("D498_6_deltaDMSO_noflu.csv", header=0, index_col=0) 
D498_6_sel_data = D498_6.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(D498_6_sel_data) 
D498_6_sel_data = pd.DataFrame(scale, columns = dat_cols) 
D498_6_sel_data 
 
g = sns.clustermap(D498_6_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 







HDL113_24=pd.read_csv("HDL113_24_deltaDMSO_noflu.csv", header=0, index_col=0) 
HDL113_24_sel_data = HDL113_24.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(HDL113_24_sel_data) 
HDL113_24_sel_data = pd.DataFrame(scale, columns = dat_cols) 
HDL113_24_sel_data 
 
g = sns.clustermap(HDL113_24_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 









HDL113_6=pd.read_csv("HDL113_6_deltaDMSO_noflu.csv", header=0, index_col=0) 
HDL113_6_sel_data = HDL113_6.loc[:,dat_cols] 
mas = MaxAbsScaler() 
scale = mas.fit_transform(HDL113_6_sel_data) 
HDL113_6_sel_data = pd.DataFrame(scale, columns = dat_cols) 
HDL113_6_sel_data 
 
g = sns.clustermap(HDL113_6_sel_data, figsize= (20, 10), cmap = 'coolwarm',  
                   linewidths = 0.01, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"concentration (max absolute scaled per column)",  
                                "orientation" :"horizontal"}, metric= "correlation") 





dat_cols='IFNg','TNFa','TNFb', 'Granzyme B','Perforin', 'IFN-a2', 'IL-12p40', 'IL-15','IL-18', 'MCP-1','MIP-1a','MIP-
1b', 'RANTES', 'MIG/CXCL9', 'IP-10','Fractalkine', 'FLT-3L', 'GM-CSF', 'IL-4','IL-5','IL-9','IL-13','IL-17E/IL-
25','MCP-3', 'Eotaxin','MDC', 'IL-8','IL-17A', 'IL-17F', 'GROa', 'G-CSF','IL-10','EGF','FGF-2','M-CSF','TGFa','IL-
1a','IL-1b','IL-1RA', 'IL-2','IL-6','sCD40L','PDGF-AA' 
data=pd.read_csv("05252021_concentrations_avg_norm by tissue.csv", header=0, index_col=0) 




g = sns.clustermap(sel_data, figsize= (20, 10), cmap = 'viridis', 
                   linewidths = 0.01, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"log (Mean x +1) pg/mL",  
                                "orientation" :"horizontal"}, metric= "correlation") 







dat_cols='IFNg','TNFa','TNFb', 'Granzyme B','Perforin', 'IFN-a2', 'IL-12p40', 'IL-15','IL-18', 'MCP-1','MIP-1a','MIP-
1b', 'RANTES', 'MIG/CXCL9', 'IP-10','Fractalkine', 'FLT-3L', 'GM-CSF', 'IL-4','IL-5','IL-9','IL-13','IL-17E/IL-
25','MCP-3', 'Eotaxin','MDC', 'IL-8','IL-17A', 'IL-17F', 'GROa', 'G-CSF','IL-10','EGF','FGF-2','M-CSF','TGFa','IL-
1a','IL-1b','IL-1RA', 'IL-2','IL-6','sCD40L','PDGF-AA' 
data=pd.read_csv("05252021_concentrations_avg_norm_per pep.csv", header=0, index_col=0) 
data 
sel_data = data.loc[:,dat_cols] 
 
 
g = sns.clustermap(sel_data, figsize= (20, 10), cmap = 'viridis', 
                   linewidths = 0.01, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"log (Mean x +1) pg/mL",  
                                "orientation" :"horizontal"}, metric= "correlation") 
g.cax.set_position((0.29, -0.10, 0.60, 0.055)) 
plt.setp(g.ax_heatmap.get_yticklabels(), rotation=0) 






#T cell associated cytokines 
dat_cols='IFNg','TNFa','TNFb', 'Granzyme B','Perforin','IL-12p40','IL-15','IL-18','GM-CSF','IL-4','IL-5','IL-9','IL-
13','IL-17E/IL-25','IL-17F', 'IL-17A', 'G-CSF','IL-10','TGFa','IL-1b','IL-2','IL-6' 
 
data=pd.read_csv("05252021_concentrations_avg_norm by tissue.csv", header=0, index_col=0) 




g = sns.clustermap(sel_data, figsize= (10, 10), cmap = 'viridis', 
                   linewidths = 0.01, linecolor = 'k', row_cluster = False,  
                   col_cluster = False,  
                      cbar_kws={"label":"log (Mean x +1) pg/mL",  
                                "orientation" :"horizontal"}, metric= "correlation") 
g.cax.set_position((0.29, -0.10, 0.60, 0.055)) 
plt.setp(g.ax_heatmap.get_yticklabels(), rotation=0) 









LL <- read.csv('AllLinearCondensedSerum.csv', header = 1) 
 
 
colnames(LL) <- c("%LLN S2+ CD4", 
                  "%LLN S2+ CD8", 
                  "%LLN S+ CD4", 
                  "%LLN S+ CD8", 
                  "%LLN S2+ Tfh", 
                  "%Lung S2+ CD4", 
                  "%Lung S2+ CD8", 
                  "%Lung S+ CD4", 
                  "%Lung S+ CD8", 
                  "%Lung S2+ Tfh", 
                  "%LLN S+ MB", 
                  "%LLN S+ BRM", 
                  "%LLN S2+ TRM CD8", 
                  "LLN S+ MB/M", 
                  "LLN S+ IgA/M", 
                  "LLN S+ IgG/M", 
                  "LLN S+ IgM/M", 
                  "LLN S+ GCB/M", 
                  "%Lung S+ MB", 
                  "%Lung S+ BRM", 
                  "%Lung S2+ TRM CD8", 
                  "Lung S+ MB/M", 
                  "Lung S+ IgA/M", 
                  "Lung S+ IgG/M", 
                  "Lung S+ IgM/M", 
                  "LLN S2+ TRM CD4", 
                  "Lung S2+ TRM CD4", 
                  "Spike IgG", 
                  "RBD IgG", 
                  "N IgG", 
                  "PSV", 
                  "%Blood S2+ CD4", 
                  "%Blood S2+ CD8", 
                  "%Blood S+ CD4", 
                  "%Blood S+ CD8", 
                  "%Blood S2+ Tfh") 
 
col2 <- colorRampPalette(c("#053061","#2166AC","#4393C3", "#92C5DE","#D1E5F0", "#FFFFFF", "#FDDBC7", 
                           "#F4A582","#D6604D", "#B2182B", "#67001F"))  
TB <- cor(LL) 
res1 <- cor.mtest(LL, method = "pearson", conf.level = .95) 
 
 
corrplot(TB, method = "circle",  
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         order = "hclust",  
         col=col2(50), type = "lower", tl.col = "black", tl.cex = 0.4, 
         p.mat = res1$p, 
         insig = "label_sig", 




Appendix B: Analysis of T cell subsets across lymphoid and barrier 
sites by CyTOF 
 In addition to understanding the tissue-wide dynamics of virus-specific T cells, we also 
wanted to examine the dynamics of polyclonal T cells across tissue sites. In particular, looking at 
how T cell subsets in barrier sites relate to each other and to subsets in lymphoid tissues. As 
discussed in Chapter 1, naïve T cells once activated may differentiate into one of many cell fates, 
defined either by effector function or by memory T cell identity. We used CyTOF to characterize 
T cells in lung, jejunum, skin, along with their tissue-draining LNs (lung-associated, mesenteric, 
and inguinal LNs, respectively), as well as blood and spleen, in order to define and compare the 
T cell landscape of these sites within and among individuals. 
 We examined T cells from eight tissue sites obtained from three donors (including male 
and female) of different ages—22, 40, and 70 years-old—staining them with a CyTOF panel of 
37 markers (listed in Table A.B-1), including memory T cell markers, homing receptors, 
residency markers, transcription factors, and cytotoxic mediators. Briefly, single cell suspensions 
from each tissue site were labeled with viability marker – Rh103 intercalator. Then, cells from 
each tissue site were barcoded using a unique combinatorial barcode of CD45 antibodies 
conjugated to monoisotopic cisplatin. Barcoded cells from each tissue site were pooled, stained 
with a panel of cell surface marker antibodies, and then washed, fixed, and permeabilized 
(eBioscience Transcription Factor Staining Kit). Afterwards, pooled cells were stained with 
additional antibodies against intracellular targets. Samples were then washed and incubated in 
0.125nM Ir intercalator (Fluidigm) diluted in PBS containing 2% formaldehyde. CyTOF 
antibodies were either purchased pre-conjugated from Fluidigm or purchased as purified and 
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subsequently conjugated in-house using MaxPar X8 Polymer Kits (Fluidigm). Data acquisition 
was performed by the Human Immune Monitoring Core at Icahn School of Medicine at Mout 
Sinai in collaboration with Dr. Adeeb Rahman. Prior to data acquisition, samples were washed 
once with PBS, washed once with de-ionized water, and resuspended at a concentration of 1 
million cells/mL in deionized water containing a 1:20 dilution of EQ 4 Element Beads 
(Fluidigm). Samples were acquired on a CyTOF2 (Fluidigm) equipped with a SuperSampler 
fluidics system (Victorian Airships) at an event rate of <500 events/second. Data were 
normalized using bead-based normalization in the CyTOF software and uploaded to Cytobank 
for initial data processing. 
For analysis, the data were first gated to exclude normalization beads, dead cells, 
doublets, and debris. Cells derived from each tissue were then deconvolved by Boolean gating on 
CD45 barcodes, leaving DNA+CD45+Rh103- live single cells for subsequent analysis. FCS 
express software was used to gate CD3+ cells. Downstream analysis and visualization was then 
performed using custom Python scripts. Specifically, dimensionality reduction was performed 
using Python implementation openTSNE to generate tSNE (t-Distributed Stochastic Neighbor 
Embedding) plots (Figure A.B-1). Then, hierarchical clustering was performed using Python 
implementation PhenoGraph (Figure A.B-1). Heatmaps of normalized and scaled marker 
expression were generated using the mean scaled expression with samples clustered by 
unsupervised hierarchical clustering using clustermap() function of data visualization library 
Seaborn (Figure A.B-1 and A.B-2).  
We found that the overall composition of T cell subsets across donors was conserved 
across donors independent of age, with the exception of a few clusters: naïve CD8 T cells were 
present in the two younger donors (female 22 yrs and male 40 yrs) but not substantially in the 
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older donor (male 70 yrs), while a TIGIT+ PD-1+ CD57+ TEM/TEMRA cluster was found in 
the blood and lung of the older donor but not in either younger donors (Figure A.B-1B-D and 
Figure A.B-3). Among tissues, the lung appeared to share many clusters with the lymphoid 
tissues, including CD4+ TCM, CD8+ TEM/TEMRA, and CD4+ and CD8+ TRM, while containing 
higher frequencies of both CD4+ and CD8+ CD57+ PD-1+ TEM (Figure A.B-1E and F). Strikingly, 
the skin and jejunum sites are phenotypically distinct from all other mucosal and lymphoid sites. 
The jejunum is predominated by CD4+ and CD8+ TRM expressing residency markers CD69 and 
CD103, while a notable portion of both circulating and tissue resident skin T cells express 
CRTH2, a marker of TH2 effector function that does not appear to be expressed in other tissue 
sites (Figure A.B-1E and F). Meanwhile, lymphoid sites appear to share many T cell clusters, 
with the three tissue-draining LNs appearing nearly identical in subset composition (Figure A.B-
1E and F). These finding demonstrate that mucosal/barrier sites contain unique T cell subsets 
with site-adapted characteristics likely governed by the tissue microenvironment, with lung T 





Table A.B-1. Antibodies for CyTOF. 
Target Tag Clone Source 
CD45 89 Y HI30 Fluidigm 
CD57 113 In HCD57 Biolegend 
CD28 141 Pr CD28.2 Biolegend 
CD19 142 Nd HIB19 Biolegend 
CD45RA 143 Nd HI100 Biolegend 
CD103 144 Nd Ber-Act8 Biolegend 
CD4 145 Nd RPA-T4 Biolegend 
CD8a 146 Nd RPA-T8 Biolegend 
Perforin 147 Sm dG9 Biolegend 
CD16 148 Nd 3G8 Biolegend 
CD127 149 Sm A019D5 Biolegend 
CD1c 150 Nd L161 Biolegend 
CD123 151 Eu 6H6 Biolegend 
CD66b 152 Sm G10F5 Biolegend 
TIGIT 153 Eu MBSA43 Fluidigm 
ICOS 154 Sm C398.4A Biolegend 
CD27 155 Gd O323 Biolegend 
CCR5 156 Gd NP-6G4 Fluidigm 
Tcf1 159 Tb 7F11A10 Biolegend 
CD14 160 Gd M5E2 Biolegend 
CD56 161 Dy B159 BD Biosciences 
gdTCR 162 Dy REA591 Miltenyi 
CXCR5 163 Dy J252D4 Biolegend 
CD69 164 Dy FN50 Biolegend 
CRTH2 165 Ho REA598 Miltenyi 
CD25 166 Er M-A251 Biolegend 
CCR7 167 Er G043H7 Biolegend 
CD3 168 Er UCHT1 Biolegend 
Tbet 169 Tm 4B10 Biolegend 
CD38 170 Er HB-7 Biolegend 
CD95 171 Yb DX2 Biolegend 
LAG3 172 Yb 11C3C65 Biolegend 
CXCR4 173 Yb 12G5 Fluidigm 
HLADR 174 Yb L243 Biolegend 
PD-1 175 Lu EH12.2H7 Fluidigm 
GranzymeB 176 Yb GB11 Invitrogen 





Figure A.B-1. CyTOF analysis of T cells from lymphoid and barrier tissues. 
(A) T cells from the blood, BM, spleen, LLN, MLN, ILN, lung, jejunum, and skin analyzed by 
CyTOF and visualized as a tSNE plot. CD4+ and CD8+ T cells were clustered by unsupervised 
hierarchical clustering.  (B) tSNE plots of T cells in tissue sites from three individual donors – 
female 22 yrs (left), male 40 yrs (middle), and male 70 yrs (right). (C) Heatmap showing mean 
scaled expression of protein markers by CD4+ (green, top) and CD8+ (blue, bottom) T cell 
subsets within each cluster identified via unsupervised hierarchical clustering. (D) Lists of CD4+ 
(green, left) and CD8+ (blue, right) T cell subsets identified via unsupervised hierarchical 
clustering. (E) tSNE plots of T cell subsets within individual tissue sites from three donors 
combined. (F) Heatmaps illustrating the frequency of CD4+ (green, left) and CD8+ (blue, right) T 
cell subsets within each tissue colored by column z-score. Tfh, follicular helper T cell; Th2, T 
helper 2 cell; Tc2, type 2 CD8+ T cell; TRM, tissue resident memory T cell; gdT, gamma-delta T 
cell; Tscm, stem cell-like memory T cell; Treg, regulatory T cell; TCM, central memory T cell; 
TEM, effector memory T cell; TEMRA, terminally differentiated effector memory T cell; SK, 
skin; LG, lung; JE, jejunum; BL, blood; SP, spleen; IN, inguinal lymph node; LN, lung-








Figure A.B-2. Graphs of scaled marker expression used for hierarchical clustering. 





Figure A.B-3. Individual donor T cell subset composition in lymphoid and barrier tissues. 
Heatmaps illustrating the frequency of (A) CD4+ and (B) CD8+ T cell subsets within tissue sites 
of individual donors – female 22 yrs (top), male 40 yrs (middle), male 70 yrs (bottom) – colored 




Appendix C: Analysis of T cell clone dynamics across lymphoid and 
barrier sites by high-throughput bulk TCR sequencing 
 To better understand the global T cell dynamics and clonal networks across lymphoid and 
barrier sites, we performed high-throughput bulk sequencing of the TCR b chain of CD4+ and 
CD8+ T cells isolated from the blood, BM, spleen, LLN, MLN, ILN, lung, jejunum, and skin of 
four donors (D461, female 22 yrs; D466, male 59 yrs; D479, male 63 yrs; D492, male 74 yrs). 
This analysis revealed tissue-specific and lineage-specific characteristics of the T cell clonal 
repertoire, as well as tissue-wide clonal networks. Specifically, CD8+ T cells appear to be overall 
more clonally expanded than CD4+ T cells from the same tissue site, while CD4+ T cells in 
barrier sites appear to be overall more clonally expanded than CD4+ T cells in lymphoid tissues 
(Figure A.C-1A, B). CD4+ and CD8+ T cells also appear to display distinct Vb and Jb gene 
usage, with gene usage within each lineage clustering primarily by donor, and not by tissue site 
(Figure A.C-1C-F). Comparing overlap across tissue sites using Morisita’s overlap index of 
individual donors and averaged across all donors, we see overall there is more overlap among 
CD8+ T cells across tissue sites than among CD4+ T cells (Figure A.C-1G, H and A.C-2). 
Moreover, blood and blood-rich sites (spleen and BM) share considerable overlap with each 
other and with the lung barrier site, while jejunum and skin barrier sites appear much more 
compartmentalized, with some overlap between skin and ILN CD4+ T cells, as well as between 




Figure A.C-1. Bulk TCR sequencing analysis of CD4+ and CD8+ T cells across human 
lymphoid and barrier sites. 
(A, B) Pie charts depicting total clonal space occupied by top n clones of CD4+ (A) and CD8+ (B) 
T cells in each indicated tissue site within each individual donor. (C, D) Vb gene usage across 
tissues and donors of CD4+ (C) and CD8+ (D) T cells depicted in heatmaps. Color intensity 
indicated column z-score. (E, F) Jb gene usage across tissues and donors of CD4+ (E) and CD8+ 
(F) T cells depicted in heatmaps. Color intensity indicated column z-score. (G, H) Heatmaps 
showing overlap of CD4+ (G) and CD8+ (H) T cell clones across tissue sites as measured by 
Morisita overlap index. Repertoire overlap for each tissue pair represents the average value from 






Figure A.C-2. Tissue overlap of CD4+ and CD8+ T cell clones across diverse tissue sites of 
individual donors.  
Heatmaps showing overlap of CD4+ and CD8+ T cell clones across tissue sites as measured by 
Morisita overlap index. Repertoire overlap for each tissue pair represents the average value from 






Appendix D: Single-cell analysis of T cell clones across lymphoid 
and barrier sites 
In appendix B, we demonstrated that T cell subsets exhibit distinct phenotypes depending 
on their tissue localization, particularly in barrier sites jejunum and skin. In appendix C, we 
showed that, despite the unique phenotypic characteristics, T cell clones are still shared across 
lymphoid and barrier sites, though jejunum and skin display more compartmentalization and less 
overall clone sharing with other sites. Here, we wanted to further understand how a T cell’s 
clonal identity relates to its phenotype. Using the 10x Genomics Chromium 5’ RNA sequencing 
(including VDJ region) single-cell analysis platform, we examined T cells in blood, BM, spleen, 
LLN, MLN, ILN, lung, jejunum, and skin of two donors (D492, male 74 yrs; D511, male 37 
yrs). We found that, congruent with our CyTOF analysis, T cells within the jejunum and skin 
barrier sites are distinct from lung and lymphoid tissues, while lung and lymphoid sites share 
similar T cell clusters (Figure A.D-1A). Lymphoid sites contained diverse T cell subset clusters 
identified via differential gene expression analysis as CD4+ naïve, CD4+ Treg, CD4+ TCM/TFH, 
CD8+ naïve, and CD8+ TEM/TEMRA, while barrier sites (lung, skin, and jejunum) contained 
primarily CD4+ and CD8+ TRM with D492 containing a unique activated TRM cluster. We also 
find that, mapping TCR sequences to T cells clustered by gene expression, TEM/TEMRA (found 
predominantly in the spleen, bone marrow, and lung) appear to be more clonally expanded than 
naïve, Treg, and TCM/TFH cells, while TRM found primarily in lung, jejunum, and skin barrier sites 




Figure A.D-1. Single-cell gene expression and TCR sequencing analysis of T cells across 
human lymphoid and barrier sites. 
(A) UMAP projections of T cells colored by cluster (top), tissue (bottom left), and donor (bottom 
right). (B) UMAP projections of T cell clones colored by cluster. Each colored circle indicates a 
T cell clone. The size of the circle illustrates the degree of clonal expansion. Light gray circles 
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2020  Oral Presentation: Human T cell immunity in barrier sites is phenotypically 
distinct but clonally connected to other sites 
The American Association of Immunologists (AAI) 
IMMUNOLOGY2020™ Annual Meeting (canceled due to COVID-19 pandemic) 
 
 
Authors: Maya M.L. Poon, Wenzhao Meng, Pranay Dogra, Nora Lam, Peter A. Szabo, Masaru 





The gut, lung, and skin are physical and immunological barriers that serve as the first line of 
defense against pathogens and foreign substances. Due to sampling limitations, previous studies 
have been limited to studying human barrier sites in isolation and often in the context of specific 
diseases. Our donor tissue resource established in collaboration with LiveOnNY offers a unique 
opportunity to examine human barrier T cell immunity as a network and elucidate how barrier 
sites are connected to each other and to lymphoid sites (lymph nodes, bone marrow, spleen).  
Here, using cytometry by time-of-flight (CyTOF) and T cell receptor (TCR) CDR3b sequencing, 
we investigate the unique defining characteristics and connectivity of T cells in barrier tissue – 
gut, lung, and skin – to lymphoid sites and blood. Through high-dimensional marker analysis by 
CyTOF, our results show that T cell subset composition and phenotype across 8 different sites 
comprise 33 clusters that are highly conserved between donors of different ages (22-70 yrs). Skin 
and gut T cells are distinct from each other and from lung, lymphoid sites, and blood, while lung 
T cells share features with lymphoid sites and blood. TCR repertoire analysis shows that, though 
majority of gut and skin T cell clones are unique to the tissue, expanded clones within these 
barrier sites share clonal overlap with other barrier and lymphoid sites. Moreover, T cells in the 
lung exhibit increased sharing with lymphoid sites and blood. Together, these results reveal how 
human T cells are compartmentalized in the skin and gut through site-specific adaptations while 
demonstrating that gut, lung, and skin barrier T cells are connected through shared specificities 






2020  Oral Presentation: Human influenza A-specific memory T cells reside within 
multiple tissues and elicit a tissue-specific antiviral response when presented 
with viral antigens. 
The American Association of Immunologists (AAI) 
IMMUNOLOGY2020™ Annual Meeting (canceled due to COVID-19 pandemic) 
 
 
Authors: Maya M.L. Poon, Wenzhao Meng, Pranay Dogra, Nora Lam, Peter A. Szabo, Alba 
Grifoni, Yuan Tian, Masaru Kubota, Rei Matsumoto, Alessandro Sette, Eline T. Luning Prak, 





Generation of memory T cells specific for conserved viral epitopes provides heterosubtypic 
protection to influenza infection. Previous mouse studies have shown that tissue-resident 
memory T cells (TRM) are critical for optimal protection. However, knowledge of human 
antiviral response is largely derived from blood. With our unique human donor tissue resource 
established in collaboration with LiveOnNY, we investigate the maintenance of influenza-
specific T cells across diverse tissue sites and their response when presented with viral antigens. 
Using multimer staining and flow cytometry, we show that influenza-specific CD8 T cells are 
maintained in the lung tissue site of infection, as well as in blood, bone marrow, multiple lymph 
nodes, and small intestines. Compared to T cells recognizing persistent cytomegalovirus 
infection, influenza-specific T cells display higher levels of canonical residency markers—CD69 
and CD103. Additionally, deep sequencing of the T cell receptor CDR3b repertoire reveals that 
influenza-specific T cells isolated from human tissue donors without active infection are clonally 
expanded and display a high degree of clonal overlap across tissue sites. When presented with 
viral antigens, influenza-specific T cells in all sites are polyfunctional and rapidly respond 
through cytokine production. Together, these studies reveal the dynamics of immune memory 






2021  Oral Presentation: Tissue localization and virus specificity shape the 
maintenance and function of human virus-specific memory T cells 
recognizing HCMV and influenza A. 
The American Association of Immunologists (AAI) 
IMMUNOLOGY2021™ Annual Meeting 
 
 
Authors: Maya M.L. Poon, Eve Byington, Wenzhao Meng, Pranay Dogra, Nora Lam, Peter A. 
Szabo, Basak Ural, Alba Grifoni, Daniela Weiskopf, Masaru Kubota, Rei Matsumoto, 





Generation and maintenance of memory T cells within tissue sites of infection is critical for 
long-term antiviral protection. Current knowledge of human antiviral responses is largely derived 
from studies sampling peripheral blood. Yet, little is known about human tissue-localized 
antiviral immunity. Utilizing our human donor tissue resource established in collaboration with 
LiveOnNY, we investigated how tissue, virus, and age shape T cell maintenance across diverse 
tissues and their function when presented with antigens derived from human cytomegalovirus 
(HCMV) or influenza A virus (flu). Using flow cytometry, we show that virus-specific CD8 T 
cells are maintained in diverse tissues with subset differentiation and distribution shaped by virus 
specificity and age. Compared to T cells recognizing HCMV, flu-specific T cells display higher 
levels of residency markers—CD69 and CD103—particularly in adult compared to pediatric 
donors. In contrast, HCMV-specific T cells are maintained in greater abundance as terminally-
differentiated effector T cells. Sequencing of the T cell receptor CDR3b chain reveals that, while 
both HCMV- and flu-specific T cells demonstrate clonal overlap across multiple tissues, HCMV-
specific T cells display greater clonality and less diversity. When presented with viral antigens, 
HCMV- and flu-specific T cells are polyfunctional. Additionally, single-cell transcriptome 
profiling reveals tissue localization is the primary determinant of antigen-driven responses. 
Together, these studies demonstrate the dynamics of T cell differentiation and maintenance 
throughout the human body, which is primarily driven by virus specificity, and the role of tissue 
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Ural, B.B., Dogra, P., Wells, S.B., Szabo, P.A., Granot, T., Senda, T., Poon, M.M.L., Lam, N., 
Lee, Y.S., Kubota, M., Matsumoto, R., Farber, D.L. (Submitted) Waning respiratory immunity 
with age due to inhaled particulate accumulation in human lymph nodes. 
 
The elderly are particularly susceptible to infectious and neoplastic diseases of the lung. 
Immune-mediated protection to new and recurrent respiratory pathogens such as SARS-CoV-2 
and influenza declines significantly with age, while the biased incidence of lung cancer with 
advanced age suggests reduced immune surveillance. Here, we reveal through analysis of human 
lymph nodes (LNs) associated with the lung and intestines from 80 organ donors aged 11-93 
years, a specific age-related decline in lung-associated but not gut-associated LN immune 
function linked to the accumulation of inhaled particulates from carbon-based pollutants. Carbon 
particulates are found in lung-associated LNs and at increased density over age, while the 
corresponding gut-associated LNs lack traces of carbon. Particulates are specifically contained 
within the CD68+CD169- subset of macrophages, which show reduced activation and phagocytic 
capacity over age, while non-particulate-containing macrophages in LN do not show these age-
associated alterations. Moreover, the structural integrity of B cell follicles and lymphatic 
drainage is disrupted in lung-associated LN with particulates. Our results reveal an anatomic 
mechanism for the progressive age-associated decline in respiratory immunity over age, by the 
cumulative effects of environmental particulates on innate and adaptive immune cells and their 
functional organization in the LN.  
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Miron, M., Meng, W., Rosenfeld, A., Dvorkin, S., Poon, M.M.L., Lam, N., Kumar, B.V., 
Louzoun, Y., Luning Prak, E.T., Farber, D.L. (2021) Maintenance of the human memory T cell 
repertoire by subset and tissue site. Genome Med. doi: 10.1186/s13073-021-00918-7 
 
Background: Immune-mediated protection is mediated by T cells expressing pathogen-specific 
T cell antigen receptors (TCR) that are maintained at diverse sites of infection as tissue-resident 
memory T cells (TRM) or that disseminate as circulating effector-memory (TEM), central 
memory (TCM), or terminal effector (TEMRA) subsets in blood and tissues. The relationship 
between circulating and tissue resident T cell subsets in humans remains elusive, and is 
important for promoting site-specific protective immunity. 
Methods: We analyzed the TCR repertoire of the major memory CD4+ and CD8+T cell subsets 
(TEM, TCM, TEMRA, and TRM) isolated from blood and/or lymphoid organs (spleen, lymph 
nodes, bone marrow) and lungs of nine organ donors, and blood of three living individuals 
spanning five decades of life. High-throughput sequencing of the variable (V) portion of 
individual TCR genes for each subset, tissue, and individual were analyzed for clonal diversity, 
expansion and overlap between lineage, T cell subsets, and anatomic sites. TCR repertoires 
were further analyzed for TRBV gene usage and CDR3 edit distance. 
Results: Across blood, lymphoid organs, and lungs, human memory, and effector CD8+T cells 
exhibit greater clonal expansion and distinct TRBV usage compared to CD4+T cell subsets. 
Extensive sharing of clones between tissues was observed for CD8+T cells; large clones 
specific to TEMRA cells were present in all sites, while TEM cells contained clones shared 
between sites and with TRM. For CD4+T cells, TEM clones exhibited the most sharing between 
sites, followed by TRM, while TCM clones were diverse with minimal sharing between sites 
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and subsets. Within sites, TRM clones exhibited tissue-specific expansions, and maintained 
clonal diversity with age, compared to age-associated clonal expansions in circulating memory 
subsets. Edit distance analysis revealed tissue-specific biases in clonal similarity. 
Conclusions: Our results show that the human memory T cell repertoire comprises clones 
which persist across sites and subsets, along with clones that are more restricted to certain 
subsets and/or tissue sites. We also provide evidence that the tissue plays a key role in 
maintaining memory T cells over age, bolstering the rationale for site-specific targeting of 
memory reservoirs in vaccines and immunotherapies.  
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Szabo, P.A., Dogra, P., Gray, J.I., Wells, S., Connors, T.J., Weisberg, S.P., Krupska, I., 
Matsumoto, R., Poon, M.M.L., Idzikowski, E., Morris, S., Pasin, C., Yates, A., Ku, A., Chait, 
M., Davis-Porada, J., Guo, X.V., Zhou, J., Steinle, M., Mackay, S., Saqi, A., Baldwin, M.R., 
Sims, P.A., Farber, D.L. (2021) Longitudinal profiling of respiratory and systemic immune 
responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity. doi: 
10.1016/j.immuni.2021.03.005 
 
Immune response dynamics in coronavirus disease 2019 (COVID-19) and their severe 
manifestations have largely been studied in circulation. Here, we examined the relationship 
between immune processes in the respiratory tract and circulation through longitudinal 
phenotypic, transcriptomic, and cytokine profiling of paired airway and blood samples from 
patients with severe COVID-19 relative to heathy controls. In COVID-19 airways, T cells 
exhibited activated, tissue-resident, and protective profiles; higher T cell frequencies correlated 
with survival and younger age. Myeloid cells in COVID-19 airways featured 
hyperinflammatory signatures, and higher frequencies of these cells correlated with mortality 
and older age. In COVID-19 blood, aberrant CD163+ monocytes predominated over 
conventional monocytes, and were found in corresponding airway samples and in damaged 
alveoli. High levels of myeloid chemoattractants in airways suggest recruitment of these cells 
through a CCL2-CCR2 chemokine axis. Our findings provide insights into immune processes 
driving COVID-19 lung pathology with therapeutic implications for targeting inflammation in 




Weisberg, S.P., Connors, T.J., Zhu, Y., Baldwin, M., Lin, W., Wontakal, S., Szabo, P.A., 
Wells, S.B., Dogra, P., Gray, J., Idzikowski, E., Stelitano, D.,  Bovier, F.T., Davis-Porada, J., 
Matsumoto, R., Poon, M.M.L., Chait, M., Mathieu, C., Branka, H., Decimo, D., Hudson, K.E., 
Zotti, F.D., Bitan, Z.C., La Carpia, F., Ferrara, S.A., Mace, E., Milner, J., Moscona, A., Hod, 
E., Porotto, M., Farber, D.L. (2021) Distinct antibody responses to SARS-CoV-2 in children 
and adults across the COVID-19 clinical spectrum. Nat Immunol. doi: 10.1038/s41590-020-
00826-9 
 
Clinical manifestations of COVID-19 caused by the new coronavirus SARS-CoV-2 are 
associated with age. Adults develop respiratory symptoms, which can progress to acute 
respiratory distress syndrome (ARDS) in the most severe form, while children are largely 
spared from respiratory illness but can develop a life-threatening multisystem inflammatory 
syndrome (MIS-C). Here, we show distinct antibody responses in children and adults after 
SARS-CoV-2 infection. Adult COVID-19 cohorts had anti-spike (S) IgG, IgM and IgA 
antibodies, as well as anti-nucleocapsid (N) IgG antibody, while children with and without 
MIS-C had reduced breadth of anti-SARS-CoV-2-specific antibodies, predominantly generating 
IgG antibodies specific for the S protein but not the N protein. Moreover, children with and 
without MIS-C had reduced neutralizing activity as compared to both adult COVID-19 cohorts, 
indicating a reduced protective serological response. These results suggest a distinct infection 
course and immune response in children independent of whether they develop MIS-C, with 




Dogra, P., Rancan, C., Ma, W., Toth, M., Senda, T., Carpenter, D., Kubota, M., Matsumoto, R., 
Thapa, P., Szabo, P., Poon, M.M.L., Li, J., Arakawa-Hoyt, J., Shen, Y., Fong, L., Lanier, L.L., 
Farber, D.L. (2020) Tissue determinants of human NK cell development, function and 
residence. Cell. doi: 10.1016/j.cell.2020.01.022 
 
Immune responses in diverse tissue sites are critical for protective immunity and homeostasis. 
Here, we investigate how tissue localization regulates the development and function of human 
natural killer (NK) cells, innate lymphocytes important for anti-viral and tumor immunity. 
Integrating high-dimensional analysis of NK cells from blood, lymphoid organs, and mucosal 
tissue sites from 60 individuals, we identify tissue-specific patterns of NK cell subset 
distribution, maturation, and function maintained across age and between individuals. Mature 
and terminally differentiated NK cells with enhanced effector function predominate in blood, 
bone marrow, spleen, and lungs and exhibit shared transcriptional programs across sites. By 
contrast, precursor and immature NK cells with reduced effector capacity populate lymph nodes 
and intestines and exhibit tissue-resident signatures and site-specific adaptations. Together, our 
results reveal anatomic control of NK cell development and maintenance as tissue-resident 
populations, whereas mature, terminally differentiated subsets mediate immunosurveillance 
through diverse peripheral sites. 
 
